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1 T h e s i s  S u m m a r y
This thesis consists of three different studies with the common aim of identifying novel genetic 
influences on cardiovascular risk in hypertensive individuals.
A candidate gene study was conducted to assess the association of genetic variation in the 
(pro)renin receptor ((P)RR), a recently-discovered member of the renin-angiotensin system, with 
blood pressure (BP) levels in two healthy Irish populations. We found a number of single nucleotide 
polymorphisms (SNPs) to be consistently associated with decreased BP (P<0.05). These same 
SNPs were associated with responses to anti-hypertensive treatment in a hypertensive population 
(P<0.05). In adrenal tissue, these SNPs did not appear to alter mRNA expression of the gene, and 
more work may be required to dissect the functional implication of the observed associations.
In two candidate pathway studies, we assessed genetic variation across genes in two biological 
pathways likely to play a role in BP regulation; ion channels (91 genes) and neurotransmitters (188 
genes), for association with BP in two healthy Irish populations. We found that SNPs in a chloride 
channel gene, in a potassium channel gene and in a gene encoding a glutamate receptor 
precursor, were associated with increased BP with experiment-wide statistical significance.
Together, these targeted association studies have identified novel genes which have not been 
previously implicated in BP control, provide new insights into the pathophysiology of BP control, and 
may represent novel drug targets and/or pharmacogenetic markers.
Finally, a genome wide association study investigated the genetic determinants of two prostanoids, 
thromboxane (TxA2) and prostacyclin (PGI2), both of which play important roles in platelet and 
vascular homeostasis. In -800 Caucasian hypertensive subjects, 6 loci were statistically 
associated with levels of TxA2/ PGI2 at experiment-wide level. These associations were strongly 
influenced by use of aspirin, which inhibits production of these prostanoids. The genetic 
determinants of TxA2 and PGI2have not been examined before and the variants identified in this 
study may be novel predictors of atherothrombotic risk and help to inform the use of anti-platelet 
agents such as aspirin.
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2  T h e s i s  I n t r o d u c t i o n
Cardiovascular diseases (CVD) are the leading cause of death globally. The direct cost of treating 
cardiovascular disease in the US is estimated at $300 billion annually, a figure likely to rise with the 
aging of the population (1).
Cardiovascular disease refers to any disease affecting the cardiovascular system. The vast 
majority of cardiovascular diseases involve atherosclerosis, a disease of the arteries in which the 
artery wall thickens as a result of an accumulation of fatty materials, such as cholesterol and 
inflammatory cells. Cardiovascular events usually arise when an atherosclerotic plaque ruptures, 
forms a blood clot (thrombus) and blocks a blood vessel, causing death of the surrounding tissue 
(infarction). When this happens in the heart, it is called a myocardial infarction (Ml); in the brain it is 
called a cerebral infarction (Cl). Ml and Cl are colloquially referred to as heart attack and stroke, 
respectively, and are the leading causes of cardiovascular morbidity and mortality. The 
development of atherosclerosis and progression to thrombus formation and infarction are 
complicated processes, which are described in more detail in chapter 5. There are a large number 
of physiological and environmental risk factors for CVD, including high blood pressure, elevated 
cholesterol, cigarette smoking, presence of diabetes mellitus, and left ventricular hypertrophy (2).
Despite the high heritability of cardiovascular risk factor traits (3), unravelling the genetic variants 
responsible is proving difficult. Three different types of genetic association studies have been 
conducted so far.
Linkage studies have been used to map genetic loci using observations of related individuals. This 
type of study has had some success in identifying genes responsible for severe, early-onset 
cardiovascular phenotypes (4), but has had relatively little success in identifying the genetic variants 
which influence more common, later-onset cardiovascular disease.
The last decade has seen a large number of ‘candidate gene studies’, where single nucleotide 
polymorphisms (SNPs) in a single gene which is hypothesized to be a good candidate for playing a 
role in cardiovascular phenotypes have been examined for association with these phenotypes. 
Candidate gene association studies have largely been conducted in small populations of various 
ethnicities, and findings have not replicated well.
Recently, advances in genotyping technologies have made ‘genome-wide association studies' 
(GWAS) possible. For this type of study, a large number of SNPs (initially -100,000, now
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commonly -1,000,000) are genotyped at regular intervals across the entire genome. The design of 
most commercial genome-wide genotyping arrays is agnostic and does not rely on prior assumption 
about the underlying physiology of a trait. In order to control for the propensity for false positive 
results due to the large number of SNPs being assayed, it is necessary to apply a stringent 
statistical correction to the results of these studies. In order to have sufficient power for potentially 
'true’ associations to surpass this correction, larger sample sizes have been mandated for GWAS 
compared to candidate gene studies. Genome-wide genotyping has also made adjustment for 
population stratification due to underlying ethnicity possible, a phenomenon which may have 
confounded results of candidate gene studies. Despite the high density of SNP genotyping on 
GWAS arrays, it remains likely that if an association is observed, it will be with a SNP that ‘tags' the 
true causal variant, rather than the causal variant itself. ‘Imputation’ techniques have been 
developed which aim to predict (or 'impute') missing genetic variation based upon the observed 
SNP data, using reference datasets such as the HapMap resource (5, 6). GWAS have identified 
multiple loci convincingly associated with CHD risk in Caucasians using broad phenotypic endpoints 
such as myocardial infarction and/or coronary revascularisation (7-14). These loci have included 
many genes involved in lipid metabolism, as well as novel chromosomal regions that do not appear 
to contribute to risk through traditional risk factors.
Despite some successes, the phenomenon of 'missing heritability', where genetic association 
studies have failed to identify all of the heritability of a trait suggested by epidemiological studies, 
has plagued many complex traits, including cardiovascular disease. This missing heritability has 
been the topic of much discussion (Figure 2-1).
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Figure 2-1. The Case of the Missing Heritability. This cartoon appeared in one of the many 
papers published on the subject of 'missing heritability’ in recent years, which have postulated many 
theories as to why a substantial amount of heritability has been as yet unaccounted for by the 
findings of genome-wide studies. From (15).
A number of reasons have been cited for the ‘missing heritability' of many disease phenotypes, 
which are discussed at length by Maher et al (Personal genomes: The case of the missing 
heritability, (15)) and in other, similar papers. The following is a list of theories which have been 
suggested to explain missing heritability:
1. Power
The types of genetic study conducted so far (linkage, candidate-gene, GWAS) have been well- 
powered only to detect certain types of genetic variants, shown within the dotted lines in Figure 2-2. 
High-penetrance variants with large effect sizes are unlikely to underlie common diseases such as 
cardiovascular disease, because evolution keeps them in check. However, multiple common and 
rare variants of small-modest effect sizes are likely to account for large portion of genetic 
susceptibility to common diseases. The studies conducted so far have not had the power to pick up 
uncommon variants with small/modest effect sizes, or indeed common variants with very small 
effect sizes. When taken as individual entities, these modest-effect genes may not pass the 
stringent statistical corrections for multiple testing which are imposed on large-scale association 
studies. It may be that it is necessary to relax statistical corrections for multiple testing, and/or to 
look at loci which lie below this bar in order to identify all variants influencing common diseases.
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Figure 2-2. From (16). Feasibility of identifying genetic variants by risk allele frequency and 
strength of genetic effect (odds ratio). Most emphasis and interest has so far been in identifying 
associations with characteristics shown within diagonal dotted lines.
2. Coverage
In addition to power issues, coverage, or the amount of genetic variation which the so-called 
'genome-wide’ chips actually identify, is also a possible explanation for some of the missing 
heritability. For example, genome-wide chips do not identify rare variation; they are not designed to 
target rare variation, and neither is rare variation well-identified by imputation. Recently, 
resequencing projects have been successful in identifying additional, rare variants in single-gene 
disorders where the causative gene was already known. Some large-scale exome sequencing and 
whole genome sequencing projects are underway, but undertaking good-quality, large-scale 
sequencing projects with the sample sizes which will be needed to detect rare variants of small 
effect is financially prohibitive for most groups at present.
Another coverage issue is the type of genetic architecture which has been examined. Most GWAS 
studies conducted so far have looked exclusively at SNPs. Other types of genetic variation, such 
as copy number variants (CNVs) may influence disease risk, however variation like this is not as 
well-studied as SNP variation.
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Incomplete ‘genome-wide’ chip coverage is also a potential culprit for the lack of findings by GWAS. 
Even discounting low-frequency variants and other types of variation (e.g. CNVs), existing chips are 
not completely ‘genome-wide’, in that they do not capture 100% of ‘common’ SNP variation across 
the whole genome. Although ‘coverage’ of the genome (in this case meaning the amount of 
genome-wide variation accounted for by the SNPs genotyped) is constantly improving as new chips 
are developed and the cost of genotyping is reduced, a large number of the GWAS studies to date 
have used chips with 300,000-500,000 SNPs. After imputation, these chips capture between 73% 
and 87% of all the variation across the genome in European populations (CEU) with a linkage 
disequilibrium (LD) value of r*>0.8 ((17, 18),Table 2-1). These numbers are similar for Asian 
populations (CHB+JPT) but drop considerably for populations of African descent (YRI) (17), Figure
2-3.
In addition to the coverage issues of each individual genome-wide chip, an additional issue arises 
when different chips are combined. In order to attain sufficient power to overcome correction for 
multiple testing, the large GWAS conducted to date have commonly used a strategy of collecting 
populations genotyped on different genome-wide chips, and imputing from these chips to acquire a 
common set of SNPs for all populations. This strategy, however, results in the loss of a number of 
SNPs which may be genotyped on one platform but not well-imputed from another. In an example 
published by Anderson et al, using the Affymetrix SNPArray 5.0 genotypes, they were able to 
accurately impute only 245,430 of the attempted 427,838 lllumina HumanHap 550 SNPs (18).
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Table 2-1. Adapted from (18). Estimates of genomic coverage for currently available 
genome-wide SNP platforms alone and after imputation. Estimates were evaluated using 
Phase II HapMap data from the CEU (residents of Utah, USA with northern and western European 
ancestry) population. Array names indicate the number of genotyped markers in units of 100,000 
(Affymetrix) or 1,000 (lllumina) -  i.e. SNP Array 5.0 contains approx 500,000 markers, HumanHap 
300 contains 300,000 markers. Coverage estimates for lllumina HumanHap 1M and Affymetrix 
SNP Array 6.0 are likely to be biased downward because the genotypes at approximately 10% of 
the SNPs on each platform are not currently publicly available for the CEU HapMap individuals. 
Where imputations are included, all SNPs passing imputation-filter thresholds and with an r2 = 0.8 
between known and imputed genotypes are included along with the SNPs on the genome-wide 
SNP chip.
Percentage of 
Genomic Coverage at 
r2 £ 0.8
Percentage of 
Genomic Coverage at 
r2 = 1
Affymetrix SNP Array 5.0 65 43
Affymetrix SNP Array 5.0 plus imputed SNPs 73 54
Affymetrix SNP Array 6.0 80 59
lllumina HumanHap 300 77 42
lllumina HumanHap 300 plus imputed SNPs 81 50
lllumina HumanHap 550 87 57
lllumina HumanHap 1M 91 68
CEU CHB+ JPT YRI
—  Array 5 0
—  Array 6 0 
Hum anHap300  
HumanHap5i>0 HumanHap650Y H/nanlM
3 0  40 60
l
100
Coverai}*umnok) aX C overage thwtfiold a%
Figure 2-3. From (17). Number of genes covered by commercially available genotyping 
arrays at various coverage thresholds. Coverage was evaluated at r2=0.8 in the four Hapmap 
populations; the Yoruba people of Ibadan, Nigeria (YRI); individuals from Tokyo, Japan JPT and 
from Beijing, China (CHB); and residents of Utah, USA with northern and western European 
ancestry (CEU). SNP Array 5.0 and 6.0: Affymetrix genotyping arrays with 500,000 and 600,000 
markers, respectively. HumanHap 300, 550, 650Y and 1M: lllumina genotyping arrays with 
300,000, 550,000, 650,000 and 1,000,000 markers, respectively.
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3. Interactions
Interactions between two or more genes (epistasls), and/or gene-environment interactions are 
thought to be common determinants of disease phenotypes, and some examples are known. 
However, these interactions are very difficult to model and identify statistically, and are therefore 
ignored in most studies.
4. Poorly characterised phenotypes
Poor phenotypic characterisation could be thwarting GWAS in two distinct ways. Firstly, many 
‘diseases’ may actually be a number of distinct diseases, with similar symptoms. As each of these 
diseases will have distinct underlying physiology, it is unlikely that the same genetic variants will be 
associated with each one, and grouping them in an association study will negatively impact the 
power of the study. In addition, complex diseases such as cardiovascular diseases may actually 
represent a collection of different diseases, which all culminate in the same endpoint. In cases 
such as these, analysing the endpoint may be too crude a measure to identify the contributing 
genetic factors, which may differ depending on which ‘sub-diseases’ are present. For 
cardiovascular disease, for example, better power to detect genetic contributions may be attained 
by using cardiovascular risk factors, such as hypertension, markers of atherosclerosis, lipid levels 
etc as the phenotype studied in genetic association studies. Secondly, poor or inconsistent 
measurement of a phenotype will negatively impact the power of a study. In addition, using study 
populations where a large number of individuals are taking medications may introduce substantial 
error to phenotypic measurement.
No one genetic association study design has emerged as being particularly successful, and 
identifying missing heritability may be best approached by using a number of distinct but 
complimentary approaches. One approach to combating both the lack of power inflicted by hefty 
statistical correction for multiple testing and genome-wide coverage issues is to reduce the genomic 
area of interest. Targeted studies using biological information to identify genes likely to be involved 
in disease susceptibility or progression, offer the advantage that these genes can then be 
comprehensively genotyped, and tested for association without having to impose the prohibitively 
stringent statistical thresholds necessary to control for the effects of multiple testing in GWAS. This 
targeted approach may involve a single candidate gene, or be expanded to include a number of 
candidate genes Involved in a common molecular pathway (‘candidate pathway’ approach). 
Although GWAS indubitably offer the advantage of the potential to discover new & unpredicted 
associations, targeted approaches play an important and complimentary role by providing a 
comprehensive analysis of genes in which associations with the phenotype of interest are likely to 
exist.
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As such there are 3 parts to this PhD project, each employing a different approach towards the 
common goal of identifying genetic contributors to cardiovascular disease. The endpoints of these 
studies are important cardiovascular risk factors; the targeted studies investigate genetic 
determinants of blood pressure, the GWAS investigate genetic determinants of two prostanoids 
important in atherothrombosis.
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3  C a n d i d a t e  G e n e  A s s o c i a t i o n  S t u d y  o f  
G e n e t i c  V a r i a n t s  i n  t h e  ( P r o ) R e n i n  R e c e p t o r  
w i t h  B l o o d  P r e s s u r e  V a r i a t i o n
3.1 In troduction
3.1.1 B lood Pressu re
The term "blood pressure" (BP) usually refers to the arterial pressure of the systemic circulation. It 
is the pressure exerted by circulating blood upon the walls of blood vessels, and is a function of 
total peripheral resistance (the sum of the resistance of all peripheral vasculature in the systemic 
circulation) and cardiac output (the volume of blood being pumped by the heart). During each 
heartbeat, BP varies between a maximum (systolic) pressure (SBP), and a minimum (diastolic) 
pressure (DBP), decreasing as the circulating blood moves away from the heart through the 
arteries.
Blood pressure is a quantitative trait that is continuously associated with an increased risk of 
cardiovascular mortality and morbidity. For clinical risk assessment, it has been necessary to 
define a threshold at which quantitative BP levels are described as a binary trait, which is called 
hypertension. An average reading of systolic >140mmHg and/or diastolic of >90mmHg on two 
consecutive clinic visits is currently considered as treatment-requiring hypertension (19).
Hypertension is common - a recent survey in Ireland found that 60% of Irish adults over 45 years 
and 74% of those over 65 years were hypertensive (20). It is even more worrying that, with or 
without medication, blood pressure was controlled to optimal levels (< 140/90mmHg) in less than 
15% of hypertensive subjects (20).
High blood pressure is a major contributor to the development of atherosclerosis and to death from 
stroke, myocardial infarction (Ml), end-stage renal disease and congestive heart failure (21). The 
World Health Organisation has recently estimated that half of heart attacks and two thirds of strokes 
are due to poorly controlled blood pressure (22).
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Elevated BP is a multifactorial disorder arising from a complex interaction of genetic, environmental 
and demographic factors (23). The major demographic and environmental factors influencing BP 
level are well known -  blood pressure is higher in men, and increases with age, and a high calorie, 
salt and/or alcohol intake results in higher BP levels. The genetic factors influencing BP variation 
are less well-known, and will be discussed at length in the following sections.
Regulation of BP by the body is controlled by a complex network of interacting pathways involving 
renal, neural, endocrine, vascular and environmental factors. The renin-anglotensin system (RAS) 
has a central role in acute and chronic regulation of blood pressure, and is described in more detail 
in section 3.1.3.
Blood pressure has traditionally been measured by taking a small number of readings with the 
auscultatory technique in a medical setting. However, such measurements often provide a poor 
estimate of ‘true’ BP levels in an individual patient for reasons such as poor technique of the 
observer, the "white-coat” effect (the transient but variable elevation of blood pressure in a medical 
setting, (24)) and the inherent variability of blood pressure (25). Ambulatory Blood Pressure 
Monitoring (ABPM) resolves a number of these issues. The monitors are typically programmed to 
take readings every 15 to 30 minutes throughout the day and night, and are usually worn for 24- 
hours. A number of studies have been conducted comparing ABPM to traditional methods and the 
general finding has been that ambulatory blood pressure predicts cardiovascular events better than 
clinic blood pressure does (26-34).
3.1.2 The G enetics of B lood P re ssu re  Variation
Genetic factors are known to play a significant role in the development of hypertension (35, 36) and 
the heritability (h2) of hypertension is estimated to be about 0.6 (37), meaning that -60% of BP 
variation is due to genetic variation. Recently, significant efforts have been made to identify the 
genetic determinants of BP variation in the general population; however despite the high heritability 
of hypertension estimated by epidemiological studies, identification of the genes responsible for 
elevated blood pressure is proving challenging. A number of different study designs have been 
adopted to try to elucidate genetic associations with BP variation, with varying degrees of success.
Linkage Studies
Linkage studies have had some success in identifying genes responsible for severe, early-onset 
monogenic blood pressure disorders, such as Barter’s and Gitleman’s syndromes (38). These have
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largely been rare mutations, imparting large quantitative effects, and have altered blood pressure 
through a common pathway; altering ion channels responsible for salt and water reabsorption in the 
kidney. Linkage studies have not been successful in identifying the genetic markers associated 
with common hypertension, however.
Candidate Gene Studies
A large number of the candidate gene studies have been conducted on members of the RAS. Twin 
studies have indicated genetic influences on the RAS components renin and aldosterone following 
volume expansion and contraction in humans (39). Although inconsistent reports have been 
published on the involvement of a number of the components of the RAS in BP 
variation/hypertension and/or response to treatment with anti-hypertensives to date, evidence for 
their involvement has largely been positive.
An insertion-deletion polymorphism in ACE1 (A C E  D /I) has been reported to be associated with 
hypertension/BP variation in most, but not all, populations (40-45). SNPs in ACE2, which has been 
proposed to counterbalance the functions of ACE1, have also been found to be associated with 
adverse cardiovascular events and hypertension and/or response to ACE-inhibitors in some, but not 
all, studies (46-51). Genetic polymorphisms in angiotensinogen (44, 52-55), angiotensin II type 1 
receptor (56-60) and renin (61-63) have also been shown to be associated in some studies with 
hypertension and/or blood pressure variation. Whether genetic variation in the aldosterone 
synthase (C YP11B 2) gene is associated with BP variation has not been as well-studied as other 
RAS members in candidate gene studies, and published studies so far have been contradictory (64, 
65). Overall, where polymorphisms in genes encoding RAS components have been associated 
with BP, the associated variation has been modest, of the order of 1-2mmHg.
A similar situation exists for the candidate gene N OS3, which encodes endothelial nitric oxide 
synthase (eNOS). Conflicting reports exist from a number of relatively small studies regarding its 
association with BP variation (66-70).
A number of reasons have been proposed to explain the inconsistency of published results from 
candidate gene studies. The majority of these studies have been conducted in relatively small 
populations of various ethnicities (primarily cohorts of European of Asian descent), and 
may have been underpowered to detect modest BP effects. The heterogeneity of the published 
studies has meant that meaningful meta-analyses have not been possible. In addition, associations 
may not in reality be consistent across sample populations of different ethnic backgrounds.
12
Genome-Wide Association Studies (GWAS)
The first genome-wide association study for hypertension/BP variation was published by the 
Welcome Trust Case Control Consortium (WTCCC) in 2007, in which they genotyped -500,000 
SNPs in 2,000 cases and 3,000 unphenotyped controls (7). Despite high expectations of the ability 
of GWAS to identify previously elusive genetic associations, the WTCCC did not find any SNPs 
which were significantly associated with hypertension after correction for multiple testing. This 
study did succeed in identifying genetic associations with other diseases, and its failure to find 
associations with hypertension may have been due to poor study design. This study used 
unphenotyped controls, and as high BP is common, misclassification bias may have led to a 
substantial reduction in power. However, four more GWAS for hypertension/BP variation were 
published between 2007 and 2009 which did not report any SNPs which were significant at an 
experiment-wide level (71-74). These four GWAS consisted of:
An analysis of -100,000 SNPs in 1,327 individuals from the Framingham Heart Study 
families, in whom SBP and DBP were analysed as continuous traits, published in 2007 (71). 
A case-control study for hypertension in 3082 Scandinavian individuals recruited as part of 
a diabetes study and genotyped at -500,000 SNPs, published in 2007 (72).
A case-control study for hypertension in a Japanese population of 1,692 individuals, only 
188 of whom were cases, genotyped at -100,000 SNPs, published in 2008 (73).
An analysis of -300,000 SNPs plus imputation for association with SBP/DBP in 4,763 
members of the North Finnish Birth Cohort, published in 2009 (74).
In 2009, however, a number of publications reported statistically significant associations between 
SNPs and hypertension/BP variation in GWAS. Wang et al conducted a hypertension case-control 
study on > 7,000 Caucasians, and reported one SNP, located in a gene desert, which was 
associated with hypertension with experiment-wide significance (75). In another study of the KORA 
cohort from Germany (76), -500,000 SNPs were genotyped in 1,694 Individuals and a common 
variant just upstream of the C D H 13  gene reached genome-wide significance for association with 
blood pressure variation. The C D H 13  gene encodes a calcium-dependent cell-cell adhesion 
glycoprotein, T-cadherin, which has been implicated as a regulator of vascular wall remodelling & 
angiogenesis. A third study in a population of 1,017 African Americans (77) genotyped at 
-1,000,000 SNPs identified loci reaching genome-wide significance for systolic BP in or near the 
genes: PMS1 (post-meiotic segregation increased 1; a DNA mismatch repair mutL/hexB protein), 
YW HAZ  (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta 
polypeptide; a signal transduction mediator), IP 0 7  (importln 7; binds & imports ribosomal proteins), 
SLC24A4 (solute carrier family 24 sodium/potassium/calcium exchanger, member 4; a potassium 
dependent sodium/calcium exchanger) and C AC AN A1H  (calcium channel, voltage-dependent, T
13
type, alpha 1H subunit; a protein in the voltage-dependent calcium channel complex). Only the 
latter gene had been previously implicated in BP regulation; voltage-gated calcium channels are 
thought to be involved in the regulation of heart contraction and T-type voltage-gated calcium 
channel proteins are the target for a number of calclum-channel blocking agents used for treatment 
of hypertension and angina; mibefradil (withdrawn in 1998 due to life-threatening interactions with 
other anti-hypertensive medications) (78), efonidipine, benidipine and manidipine (79).
Two exceptionally large GWAS studies were published together in Nature Genetics in 2009, from 
the CHARGE and Global BPgen consortia. Using large population cohorts of -30,000 participants, 
and genetic information from large genome-wide chips with imputation, each reported positive 
findings for associations with BP and/or hypertension (80, 81). When the two consortia conducted 
a meta-analysis of their individual ‘tophits’, associations, 13 loci were experiment-wide significant 
(Table 3-1). Each of these associations explained only a very small proportion of the total variation 
in systolic or diastolic blood pressure (approximately 1mmHg per allele SBP or 0.5mmHg per allele 
DBP) and the sum of these associations explains only 1-2% of the total blood pressure variation 
seen in populations of European descent. Despite the small amount of variation explained by 
individual loci, however, the findings of this these studies have clinically meaningful aggregate 
effects. Observational data indicate that a prolonged reduction in SBP of 2mmHg corresponds to 
6% reduction in stroke and 5% reduction in coronary artery disease (82).
The majority of the CHARGE/BPgen findings were at loci not previously known, or suspected, to be 
involved in BP regulation. Some hits were unsurprising, however. Two loci potentially affect 
calcium transport. CACNB2  (calcium channel, voltage-dependent, beta 2 subunit) encodes a 
member of a family of voltage-gated calcium channels, several of which are known to affect BP 
regulation (83, 84) and serve as targets of calcium channel blockers (85). ATP2B1  (ATPase, Ca++ 
transporting, plasma membrane 1) encodes a plasma membrane calclum/calmodulin-dependent 
ATPase that is expressed in vascular endothelium and is involved in calcium pumping from the 
cytosol to the extracellular compartment (86).
One locus, CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1), had been 
previously implicated in BP regulation. CYP17A1  encodes steroid 17-alpha-hydroxylase, an 
enzyme necessary for steroidogenesis. Mutations in CYP17A1  are found in individuals with 17a- 
hydroxylase deficiency, which is characterized by congenital adrenal hyperplasia with apparent 
mineralocorticoid excess, salt retention, hypokalemia and hypertension (87). This finding therefore 
represents an example of a common variant in a gene known to cause rare forms of hypertension 
being associated with common BP variation.
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Only one CHARGE/BPgen locus can be linked to the RAS based on current knowledge; the C SK- 
ULK3 locus. C SK  (c-src tyrosine kinase) encodes a cytoplasmic tyrosine kinase, which is Involved 
in angiotensin ll-dependent vascular smooth muscle cell proliferation (88).
Table 3-1. Genome-wide significant loci from the CHARGE and Global BPgen GWAS after meta­
analysis following exchange of the top 30 most strongly associated loci from each study for lookup in 
the other. Adapted from (80). Beta is the effect size on BP (systolic or diastolic) in mmHg, per allele based on 
the additive genetic model. Hypertension in the CHARGE study was defined as SBP > 140 or DBP > 90 mm 
Hg or drug treatment for hypertension at time of assessment.
Location Nearest gene Beta P-value
CHARGE
systo lic blood pressure
10q24 CYP17A1 17-a hydroxylase 1.05 1.28E-10
11p15 PLEKHA7 Pleckstrin homology domain containing, family A member 7 0.65 1.89E-09
12q21 ATP2B1 Plasma membrane calcium pump 0.85 3.76E-11
12q24 SH2B3 Lymphocyte adapter protein 0.58 4.52E-09
diastolic blood pressure
3p22 ULK4 Unc-51-like kinase 4 0.49 2.54E-09
10p12 CACNB2 Calcium channel voltage-dependent subunit beta 2 0.37 1.24E-08
12q21 ATP2B1 Plasma membrane calcium pump 0.50 1.47E-09
12q24 SH2B3 Lymphocyte adapter protein 0.48 2.58E-14
12q24 TBX3-TBX5 T-box transcription factor 3/5 -0.35 3.75E-08
15q24 CSK-ULK3 C-SRC kinase/Unc-51-like kinase 3 0.40 1.84E-10
hypertension
12q21 ATP2B1 Plasma membrane calcium pump 0.15 1.74E-11
Global BPgen
systolic blood pressure
1p36 MTHFR 5,10-methylenetetrahydrofolate reductase (NADPH) -0.85 2.00E-13
10q24 CYP17A1 17-a hydroxylase 1.16 7.00E-24
17q21 PLCD3 Phospholipase C-delta-3 0.57 1.00E-08
diastolic blood pressure
4q21 FGF5 Fibroblast growth factor 5 0.50 1.00E-21
10q21 C10orf107 Chromosome 10 open reading frame 107 -0.39 1.00E-09
12q24 SH2B3 Lymphocyte adapter protein -0.46 3.00E-18
15q24 CYP1A2 Cytochrome P450, family 1, subfamily A, polypeptide 2 0.43 1.00E-23
17q21 ZNF652 Zinc finger protein 652 0.31 5.00E-09
16
As discussed in the introduction to this thesis, the burden of statistical correction for multiple testing 
in GWAS is substantial, and in some cases prevents true associations from attaining statistical 
significance. This phenomenon is illustrated here by the fact that the genome-wide significant 
findings of each of the BP GWAS independently did not identify any common loci, indicating that 
despite the large sample sizes, the studies were fraught with Type II error and were underpowered 
to detect effects with statistical significance after correction for multiple testing. Large consortia 
such as the International Consortium for Blood Pressure (ICBP) are assembling larger & larger 
sample sizes, and their meta-analysis of BP phenotypes due to be published this year is the largest 
BP study to be published to date. This study may help to Identify variants with small effect sizes 
which studies so far have not had the power to detect.
Hypothesizing that perhaps a different approach was required to uncover the ‘missing heritability' of 
BP variation, a study published by Padmanabhan et al in 2010 adopted an ‘extreme phenotype’ 
approach (89). In this study, hypertensive cases and controls were drawn from the extremes of the 
BP distribution, in an effort to increase power. The authors detected a single locus which was 
significantly associated with hypertension in their initial genome-wide scan of 1,621 hypertensive 
cases and 1,699 controls, which they validated in large-scale population and case-control studies, 
where extreme criteria for selection of cases and controls had been used. The associated SNP was 
located upstream of the Uromodulin gene (UM OD\ combined P value of 3.6*10~11) and the minor 
allele was found in this study to be associated with a lower risk of hypertension (OR [95%CI]: 0.87 
[0.84-0.91]). Following additional functional experiments, they found that this SNP was also 
associated with reduced urinary uromodulin excretion, better renal function; and a 7.7% per-allele 
reduction in risk of CVD events after adjustment for other covariates. Uromodulin (also known as 
Tamm-Horsfall protein) is the most abundant protein in mammalian urine & may act as a 
constitutive inhibitor of calcium crystallization in renal fluids (90). It Is almost exclusively expressed 
in the thick portion of the ascending limb of Henle (91), suggesting a putative role of this variant in 
hypertension through an effect on sodium homeostasis.
Two further large-scale association studies for BP variation are about to be published. The ICBP 
consortium have conducted a genome-wide meta-analysis of-130,000 subjects, identifying 16 
novel loci, and replicating the associations of 12 of the 13 loci reported by the CHARGE/BPgen 
consortia (private correspondence). A separate, large-scale study using the cardiovascular-specific 
‘CVD50K’ chip, which contains 50,000 SNPs at loci predicted to be involved in cardiovascular 
disease, has unearthed a further 6 novel loci associated with BP variation (private correspondence). 
These studies bring to 37 the number of BP loci identified by large-scale, genome-wide association 
studies, which are individually associated with small changes in BP values, a number which still 
explains relatively little of the heritability.
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It is likely that a number of the reasons for missing heritabllity of common diseases cited in the 
introduction to this thesis apply to the missing heritability in hypertension. In particular, for a 
disease such as hypertension which consists of a single phenotype (in this case BP variation), good 
phenotypic measurement is paramount. Most genetic association studies for BP conducted so far 
have used populations where BP was measured using traditional, clinic measurements rather than 
the more accurate ambulatory BP measurement, which will have negatively impacted the power of 
the studies. In addition, many studies, including the large-scale GWAS, have used populations 
where a large number of individuals are taking one or more BP-lowering agents. Although attempts 
are usually made to adjust for this, because of the variety in type and number of anti-hypertensives 
being taken, and because of inter-individual variation in response to different anti-hypertensive 
agents, this adjustment is usually crude. Using heavily medicated populations may therefore 
introduce substantial error to these studies.
3.1.3 The R enin-A ngiotensin  System
The study described in this chapter was a candidate gene association study of the (pro)renin 
receptor, a newly-discovered member of the Renin-Angiotensin System. Previous work by the 
group found that a distal enhancer polymorphism (REN-5312C/T, or ‘REN-5312’) in the (pro)renin 
gene is associated with BP variation and response to treatment with anti-hypertensives in Irish 
populations (62, 63). As the (pro)renin receptor is known to facilitate activation of (pro)renin to an 
enzymatic state similar to that of renin (section 3.1.5), we hypothesized that polymorphisms in the 
gene encoding the receptor may also play a role in BP variation and response to treatment with 
anti-hypertensives in Irish populations.
The renin-angiotensin system (RAS) is a system of hormones which regulate fluid homeostasis and 
other factors which determine BP. When blood volume is low, juxtaglomerular cells in the kidneys 
secrete renin, which cleaves angiotensin I from angiotensinogen (Figure 3-1). Angiotensin I is then 
converted to angiotensin II by the angiotensin converting enzyme (ACE). Angiotensin II binds to the 
Angiotensin II type 1 (AT1) receptor, causing a plethora of blood pressure-raising effects, including 
vasoconstriction, the potentiation of sympathetic nerve activity, and the stimulation of aldosterone 
release from the adrenal cortex. Aldosterone release causes the tubules of the kidneys to increase 
the reabsorption of sodium and water into the blood, increasing BP.
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Figure 3-1. Simplified overview of the proteins, peptides, enzymes, and receptors of the 
renin angiotensin system (from (92)). The classic pathway is shaded in grey. Renin cleaves the 
decapeptide angiotensin I from angiotensinogen. Angiotensin I is then converted to angiotensin II 
by the removal of the two carboxyterminal amino acids. Angiotensin II binds two receptor subtypes, 
AT1, and AT2. Ang=angiotensin. ACE=angiotensin converting enzyme. R/P-R=renin/prorenin 
receptor.
The effects of all the angiotensin peptides produced by the RAS are mediated through specific cell 
surface receptors, indicated in blue in Figure 3-1. A summary of these four receptors and their 
downstream effects is provided in Table 3-2 below. The Influence of the RAS on the development 
of atherosclerosis is mainly brought about by the ATI-mediated effects of Ang II (Figure 3-2). The 
AT2 receptor, which is also bound by Ang II, antagonizes many effects of the AT1 receptor. The 
recently-discovered (pro)renin receptor is thought to play a key role in the renin-angiotensin system 
(RAS). As (pro)renin Is the catalyst for the first step in the RAS cascade, the conversion of 
Angiotensinogen to Ang I (Figure 3-1), it has downstream effects on all the products of the RAS.
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Table 3-2. Cell surface receptors of the RAS (adapted from (92)). LW=Leu-val-val-hemorphin.
R e c e p to r L ig a n d  (s) E ffe c ts
A T I
A n g io te n s in  II ty p e  1 
re c e p to r A n g  II, A ng III
V a s o c o n s tric tio n , s t im u la tio n  o f  a ld o s te ro n e  
re le a s e  and  s y m p a th e tic  n e rv e  a c tiv ity , p ro m o tio n  
o f  ce ll g ro w th , m a tr ix  d e p o s it io n , in f la m m a tio n .
A T 2
A n g io te n s in  II ty p e  2 
re c e p to r A n g  II
A n ta g o n is m  o f  th e  e ffe c ts  o f  A T I ,  p ro m o tio n  o f  
a p o p to s is , p ro te s t io n  o f  n e u ra l t is s u e , p o ss ib le  
s y n erg ism  w ith  A T I  in  p ro m o tin g  in f la m m a tio n .
A n g io te n s in  IV A n g  IV , LVV-
V a s o d ila tio n , d e c re a s e d  tu b u la r  s o d iu m  tra n s p o rt, 
im p ro v e d  m e m o ry , poss ib ly  p ro m o tin g
A T 4 re c e p to r h a e m o rp h in  7 in fla m m a tio n .
R /P -R
R e n in /p ro  re n in  
re c e p to r R en in  and p ro re n in
In crease  o f  a n g io te n s in  g e n e ra tio n , fu r th e r  
in d e p e n d e n t  p ro m o tio n  o f  m a tr ix  d e p o s itio n .
Oxidative stress Inflam m ation
N A P ^ P jH o c ld a s e  a c t iv it y  T V a scu la r p e m ie a b ili ly  T , le u co cyte  In f i l t r a t e n  1
R e active  o x y g e n  sp e c e s  T A ct N a tio n  o f  s ig  n a ilin g  p a th w a y s ( N F rfi )
L D L  percw idatiorv  L Q X - 1 1
P r o d u c t io n  o f  in fla m m a to ry  m e d ia to rs  a • . * I I  ■ A d b e s b n  rrw kK u le s  (V CA M -1^ IC A M -1  )
A n g i o t e n s i n  l l  * C h e m c M n e s ( M C P - lJ n t e r le u M n 8  )
■  C y t c k lm s  (In te rle u k in  1  fc 6 , T N F a  ) 
N itr ic  o x id e  J .  G ra r / lh  fa c to rs
V a » :o n s tr » :t io n P io life r a t b n  o fV S M  C s
P A l-1  Ä C tN a tico M atrix d e p o s it io n
P la te le t  a g g r e g a t e MM P  a c t iv a tio n
Endothelial dysfunction Tissue rem rxM ling
Figure 3-2. Schematic illustration of important effects of angiotensin II on mechanisms 
associated with atherosclerosis (from (92)). The various interactions between several 
angiotensin II induced processes are not illustrated. ICAM-1 intercellular adhesion molecules. LO X- 
1=lectin-like oxidized LDL receptor. MCP-1=monocyte chemoattractant proteins. MMP=matrix 
metalloproteinases. PAI-1=plasminogen activator inhibitor. VSM Cs=vascular smooth muscle cells. 
VCAM-1= vascular adhesion molecules.
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Until recently, it was thought that the juxtaglomerular epitheloid cells, located in the walls of renal 
afferent arterioles (Figure 3-3), were the main source of renin in the body (93), and that renin of 
renal origin was predominantly responsible for the generation of Ang II in the circulation (94).
Renin secretion from the juxtaglomerular apparatus in the kidney is regulated by four mechanisms: 
(i) arterial BP, (ii) sympathetic nervous system activity, (iii) sodium balance and (iv) negative 
feedback regulation by Ang II (95), Figure 3-3.
(i) Arterial BP: The afferent arterioles are a group of blood vessels which branch from the renal 
artery and supply the nephrons in the kidney. When renal blood flow is reduced (indicating 
hypotension), the macula densa, a discrete region of specialised columnar epithelial cells in the 
distal renal tubule (Figure 3-3), releases prostaglandins. These prostaglandins cause the 
juxtaglomerular cells lining the afferent arterioles to release renin, activating the RAS and 
increasing blood pressure.
(ii) Sympathetic stimulation: Sympathetic nervous system activity is responsible for the increase in 
renin on standing and exercise, and is mediated by Pi adrenoceptors on the juxtaglomerular 
apparatus (96). p-blockers reduce blood pressure through blockade of these adrenoceptors and 
subsequent reduction in renin release (97, 98).
(iii) Sodium balance: The macula densa cells sense sodium flux through the Na+K+2CI~ transporter. 
Prostaglandins and adenosine act as signals from the macula densa to the juxtaglomerular 
apparatus, respectively stimulating and inhibiting renin release (99).
(iv) Negative feedback by Ang II: Ang II acts via ATi receptors on the juxtaglomerular cells to inhibit 
the release of renin, thus reducing plasma renin activity (PRA) and the production of Ang I and Ang
11.(100) The importance of Ang II feedback on regulation of renin release is illustrated by the fact
that use of ACE inhibitors or angiotensin receptor blockers (ARBs) lead to several-fold increases in
plasma renin (101)
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Figure 3-3. (I) Bowman's Capsule. Adapted from httD://en.wikipedia.orq/. The Bowman's capsule (or glomerular capsule) is a cup-like sac at the 
beginning of the tubular component of a nephron in the kidney that performs the first step in the filtration of blood to form urine. A: Renal corpuscle, B: 
Proximal tubule, C: Distal convoluted tubule, D: Juxtaglomerular apparatus, 1: Basement membrane, 2: Bowman's capsule parietal layer, 3: Bowman's 
capsule visceral layer, 3a: Pedicels, 3b: Podocyte, 4: Bowman's space (urinary space), 5a: Mesangium (Intraglomerular cell), 5b: Mesangium 
(Extraglomerular cell) 6: Juxtaglomerular cells, 7: Macula densa, 8: Myocytes (smooth muscle), 9: Afferent arteriole, 10. Glomerulus Capillaries, 11: 
Efferent arteriole. (II) The four regulators of renin secretion. From (102). JGA, juxtaglomerular apparatus.
The classical concept of the renin-angiotensin system (RAS) is that of a blood-borne cascade 
where (pro)renin produced in the kidney catalyses the production of Angll. However, (pro)renin has 
been found in a wide variety of human tissues (103-110), and extra-renal (pro)renin may play an 
important role in the RAS. Indeed, an increasing number of studies suggest the existence of a local 
angiotensin-generating system in several tissues (111). This ‘tissue RAS’ can act locally to meet 
specific needs for individual tissues and it can operate, in whole or in part, independently of the 
circulating counterpart. Little is known about the regulation of tissue RAS.
Blood pressure is modifiable by lifestyle changes and/or pharmacological intervention. Many major 
classes of pharmacological anti-hypertensives target the RAS. The pathway can be blocked at its 
rate-limiting step (direct renin inhibition or p blockade), the synthesis of the active product, 
angiotensin II (ACE inhibitor), or at the receptor for angiotensin (angiotensin receptor blocker) 
(Figure 3-4). Other anti-hypertensive agents such as calcium-blocking drugs and diuretics, cause 
vasodilation of the arteries, decreasing BP, and also exert a natriuretic response (112), increasing 
the discharge of sodium and water in the urine and decreasing blood volume (Figure 3-4).
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Figure 3-4. From (102). Effects of the main classes of antihypertensive drugs upon the 
renin-angiotensin system. ACE, angiotensin converting enzyme; AT! receptor, Angiotensin II 
type 1 receptor.
3.1.4 Renin and Prorenin
Renin is synthesized as preprorenin, which is cleaved during translation to form prorenin, the 
immediate precursor of renin, by removal of a 23-amino-acid signal peptide (113, 114). The 
inactivity of prorenin is believed to be due to a 43-amino acid N-terminal propeptide, which covers 
the enzymatic cleft & prevents angiotensinogen from binding.
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The conversion of inactive prorenin to renin can occur by either proteolytic or non-proteolytic means 
(Figure 3-5). Proteolytic activation involves the cleavage of the propeptide segment by proteases 
and is irreversible. This processing is believed to be performed by a protease such as cathepsin B 
in the renin-producing cells of the juxtaglomerular apparatus (115). Non-proteolytic activation of 
prorenin is reversible, and is thought to involve the unfolding of the prosegment from the enzymatic 
cleft. It can be induced by exposure to cold (4degC) or low pH (pH=3.3) (116). It can also be 
induced by binding to certain proteins, such as the /V-acyl-D-glucosamine 2-epimerase (117), the 
mannose-6-phosphate receptor (118), or the prorenin/renin receptor (119). Kinetic studies have 
suggested that under physiological conditions, equilibrium between active & inactive prorenin 
exists. As inactivation is highly temperature-dependent, it occurs quickly under physiological 
conditions of 37°C and neutral pH. Under physiological conditions therefore, <2% of prorenin is in 
the ‘open’ (enzymatically active) form and >98% exists in the closed, inactive form (120).
prosegment
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(Inactive)
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y  (pro)renln receptor
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Binding to the 
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Figure 3-5. Proteolytic and Non-proteolytic activation of prorenin (from(121)). Aog, 
angiotensinogen; Ang, angiotensin.
Ang I
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3.1.5 The D is c o v e ry  o f th e  (P ro )R en in  R e ce p to r ((P)RR)
The existence of a prorenin receptor was suspected long prior to its discovery. Although (pro)renin 
has been found in a wide variety of human tissues (103-110), the (pro)renin gene appears to be 
expressed only in a sub-set of these tissues, although human studies are limited. In mice and rats, 
(pro)renin gene expression has been detected in adrenal glands, testis, and ovaries, liver, whole 
brain, and hypothalamus and, at lower levels, in spleen, thymus, lung, and prostate (103). In 
humans the gene has so far been found to be expressed in kidney, adrenal gland, placenta, and 
saphenous vein tissues (122). In tissues believed not to express the renin gene, e.g. heart and 
vascular wall, angiotensin generation must depend on (pro)renin uptake from the circulation.
Simple diffusion does not account for the relatively high levels of renin found in these organs (123), 
and it was proposed that a receptor-mediated mechanism make be responsible for the renin 
uptake.
Initially, the mannose 6-phosphate/insulin-like growth factor II receptor, M6P/IGF2R (118, 124), 
which non-selectively binds M6P-containing proteins such as renin and prorenin, was proposed as 
the receptor responsible. However, binding of (pro)renin to this receptor does not result in Ang II 
generation, and it is now believed that M6P is a clearance receptor (125).
The second receptor proposed to uptake circulatory renin was the (pro)renin receptor. It was first 
identified and cloned in vitro by Nguyen et al in 2002 (119). As the receptor specifically binds both 
renin and prorenin, it was named (pro)renin receptor ((P)RR). The ATP6AP2  gene, which encodes 
the (P)RR, is located on the X  chromosome at locus p11.4. The (P)RR  gene is 2044bp long, which 
is processed into a wild-type mRNA transcript containing 9 exons. This mRNA encodes a 350- 
amino-acid protein, which is highly conserved among species (126), Figure 3-6.
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Figure 3-6. Schematic structure of the (pro)renin receptor (adapted from (127)). The (P)RR  
is a single transmembrane type-1 receptor. It has a signal peptide (SP), indicative of a secreted 
protein; an extracellular domain (ED) responsible for renin and prorenin binding; a single 
transmembrane domain (TD) and a short cytoplasmic domain (CD) involved in the intracellular 
signalling.
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The (P)RR has been reported to bind equally well to renin and prorenin with high affinity (Kd=20nM) 
(119, 128). Renin and prorenin bound to the receptor are not internalized or degraded (129). The 
binding of renin and prorenin to the receptor is characterized by three, somewhat debated, events:
1. A number of studies report that binding to the (P)RR increases renin catalytic activity by a 
factor of 5 (119, 128). One study, however, by Batenburg et al found that renin does not 
bind to smooth muscle cells isolated from transgenic rats overexpressing (P)RR in that cell 
type at all (130).
2. All of the studies published so far have agreed that prorenin binds to the (P)RR, and that 
this increases its catalytic activity via non-proteolytic activation on receptor binding, 
whereby the molecule undergoes a conformational change in which the prosegment is 
opened, exposing the active site (119, 130). The amount of enzymatic activation that 
occurs on binding was originally reported to be >40%, compared to the basal -1% (131, 
132). However, the Batenburg study, although finding that prorenin does bind to the 
transgenic rat cells, report the amount of enzymatic activation that occurs on its binding to 
be much lower (2-fold over the basal (1% to 2%)), (130).
3. (Pro)renin binding to the (P)RR has been shown to trigger the activation of Ang-ll 
independent intracellular signalling pathways (Figure 3-7 and Figure 3-8). In 2006, Ichihara 
et al showed that the three members of the mitogen-activated protein kinases (MAPK) 
family known to be activated by Angll -mediated AT1 activation; extracellular signal- 
regulated kinases 1/2 (ERK 1/2), p38, and c-Jun N-terminal kinase (JNK) (133), remained 
activated (phosphorylated) even after inhibition of this pathway by ACE inhibition or AT1 
deletion in the kidneys of diabetic mice (134). The proposed mechanism for their residual 
phosphorylation was activation by (pro)renin binding to the (P)RR. (Pro)renin binding to the 
(P)RR has been shown to provoke the phosphorylation of ERK1/2 in cultured human 
mesengial (119) and monocyte (135) cells, and to upregulate expression of ERK 1/2- 
regulated profibrotic molecules such as TGFp, plasminogen activator inhibitor-1 (PAI-1), 
collagen I, and fibronectin (136-138). The receptor may also activate the MAP kinase p38- 
heat shock protein 27 cascade, as suggested by the fact that prorenin has been shown to 
concentration-dependently activate p38 MAPK and simultaneously phosphorylate HSP27 in 
rat cardiomyocytes (138). In addition to activation of MAPK pathways, (P)RR signaling may 
act as a negative feedback pathway. A number of experiments by Schefe et al (139) have 
suggested that on activation of the (P)RR, the transcription factor promyelocytic zinc finger 
(PLZF) is translocated to the nucleus and represses transcription of the (P)RR itself, 
allowing high (pro)renin levels to suppress (P)RR expression, preventing excessive
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receptor activation. As promyelocytic zinc finger is also involved in Ang II AT2 receptor 
signalling (135), it has been proposed that prorenin/renin signalling provides for cross-talk 
to Ang II-AT2 receptor signalling, however this assertion needs to be further defined. 
Although there is a substantial amount of experimental support for this, how exactly 
renin/prorenin binding to the (P)RR triggers MAPK signalling is unknown, and difficult to 
visualize given that the (P)RR is not a signalling receptor.
renin prorenin
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Figure 3-7. Potential (pro)renin-induced effects mediated via the (pro)renin receptor ((P)RR), 
which do not involve Angiotensin generation (adapted from(121)). It has been proposed that 
(P)RR activation by (pro)renin activates the mitogen-activated protein kinase (MAPK) signaling 
pathways p42/44 (ERK 1/2)/Transforming growth factor p (TGFP), leading to upregulation of 
profibrotic molecules such as TGF/3, plasminogen activator inhibitor-1 (PAI-1), collagen I, and 
fibronectin and the p38-heat shock protein 27 (HSP27) cascade, which regulates of actin filament 
dynamics. The (P)RR is also proposed to regulate its own expression, via the promyelocytic zinc 
finger (PLZF) signalling pathway, that functions as a negative feedback loop.
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Figure 3-8. The two faces of the (pro)renin receptor (from(140)). Activation of the Angll- 
dependent pathway is widely accepted to lead to organ damage and fibrosis. The in vivo 
consequences of activation of the Ang-ll independent pathway remain to be defined. ERK1/2, 
extracellular signal-regulated kinases 1/2, also known as p42/44; HSP27, heat shock protein 27; 
The Phosphatidylinositol 3-kinase (PI3K)-p85 pathway refers to the promyelocytic zinc finger 
(PLZF) signalling pathway mentioned in Figure 3-7; TGFIJ, transforming growth factor IS; PAI-1, 
plasminogen activator inhibitor-1; HRP, handle region peptide, hypothesised to prevent (pro)renin 
binding to the (P)RR (section 3.1.6).
3.1.6 Investigation of (P )R R  b lockade with the Handle R eg io n  Peptide (H R P)
Although the important finding that the (P)RR increases renin activation and allows the activation of 
(pro)renin is unrefuted, exactly how prorenin and renin bind to (P)RR has not yet been resolved. It 
has been proposed that (P)RR binds to a specific part of the prosegment, called the ‘handle region’ 
(141), upon which (pro)renin becomes catalytically active. Hypothetical peptidic antagonists, known 
as ‘handle region peptides’ (HRPs, also known as PRRB/PRAM-1) have been developed. They are 
proposed to mimic the handle region and thus bind competitively to the receptor, preventing 
(pro)renin binding (Figure 3-9).
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A number of in vivo studies support the role of the H RP as a therapeutic (P )R R  antagonist, largely 
from Ichihara and his collaborators (134, 142-144). Whether the observed effects of H RP infusion 
are due to the effect of prorenin binding blockade on Ang-ll levels, and/or to an Ang-independent 
mechanism, remains to be understood. HRP infusion has been shown to normalize the elevated 
renal Ang II content in diabetic rats, preventing development of diabetic nephropathy without 
affecting blood pressure (143). It has also been shown to normalize the elevated cardiac Ang II 
content in stroke-prone spontaneously hypertensive rats, preventing cardiac fibrosis without 
affecting blood pressure (142). These data suggest that these phenomena depended on prorenin- 
induced tissue Ang II generation. Susie et al (145) repeated the test of HRP in spontaneously 
hypertensive rats and found that it considerably reduced serum creatinine, left ventricular mass, and 
cardiac fibrosis and improved cardiac function without affecting blood pressure in rats fed a high- 
salt diet. The same group have reported that all of the negative effects of a high-salt diet on renal 
blood flow, urinary albumin excretion, and glomerular filtration rate in spontaneously hypertensive 
rats disappeared if the animals were treated with an angiotensin receptor blocker (146) implicating 
Ang II in the kidney pathology. Matavelli et al (147) also recently revisited the role of H RP in 
diabetic nephropathy, and found that both an angiotensin receptor blocker (valsartan) and HRP 
reduced urinary albumin and renal inflammatory markers in diabetic rats, suggesting again that the 
effects are mediated by reduced Ang-ll generation.
Another study from the Ichihara group, however, indicates that the beneficial effects of the H RP are 
independent of Ang-ll generation. H RP was found to be effective in reversing diabetic renal 
damage in mice with inactivation of the AT1 receptor (134), despite the fact that in these animals 
Ang II has been shown unable to exert its normal effects (148). This lead to the suggestion that the 
signalling mechanism of (P )R R  was independent of Ang II. However, mice express two AT1 
receptors (AT1a and AT1b), and the presence of the AT1b receptor in AT1a-deficient mice still 
allows for the possible contribution of Ang II signalling in these pathologies.
More recent in vivo studies, however, have failed to replicate any of the earlier therapeutic effects of 
HRP. Muller et al, 2008 (149) showed that chronic HRP treatment failed to improve Ang-ll 
dependent target organ damage in renovascular hypertensive Goldblatt rats. Another group 
showed HRP infusion did not reduce blood pressure in mice with elevated circulating prorenin 
(150). Feldt et al., 2008 (151) showed HRP to be ineffective in double transgenic rats expressing 
both human renin and human angiotensinogen.
The use of cell culture models in vitro have also produced conflicting results regarding the action of 
the HRP. Although it has been reported that H RP displaces both renin and prorenin from (P)RR  
with an inhibition constant of 7nM (131), recent reports have been unable to confirm that H RP
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blocks either prorenin binding or signalling through (P )R R  in cultured cells (130, 135, 151). 
Furthermore, H RP did bind to cells which expressed a (P )R R  variant lacking the region which the 
HRP supposedly binds to (135). These results challenge the concept that H RP acts as a specific 
(P )RR  antagonist.
Thus, the prorenin prosegment-derived peptides (HRP, PRRB, and PRAM-1) have a mode of action 
that is still difficult to discern from either cell culture or whole animal studies. It is, in fact, difficult to 
conceive how HRP, a peptide analogous to a portion of the prorenin prosegment, can compete for 
binding of renin, which does not contain the prosegment (Figure 3-9). Possibly, the in-vivo effects 
of HRP involve an alternative, as yet unknown mechanism, unrelated to the (pro)renin receptor.
I  *
angiotensin-independent effects
Figure 3-9. From (120). Model depicting prorenin activation by the (pro)renin receptor, 
allowing prorenin to generate angiotensin I from angiotensinogen. In addition, prorenin 
binding to the receptor results in effects (intracellular signalling) that are independent of angiotensin 
generation. HRP is assumed to block both prorenin activation and the direct prorenin induced 
effects.
3.1.7 Other roles of the (P )R R
It is becoming increasingly obvious that the (P)RR  does more than bind renin and prorenin. (P)RR  
is ubiquitously expressed in humans, and attempts to inactivate the gene for (P )RR  in the mouse 
result in pre-implantation lethality of the embryo (126). In contrast, inactivation of the renin- 
angiotensin system components (e.g., angiotensinogen, renin, or A C E ) in the mouse does not 
result in embryonic lethality (152).
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The additional role(s) of the (P)RR are likely to involve its role as a critical component of vacuolar 
proton-transporting ATPase (v-H+-ATPase). Although it was originally reported that (P)RR had no 
homology with any known membrane protein (119), it has since been realized that the coding 
sequence of (P)RR is identical to that of ATP6AP2, an accessory protein to v-H+-ATPase (153), 
Figure 3-10 . The role of the v-H+-ATPase is to acidify intracellular vesicular bodies including 
endosomes and lysosomes, as well as to acidify urine in the collecting ducts.
A recent study (154) has revealed that the (P)RR is a component of the Wnt receptor complex. 
Wnt/b-catenin signalling is important in stem cell biology, embryonic development, and disease, 
including cancer. (P)RR functions in a renin-independent manner as an adaptor between Wnt 
receptors and the v-H+-ATPase complex.
A mutation in A TP6A P2  in humans which results in a frame deletion of exon 4 leads to mental 
retardation and epilepsy ((154). This same A4 mutation has also been shown to lead to 
redistribution of (P)RR in neuronal cells (155).
It is possible therefore that the (P)RR is involved in a multitude of cellular functions, and that only 
part of the (P)RR produced which makes it to the cell surface binds renin and prorenin.
In addition to its role as a binding partner for v-H+-ATPase, it has recently been discovered that the 
(P)RR can be cleaved by furin to release a renin-binding form into the circulation (156) (Figure 
3-10). The biological function of such a soluble (P)RR is unknown.
Some of these additional roles of the (P)RR may have cardiovascular effects independent of the 
role of the (P)RR in BP regulation. One study has shown that in rats recombinantly expressing the 
human (P)RR, the (P)RR contributes to the regulation of renal cortical COX-2 expression (157).
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Figure 3-10. Schematic representation showing the three proposed roles of (P)RR/ATP6AP2. 
Adapted from (158). First, (P)RR exists as a dimer on the cell surface and can bind renin, 
prorenin, and peptides corresponding with a portion of the prorenin prosegment (HRP, PRRB, and 
PRAM-1 ). Binding of renin and prorenin triggers the phosphorylation of MAPKs. Shown in white 
boxes are the binding affinities of rat renin and human prorenin, as well as the calculated inhibitory 
constant for HRP (data are from References 12 and 13). The red box in the prorenin prosegment 
shows the location of the peptide sequence corresponding to HRP. Second, (P)RR may also be 
cleaved by furin to release a renin/prorenin-binding protein in the circulation. Third, (P)RR is 
identical to ATP6AP2, a protein that associates with vacuolar-type H_-ATPase. It is not clear 
whether (P)RR exists as a monomer or dimer in the second and third roles.
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3.1.8 The role of the (Pro)Renin Receptor in the Renin Angiotensin System
The discovery of the (P)RR has revolutionized the way in which the RAS is viewed. The discovery 
of the (P)RR has provided a new molecular basis for a functional role of prorenin, as well as 
increased renin activation. This may lead to a better understanding of tissue angiotensin 
production. It could also have therapeutic potential, as it may be that an effective (P)RR inhibitor 
would be far more potent as a blocker of tissue angiotensin generation than the renin inhibitors 
currently available. Much work still needs to be done however, such as developing (pro)renln 
receptor antagonists other than the HRP to confirm the beneficial findings of (P)RR blockade in 
animal models. The role of the (P)RR in the RAS is likely go beyond angiotensin generation, 
however. The discovery of the Angll independent signalling mediated by the (P)RR adds exciting 
new information and a new level of complexity to the RAS.
3.1.9 Human G enetic Stu d ie s
The results of the first, and only, candidate gene association study published to date to Investigate 
the (pro)renin receptor were published in 2009 (159). The (P)RR gene was sequenced in 60 
Japanese women (Figure 3-11), and a subset of the 11 polymorphisms found were genotyped in a 
larger Japanese population. They found that a SNP in intron 5 of the (P)RR gene, rs5918007, was 
associated with ambulatory BP in a relatively small (N=357) population of Japanese men (Table
3-3). No association was found between the same SNP and ambulatory BP in women. As the 
(P)RR gene is situated on the X chromosome, the authors suggest that the effects of Lyonisation 
and/or the effects of sex hormones on (P)RR may effect this apparent gender-specificity. However, 
replication studies are needed to establish the verity of these apparent gender-specific effects.
This study showed for the first time the potential importance of the (P)RR gene in BP regulation in 
humans.
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Figure 3-11. Polymorphisms in the (P )R R  gene in Japanese women (n = 60). Adapted from 
(159). White boxes and black boxes indicate the non-coding regions and coding regions, 
respectively. Two-headed arrows under the boxes indicate the regions sequenced. (+1) indicates 
the initiation site of mRNA transcription. IVS, intervening sequence.
Table 3-3. Clinical characteristics and BP values according to the alleles of IVS5+169C>T in 
men. Adapted from (159).
Adjusted
C(n = 310) T(n=47) Pvalue P value
Clinical characteristics
Age, years 60.7 ±9,6 63.4±9.5 0.07
Body mass Index, kg/m2 23.3±2.8 23.3 ±2.6 1
Antihypertensive 
medications, %
35.2 46,8 0.1
Hypertension, % 49.4 61.7 0.1
Cardiovascular disease, % 13.9 12.8 0.8
Ambulatory blood pressure
24-h systolic, mm Hg 12S.0±11.6 131.4±14.6 <0.001* 0.006
24-h diastolic, mmHg 73.9±6.9 77.7±8.3 <0.001* 0.003
Daytime systolic, mm Hg 130.5±12.6 136.5±)62 0.004 0.02
Daytime diastolic, mm Hg 78.0±7.S 81.4±9.2 0.006 0.02
Nighttime systolic, mmHg 114.4±12.8 121.5±14.6 <0.001* <0.001*
Nighttime diastolic, 66.1 ±7.1 70.4±7.7 <0.001* <0.001*
mmHg
Ambulatory blood pressure
Systolic, mmHg 136/4 ±17.0 138.0 ±20.4 0.5
Diastolic, mmHg 76.9 ±10.6 75.8±11.5 0.5
Continuous values are expressed as mean ± s.d. Adjusted P values: adjusted for age, 
body mass index, use of antihypertensive medications, prevalence of diabetes melliius, 
history of previouscardiovascular disease, currentsmoking and current drinking.
IVS, intervening sequence.
‘ Differences of P < 0.001 (=0.05/48) were considered statistically significant after 
Bonferrani correction.
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As mentioned in Chapter 1, two large-scale GWAS recently published associations between genetic 
polymorphisms and BP (80, 81). However, most of the genotyping chips used for these studies did 
not provide information on variation in the (P)RR gene in European populations (Figure 3-12).
3.1.10 Stu dy H ypotheses
The newly-discovered (P)RR plays an important role in the RAS as a binding partner of (pro)renin; 
upregulating renin enzymatic activity and allowing activation of the inactive prorenin, aswell as 
possibly mediating tissue uptake of (pro)renin. This group has previously demonstrated 
associations between genetic variation in the (pro)renin gene and BP variation and response to 
anti-hypertensive treatment, and it is hypothesized here that genetic variation in the gene encoding 
the (pro)renin receptor may also be associated with these phenotypes. In addition, it was 
hypothesized that genetic variation in the (P)RR gene may affect mRNA transcript levels , as 
quantified by real-time PCR. As human kidney samples were unavailable for this study, and as 
immunostaining of the adrenal gland has previously shown high levels of the (P)RR protein in the 
adrenal medulla and in the adipose tissue around the adrenal glands (160), it was decided to 
conduct this analysis using human adrenal tissue.
Specifically, the hypotheses tested in this chapter were:
1(a). Genetic variation in the (P)RR gene, including a 20kb upstream promoter region, is 
associated with variation in blood pressure in a European population.
1(b). Genetic variation in the (P)RR gene, including a 20kb upstream promoter region, is 
associated with response to RAS blockade in a European population.
1(c). Genetic variation in the (P)RR gene, including a 20kb upstream promoter region will affect 
mRNA levels in human tissue samples.
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3 . 2  M a t e r i a l s  a n d  M e t h o d s
3.2.1 S tu d y  P o p u la t io n s
We tested for associations between SNPs in the gene encoding the (P)RR and BP level in two 
healthy populations, Healthy Population I and Healthy Population II. We tested for associations 
between SNPs in the gene encoding the (P)RR and response to anti-hypertensive therapy in a 
hypertensive, clinical trial population (Hypertensive Population). We tested for associations of 
transcript levels of the (P)RR with genotypes in a renal transplant population (Transplant 
Population).
AIB II (Healthy Population I): This population was comprised of 387 individuals who participated 
in the first two phases of the AIB (Allied Irish Bank) study. The AIB I study recruited 815 current 
and retired Caucasian bank employees and their spouses aged between 18 and 80 years between 
1989 and 1991 (161). All participants were free of diagnosed hypertension and vasoactive drugs 
when recruited. At the baseline (phase I) examination, age, gender, smoking habit, alcohol 
consumption, salt intake, past medical history, current drug treatments, height, weight, clinic and 
24-hour ambulatory blood pressures were recorded. Between 1996 and 2001, after a mean interval 
of 8.4 years, 441 subjects responded to a written invitation to undergo repeated assessments 
(phase II). At this time, only four subjects were taking antihypertensive medication, and these 
discontinued therapy one week prior to the phase II assessments. At the phase II examination, all 
phase I measurements were repeated, and in addition blood was drawn for biochemical 
measurements and for the extraction of DNA. 9 participants were excluded because of technically 
unsatisfactory ABPM recordings, and 45 participants were excluded because DNA extraction was 
unsuccessful. All remaining individuals (N=387) were included in this study population. All subjects 
provided written informed consent to each phase of the study, which was approved by the 
Beaumont Hospital Research Ethics Committee.
AIB III (Healthy Population II): This population was comprised of 1022 healthy volunteers who 
took part in phase III of the Allied Irish Bank blood pressure study. The AIB III study recruited 
current and retired Caucasian bank employees and their spouses aged between 18 and 80 years 
between June 2003 and June 2004. All participants were free of diagnosed hypertension and 
vasoactive drugs when recruited. Age, gender, smoking habit, alcohol consumption, salt intake, 
past medical history, current drug treatments, height, weight and clinic blood pressure were 
recorded. Blood samples were drawn for biochemical measures and for the extraction of DNA. All
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subjects provided written informed consent. The study protocol was approved by the Beaumont 
Hospital Research Ethics Committee (REC# 03/27).
Hypertensive Population: The subjects of this population were recruits to a randomized, double­
blind, active comparator, parallel group, BP lowering trial. Methods and study design have been 
described in detail elsewhere (162). Briefly, 345 White patients, aged between 21 and 70 years, 
with mild-to-moderate hypertension were recruited from 5 hospital outpatient clinics in Ireland. 
Participants were required to have an off-treatment average daytime systolic ABPM >140 mm Hg, 
and were not eligible if they had secondary hypertension, malignant hypertension, diabetes mellitus, 
coronary artery disease, or cerebrovascular disease. After an antihypertensive drug free period of at 
least 2 weeks, the patients were randomly assigned to receive 37.5 mg, 75 mg, 150 mg, or 300 mg 
aliskiren, or 100 mg losartan, daily for 4 weeks. Clinic BP measurement and ABPM were performed 
at baseline and after 4 weeks of study treatment. Blood chemistry, plasma renin activity (PRA), and 
aliskiren levels were measured from venous blood samples drawn from the patients while seated, at 
baseline and 24 hours after the last dose of randomized study treatment. Two hundred and fifty- 
nine individuals provided an additional blood sample at baseline for DNA extraction and anonymous 
genotyping—of these 47 were not randomized to study treatment, 44, 44, 41, and 43 were assigned 
to 37.5 mg, 75 mg, 150 mg, and 300 mg aliskiren, respectively, (‘ALISKIREN’ group) and 40 were 
assigned to 100 mg losartan (‘LOSARTAN’ group). All participants provided written informed 
consent both for the clinical trial and for further genetic analyses concerning cardiovascular 
disease. The study protocol was approved by the Beaumont Hospital Research Ethics Committee 
(REC# 00/07).
Transplant Population: Whole human adrenal glands were collected from 20 donors following 
kidney transplants at Beaumont hospital. Informed assent was acquired for the use of organs or 
tissues unsuitable of transplantation for research purposes from the next-of-kin in each case.
Ethical approval was granted by the by the Beaumont Hospital Research Ethics Committee (REC# 
07/64) for these acquisitions. Whole adrenal glands were trimmed and dissected into ~9 equally 
sized cross-sectional slices, frozen immediately in liquid nitrogen & stored at -80°C.
3.2.2 Blood P ressu re  and Laboratory M easurem ents
Three different measurements of blood pressure were assessed in this study; systolic blood 
pressure (SBP), a measure of the peak pressure in the arteries occurring near the beginning of the 
cardiac cycle; diastolic blood pressure (DBP), a measure of the lowest pressure (at the resting
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phase of the cardiac cycle); and pulse pressure (PP), the arithmetic difference between systolic 
blood pressure (SBP) and diastolic blood pressure (DBP). There is evidence to suggest that pulse 
pressure (PP) is a more accurate predictor of risk of coronary heart disease (CHD), particularly in 
middle-aged and older subjects, than either SBP or DBP alone (163).
Sitting clinic BP was measured from the right arm using a regularly calibrated validated automated 
sphygmomanometer (Omron HEM-705CP) (AIBIII & Speedel), or a mercury sphygmomanometer 
(AIBII). Blood pressure was measured in the brachial artery 3 times at 5-minute intervals. The 
mean of the last 2 measurements was recorded as representative of clinic BP. Ambulatory BP 
measurements were made every half-hour throughout a 24-hour period using validated oscillometric 
90202 or 90207 SpaceLabs recorders (SpaceLabs, Wokingham, Berkshire, UK). Mean daytime 
(mean of all measurements between 0900 and 2100 hours), and night-time (mean of all 
measurements between 0100 and 0600 hours) systolic and diastolic pressures were calculated for 
each individual for each phase. For AIBII, both the phase I and phase II, clinic, daytime and night­
time, BP measurements were included in the analyses models.
3.2.3 Selection of Tag  S N P s
It was decided to use the information provided by the International Hapmap Project 
(www.hapmap.org) to guide the selection of SNPs to be genotyped in this project. Only SNPs with 
a MAF (minor allele frequency) of 5% or above in European populations were considered, as the 
study size did not provide good power to detect differences in BP associated with variants present 
in the population at a frequency of less than 5%. 21 SNPs with MAF >0.05 in the (P)RR gene and 
20kb upstream promoter region were genotyped & found to be polymorphic in European 
populations in Hapmap Build 3. Eight tagging SNPs which captured variation across all 21 Hapmap 
SNPs completely (r2 =1) were genotyped (Table 3-4). In addition, the SNP found to be significantly 
associated with BP in a Japanese population, rs5918007 (159), was genotyped and found to be 
polymorphic in this Irish population (MAF=0.11).
Figure 3-12 shows a screenshot of the (P)RR gene and 20kb upstream from The International 
Hapmap Project website, with SNPs genotyped/tagged in this study (r2 =1) indicated by pink 
symbols. SNPs which are genotyped on or tagged by the four common genome-wide genotyping 
chips are also indicated. None of the SNPs in the upstream region are genotyped on or tagged by 
the genome-wide chips. In the genic region, 7 of the 10 SNPs polymorphic in European
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populations (MAF >0.05) are genotyped on or tagged by the lllumina 1M chip, but are not covered 
by any of the other genome-wide SNP chips.
Figure 3-13 shows a graphic representation of the linkage disequilibrium (LD) between the 9 
genotyped SNPs in all three study populations merged. Two markers which are always inherited 
together are said to be in total LD, and typically have a pairwise correlation (r2 value) of 1, indicated 
in this graphic by a dark red colour, r2 values below 1 indicate partial LD. It is evident from this 
graphic that the 5 downstream SNPs form a strong LD block, and are all well correlated (r2>0.7) 
with each other. SNPs in the upstream prompter region very poorly correlated with this block 
(^<0.4), and less well-correlated with each other.
Table 3-4. All HapMap SNPs which were polymorphic in the CEU population (MAF>0.05) 
within the region chrX, position 40305160-40350830 (encompassing the (P)RR gene plus 
20kb upstream). 8 tagging SNPs (Tag 1-8) capture 21 of 21 alleles at r2 = 1.0.
Tag SNPs SNP Name Chromosome Position MAF
Tag 1 rs6610426 chrX 40305187 0.07
Tag 2 rs5917375 chrX 40308560 0.06
Tag 3 rs7886010 chrX 40308910 0.19
Tag 4 rs5918002 chrX 40310103 0.08
rs5963806 chrX 40312262 0.09
Tag 5 rs12836816 chrX 40313348 0.09
rs 12860626 chrX 40313446 0.08
rs4827038 chrX 40313555 0.08
rs4240044 chrX 40313608 0.07
rs884563 chrX 40314854 0.08
Tag 6 rs5963807 chrX 40315973 0.07
rs2971599 chrX 40323653 0.07
rs2968915 chrX 40324378 0.09
rs2968917 chrX 40327762 0.08
Tag 7 rs3112296 chrX 40329375 0.09
rs2968919 chrX 40334206 0.09
rs3112298 chrX 40338848 0.07
rs3111731 chrX 40339517 0.09
rs3111732 chrX 40340675 0.07
Tag 8 rs3112299 chrX 40341905 0.06
rs5918008 chrX 40345503 0.07
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F ig u re  3 -1 2 . S c re e n s h o t o f  th e  (P )R R  g e n e  a n d  2 0 k b  u p s tre a m  fro m  T h e  In te rn a t io n a l H a p m a p  P ro je c t  
w e b s ite  (w w w .h a p m a p .o rg ). All S N P s  geno typed in phases 1 -3  a re  included. T h e  J a p a n e s e  S N P , 
rs 5 9 1 8 0 0 7 , w as  not geno typed as part o f H a p M a p  but its location is indicated in th e  plot. T h e  red and blue  
shaded  rectangles indicate re lative a lle le  frequ en c ies  o f m ajor and  m inor a lle les  in th e  population g eno typed  as  
part o f th e  H ap m ap  project. This plot indicates with arrow s S N P s  included on th e  tw o m ost com p reh ens ive  
genotyping chips used in G W A S  studies, lllum ina 1 M -D u o  and A ffym etrix  6 .0 , w ith ap p ro x  1 million S N P s  
each . S N P s  which w ould b e  tag g ed  by th e se  S N P s  (b ased  on H a p M a p  LD  estim ates ) a t ^ = 0 .8  a re  also  
indicated. T h e  equ ivalen t 5 0 0 ,0 0 0 -S N P  chips do not include a n y  S N P s  in th is region. S N P s  g eno typed  in this 
study and S N P s  which th ey  tag g ed  (^ = 0 .8  based  on H a p M a p  LD  e s tim a te s ) a re  indicated with pink m arkers. 
T h e  (P )R R  g en e , also called A T P 6 A P 2 , Is indicated along with th e  E nsem bl accession num ber. Population  
descriptors: A S W  (A): African an ces try  in S o u th w est U S A ; C E U  (C ): U tah  residents with N orthern  and  
W estern  E uropean ancestry  from  th e  C E P H  collection; C H B  (H ): H an  C h in e s e  in Beijing, C hina; C H D  (D ): 
C h in ese  in M etropolitan D en ver, C olorado; G IH  (G ): G ujarati Indians in H ouston, T exas ; J P T  (J): J a p a n e s e  in 
Tokyo , Japan; L W K  (L): Luhya In W e b u y e , K enya; M E X  (M ): M ex ican  an ces try  in Los A n g eles , California; 
M K K  (K): M aasa i in K inyaw a, K enya; T S I (T ): T o scan s  in Italy; Y R I (Y ): Y o ru b a  in Ibadan , N igeria .
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Figure 3-13. Linkage Disequilibrium (LD) between each of the 9 genotyped SNPs, based on 
merged data from the 3 study populations. Colours represent r2 values between SNPs, with red 
indicating total correlation (r2=1).
3.2.4 Genotyping
Genotyping of the 9 chosen SNPs in Healthy Populations I and II and the Hypertensive Population 
was performed at K Biosciences genotyping facility, Herts, UK, using the KASPar genotyping 
system. Genotyping calling was done using the Kluster software. The overall genotyping call rate
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was 98.5%. Quality control was performed as outlined in Table 3-5, resulting in a final combined 
population of 1,613. All 9 SNPs passed quality control.
Table 3-5. Quality control procedure and exclusions for the 9 chosen (P)RR SNPs in Healthy 
Populations I and II and the Hypertensive Population. *As the gene encoding the (P)RR is 
situated on the X chromosome, Hardy-Weinberg P-values were calculated using females only.
Sample Exclusions: S tarting  sam ple n u m be r N=1619
Sample call rate: Excluded samples with genotyping call rate <95% (N=5) N=1614
Sample dup lica tes:
All declared and hidden blanks were correctly called (N=1026). Of 124 
hidden sample duplications, 122 were consistent, giving an error rate of 
0.8%. The inconsistent duplications were excluded from analysis (N=l). N=1613
Sex check:
Excluded samples with X chromosome heterozygosity inconsistent with 
phenotypic sex (N=0). N=1613
Sample re la tedness: Too few SNPs genotyped to check N=1613
SNP Exclusions: S ta rting  SNP nu m be r N=9
SNPcall ra te : Excluded SNPs with low (<95%) genotype call rate (N=0) N=9
Hardy-Weinberg: Excluded SNPs with Hardy-Weinberg P <10'06 (N=0)* N=9
Genotyping of the 9 (P)RR SNPs in the Transplant Population was also performed at K Biosciences 
genotyping facility, Herts, UK, using the KASPar genotyping system. Genotyping calling was done 
using the Kluster software. The overall genotyping call rate was 97%. Quality control was 
performed as outlined in Table 3-6, resulting in a final population of 19. All 9 SNPs passed quality 
control.
Table 3-6. Quality control procedure and exclusions for the 9 chosen (P)RR SNPs in the 
Transplant Population. *As the gene encoding the (P)RR is situated on the X chromosome, 
Hardy-Weinberg P-values were calculated using females only.
Sample Exclusions: S ta rting  sam ple nu m be r N=19
Sample call rate: Excluded samples with genotyping call rate <95% (N=0) N=19
Sample duplicates:
All declared and hidden blanks were correctly called (N=12). Of 9 hidden 
sample duplications, 9 were consistent, giving an error rate of 0%. N=19
Sex check:
Excluded samples with X chromosome heterozygosity inconsistent with 
phenotypic sex (N=0). N=19
Sample re la tedness: Too few SNPs genotyped to check N=19
SNP Exclusions: S tarting  SNP n u m be r N=9
SNP call ra te : Excluded SNPs with low (<95%) genotype call rate (N=0) N=9
Hardy-Weinberg: Excluded SNPs with Hardy-Weinberg P <10‘OB (N=0)* N=9
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3.2.5 Association Analysis
The association analysis was performed using Plink statistical software 
(http://pngu.mgh.harvard.edu/purcell/plink/) and R statistical software (http://cran.r-project.org/), 
both of which are freely available. Linear regression models were fit for each of the clinical 
endpoints (SBP, DBP and PP) and adjusted for the covariates indicated in the legend of each table. 
No minor allele filter was imposed on SNPs in this study. All SNPs were present in study 
populations at a frequency of at least 5%.
This paragraph pertains to the assessment of the association between (P)RR polymorphisms and 
BP response to treatment with anti-hypertensives (section 3.3.4). Clinic and ambulatory ‘baseline’ 
BP were measured in the hypertensive population following an antihypertensive drug free period of 
at least 2 weeks. Clinic and ambulatory 'on treatment’ BP were measured again following 4 weeks 
of randomised treatment (as described in section 3.2.1). Response to treatment was measured as 
[baseline BP]- [on-treatment BP], so that positive values indicate a drop in BP. In studies such as 
these, where the phenotype of interest is change from baseline, it is important to ensure that the 
phenotype is not dictated by the baseline score. This is especially pertinent when baseline score is 
well-correlated with change from baseline, as is the case with BP response to anti-hypertensives. 
Controlling for baseline score is accomplished by including baseline score in the analysis model. 
Simulation has illustrated that the inclusion of baseline score as a covariate has the highest 
statistical power of all of the possible methods (164).
The fact that the (P)RR gene is located on the X-chromosome presents some complications for the 
analysis of data such as these. X-inactivation is a process by which one of the two copies of the X 
chromosomes present in females is inactivated by packaging into transcriptionally inactive 
heterochromatin, thereby preventing the female having twice as many X chromosome gene 
products as the male. This process occurs at random in humans, with the paternal or maternal 
allele randomly ‘chosen’ for inactivation in each cell type. This means that for heterozygotic female 
minor allele carriers, expression of one allele may be skewed over that of the other. It may be that 
males, in whom X-inactivation does not occur, may provide a more reliable model of (P)RR gene 
associations than females, especially if many of the females are heterozygotic for the tagging 
SNPs. Because of the (P)RR gene location on the X chromosome, sex-specific analyses were 
performed aswell as whole-population sex-adjusted analyses.
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3.2.6 Realtime PCR
The frozen tissue was ground at -80°C in a sterile mortar and pestle. Total RNA was extracted from 
the ground tissue using QIAGEN RNeasy Plus Mini kit, according to the protocol supplied. DNA 
was extracted using QIAGEN QIAamp DNA blood Midi kit according to the protocol supplied.
Real-time PCR was used to quantify mRNA transcript levels, using the Taqman system. Whole 
RNA was first transcribed to mRNA, and then primers specific to certain parts of the mRNA 
transcript were used to amplify the RNA for quantification. The ATP6AP2 gene is known to undergo 
alternative splicing (Figure 3-14), and a number of different splice variants are predicted ((154), 
Figure 3-15). Because of this, we used two sets of primers, each pair amplifying different portions 
of the mRNA (Figure 3-16). These primers were designed by Applied Biosystems for use with the 
Taqman reporter system. Both primers used were designed to span an exon junction and should 
not therefore detect genomic DNA. Details of the two primers and identification numbers are given 
below, and their genic locations can be seen on Figure 3-16.
Primer 1 (Applied Biosystems Hs00366626_m1): Amplicon length 120bp, amplifies exons 1-2. 
Primer 2 (Applied Biosystems Hs00997145_m 1): Amplicon length 141bp, amplifies exons 8-9.
Eicon Ex<*n Exon Emmi Exon
Protein A Protein B Pioiein C
Figure 3-14. Alternative Splicing. From (165). A single gene can produce multiple related 
proteins, or isoforms, by means of alternative splicing.
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ENSP00000467051 Exon« 2TwiltriptlWflthi 322 bps Knowi processed transcript
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Figure 3-15. Predicted ATP6AP2 mRNA transcripts (from www.ensembl.org). Several 
different mRNA transcripts of the (P)RR are known to be produced from the gene due to alternative 
splicing. These mRNA transcripts are translated to produce functional protein isoforms, some of 
which lack the transmembrane and intracellular domains. A splice variant which excludes exon 4 
has been shown to be associated with X-linked retardation and epilepsy (154).
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Exon/lntron structure of ATP6AP2 RNA
Primer: 1F 1R 2F 2R
RNA Splicing -> mRNA, 
Translation
1 2 3 4 5 6 7 8 9
L-pJ I_________________
signal peptide topological domain
extracellular
Protein domain structure of ATP6AP2
Figure 3-16. Structure of ATP6AP2 RNA and protein. The location of the two primer sets which 
were used for rtPCR are indicated. 1F: Primer 1 forward, 1R: primer 1 reverse (Hs00366626_m 1 ), 
2F: primer 2 forward, 2R: primer 2 reverse (Hs00997145_m1).
------T------i
transmembrane topological domain 
domain cytoplasmic
The quantitative endpoint for real-time PCR is the threshold cycle (CT), the point during PCR cycling 
at which amplification of the PCR product is such that the fluorescent signal of the reporter dye 
crosses an arbitrarily placed threshold. The larger the starting quantity of the target molecule, the 
earlier a significant increase in fluorescence is observed. The parameter CT is defined as the 
fractional cycle number at which the fluorescence generated by cleavage of the probe passes a 
fixed threshold above baseline.
The precise amount of total RNA added to each reaction and its quality are both difficult to assess. 
For this reason, transcripts of the gene coding for 18S ribosomal RNA (rRNA) were also quantified 
as an endogenous RNA control, and each sample was normalized on the basis of its 18S rRNA 
content. 18SrRNA is the structural RNA for the small eukaryotic ribosomal subunit (40S), and thus 
one of the basic components of all eukaryotic cells.
Gene expression was quantified using relative quantification, or the ‘comparative CT’ method, where 
the data are presented relative to another gene, often referred to as an internal control. This 
method assumes that the efficiency of the PCR is close to 1 and that the PCR efficiency of the 
target gene is similar to the internal control gene.
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Total RNA was extracted from the cell lines indicated using the RNeasy mini kit (QIAGEN, Crawley, 
UK) according to the manufacturer’s instructions, RNA was finally eluted in diethylpyrocarbonate- 
treated water (30^ 1) and stored at -80°C. The quantity and quality of the extracted RNA was 
confirmed by absorption measurements at 260 and 280 nm. Single-strand cDNA was synthesized 
using 1fjg RNA using the ImProm II reverse transcriptase kit (Promega), in a total volume of 20|jl.
For quantitative real-time PCR, 2|j| cDNA was loaded in a 96-well plate with 10(jl TaqMan Gene 
Expression Master mix (Applied Biosystems), 1pl primer mix (Applied Biosystems) and 7pl PCR- 
grade water. Amplification was carried out in a 7500 Fast Real-time PCR System (Applied 
Biosystems) as follows: a preincubation step at 95°C for 10 min was followed by 40 cycles of 
denaturation at 95°C for 20 sec, annealing at 60°C for 30 sec, and elongation at 72°C for 30 sec. All 
samples were normalized for 18S rRNA expression levels.
All samples were assayed in triplicate. The mean CT values of the 18S endogenous controls for 
each sample were within the range 12.7-14.3 for 18 of 20 samples assayed. The two samples for 
which this was not the case were excluded from further analysis. Within-replicate standard 
deviation of CT values was consistently <0.05 for each of the primers used. The reference sample 
was chosen as the sample for which ACT (CT for the ATP6AP2 assay- CT for the endogenous 
control) was closest to the population mean value, and in this population was sample ADR018. AA 
CT was calculated as the difference between A CT of each sample and A CT of the reference 
sample. Final fold changes for each sample relative to the reference sample were calculated as 
2A(-AA CT).
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3 .3  G e n e t i c  A s s o c i a t i o n  S t u d y ;  R e s u l t s
3.3.1 B ase lin e  C haracte ristics
Baseline characteristics for the AIBII, AIBIII and hypertensive populations are shown below.
T a b le  3 -7 .  B a s e l in e  p o p u la t io n  c h a r a c t e r is t i c s  f o r  th e  3 8 0  in d iv id u a ls  in  t h e  A IB I I  p o p u la t io n  
f o r  w h o m  B P  m e a s u r e m e n t s  w e r e  a v a i la b le .  Characteristics shown were measured at phase II. 
IQR: Inter quartile range; SD: Standard deviation; N: Number of subjects included in the analysis; 
SBP: Systolic blood pressure; BMI: Body mass index; REN-5312; Renin distal enhancer 
polymorphism.
Demographic and Clinical Characteristics Men (N=221) Women (N=159)
Age (years): Mean ± SD 38.8 ±9.2 33.8 ±10.1
BMI (kg/m2): Mean±SD 26.5 ±3.4 24.3 ±3.7
Alcohol intake (units/wk): Median [IQR] 15 [8-24] 6 [2-11]
Salt usage at table: N (%) 127 (57%) 96(60%)
Current smoking: N(%) 70(32%) 43 (27%)
Daytime SBP (mmHg): M eaniSD 128.3 ±10.3 118.5 ±9.9
REN-5312 minor allele carriers: N (%) 70 (32%) 57(36%)
T a b le  3 -8 .  B a s e l in e  p o p u la t io n  c h a r a c t e r is t i c s  f o r  th e  1 0 2 2  in d iv id u a ls  in  t h e  A IB I I I  
p o p u la t io n  f o r  w h o m  B P  m e a s u r e m e n t s  w e r e  a v a i la b le .  IQR: Inter quartile range; SD:
Standard deviation; N: Number of subjects included in the analysis; SBP: Systolic blood pressure; 
BMI: Body mass index; REN-5312; Renin distal enhancer polymorphism.
Demographic and Clinical Characteristics Men (N=492) Women (N=530)
Age (years): Mean ± SD 47.9 ±14.0 46.3 ±13.7
BMI (kg/m2): Mean±SD 27.0 ±3.5 25.1 ±4.1
Alcohol intake (units/wk): Median [IQR] 12 [6-20] 5 [2-9]
Salt usage at table: N (%) 375(76%) 396 (75%)
Current smoking: N (%) 60(12%) 84(16%)
Clinic SBP (mmHg): Mean±SD 126.4 ±17.2 120.4 ±18.5
REN-5312 minor allele carriers: N (%) 160(32%) 173 (33%)
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Table 3-9. Baseline population characteristics fo r the 211 individuals in the ypertensive 
Population for whom BP measurements were available. IQR: Inter quartile range; SD: 
Standard deviation; N: Number of subjects included in the analysis; SB P : Systolic blood pressure; 
BMI: Body m ass index; PRA: Plasm a renin activity; R E N -5312 ; Renin distal enhancer 
polymorphism.
Demographic and Clinical Characteristics
Losartan Men 
(N=24)
losartan Women 
(N=15>
Aliskfren Men 
(N=113)
Aliskiren Women 
(N=59)
Age (years): Mean ± SD 54.7110.0 56.516.7 49.5111.0 54.618.2
BMI (kg/m2): Mean±SD 29.0 + 3.7 27.215.5 29.914.6 28.815.6
Alcohol intake (units/wk): Median [IQR] 10 [1.5-18] 3 [0-5.5] 10 [2.75-20.25] 2[0-7.5]
Salt usage at table: N (%) 13 (54%) 13 (87%) 55 (49%) 29 (49%)
Current smoking: N (%) 4(17%) 4(27%) 15(13%) 10(17%)
PRA(ng/mL*hour): MeanlSD 1.1510.77 0.8310.94 1.2111.14 0.7910.77
Daytime SBP (mmHg): Mean ± SD 154.1111.8 151.3110.9 152.8110.8 152.6114.6
REN-5312 minor allele carriers: N (%) 10(42%) 5 (33%) 46 (41%) 16(27%)
3.3.2 Power Calculations
The statistical power of a study is the probability that the test will reject the null hypothesis when the 
null hypothesis is false, and is an important param eter to consider before interpreting the results of 
a study. If power is low, the probability that the test will make a type II error (false negative 
decision) is high, and many ‘real’ associations may be m issed. Power can either be calculated 
before (a priori or prospective power analysis) or after (post-hoc or retrospective power analysis) 
data are collected. Post-hoc power analysis u ses the obtained sam ple and effect sizes to 
determine what the power of the study w as, assum ing the effect size in the sam ple w as equal to the 
effect size in the population. This type of power analysis w as conducted here to help to a s s e s s  
how likely the study w as to have identified ‘true’ associations, assum ing that they exist. Power w as 
calculated using the Quanto power calculator (http://hydra.usc.edu/gxe/) with the sam e param eters 
(assuming a continuous variable, an additive inheritance model, gene-only effects (no gene-gene or 
gene-environment interactions were accounted for), and a 2-sided test). Post-hoc power 
calculations were performed, where power w as estimated assum ing a variety of minor allele 
frequencies (MAF) of the genetic variants; MAF 0.05, and all allele frequencies increasing in 
increments of 0.05 from MAF0.05 to MAF 0.5. The power calculations were performed assum ing 
the Bonferroni-corrected type I error (a) rate for the study of 0.005 (section 3.3.3).
Figure 3 - 17  shows that although this study had slightly improved power to detect changes in 
ambulatory BP compared to clinic m easurem ents, overall the study did not have good power to 
detect modest (0.5-2mmHg) changes in BP, or changes in BP associated with low frequency 
variants. This study had good (-80% ) power to detect associations between SN P s and BP
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changes of à 3mmHg at minor allele frequencies of ~15% and above for systolic BP, and Ï  2mmHg 
for diastolic BP. At lower (<10%) allele frequencies, ttt study had good power to detect larger (> 
3mmHg) changes in diastolic, but not systolic BP.
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Figure 3-17. Post-hoc power plots for association between (P)RR SNPs and daytime and 
nighttime ambulatory BP levels in the AIBII population (N=755), and clinic BP levels in the 
AIBIII population (N=1022). The power of this study to detect associations between (P)RR SN P s 
and BP levels at a type I error (a) level of 0.005 w as plotted. The population mean ± standard 
deviation of daytime S B P  (day SB P ) w as 125m m H g ± 12mmHg, daytime DBP (day DBP) w as 
79mmHg ± 8mmHg, nighttime S B P  (night SB P ) w as 107m m Hg ± 1 1  mmHg, nighttime DBP (night 
DBP) w as 62mmHg ± 8mmHg, clinic S B P  w as 123m m H g ± 18mmHg, clinic DBP w as 77mmHg ± 
10mmHg. Power w as plotted assum ing five different main effect s izes of BP  associated with 
carriership of one minor allele (0.5, 1 ,  2, 3, or 4 mmHg). The maximum effect size per minor allele 
carried observed in the results of this study w as 5mmHg.
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3.3.3 Association between (P)RR polymorphisms and BP variations in two 
independent, healthy populations
The Bonferroni-corrected P-value threshold for this study was P<0.006 (0.05/9). However, the 9 
genotyped SNPs exist in two major LD blocks (Figure 3-13), and this threshold is likely to be overly- 
conservative. In the following plots, P-values <0.05 are highlighted in bold font.
AIBII Population
In all AIBII subjects, no SNPs were significantly associated with any BP measurement in excess of 
Bonferroni correction. All 9 SNPs were consistently associated with decreased ambulatory systolic 
and diastolic BP (Table 3-10). Four SNPs were associated with BP phenotypes at P<0.05, three of 
which were located in the upstream region and one, rs3112296, in intron 1 of the gene. rs6610426 
was associated with decreased daytime DBP of-0.8mmHg per minor allele carried (P=0.05). 
rs5917375 was associated with decreased daytime SBP of 1.5mmHg per minor allele, P=0.05. 
rs7886010 was associated with reduced nighttime SBP (-1.3mmHg, P=0.01) and DBP (-0.9mmHg, 
P=0.01) and decreased clinic SBP (-1.9, P=0.02). rs3112296 was associated with decreased 
daytime DBP (-0.9mmHg, P=0.05).
When the sexes were analysed separately, the overall pattern of association of all 9 SNPs with 
decreased SBP and DBP remained. In women only, three of the upstream SNPs, rs5917375, 
rs7886010 and rs5918002, were associated with decreased clinic SBP and/or DBP (Table 3-11). In 
men only, two of the upstream SNPs, rs6610426 and rs7886010, were associated with decreased 
daytime DBP and nighttime SBP, respectively (Table 3-12).
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Table 3-10. Associations between the 9 genotyped tagging SNPs listed in chromosomal order and BP measurements in all subjects in the 
AIBII population (N=760). Analyses were adjusted for: age, sex, and REN-5312 genotype. BP, base-pair position on chromosome 23 (chromosome 
X); MAF, minor allele frequency; BETA values indicate change in BP (mmHg) per copy of the minor allele.
CHR SNP BP MAF
Day SBP 
BETA P
N ight SBP 
BETA P
C lin ic  SBP 
BETA P
Day DBP 
BETA P
N ight DBP 
BETA P
C lin ic  DBP 
BETA P
Day PP 
BETA P
N ight PP 
BETA P
C lin ic  PP 
BETA P
23 !rs6610426 40305187 0.18 -1.1 0.06 -0.6 i 0.30 -1.21 0.14 -0.8 0.05 -0.2! 0.57 -0.9! 0.08 -0.3 0.47 -0.4 0.31 -0.3 0.60
23 !rs5917375 40308560 0.09 -1.5 0.05 -0.8 0.25 -1.6 0.15 -1.0 0.08 -0.3' 0.59 -0.8! 0.26 -0.6! 0.30 -0.6l 0.23 -0.8 0.32
23 rs7886010 40308910 0.20 -0.9 0.10 -1.3! 0.01 -1.9 0.02 -0.5 0.24 -0.9: 0.01 -0.9! 0.08 -0.4 ; 0.25 -0.4 0.26 -1.0! 0.09
23 <rs5918002 40310103 0.14 -0.7 0.28 -0.2 0.76 -0.5! 0.61 -0.3 0.52 -0.2 0.63 -0.6! 0.28 -0.4! 0.36 0.0 0.95 0.2 0.82
23 1 rs12836816i 40313348 0.12 -1.2 0.07 -0.6 0.36 -0.5^ 0.58 -0.9' 0.06 -0.1 0.86 -0.5! 0.38 -0.3 0.52 -0.5! 0.21 O.Ol 1.00
23 PS5963807 40315973 0.11 -1.0 0.14 -0.51 0.46 0.2 0.87 -0.7 0.13 -O.1; 0.86 -0.2! 0.71 -O.3 : 0.58 -0.4! 0.34 0.4; 0.59
23 rs3112296 40329375 0.13 -1.1 0.10 -0.6 0.37 -0.5 0.59 -0.9i 0.05 -0.1! 0.78 -0.6! 0.34 -0.2 0.73 -0.4! 0.27 0.1 0.93
23 rs3112299 40341905 0.12 -0.7 0.30 -0.4: 0.54 0.7 0.50 -0.5 0.26 -0.1: 0.83 0.1; 0.86 -0.2 0.74 -0.3! 0.47 0.5 0.44
23 rs5918007 40342029 0.11 -0.6 0.37 -0.5' 0.45 0.3 0.77 -0.5 0.33 -0.11 0.77 0.0! 0.95 -0.1 0.78 -0.4! 0.38 0.3 0.72
Table 3-11. Associations between the 9 genotyped tagging SNPs listed in chromosomal order and BP measurements in women only in the 
AIBII population (N=318). Analyses were adjusted for age and REN-5312 genotype. BP, base-pair position on chromosome 23 (chromosome X); 
MAF, minor allele frequency; BETA values indicate change in BP (mmHg) per copy of the minor allele.
CHR SNP BP MAF
Day SBP 
BETA P
N ight SBP 
BETA P
C lin ic  SBP 
BETA P
Day DBP 
BETA P
N ight DBP 
BETA P
C lin ic  DBP 
BETA P
Day PP 
BETA P
N ight PP 
BETA P
C lin ic  PP 
BETA P
23 rs6610426 40305187 0.14 -0.7 0.57 -0.8 0.44 -1.3 0.45 -0.3 0.73 -0.2 0.80 -0.5 0.63 -0.4 0.62 -0.6 0.35 -0.8 0.49
23 rs5917375 40308560 0.08 -2.4 0.14 -2.1 0.14 -5.0 0.04 -1.3 0.27 -1.1 0.29 -2.7 0.07 -1.1 0.29 -1.0 0.24 -2.3 0.16
23 rs7886010 40308910 0.17 -1.1 0.33 -1.6 0.08 -4.1 0.01 -0.6 0.46 -1.2 0.08 -2.8 0.01 -0.5 0.48 -0.4 0.45 -1.3 0.24
23 rs5918002 40310103 0.14 -1.5 0.20 -1.4:" 0.16 -2.5' 0.15 -0.9 0.25 -0.9 0.19 -2.7 0.01 -0.5 0.47 -0.5 0.45 0.2 0.85
23 rs 12836816 40313348 0.09 -0.9 0.55 0.2 0.90 -1.1 0.63 -0.4 0.71 0.2 0.87 -1.9 0.17 -0.5 0.61 0.0 0.99 0.8 0.59
23 rs5963807 40315973 0.10 -0.9 0.50 0.1 0.97 -1.2: 0.58 -0.5 0.59 0.1 0.89 -2.0 0.11 -0.4 0.65 -0.1 0.92 0.9 0.53
23 rs3112296 40329375 0.11 -0.7 0.63 0.1 0.95 -1.2 0.57 -0.6 0.54 0.0 0.96 -1,8? 0.15 -0.1 0.95 0.1 0.89 0.6; 0.65
23 rs3112299 40341905 0.11 -0.1 0.96 0.5 0.69 0.1 0.96 -0.4 0.69 -0.1 0.94 -1.0 0.41 0.3 0.73 0.5 0.47 1.1 0.41
23 rs5918007 40342029 0.11 0.1 0.96 0.5 0.64 0.1 0.95 -0.3 0.73 -0.1 0.95 -1.0 0.42 0.4 0.64 0.6 0.41 1.1 0.40
Table 3-12. Associations between the 9 genotyped tagging SNPs listed in chromosomal order and BP measurements in men only in the
AIBII population (N=442). Analyses were adjusted for age and REN-5312 genotype. BP, base-pair position on chromosome 23 (chromosome X); 
MAF, minor allele frequency; BETA values indicate change in BP (mmHg) per copy of the minor allele.
CHR SNP BP MAF
Day SBP 
BETA P
Day DBP 
BETA P
Day PP 
BETA P
N igh t SBP 
BETA P
N igh t DBP 
BETA P
N igh t PP 
BETA P
C lin ic  SBP 
BETA P
C lin ic  DBP 
BETA P
C lin ic  PP 
BETA P
23 rs6610426 40305187 0.20 -1.2 0.07 -0.9 0.05 -0.3 0.57 -0.5 0.45 -0.2 0.64 -0.3 0.49 -1.2 0.20 -1.0 0.09 -0.2 0.80
23 rs5917375 40308560 0.10 -1.4 0.11 -0.8 0.23 -0.6 0.30 -0.6 0.51 0.0 0.95 -0.6 0.27 -0.8 0.51 -0.3 0.74 -0.6 0.56
23 rs7886010 40308910 0.22 -0.9 0.18 -0.4 0.38 -0.5 0.30 -1.2 0.05 -0.8 0.06 -0.4 0.33 -1.2 0.17 -0.3 0.58 -0.9 0.18
23 rs5918002 40310103 0.14 -0.4 0.58 0.1 0.93 -0.5 0.37 0.2 0.75 0.1 0.80 Ò T 0.82 0.3 0.79 0.2 0.72 0.0 0.96
23 rs 12836816 40313348 0.14 -1.3 0.09 -0.9 0.09 -0.4 0.48 -0.8 0.32 -0.1 0.93 -0.7 0.15 -0.4 0.70 -0.1 0.84 -0.3 0.74
23 rs5963807 40315973 0.12 -1.1 0.17 -0.7 0.24 -0.4 0.46 -0.7 0.40 0.0 0.95 -0.6 0.21 0.5 0.63 0.4 0.56 0.1 0.89
23 rs3112296 40329375 0.14 -1.2 0.10 -0.9 0.09 -0.3 0.55 -0.7 0.33 -0.1 0.91 -0.7 0.16 -0.3 0.76 -0.1 0.83 -0.2 0.82
23 rs3112299 40341905 0.13 -1.0 0.22 -0.5 0.39 -0.5 0.39 -0.7 0.37 0.0 0.97 -0.7 0.18 0.8 0.47 0.5 0.45 0.3 0.76
23 rs5918007 40342029 0.12 -0.9 0.26 -0.4 0.48 -0.5 0.38 -0.9 0.27 -0.1 0.91 -0.8 0.11 0.3 0.78 0.5 0.52 -0.2 0.86
AIBIII Population
In all AIBIII subjects, as with the AIBII population, no SNPs were significantly associated with any 
BP measurement in excess of Bonferroni correction. Again, the minor alleles of the majority of the 
SNPs were consistently associated with decreased BP (Table 3-13). One SNP was associated with 
decreased clinic PP at P<0.05; rs5917375 (-1.6mmHg, P=0.05).
In the sex-specific analyses, no SNPs were significantly associated with any BP measurement in 
excess of Bonferroni correction, however the pattern of associations with decreased BP values 
remained (Table 3-14, Table 3-15).
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Table  3-13. A s s o c ia tio n s  be tw een th e  9 ge n o typ e d  ta g g in g  SNPs lis te d  in  ch ro m o s o m a l o rd e r  and BP 
m easurem en ts  in  a ll s u b je c ts  in  the  A IB III p o p u la tio n  (N=1022). Analyses were adjusted for age, sex and 
REN-5312 genotype. BP, base-pair position on chromosome 23 (chromosome X); MAF, minor allele 
frequency; BETA values indicate change in BP (mmHg) per copy of the minor allele.
C linic SBP Clinic DBP Clinic PP
CHR SNP BP MAF BETA P BETA P BETA P
23 rs6610426 40305187 0.15 -0.8 0.33 -0.5 0.28 -0.3 0.62
23 rs5917375 40308560 0.08 -1.9 0.10 -0.3 0.66 -1.6 0.05
23 rs7886010 40308910 0.18 -1.3 0.09 -0.5 0.29 -0.9 0.14
23 rs5918002 40310103 0.13 -1.3 0.14 -0.2 0.66 -1.1 0.10
23 rs12836816 40313348 0.11 -0.1 0.89 -0.5 0.36 0.3 0.62
23 rs5963807 40315973 0.10 -0.6 0.56 -0.4 0.43 -0.1 0.85
23 rs3112296 40329375 0.11 -1.1 0.24 -0.7 0.17 -0.4 0.58
23 rs3112299 40341905 0.10 -0.2 0.84 0.0 0.98 -0.2 0.77
23 rs 5918007 40342029 0.11 -0.2 0.84 -0.1 0.79 -0.1 0.94
Table 3-14. A s s o c ia tio n s  be tw een the  9 g e n o typ e d  ta g g in g  SNPs lis te d  in  ch ro m o s o m a l o rd e r and  BP 
m easurem en ts  in  w o m e n  o n ly  in  the  AJBIII p o p u la tio n  (N=530). Analyses were adjusted for age and REN-
5312  genotype. BP, base-pair position on chromosome 23 (chromosome X); MAF, minor allele frequency; 
BETA values indicate change in BP (mmHg) per copy of the minor allele.
CHR SNP BP MAF
Clinic SBP 
BETA P
C linic DBP 
BETA P
Clinic PP 
BETA P
23 rs6610426 40305187 0.16 -1.4 0.32 -0.6 0.43 -0.8 0.44
23 rs5917375 40308560 0.07 -1.7 0.40 -0.5 0.65 -1.2 0.42
23 rs7886010 40308910 0.17 -1.6 0.25 0.0 0.99 -1.7 0.11
23 rs5918002 40310103 0.12 -0.8 0.61 0.7 0.41 -1.6 0.18
23 rs12836816 40313348 0.10 1.5 0.40 0.5 0.63 1.0 0.43
23 rs5963807 40315973 0.08 -0.8 0.69 0.0 0.98 -0.8 0.59
23 rs3112296 40329375 0.10 0.5 0.78 0.2 0.81 0.3 0.84
23 rs3112299 40341905 0.09 -0.7 0.72 0.0 0.97 -0.7 0.60
23 rs5918007 40342029 0.09 -0.3 0.85 0.1 0.94 -0.4 0.76
Table 3-15. A s s o c ia tio n s  betw een th e  9 g e n o typ e d  ta g g in g  SNPs lis te d  in  ch ro m o s o m a l o rd e r and  BP 
m easurem ents  in  m en o n ly  in  the  A IB III p o p u la tio n  (N=492). Analyses were adjusted for age and REN- 
5312  genotype. BP, base-pair position on chromosome 23 (chromosome X); MAF, minor allele frequency; 
BETA values indicate change in BP (mmHg) per copy of the minor allele.
Clinic SBP Clinic DBP Clinic PP
CHR SNP BP MAF BETA P BETA P BETA P
23 rs6610426 40305187 0.15 -0.5 0.60 -0.5 0.41 -0.1 0.95
23 rs5917375 40308560 0.08 -2.0 0.13 -0.2 0.79 -1.8 0.07
23 rs7886010 40308910 0.20 -1.1 0.22 -0.7 0.18 -0.4 0.54
23 rs5918002 40310103 0.14 -1.5 0.14 -0.6 0.28 -0.9 0.26
23 rs12836816 40313348 0.13 -0.9 0.39 -0.8 0.17 -0.1 0.92
23 rs 5963807 40315973 0.11 -0.6 0.60 -0.6 0.39 0.0 0.97
23 rs3112296 40329375 0.13 -1.9 0.08 -1.1 0.07 -0.8 0.33
23 rs3112299 40341905 0.12 -0.1 0.93 0.0 0.98 -0.1 0.90
23 rs5918007 40342029 0.12 -0.2 0.84 -0.2 0.75 0.0 0.98
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Haplotype analysis
In the all subjects AIBII population, the 3 most distal upstream SNPs and 1 intronic SNP were 
associated (P<0.05) with BP phenotypes (Table 3-10). As the 3 upstream SNPs are not well 
correlated with any other SNPs the (P)RR gene (Figure 3-13), a haplotype analysis was carried out 
to ascertain whether these 4 SNPs had a larger combined effect on BP variation than they did 
individually. As the associations were strongest with ambulatory BP measurements, these 
measurements were used as the phenotype for the haplotype analysis. Four of the seven possible 
haplotypes had a frequency of > 0.01 in the population, and were used in the analysis.
Table 3-16. The four haplotypes used in the haplotype analysis with their m inor (A1) and 
major (A2) alleles, and (minor allele) frequency in all AIBII subjects (N=760).
CHR SNP BP A1 A2 Frequency
23 rs6610426 40305187 G A 0 .18
23 rs59 17375 40308560 T C 0.09
23 rs7886010 40308910 G A 0.20
23 rs3 112 2 9 6 40329375 C T 0 .13
Table 3-17. Results of the ‘Each-vs-Others’ haplotype analysis in all AIBII subjects (N=760) 
using common (frequency >1%) haplotypes of the four (P)RR gene SNPs associated with BP 
phenotypes. Analyses were adjusted for age, sex and REN-5312 genotype. BETA: change in BP 
(mmHg) associated with carriership of one copy of the haplotype; P: P-value for association.
Day SBP Night SBP Day DBP Night DBP
HAPLOTYPE FREQUENCY BETA P BETA P BETA P BETA P
GTGC 0.07 -0.66 0.43 -0.07 0.93 -0 .7 1 0.24 -0 .17  0.76
GCAC 0.0 1 -1.48  0.22 - 1 . 1 0  0.48 -1.3 2  0 .12 -0.03 0.90
ACAC 0.04 -0.03 0.47 -0.73 0.42 0.23 0.54 0.24 0.90
GTGT 0.02 -2.20 0.05 -2 .6 1 0.06 -0.68 0.20 -0.93 0.28
ACGT 0 . 1 1 0.58 0 .7 1 -1.0 8  0.04 0.81 0.86 -0.85 0.02
GCAT 0.07 0.67 0.77 0 .15  0.90 0.56 0 .7 1 0 .19  1.00
ACAT 0.68 1 . 1 3  0.03 0.55 8.1E-03 0.93 0.06 0.36 0.04
Table 3-17 shows that the all major allele haplotype (ACAT) was consistently associated with 
increased BP compared to all other haplotypes, across all ambulatory BP phenotypes. The major 
allele haplotype was, however, associated with similar BP changes to those associated with each 
SNP individually (Table 3-10), and P-values were not greatly improved.
58
3.3.4 Association between (P)RR polymorphisms and BP response to 
treatment with the BP lowering drugs Losartan and Aliskiren
Losartan
Response to treatment with Losartan was normally distributed, as shown in Figure 3-18. Baseline 
clinic SBP correlated well with response to treatment in this study, and baseline BP was therefore 
included as a covariate in all analyses.
daySBP response to Losartan treatment dayDBP response to Losartan treatment
response to treatment (mmHg) response to treatment (mmHg)
Figure 3-18. Distribution of daytime ambulatory SBP and DBP responses to treatment with 
Losartan in those randomised to this drug (N=39). Response to treatment was measured as 
[baseline BP]- [on-treatment BP], so that positive values indicate a drop in BP.
There were no statistically significant associations observed between carriership of any of the 
(P)RR SNPs and response to treatment with the angiotensin II receptor antagonist Losartan. 
Carriership of the minor alleles of two of the upstream SNPs, rs7886010 and rs5918002, were 
marginally but consistently associated with a reduced ambulatory BP-lowering response to 
treatment with Losartan in the hypertensive population, especially in men (Table 3-18 - Table 3-20).
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Table 3-18. Associations between the 9 genotyped tagging SNPs listed in chrom osom al order and BP measurements in all hypertensive  
individuals randomised to Losartan treatm ent (N=39). Analyses were adjusted for age, sex, baseline BP, plasma renin activity, weight and REN-5312 
genotype. BP, base-pair position on chromosome 23 (chromosome X); MAF, minor allele frequency; positive BETA values indicate a drop in BP 
(mmHg) in response to treatment per copy of the minor allele carried.
CHR SNP BP MAF
DaySBP 
BETA P
Night SBP 
BETA P
Clinic SBP 
BETA P
Day DBP 
BETA P
Night DBP 
BETA P
Clinic DBP 
BETA P
Day PP 
BETA P
Night PP 
BETA P
Clinic PP 
BETA P
23 rs 6610426 40305187 0.09 2.03 0.75 -1.0 0.87 3.9 0.63 0.0 1.00 -2.6 0.53 3.2 0.45 0.9 0.82 2.0 0.50 2.1 0.70
23 rs5917375 40308560 0.04 5.20 0.67 -6.8 0.55 -5.1 0.70 6l6 0.33 -2.5 0.76 3.6 0.64 -0.3 0.96 -7.2 0.23 -8.3 0.33
23 rs7886010 40308910 0.18 -6.46 0.09 -4.5 0.22 4.4 0.36 -4.0 0.08 -4.7 0.07 3.3 0.26 -2.2 0.36 -0.3 0.88 0.1 0.99
23 rs5918002 40310103 0.15 -5.45 0.20 -2.3 0.57 3.7 0.47 -4.5 0.08 -4.6 0.11 3.7 0.25 -0.8 0.78 1.1 0.61 -1.1 0.75
23 rs12836816 40313348 0.15 3.58 0.36 -2.6 0.48 7.0 0.16 0.3 0.90 -2.2 0.42 2.6 0.38 2.7 0.27 0.1 0.97 5.1 0.13
23 rs5963807 40315973 0.12 3.23 0.45 -2.4 0.56 2.7 0.62 -0.3 0.90 -1.2 0.68 0.9 0.77 3.5 0.19 -1.2 0.59 2.3 0.53
23 rs3112296 40329375 0.17 3.27 0.38 -1.5 0.68 4.5 0.37 -0.5 0.80 -1.5 0.57 1.3 0.67 3.4 0.15 0.6 0.79 3.9 0.24
23 rs3112299 40341905 0.12 3.23 0.45 -2.4 0.56 2.7 0.62 -0.3 0.90 -1.2 0.68 0.9 0.77 3.5 0.19 -1.2 0.59 2.3 0.53
23 rs 5918007 40342029 0.12 3.23 0.45 -2.4 0.56 2.7 0.62 -0.3 0.90 -1.2 0.68 0.9 0.77 3.5 0.19 -1.2 0.59 2.3 0.53
Table 3-19. Associations between the 9 genotyped tagging SNPs listed in chromosomal order and BP measurements in female hypertensive 
individuals randomised to Losartan treatment (N=15). Analyses were adjusted for age, baseline BP, plasma renin activity, weight and REN-5312 
genotype. BP, base-pair position on chromosome 23 (chromosome X); MAF, minor allele frequency; positive BETA values indicate a drop in BP 
(mmHg) in response to treatment per copy of the minor allele carried.
CHR SNP BP M AF
Day SBP 
BETA P
N ig h t SBP 
BETA P
C lin ic  SBP 
BETA P
Day DBP 
BETA P
N ig h t DBP 
BETA P
C lin ic  DBP 
BETA P
Day PP 
BETA P
N ig h t PP 
BETA P
C lin ic  PP 
BETA P
23 rs6610426 40305187 0.17 5.0 0.69 -2.6 0.S6 6.3 0.72 -0.8 0.88 -4.2 0.59 1.0 . 2.2 0.82 -1.0 0.89 -0.6 0.95
23 rs5917375 40308560 0.10 -0.6 0.97 0.68 -10.8 0.56 -1.6 0.80 -8.7 0.45 2.4 0.76 -1.1 0.93 -8.2 0.42 -9.4 0.38
23 rs7886010 40308910 0.27 -9.4 0.32 -15.8 0.16 1.9 0.88 -2.2 0.57 -7.0 0.25 3.0 0.55 -6.7 0.43 -7.5 0.18 -0.2 0.98
23 rs5918002 40310103 0.20 -4.8 0.71 -10.2 0.51 -2.9 0.84 -4.7 0.31 -6.0 0.45 3.5 0.55 1.2 0.91 -5.3 0.49 -3.9 0.64
23 rs12836816 40313348 0.13 8.6 0.51 -0.8 0.96 22.8 0.19 -0.7 0.89 -4.5 0.59 2.1 0.82 6.1 0.55 2.2 0.78 11.4 0.26
23 rs5963807 40315973 0.10 3.6 0.81 1.2 0.96 -11.9 0.55 -5.4 0.33 -9.2 0.44 -5.7 0.50 11.1 0.37 2.9 0.77 -3.0 0.80
23 rs3112296 40329375 0.17 8.0 0.52 3.3 0.85 9.1 0.66 -3.3 0.47 -4.6 0.58 -7.2 0.39 9.7 0.31 5.4 0.49 6.8 0.56
23 rs3112299 40341905 0.10 3.6 0.81 1.2 0.96 -11.9 0.55 -5.4 0.33 -9.2 0.44 -5.7 0.50 11.1 0.37 2.9 0.77 -3.0 0.80
23 rs5918007 40342029 0.10 3.6 0.81 1.2 0.96 -11.9 0.55 -5.4 0.33 -9.2 0.44 -5.7 0.50 11.1 0.37 2.9 0.77 -3.0 0.80
Table 3-20. Associations between the 9 genotyped tagging SNPs listed in chromosomal order and BP measurements in male hypertensive 
individuals randomised to Losartan treatment (N=24). Analyses were adjusted for age, baseline BP, plasma renin activity, weight and REN-5312 
genotype. BP, base-pair position on chromosome 23 (chromosome X); MAF, minor allele frequency; positive BETA values indicate a drop in BP 
(mmHg) in response to treatment per copy of the minor allele carried.
CHR SNP BP M AF
Day SBP 
BETA P
N ig h t SBP 
BETA P
C lin ic  SBP 
BETA P
Day DBP 
BETA P
N ig h t DBP 
BETA P
C lin ic  DBP 
BETA P
DayPP 
BETA P
N ig h t PP 
BETA P
C lin ic  PP 
BETA P
23 rs6610426 40305187 0.04 -1.5 0.85 -1.4 0.82 3.8 0.67 -6.1 0.17 -4.3 0.46 1.1 0.87 -1.3 0.81 5.4 0.18 5.7 0.40
23 rs5917375 40308560 0.00 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
23 rs7886010 40308910 0.13 -8.1 0.07 -1.6 0.68 2.0 0.77 -5.2 0.09 -6.0 0.08 5.8 0.23 -2.0 0.46 2.8 0.18 -3.3 0.39
23 rs5918002 40310103 0.13 -8.1 0.07 -1.6 0.68 2.0 0.77 -5.2 0.09 -6.0 0.08 5.8 0.23 -2.0 0.46 2.8 0.18 -3.3 0.39
23 rs 12836816 40313348 0.17 3.0 0.47 -3.8 0.23 6.0 0.20 -0.2 0.93 -3.1 0.32 2.2 0.55 1.9 0.40 -0.9 0.70 4.0 0.22
23 rs5963807 40315973 0.13 4.0 0.37 -4.0 0.25 6.2 0.24 1.8 0.49 -1.9 0.56 2.9 0.47 2.5 0.30 -1.9 0.38 3.4 0.35
23 rs3112296 40329375 0.17 3.6 0.33 -3.6 0.27 6.6 0.17 0.3 0.89 -2.6 0.42 2.2 0.57 2.2 0.33 -1.0 0.67 4.2 0.18
23 rs3112299 40341905 0.13 4.0 0.37 -4.0 0.25 6.2 0.24 1.8 0.49 -1.9 0.56 2.9 0.47 2.5 0.30 -1.9 0.38 3.4 0.35
23 rs5918007 40342029 0.13 4.0 0.37 -4.0 0.25 6.2 0.24 1.8 0.49 -1.9 0.56 2.9 0.47 2.5 0.30 -1.9 0.38 3.4 0.35
Aliskiren
Response to treatment with Aliskiren was approximately normally distributed in this study, as shown 
in Figure 3-19. As with Losartan, baseline clinic SBP correlated well with response to treatment in 
this study, and baseline BP was therefore included as a covariate in all analyses.
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Figure 3-19. Distribution of daytime ambulatory SBP and DBP responses to treatment with 
Aliskiren in those randomised to this drug (N=173). Response to treatment was measured as 
[baseline BP]- [on-treatment BP], so that positive values indicate a drop in BP.
In the hypertensive population randomised to treatment with the direct renin inhibitor Aliskiren, there 
was an overall pattern of an increased daytime and clinic BP response to treatment associated with 
carriership of the minor alleles of the 9 genotyped SNPs (Table 3-21 ). Carriership of the minor 
allele of rs3112296 was associated with increased daytime PP response to treatment (1.8mmHg 
increased PP lowering response/minor allele carried, P=0.05), which appears to have been driven 
by an increased SBP-lowering response to treatment.
In the sex-specific analyses, there were no significant associations in the female-only cohort (Table
3-22), although the overall pattern of increased daytime BP response to treatment was evident. In 
the male-only cohort, a number of associations were observed at P<0.05 between SNPs in the 
(P)RR and increased clinic SBP and DBP response to treatment, aswell as increased daytime PP 
response to treatment (Table 3-23).
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Table 3-21. Associations between the 9 genotyped tagging SNPs listed in chromosomal order and BP measurements in all hypertensive 
individuals randomised to Aliskiren treatment (N=173). Analyses were adjusted for age, sex, baseline BP, plasma renin activity, weight, aliskiren 
dose (37.5, 75, 150, 300mg) and REN-5312 genotype. BP, base-pair position on chromosome 23 (chromosome X); MAF, minor allele frequency; 
positive BETA values indicate a drop in BP (mmHg) in response to treatment per copy of the minor allele carried.
CHR SNP BP MAF
Day SBP 
BETA P
Night SBP 
BETA P
Clinic SBP 
BETA P
Day DBP 
BETA P
Night DBP 
BETA P
Clinic DBP 
BETA P
Day PP 
BETA P
Night PP 
BETA P
Clinic PP 
BETA P
23 rs6610426 40305187 0.11 0.8 0.60 -0.4 0.83 -1.0 0.65 0.3 0.77 0.0 0.98 -0.9 0.54 0.6 0.51 -0.3 0.74 -0.1 0.93
23 rs5917375 40308560 0.04 2.7 0.40 -3.2 0.41 1.1 0.79 1.1 0.61 -1.6 0.55 2.3 0.41 1.7 0.36 -1.5 0.47 -0.7 0.83
23 rs7886010 40308910 0.18 0.5 0.66 0.2 0.88 1.2 0.52 0.4 0.65 -0.5 0.66 2.0 0.08 0.1 0.84 0.8 0.34 -0.2 0.88
23 rs5918002 40310103 0.11 0.7 0.65 -1.1 0.56 3.1 0.16 0.3 0.76 -0.5 0.70 2.4 0 .1 1 0.3 0.78 -0.7 0.52 1.2 0.49
23 rs12836816 40313348 0.10 2.9 0.07 0.2 0.93 0.9 0.71 1.0 0.35 0.4 0.78 1.7 0.26 1.7 0.06 -0.3 0.80 -0.8 0.63
23 rs5963807 40315973 0.08 1.6 0.38 -0.5 0.82 4.0 0.13 0.1 0.91 0.4 0.81 3.1 0.07 1.2 0.25 -1.0 0.38 1.4 0.49
23 rs3112296 40329375 0.10 2.8 0.09 -0.3 0.88 0.7 0.76 0.7 0.53 -0.1 0.93 1.7 0.28 1 .8 0.05 -0.3 0.76 -1.0 0.59
23 rs3112299 40341905 0.08 1.2 0.49 -0.8 0.72 3.8 0.14 0.0 0.97 0.2 0.90 3.0 0.07 0.9 0.37 -1.1 0.32 1.2 0.52
23 rs5918007 40342029 0.08 1.1 0.56 -0.7 0.74 3.8 0.14 0.0 0.98 0.5 0.77 3.0 0.07 0.8 0.46 -1.3 0.24 1.2 0.55
Table 3-22. Associations between the 9 genotyped tagging SNPs listed in chromosomal order and BP measurements in female hypertensive 
individuals randomised to Aliskiren treatment (N=59). Analyses were adjusted for age, baseline BP, plasma renin activity, weight, aliskiren dose 
(37.5, 75, 150, 300mg) and REN-5312 genotype. BP, base-pair position on chromosome 23 (chromosome X); MAF, minor allele frequency; positive 
BETA values indicate a drop in BP (mmHg) in response to treatment per copy of the minor allele carried.
CHR SNP BP MAF
Day SBP 
BETA P
Night SBP 
BETA P
Clinic SBP 
BETA P
Day DBP 
BETA P
Night DBP 
BETA P
Clinic DBP 
BETA P
DayPP 
BETA P
Night PP 
BETA P
Clinic PP 
BETA P
23 rs6610426 40305187 0.17 1.0 0.75 -0.8 0.82 -3.2 0.54 1.0 0.58 0.5 0.84 -1.3 0.66 0.9 0.67 -0.9 0.70 -2.0 0.60
23 rs5917375 40308560 0.10 3.7 0.37 -1.1 0.81 2.0 0.78 2.5 0.31 -1.2 0.69 3.3 0.41 2.2 0.43 0.5 0.87 -0.5 0.92
23 rs7886010 40308910 0.27 2.9 0.23 0.2 0.93 0.3 0.94 1.6 0.25 -1.2 0.49 3.2 0.16 1.2 0.47 1.4 0.42 -2.5 0.39
23 rs5918002 40310103 0.20 2.9 0.34 0.7 0.85 5.5 0.28 1.8 0.32 -0.6 0.80 4.7 0.11 1.0 0.62 0.9 0.68 1.0 0.78
23 rs12835816 40313348 0.13 2.2 0.49 -1.9 0.58 0.3 0.96 1.4 0.45 0.3 0.90 1.7 0.57 1.2 0.57 -1.7 0.46 -1.0 0.79
23 rs5963807 40315973 0.10 3.8 0.32 -0.7 0.86 -0.8 0.90 2.0 0.36 -1.0 0.73 1.0 0.78 1.9 0.46 0.4 0.88 -1.8 0.70
23 rs3112296 40329375 0.17 3.1 0.42 -3.4 0.42 -1.5 0.80 2.2 0.31 -1.7 0.54 0.7 0.85 0.9 0.73 -1.3 0.62 -1.7 0.70
23 rs3112299 40341905 0.10 1.8 0.62 -2.6 0.52 -1.5 0.80 1.3 0.54 -1.7 0.54 0.3 0.93 0.8 0.74 -0.6 0.82 -1.6 0.71
23 rs5918007 40342029 0.10 1.1 0.77 -1.7 0.68 -1.9 0.77 1.9 0.41 -0.1 0.96 0.3 0.93 -0.1 0.98 -1.1 0.70 -2.3 0.62
Table 3-23. Associations between the 9 genotyped tagging SNPs listed in chromosomal order and BP measurements in male hypertensive 
individuals randomised to Aliskiren treatment (N=114). Analyses were adjusted for age, baseline BP, plasma renin activity, weight, aliskiren dose 
(37.5, 75, 150, 300mg) and REN-5312 genotype. BP, base-pair position on chromosome 23 (chromosome X); MAF, minor allele frequency; positive 
BETA values indicate a drop in BP (mmHg) in response to treatment per copy of the minor allele carried.
CHR SNP BP MAF
Day SBP 
BETA P
Night SBP 
BETA P
Clinic SBP 
BETA P
Day DBP 
BETA P
Night DBP 
BETA P
Clinic DBP 
BETA P
DayPP 
BETA P
Night PP 
BETA P
Clinic PP 
BETA P
23 rs6610426 40305187 0.10 0.7 0.67 0.6 0.79 0.1 0.96 0.3 0.83 0.2 0.92 -0.6 0.71 0.7 0.47 0.5 0.63 0.8 0.66
23 rs5917375 40308560 0.02 6.7 0.21 -0.7 0.92 2.1 0.72 1.4 0.72 0.7 0.90 2.4 0.53 5.4 0.07 -1.6 0.60 -0.7 0.88
23 rs7886010 40308910 0.17 0.3 0.84 0.7 0.73 1.5 0.45 0.4 0.69 0.1 0.94 1.9 0.17 0.1 0.94 0.6 0.45 0.4 0.80
23 rs5918002 40310103 0.10 0.8 0.65 -0.3 0.92 3.8 0.14 0.5 0.70 0.1 0.94 3.0 0.09 0.5 0.59 l o 0.71 1.6 0.42
23 rs12836816 40313348 0.09 2.7 0.13 0.8 0.73 12 0.65 0.9 0.50 0.3 0.85 1.6 0.36 1.9 0.04 0.4 0.69 -0.9 0.67
23 rs5963807 40315973 0.07 0.4 0.85 -0.1 0.98 5.7 0.04 -0.5 0.73 1,0 0.61 3.7 0.05 1.1 0.28 -1.0 0.37 2.4 0.27
23 rs3112296 40329375 0.09 2.4 0.17 0.7 0.77 1.5 0.57 0.2 0.86 0.3 0.87 1.9 0.27 2.3 0.01 0.3 0.78 -0.8 0.70
23 rs3112299 40341905 0.07 0.4 0.83 0.0 0.99 5.7 0.04 -0.5 0.73 0.9 0.63 3.7 0.05 1.2 0.28 -1.0 0.37 2.3 0.28
23 rs5918007 40342029 0.07 0.4 0.85 -0.1 0.96 5.5 0.05 -0.5 0.75 1.0 0.61 3.7 0.05 1.2 0.26 -1.1 0.33 2.2 0.28
3 . 4  m R N A  Q u a l i f i c a t i o n ;  R e s u l t s
Linear regressions were performed of genotype assuming an additive genetic model (coded 0,1,2) 
on mRNA fold change calculated as described above. There were no statistically significant 
associations between mRNA levels and genotype of any of the 9 (P)RR SNPs. In addition, t-tests 
of average fold change in carriers versus major allele homozygotes did not reveal any statistical 
associations.
Overall, expression levels were similar between the two primers, indicating that most isoforms of the 
(P)RR mRNA present in adrenal glands contain exons 1, 2, 8 and 9. Expression levels of (P)RR 
mRNA were highly variable between individuals analyzed in this study, but did not appear to be 
affected by any of the SNPs genotyped in this study.
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Figure 3-20. Fold changes of mRNA levels relative to the arbitrarily-chosen reference 
sample, ADR018, by genotype of the (P)RR SNP, rs6610426. Fold changes for primer 1, 
Hs00366629, which assayed a segment of mRNA spanning exons 1 and 2 are shown on the left 
and fold changes for primer 2, Hs00997145, which assayed a segment of mRNA spanning exons 8 
and 9, are shown on the right.
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Figure 3-21. Fold changes of mRNA levels relative to the arbitrarily-chosen reference 
sample, ADR018, by genotype of the (P)RR SNP, rs5917375. Fold changes for primer 1,
Hs00366629, which assayed a segment of mRNA spanning exons 1 and 2 are shown on the left 
and fold changes for primer 2, Hs00997145, which assayed a segment of mRNA spanning exons 8 
and 9, are shown on the right.
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Figure 3-22. Fold changes of mRNA levels relative to the arbitrarily-chosen reference 
sample, ADR018, by genotype of the (P)RR SNP, rs7886010. Fold changes for primer 1, 
Hs00366629, which assayed a segment of mRNA spanning exons 1 and 2 are shown on the left 
and fold changes for primer 2, Hs00997145, which assayed a segment of mRNA spanning exons 8 
and 9, are shown on the right.
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Figure 3-23. Fold changes of mRNA levels relative to the arbitrarily-chosen reference 
sample, ADR018, by genotype of the (P)RR SNP, rs5918002. Fold changes for primer 1,
Hs00366629, which assayed a segment of mRNA spanning exons 1 and 2 are shown on the left 
and fold changes for primer 2, Hs00997145, which assayed a segment of mRNA spanning exons 8 
and 9, are shown on the right.
67
Hs00366629_m1 primer by rs12836816
0)CT>
U2
a
(E £  (H K  -
O  Q  Q  O  Cl< < < < <
Hs00997145_m1 primer by rs12836816
a>O)c(0u2
a
Subjects (N=18)
□ cc
■  CT
■ 77
o □
O  O  T- T— r -  r-O O O O O Oa ec <r ac o q a o< < < < < < < ct o: o ~< O Q Q O < < < <
Subjects (N=18)
Figure 3-24. Fold changes of mRNA levels relative to the arbitrarily-chosen reference 
sample, ADR018, by genotype o f the (P)RR SNP, rs12836816. Fold changes for primer 1, 
Hs00366629, which assayed a segment of mRNA spanning exons 1 and 2 are shown on the left 
and fold changes for primer 2, Hs00997145, which assayed a segment of mRNA spanning exons 8 
and 9, are shown on the right.
Hs00366629_m1 primer by rs5963807 Hs00997145_m1 primer by rs5963807
Subjects (N=18) Subjects (N=18)
Figure 3-25. Fold changes of mRNA levels relative to the arbitrarily-chosen reference 
sample, ADR018, by genotype of the (P)RR SNP, rs5963807. Fold changes for primer 1, 
Hs00366629, which assayed a segment of mRNA spanning exons 1 and 2 are shown on the left 
and fold changes for primer 2, Hs00997145, which assayed a segment of mRNA spanning exons 8 
and 9, are shown on the right.
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Figure 3-26. Fold changes of mRNA levels relative to the arbitrarily-chosen reference 
sample, ADR018, by genotype of the (P)RR SNP, rs3112296. Fold changes for primer 1, 
Hs00366629, which assayed a segment of mRNA spanning exons 1 and 2 are shown on the left 
and fold changes for primer 2, Hs00997145, which assayed a segment of mRNA spanning exons 8 
and 9, are shown on the right.
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Figure 3-27. Fold changes of mRNA levels relative to the arbitrarily-chosen reference 
sample, ADR018, by genotype of the (P)RR SNP, rs3112299. Fold changes for primer 1, 
Hs00366629, which assayed a segment of mRNA spanning exons 1 and 2 are shown on the left 
and fold changes for primer 2, Hs00997145, which assayed a segment of mRNA spanning exons 8 
and 9, are shown on the right.
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Figure 3-28. Fold changes o f mRNA levels relative to the arbitrarily-chosen reference 
sample, ADR018, by genotype of the (P)RR SNP, rs5918007. Fold changes for primer 1, 
Hs00366629, which assayed a segment of mRNA spanning exons 1 and 2 are shown on the left 
and fold changes for primer 2, Hs00997145, which assayed a segment of mRNA spanning exons 8 
and 9, are shown on the right.
3.5 Discussion
3.5.1 Genetic Association Study
In this, the first candidate-gene assessment of the (P)RR in Caucasian populations, the gene and 
20kb of its upstream region were comprehensively genotyped, accounting for all genetic variation 
present in Caucasian populations at a frequency of = 5%. Overall, the 9 (P)RR SNPs were 
associated with decreased BP in the two AIB populations studied (Table 3-10-Table 3-15), although 
none of these associations reached experiment-wide significance.
A particular strength of this study was the high-quality BP phenotypes of the two populations used. 
Both populations were healthy volunteers, free of anti-hypertensive medication. In the AIBII 
population, repeat ambulatory BP measurements were available, which have been shown to be a 
better prognostic measure than the more commonly used clinic BP measurements. Indeed, the 
associations were more pronounced in the AIBII population and power graphs (Figure 3-17) 
indicated that there was greater power to detect associations with BP in this population, , reflecting
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the increased power associated with high-quality phenotypes. The SNPs located in the 20kb region 
upstream of the gene were particularly strongly associated with decreased BP.
As so few of the (P)RR variants are covered on the common genome-wide chips (Figure 3-12), and 
the only candidate gene study published to date was conducted in an Asian population, it is unlikely 
that associations between BP variation and polymorphisms in the (P)RR gene have been well- 
interrogated in populations of European descent. The results of this study indicate small, but 
consistent associations between SNPs in the upstream region of the (P)RR gene and decreased 
BP in healthy populations, which warrant follow-up in a larger population.
This chapter also included the results of the first investigation into the effects of (P)RR SNPs on BP- 
lowering with anti-hypertensive agents in a hypertensive population. There were no significant 
associations observed between (P)RR SNPs and response to the angiotensin II receptor antagonist 
Losartan, and overall the response was variable. However two of the upstream SNPs, rs7886010 
and rs5918002, appeared to be marginally associated with a reduced ambulatory BP-lowering 
response to treatment with Losartan in the hypertensive population, especially in men. These same 
SNPs were also associated with decreased BP in AIBII. If these polymorphisms lead to reduced 
(P)RR gene expression, it may be that resultant reduced activation of renin/prorenin leads to 
reduced effects of Angll receptor blockade. In studies using the HRP to block the (P)RR in animal 
models, some treatment overlap has been observed between treatment with a angiotensin receptor 
blockers and (P)RR blockade (147).
In the hypertensive population randomised to treatment with the direct renin inhibitor Aliskiren, there 
was an overall pattern of an increased daytime and clinic BP response to treatment associated with 
carriership of the minor alleles of the 9 genotyped SNPs (Table 3-21), with some of these 
associations significant at P<0.05 in the male population. Again assuming that these 
polymorphisms lead to reduced (P)RR gene expression, one potential explanation for this 
observation is that this results in less active renin available to bind to the renin inhibitor. If the 
inhibitor usually becomes saturated due to high levels of active renin, it may be that in individuals 
with reduced (P)RR, a larger BP-lowering effect is observed because the inhibitor has not reached 
saturation.
As mentioned in section 3.2.5, the fact that the (P)RR gene is located on the X-chromosome 
presents some complications for the interpretation these results. It was hypothesised in section 
3.2.5 that males, in whom X-inactivation does not occur, may provide a more reliable model of 
(P)RR gene associations than females, especially if many of the females are heterozygotic for the 
tagging SNPs. This theory was not borne out however in this study, where associations between
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the SNPs and BP variation in the healthy population were of similar strength in men and women 
when analyzed separately. Although associations between SNPs and response to treatment were 
particularly pronounced in men-only analyses, this is likely due to the fact that there were 
substantially more men than women in the hypertensive cohort.
3.5.2 m R N A  Q u a lif ic a tio n
Expression levels of (P)RR mRNA were not correlated with the genotypes of any of the (P)RR 
SNPs in this study. Expression levels did vary between individuals, indicating that (P)RR 
expression in adrenal glands may be subject to transcriptional regulation by some means not 
captured by the genetic variants assayed here -  possibly trans-regulation by another protein.
The fact that the (P)RR SNPs do not appear to influence gene expression was unexpected given 
their apparent affect on BP regulation. However, a number of studies have indicated that tissue- 
specificity is important when assessing gene expression levels (166), and it may be that these 
SNPs do regulate (P)RR gene expression in other tissues. There are no published studies to date 
which have assessed correlation of genetic variants in the (P)RR gene with gene expression. 
However, the (P)RR protein is also known to be expressed in the kidney (119), which, given the BP- 
lowering effects of these SNPs, may show genotype-mediated differences in (P)RR expression.
The sample size of 18 individuals in the tissue expression study is small, and for most SNPs no 
minor allele homozygotes were analyzed. Although these data show no evidence of a trend for 
association with genotype, it is possible that one would become evident in a larger sample size.
Another shortcoming of this study was that sex of the donors was not known. As mentioned 
previously, the (P)RR gene is located on the X chromosome, and therefore mRNA levels may differ 
between males and females due to the number of X chromosomes present.
In addition, genotype of the REN-5312 polymorphism was not known in the donor population. It is 
possible that renin levels (known to be associated with the REN-5312 SNP) could control (P)RR 
gene expression via a feedback loop. The presence of polymorphisms which affect renin 
expression may be confounding this study.
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4  C a n d i d a t e  P a t h w a y  A s s o c i a t i o n  S t u d y  o f  
G e n e t i c  V a r i a n t s  i n  I o n  C h a n n e l  S t u d i e s  a n d  
N e u r o t r a n s m i t t e r  R e c e p t o r s  w i t h  B l o o d  
P r e s s u r e  V a r i a t i o n
4.1 Introduction
As discussed in the introduction to this thesis and in chapter 3, approaches complimentary to 
genome-wide association studies may be necessary to identify all the of the genetic variants 
contribution to control of BP regulation. Accordingly, we designed this study to interrogate multiple 
candidate genes along pathways chosen on the basis of prior biological knowledge. We elected to 
consider two pathways of known importance to BP regulation in this study; ion channels and 
neurotransmitters.
4.1.1 Ion T ra n s p o rte rs
Renal control of fluid volume is an important aspect of BP control, and a popular model postulates 
that the relationship between renal sodium excretion and BP (the pressure-natriuresis relationship) 
defines the BP homeostatic set-point (167). According to this model, any increase in sodium 
retention produces an initial blood volume expansion, causing BP to increase via a rise in cardiac 
output. Eventually, tissue over-perfusion leads to an increase in peripheral resistance that returns 
resting cardiac output towards normal (whole-body autoregulation). Renal sodium excretion is 
mediated by Ion channels in the renal epithelia (Figure 4-1). Over 75% of Na+ is reabsorbed in the 
proximal nephron, mainly via Na+/H+ exchange (mediated via exchangers such as NHE1), whose 
rate is determined by Na+ delivery (Glomerular Filtration Rate) and Starling forces in the nephron. 
The remaining filtered Na+ is re-absorbed in the distal nephron via sodium co-transporters and the 
aldosterone-regulated ENaC sodium ion channel (Figure 4-1). Under normal sodium dietary 
loading, approximately 1-5% of the filtered Na+ passes into the urine.
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Twin studies have indicated genetic influences on the renal excretion of sodium and potassium 
following volume expansion and contraction in humans (39). In addition, the vast majority of the 
genes identified so far which cause rare Mendelian BP disorders have been genes encoding ion 
channels which alter renal salt reabsorption (168, 169) (Figure 4-1). Several of these disorders, 
exemplified by Bartter's and Gitelman's syndromes, are recessive traits that lower blood pressure. 
Bartter's syndrome features massive renal salt wasting and hypotension, often resulting in neonatal 
death. It is caused by recessive loss-of-function mutations in any of four genes required for normal 
renal NaCI reabsorption (170-173), including the Na-K-2CI co-transporter gene SLC12A1 and the 
inward rectifier K+ channel gene KCNJ1. Gitelman's syndrome is a less severe salt-wasting 
disease caused by recessive loss-of-function mutations in the NaCI co-transporter gene SLC12A3  
(174).
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Figure 4-1. Adapted from (168). Mutations altering blood pressure in humans. A diagram of 
a nephron, the filtering unit of the kidney, is shown. The molecular pathways mediating NaCI 
reabsorption in individual renal cells in the thick ascending limb of the loop of Henle (TAL), distal 
convoluted tubule (DCT), and the cortical collecting tubule (CCT) are indicated, along with the 
pathway of the renin-angiotensin system, the major regulator of renal salt reabsorption. Inherited 
diseases affecting these pathways are indicated, with hypertensive disorders in red and 
hypotensive disorders in blue. Al, angiotensin I; ACE, angiotensin converting enzyme; All, 
angiotensin II (All); MR, mineralocorticoid receptor; GRA, glucocorticoid-remediable aldosteronism; 
PHA1, pseudohypoaldosteronism, type-1; AME, apparent mineralocorticoid excess; 11 bHSD2,
11 b-hydroxysteroid dehydrogenase-2; DOC, deoxycorticosterone; and PT, proximal tubule.
74
This information may be applicable to common BP variation in two ways. One hypothesis, for which 
GWAS findings have provided some evidence, is that other, more common variants in the same 
genes in which rare mutations cause severe BP disorders may influence BP variation in the general 
population. This hypothesis was tested in a study published by Tobin et al (175), which examined 
common variation in 11 candidate loci previously associated with Mendelian BP disorders in -2,000 
individuals with ambulatory BP measurements. They found that common variants in KCNJ1, rare 
mutations in which cause Bartter syndrome type 2, were associated with modest (~1.5mmHg) 
decreases in BP.
The second hypothesis is that individuals who are heterozygous for these same mutations, which in 
their homozygous recessive forms cause severe disease, may display an intermediate phenotype. 
The prevalences of Bartter's and Gitelman's syndromes (estimated at — 1 per million and 1 per 
40,000, respectively) (174, 176) suggest that heterozygous disease alleles should be present in at 
least 1% of the population (likely to be an underestimate, owing to early lethality of Bartter's 
syndrome). This second hypothesis was tested by Ji et al, who examined SLC12A1, SLC12A3 and 
KCNJ1 for association with BP levels in 3,125 members of the Framingham Heart Study (FHS) 
offspring cohort (177). The carrier state for rare functional mutations in SLC12A3, SLC12A1 and 
KCNJ1 was found to be associated with reduced blood pressure in FHS participants. These results 
establish the role of altered renal salt handling in blood pressure variation in a general population.
The recent implication of the WNK (with no k (lysine)) / STK (src-type kinase) pathway in BP 
regulation has provided further evidence for the implication of genes encoding ion channels & 
related proteins associated with rare BP disorders in common BP variation. Mutations in WNK1 
and WNK4 (which encode lysine deficient protein kinase 1/4, members of a family of serine- 
threonine kinases) have been shown to cause the rare, familial autosomal dominant disease 
‘pseudohypoaldosteronism type II’ (PHAII, also known as Gordon’s syndrome), characterized by 
early-onset hypertension and hyperkalemia (elevated plasma K+) (178).
Wild-type WNK1 and WNK4 inhibit the thiazide-sensitive NaCI co-transporter in the distal tubule. 
Mutated proteins no longer inhibit this co-transporter effectively and are associated with increased 
co-transporter activity, excessive chloride and sodium reabsorption, and volume expansion. 
Common SNPs in the WNK1 and WNK4 genes have been shown to be associated with BP 
variation in the general population. Initially conflicting reports about associations between SNPs in 
these genes and BP variation/hypertension/response to treatment with diuretics were published 
(179-186). Recently, however, a large study of seven independent populations found that 
polymorphisms in the WNK1 gene were associated with BP variation and urinary potassium 
excretion (187).
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Although not genome-wide significant, a GWAS conducted in 2009 (188) reported strong 
association signals with common variants in STK39 (serine/threonine kinase gene 39), which 
encodes the SPAK (Ste20-related proline-alanine rich kinase) protein. A growing body of evidence 
indicates that SPAK interacts with cation-chloride co-transporters. Mutations in these co­
transporters cause monogenic forms of BP dysregulation as a part of an evolutionarily conserved 
signalling pathway important in controlling salt transport in osmotic cell volume regulation (5). In 
addition to the known effects of SPAK on the loop diuretic-sensitive Na+-K+-2CI' co-transporter 
(NKCC1), SPAK also phosphorylates its isoform, NKCC2, and the thiazide-sensitive NaCI co­
transporter (NCC) (6). These transporters play major roles in renal salt excretion, as evidenced by 
the direct involvement of NCC and NKCC2 in Gitelman and Bartter syndrome (7, 8). Cell-based 
functional studies have shown that SPAK is phosphorylated by WNK1 and WNK4 (6, 9). In vivo, 
STK39 is expressed in the distal nephron, where it may interact with these proteins (188).
In addition to their role in fluid homeostasis, ion channels regulate BP by influencing vascular tone 
(the contractile activity of vascular smooth muscle cells (VSMCs) in arterial walls) and cardiac 
contractility. Vasodilation decreases total peripheral resistance, while a decrease in cardiac 
contractility decreases cardiac output, both resulting in decreased BP.
In the heart, intracellular calcium, the level of which is regulated by calcium channel activity, is 
necessary to initiate cardiac contraction, and decreased intracellular calcium results in a decrease 
in cardiac contractility (189).
Vascular smooth muscle contraction is triggered by calcium/calmodulin dependent phosphorylation 
of the regulatory myosin light chain. Calcium influx through ion channels and calcium release from 
intracellular stores have been proposed as the major source of this activator calcium (190). The 
importance of calcium channels in BP regulation is confirmed by the efficiency of calcium channels 
blockers as a BP-lowering agent (191-193). Calcium channel blockers work by blocking voltage- 
gated calcium channels in cardiac muscle and blood vessels. This decreases intracellular calcium, 
leading to a reduction in muscle contraction (vasodilation).
Potassium channels also play an important role in regulating vascular tone. Vasoactive substances 
released by the endothelium activate potassium channels in the cell membrane and so increase 
potassium efflux (194), causing hyperpolarization of vascular smooth muscle, which contributes to 
relaxation by closing voltage-dependent calcium channels.
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Although a wide range of ion channels are known to affect BP regulation, there has been a bias in 
the literature to date for candidate gene studies of sodium channels. The more comprehensive 
pathway analysis conducted in this study also includes potassium, chloride and calcium channels.
4.1.2 Neurotransmitters
It has been known for some time that the autonomic nervous system, and particularly the 
sympathetic nervous system, plays a role in the control of blood pressure variation (195). There is 
growing evidence that essential hypertension is commonly neurogenic and is initiated and 
sustained by over-activity of the sympathetic nervous system (196). Elevated sympathetic nerve 
activity is present in most forms of human hypertension (197-199) and a causal relationship is 
suggested by the well-documented antihypertensive efficacy of sympatholytic drugs (inhibitors of 
the postganglionic functioning of the sympathetic nervous system, for example, a1- or (3-adrenergic 
receptor antagonists).
However, the precise causal mechanisms leading to sympathetic augmentation in hypertensive 
subjects are still poorly understood, and elevated sympathetic nerve activity might not be the sole 
mechanism involved in neurogenic hypertension. One commonly cited mechanism is the resetting 
of renal volume control to higher levels of BP by a rise in sympathetic tone to the kidney (200) or by 
affecting hormones whose production is partly controlled by the autonomic nervous system (for 
example, angiotensin II (201)). The role of this mechanism is supported by recent clinical trials 
which have demonstrated the blood pressure-lowering effects of renal denervation in patients with 
resistant hypertension (202). Abnormalities in the neural control of the heart and blood vessels may 
also be involved in BP control.
Although neurotransmitters have not been well investigated in genetic studies of BP variation, some 
reports have been published. These studies have largely involved components of the sympathetic 
nervous system involved in the "fight-or-flight” response, such as catecholamines (especially 
epinephrine and norepinephrine, hormones released by the adrenal glands in response to stress), 
and their adrenergic receptors. Plasma levels of norepinephrine have been associated in some 
studies with essential hypertension (203), and twin studies investigating the genetic influences on 
plasma and urinary norepinephrine after volume expansion and contraction suggest that this 
sympathetic nervous system activity is influenced by heritable factors which may contribute to the 
development of hypertension in some individuals(204). |3-2 adrenergic receptors mediate, among
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other things, vasodilation, and impaired function of p-2 adrenergic receptors has been implicated in 
salt-sensitive hypertension in Europeans (12). Genetic variation in the ADRB2 gene encoding the 
P-2 adrenergic receptor has been shown to be associated with hypertension in candidate gene 
studies in both European and Han Chinese populations (205-208).
Additionally, pathway analysis in recent GWAS has identified neurophysiological processes such as 
the glutamate regulation of dopamine (209) and transmission of nerve impulses (77) as 
overrepresented In the genes most strongly associated with hypertension in Europeans or blood 
pressure in African-Americans, (Table 4-1 and Table 4-2, respectively).
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Table 4-1. From (209). Pathways significantly overrepresented by genes associated with 
hypertension identified by GWAS in the Welcome Trust Case Control consortium, a population of 
European descent. Although a lack of genome-wide significant associations was observed for 
hypertension, a long list of significant and interconnected pathways was detected after pathway 
analysis of the most strongly associated SNPs from the GWAS of hypertension. The most 
significant pathway overrepresented in the genes most strongly associated with hypertension 
suggests a role for defects in dopamine signalling. Specifically, genes found among the most 
strongly associated with hypertension included the AMPA receptor (GRIA4), NMDA receptor 
(GRIN2A), and GABA-A receptor (GABRB3), which are all involved in glutamate regulation of 
dopamine D1A receptor signalling.
Pathway p-va lue
Neurophysioiogical process .Glutamate regulation of Dopamine 0.0002
D lA  receptor signaling
Regulation of lipid metabolism.Regulation of lipid metabolism 0.0005
by niacin and isoprenaline
Signal transduction_cAMP signaling 0.002
Cell adhesion_Endothelial cell contacts by non-junctional mechanisms 0.002
Immune response _MIF - the neuroendocrine-macrophage connector 0.004
Immune response _PGE2-induced pain processing 0.008
Apoptosis and survivaLBAD phosphorylation 0.01
Signal transduction_PKA signaling 0.01
Transcription. ChREBP regulation pathway 0.01
DevelopmencAipha-l adrenergic receptors signaling via cAMP 0.02
Celladhesion_Endothelial cell contacts by junctional mechanisms 0.02
Muscle contraction. GPCRs in the regulation of smooth muscle tone 0.02
Cytoskeleton remodeling_EphB receptors in dendritic spine 0.02
morphogenesis and synaptogenesis
Cell cycle.Chromosome condensation in prometaphase 0.03
Cytoskeleton re model ing_Role PKA in cytoskeleton reorganization 0.03
Signal transduction_Ca!cium signaling 0.04
Plasmalogen biosynthesis 0.04
Immune response _PGE2 signaling in immune response 0.04
Development.Beta-adrenergic receptors regulation of ERK 0.04
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Table 4-2. From (77). GeneGo pathways significantly overrepresented by genes associated with 
systolic and diastolic blood pressure identified by GWAS in an African-American population.
GeneGo Biological Process p
Transport_Synaptic vesicle exocytosis 4.525e-3
Neurophysiological process_Transmission of nerve impulse 1.050e-2
DNA damage_Checkpoint 3.169e-2
Transport_Potassium transport 4.885e-2
Reproduction_FSH-beta signaling pathway 4.986e-2
Cell adhesion_Cell junctions 5.213e-2
Development_Blood vessel morphogenesis 6.740e-2
Signal transduction_Androgen receptor signaling cross-talk 1.250e-1
Signal transduction_ESR1-membrane pathway 1.595e-1
Muscle contraction 2.599e-1
4.1.3 Study hypothesis and design
The strategy for this study was to perform screening gene-centric experiments with dense SNP 
coverage of multiple genes, selected on the basis of known involvement in two pathways important 
to BP regulation; (i) ion channels involved in BP-related physiological pathways such as renal salt 
reabsorption, neuronal signalling and smooth muscle contraction and (ii) neurotransmitters involved 
in the autonomic nervous system. This study was performed in two independent population-based 
samples of individuals with repeated clinic and ambulatory blood pressure measurements, who 
were free of anti-hypertensive medication.
The study design was as follows:
1. Test the hypothesis by looking for associations between 4424 SNPs covering 279 
candidate genes from the (i) ion channel and (ii) neurotransmitter pathways in a 'screening’ 
population of 358 individuals with clinic BP measurements.
2. Replicate the SNPs most significantly (P < 0.01) associated with BP variation in a further 
cohort, comprising 382 individuals with both clinic and ambulatory BP measurements.
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4 .2  M a te r ia ls  a n d  M e th o d s
4.2.1 Study Populations and BP measurement
Screening Population (AIBIIIB): 358 individuals were randomly selected from a cohort of 1024 
volunteers to the Allied Irish Bank Phase III blood pressure study (described in section 3.2.1).
These 358 individuals were chosen as the screening population because genotyping had been 
carried out on them as part of a multicentre epilepsy study (210).
Replication Population (AIBII): This population was comprised of the 387 individuals who 
participated in the first two phases of the AIB study, as described in section 3.2.1. Repeat 
ambulatory BP measurements were available for these subjects.
4.2.2 Blood Pressure and Laboratory Measurements.
As in the (P)RR study, it was decided to assess 3 different measurements of blood pressure in this 
study; systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP). 
Ambulatory and clinic BP was measured as described in section 3.2.2. For the Replication 
Population, both the phase I and phase II, clinic, daytime and night-time, BP measurements were 
included in the analyses models.
4.2.3 Genotyping and selection of candidate genes
Screening study: The ion channel and neurotransmitter genes analyzed in this study were 
originally selected as targets for a multicentre epilepsy study (210). The ion channels selected 
included all known members of the voltage-gated sodium and calcium channels, as well as a subset 
of members of the chloride and potassium channels. The neurotransmitters selected included key 
receptors, metabolisers, and transporters of the major neurotransmitters GABA, acetylcholine, 
glutamate and norepinephrine. Major targets, transporters, and metabolisers of the principal 
antiepileptic drugs were also included.
A combined direct (i.e., genotyped) and indirect (i.e., captured through linkage disequilibrium) 
tagging SNP mapping strategy was employed to capture all common variation across the set of 279 
candidate genes. A total of 1,758 functional and 3,442 tagging SNPs were genotyped across these
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279 candidate genes. These were comprised of 1,857 SNPs in 91 ion channel genes and 2,464 
SNPs in 188 neurotransmitter genes.
A summary of SNPs selected for genotyping is given in Table 4-3. A full list of SNPs along with 
details of SNP selection and details of the genotyping and the quality control criteria applied can be 
found in the online supplementary data of Cavalleri et al (210). SNP genotyping was performed on 
the Illumina GoldenGate platform, by the Duke Institute for Genome Sciences and Policy 
sequencing facility at Durham, North Carolina.
Table 4-3. Adapted from (210). Summary of SNPs selected for genotyping. * includes both 
synonymous and non-synonymous variants. ‘Functional’ SNPs are proposed to be such based on 
bioinformatic investigations. A panel of 103 SNPs was included for stratification analysis.
Category N
Functional
Total functional 879
Exons* 455
Promoter regions 182
Regulatory regions 63
Transcription factor binding sites 179
Other
Stratification check 103
Tagging 3,442
Total 4,424
Replication study: All SNPs which were associated with SBP, DBP or PP with a P-value of <0.01 
in the screening study were considered for inclusion in the replication study. We excluded 6 SNPs 
because they were in total linkage disequilibrium with another SNP in the same dataset ((^=1). 3 
SNPs were replaced with surrogates (i^=1) due to low designability scores. 34 SNPs in 20 ion 
channel genes and 62 SNPs in 33 neurotransmitter genes were selected for replication based on 
these criteria. A full list of the 96 SNPs included in the replication study is shown in Table 4-4. 
SNP genotyping was performed on the lllumina VeraCode platform, by the Duke Institute for 
Genome Sciences and Policy sequencing facility at Durham, North Carolina.
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Statistical Analyses:
In both the screening and the replication studies, analyses were performed using the software 
package PLINK version 1.07 (211) and R version 2.12.1 (http://www.r-project.org/). Quality control 
measures were applied, and SNPs with >1% missing genotype data were excluded. For the 
screening study, after quality control, 1485 SNPs in ion channels and 2292 SNPs in 
neurotransmitters remained in the final analyses. For the replication study, after quality control, 29 
ion channel SNPs and 60 neurotransmitter SNPs remained for analysis.
For the screening study, a linear regression, using the genotype as an additive covariate and blood 
pressure - clinic SBP, DBP or PP - as the response, was fitted for each SNP individually. All 
analyses were adjusted for age and sex. For the replication study, a linear regression, using the 
genotype as an additive covariate and blood pressure -  both clinic and ambulatory (daytime and 
night-time) SBP, DBP or PP - as the response, was fitted for each SNP individually. All analyses 
were adjusted for age and sex. In addition, as data for the replication population were collected in 
two phases (mean interval 8.4 years), a mixed model analysis was performed in addition to the 
linear regression analysis. The mixed model analysis included an additional random-effect term 
which included in the model the intra-individual variation in BP measurements after adjustment for 
time (age), and was performed using the R package nlme (212).
Population stratification was not anticipated to be a problem, due to the fact that all study 
participants were Caucasian Europeans. A genomic control lambda value for quantifying any 
potential population stratification effects was calculated from the QQ plots of association P-values 
using WGAViewer (213), assuming a 2 degrees of freedom chi distribution of the -2log(e)P 
measures (214). In each case, the lower 95% of the P values were distributed in accordance with 
random expectation, giving lambda values of «1, indicating that any effect of population stratification 
in this study was minimal.
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4.3 Results Part 1 ; Ion Channels
4.3.1 Ion channel screening study; QQ plots and replication SNPs
QQ plots of the P-values for association of the ion channel SNPs with BP phenotyped in the 
screening population are shown below (Figure 4-2). For both common (MAF £ 5%) and rare (MAF 
< 5%) SNPs, observed P-values deviated upwards from the expected line for SBP and PP. The 
QQ plot for DBP did not demonstrate enrichment for significant associations. P-values for 9 ion 
channel SNPs associated with SBP exceeded the 99% probability envelopes, hence the null 
hypothesis of no influence of these variants on BP was rejected and a replication study was carried 
out to confirm positive associations.
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SBP* Screening Population (N=358) DBP* Screening Population (N=358)
■  MAF >0.05
■  0.01 < MAF <0.05
 1----- -------------------1--------------------r
2 4 6
-log10 (expected P-value) -log10 (expected P-value)
Figure 4-2. QQ plots of P-values for 
association of the 1485 ion channel SNPs used 
in the screening study with clinic BP 
measurements. Observed P-values for 
association were plotted against those which would 
be expected under the null hypothesis of no 
^  association (black line). Shaded regions are 99%
92 probability envelopes (which depend on number of
$ SNPs and hence are different sizes for common
o, 2 ar,d low-frequency SNPs). SNPs were divided into
those with a minor allele frequency (MAF) in the
o population of = 5% (red), or < 5% (blue). Genomic
control A values were calculated including only 
SNPs with MAF = 0.01 and the lower 95% of the 
distribution and were as follows: SBP: A=1.03, 
DBP: A=0.99, PP: A=1.00. SBP, systolic blood 
pressure; DBP, diastolic blood pressure, PP, 
pulse pressure. ‘Adjusted for the covariates age 
and sex.
All ion channel SNPs which were associated with SBP, DBP or PP with a P-value of =0.01 in the 
screening study were included in the replication study. This included 34 ion channel SNPs (Table 
4-4).
PP* Screening Population (N=358)
-log10 (expected P-value)
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Table 4-4. 34 ion channel SNPs associated with SBP, DBP or PP with a P-value of <0.01 in 
the screening study. One SNP, rs3747977, was replaced by a surrogate (1^=1) for the replication 
study due to poor designability. ‘ replacing rs3747977. Bold font indicates P-values from the 
screening study of <0.01.
SNP CHR BP GENE MAF
systo lic BP 
BETA P
diasto lic  BP 
BETA P
pulse pressure 
BETA P
rs 1862260 19 13452771 CACNA1A 0.47 -2.47 0.01 -0.48 0.47 -1.98 3.7E-03
rsll20559 19 13460575 CACNA1A 0.09 0.94 0.60 3.44 5.7E-03 -2.50 0.04
rs6766988 3 53814509 CACNA1D 0.10 4.81 4.1E-03 2.12 0.07 2.69: 0.02
rs 198544 17 46000503 CACNA1G 0.49 1.64 0.12 -0.28 0.70 1.93 6.8E-03
rs2158408 17 46035655 CACNA1G 0.24 -1.55 0.20 -2.18 7.8E-03 0.63 0.45
rs3768655 2 152539530 CACNB4 0.11 4.54: 4.9E-03 1.95 0.08 2.59 0.02
rs757200 16 24227194 CACNG3 0.30 3.15: 3.5E-03 1.31 0.08 1.84 0.01
rs 740557 17 62451138 CACNG4 0.15 4.47 1.3E-03 1.91 0.05 2.55 7.6E-03
rs 758664 17 62301733 CACNG5 0.35 1.86 0.10 -0.32 0.68 2.17' 4.6E-03
rs6770808 3 185547765 CLCN2 0.22 -2.25 0.06 0.14 0.86 -2.39 3.4E-03
rs2228291 3 185557748 CLCN2 0.22 2.74 0.02 2.14 8.7E-03 0.61! 0.46
rs3810740 23 9536110 CLCN4 0.21 2.85 0.05 2.65 5.9E-03 0.20 0.84
rs5933811 23 9544329 CLCN4 0.20 2.80 0.05 2.76 4.4E-03 0.03 0.97
rs7523558 1 16092037 CLCNKA 0.05 -7.15, 1.3E-03 -3.33 0.03 -3.82 0.01
rs945425 1 16093717 CLCNKA 0.32 3.55 9.6E-04 1.12 0.13 2.43 9.7E-04
rs 1889785 1 16094034 CLCNKA 0.48 -3.61: 2.5E-04 -1.40 0.04 -2.21 1.1E-03
rs 1805152 1 16101806 CLCNKA 0.41 3.37 7.4E-04 1.12 0.11 2.25 1.0E-03
rs6604912 1 16129292 CLCNKB 0.46 -3.70 2.4E-04 -1.53 0.02 -2.16 1.7E-03
rs 10513488 3 157638338 KCNAB1 0.04 5.55 0.04 -0.38 0.83 5.93 1.1E-03
rs6777084 3 157641633 KCNAB1 0.03 10.22 1.3E-03 -0.41 0.85 10.63 8.6E-07
rsl546750 3 157668593 KCNAB1 0.39 -2.25 0.03 -2.02 3.2E-03 -0.23 0.74
rs4254605 3 157721236 KCNAB1 0.21 -3.44 6.3E-03 -1.74 0.04 -1.70 0.05
rs3821686 3 157748641 KCNAB1 0.20 -1.97 0.10 -2.63 1.6E-03 0.66 0.43
rs3205229* 1 6092827 KCNAB2 0.32 -0.91 0.41 -2.42 1.4E-03 1.51 0.05
rs7645550 3 180451335 KCNMB3 0.40 2.77 0.01 2.21 2.4E-03 0.55 0.45
rsll83319 3 180451808 KCNMB3 0.39 -2.61 0.01 -1.95 6.4E-03 -0.65 0.36
rs756851 11 2563940 KCNQ1 0.14 -2.24 0.12 0.61 0.54 -2.85 3.6E-03
rs 16904603 8 133212154 KCNQ3 0.19 4.43 6.7E-04 0.98 0.27 3.45 1.1E-04
rsl6883374 6 73904625 KCNQ.5 0.04 -1.89 0.49 3.23 0.09 -5.12 5.8E-03
rs9341413 6 73956811 KCNQ5 0.24 -2.03 0.08 -2.10 7.7E-03 0.07 0.93
rs10048748 2 165821833 SCN3A 0.27 3.29 4.3E-03 1.72 0.03 1.57 0.05
rs6432812 2 165837125 SCN3A 0.29 3.67 1.1E-03 1.75 0.02 1.91 0.01
rs 1275085 11 123018370 SCN3B 0.06 -5.69 8.4E-03 -4.05 5.4E-03 -1.64 0.27
rsl0876202 12 50299849 SCN8A 0.09 2.94 0.09 3.15 7.7E-03 -0.21 0.86
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4.3.2 Ion channel replication study; power calculations
As mentioned in section 3.3.2, the statistical power of a study is the probability that the test will 
reject the null hypothesis when the null hypothesis is false. As in chapter 3, a post-hoc power 
analysis was used for this study to help to indicate how likely the study was to have identified ‘true’ 
associations, assuming that they exist. For the replication study, power was calculated using the 
Quanto power calculator (http://hydra.usc.edu/gxe/). Power was calculated assuming a continuous 
variable, an additive inheritance model, gene-only effects (no gene-gene or gene-environment 
interactions were accounted for), and a 2-sided test. Power was estimated assuming a variety of 
minor allele frequencies (MAF) of the genetic variants; MAF 0.01, MAF 0.05, and all allele 
frequencies increasing in increments of 0.05 from MAF0.05 to MAF 0.5. In order to correct for the 
effects of testing many thousands of SNPs (multiple testing), it was necessary in this study to 
impose a type I error rate more stringent than the commonly used 5% (0.05). Because of this, 
power was calculated assuming a type I error rate of 5.7x1 O'04, which was the Bonferroni-corrected 
error threshold used for this study (section 4.3.4).
Figure 4-3 indicates that overall, this study only had good (-80%) power to detect SNPs which were 
both relatively common (MAF>20%) and associated with substantial BP effect sizes (>4mmHg 
change per minor allele), at a type I error rate of 5.7x1 O'04.
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F igu re  4-3. P ow er p lo ts  fo r  a s s o c ia tio n  be tw een io n  cha nn e l SNPs and a m b u la to ry  (d a y /n ig h t)  and 
c lin ic  BP leve ls . The power o f this study to detect associations between ion channel SNPs and SBP and 
DBP levels in the replication population (N=760), a t a type I error (a) level o f 5.7x1 O'04 w as plotted. The 
population mean ± standard deviation o f daytime SBP (daySBP) was 123mmHg ± 21 mmHg, nighttim e SBP 
(nightSBP) was 105mmHg ± 19mmHg and c lin icS B P  was 119mmHg ± 25mmHg. The population mean ± 
standard deviation o f daytime DBP (dayDBP) was 77mmHg ± 14mmHg, nighttim e DBP (nightDBP) was 
61 mmHg ± 13mmHg and clin ic DBP was 75m m Hg ± 16mmHg. Power was plotted assum ing five  different 
main effect sizes o f SBP associated with carriership o f one m inor allele (0 .5 ,1 ,2 , 4, o r 6  mmHg). The 
maximum effect size per m inor allele carried observed in the results o f the ion channel study was 7mmHg.
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4.3.3 Ion channel replication study; QQ plots
The QQ plots for the 29 ion channel SNPs which were successfully genotyped in the replication 
study (Figure 4-4-Figure 4-6) illustrate a strong enrichment for significant associations, indicating 
that a large number of the SNPs that were significantly associated with BP in the screening study 
(P<0.01) were also associated with BP in the replication study. Observed P-values exceed the 99% 
probability envelopes for association with ambulatory SBP and DBP, particularly.
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Figure 4-4. QQ plots o f P-values for 
association of the 29 ion channel SNPs 
genotyped in the replication study with  
daytime ambulatory BP measurements.
Observed P-values for association were 
plotted against those which would be 
expected under the null hypothesis of no 
association (black line). Shaded regions are 
99% probability envelopes. SNPs were 
divided into those with a minor allele 
frequency (MAF) in the population of = 5% 
(red), or < 5% (blue). SBP, systolic blood 
pressure; DBP, diastolic blood pressure,
PP, pulse pressure. ‘Adjusted for the 
covariates age and sex.
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Figure 4-5. QQ plots of P-values fo r 
association o f the 29 ion channel SNPs 
genotyped in the replication study w ith  
nighttime ambulatory BP measurements.
Observed P-values for association were 
plotted against those which would be 
expected under the null hypothesis of no 
association (black line). Shaded regions 
are 99% probability envelopes. SNPs were 
divided into those with a minor allele 
frequency (MAF) in the population of = 5% 
(red), or < 5% (blue). SBP, systolic blood 
pressure; DBP, diastolic blood pressure, 
PP, pulse pressure. ‘Adjusted for the 
covariates age and sex.
90
clinicSBP* Replication Population (N=746)
-logio (expected P-value)
clinicPP* Replication Population (N=746)
-iog10 (expected P-value)
91
clinicDBP* Replication Population (N=746)
-log10 (expected P-value)
Figure 4-6. QQ plots o f P-values for 
association o f the 29 ion channel SNPs 
genotyped in the replication study with  
clinic BP measurements. Observed P- 
values for association were plotted against 
those which would be expected under the 
null hypothesis of no association (black line). 
Shaded regions are 99% probability 
envelopes. SNPs were divided into those 
with a minor allele frequency (MAF) in the 
population of = 5% (red), or < 5% (blue). 
SBP, systolic blood pressure; DBP, diastolic 
blood pressure, PP, pulse pressure. 
‘Adjusted for the covariates age and sex.
4.3.4 Ion Channel Replication Study; Results
Table 4-5 summarizes the associations of the 9 ion channel SNPs which were consistently 
associated with variation in any BP phenotype in both the screening and replication studies, where 
P-values for both studies were <0.05 and the association had the same direction of effect in both 
studies.
The 9 SNPs included two SNPs in the voltage-gated chloride channel CLCN2, rs2228291, which 
was associated with increased SBP and DBP, and rs6770808, which was associated with 
decreased PP. SNPs in three voltage-gated potassium channels were also consistently associated 
with BP phenotypes; rs10513488 in KCNAB1 was associated with increased SBP and PP; 
rs3205229 in KCNAB2 was associated with decreased DBP and increased PP; and rs16904603 in 
KCNQ 3  was associated with increased SBP and PP. Two SNPs in the voltage-gated sodium 
channel SCN3A, rs10048748 and rs6432812 were both associated with increased DBP and one 
SNP in the related SCN3B  gene rs1275085, was associated with decreased SBP and DBP.
The Bonferroni correction for multiple testing was applied to provide a 5% overall false positive rate 
control and was calculated, based on 29 SNPs and 3 phenotypes, as 0.05/87,or 5.7x1 O'04. Two of 
the 9 SNPs consistently associated with BP phenotypes had P-values for association which 
exceeded the Bonferroni correction for multiple testing; rs10513488 in KCNAB1 and rs2228291 in 
CLCN2  (shown in red in Table 4-5).
Permutation testing was performed in order to obtain an empirical P-value for each SNP which 
would control for multiple testing, and reflect the chance of seeing a test statistic of the given size, 
given the number of tests performed. As permutation preserves the correlation between SNPs, it 
provides a less stringent correction for multiple testing in comparison to the Bonferroni, which 
assumes all tests are independent. Permutation was performed in PLINK using the ‘MaxT’ 
permutation procedure and performing 1000 permutations. For each permutation, phenotype- 
genotype labels were swapped and a new test statistic calculated to provide a new dataset sampled 
under the null hypothesis. The corrected P-values were then calculated by comparing each test 
statistic against the maximum of all permuted statistics (i.e. over all SNPs) for each single replicate. 
These P-values are shown in Table 4-5, indicated in italics. They are in accordance with the 
statistical P-values, and indicate that after correction for multiple testing, rs10513488 was 
associated with increased clinic SBP at P=0.02, and that rs2228291 was associated with increased 
daytime and nighttime DBP at P=5.0x10'°3 and 1.0x10"°4, respectively, in this study.
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The regional association plot for rs10513488 (Figure 4-7) shows that four other SNPs in the region 
were genotyped in the replication study, however none of these SNPs was associated with SBP, 
nor in high LD with rs10513488. The regional association plot for rs2228291 (Figure 4-9), similarly, 
showed that there was only one other SNP genotyped in the region, which was neither associated 
with DBP nor in high LD with rs2228291.
The boxplots below show the distribution of the BP phenotype most strongly associated with these 
2 SNPs, based on the number of minor alleles carried (Figure 4-8 and Figure 4-10). There were no 
minor allele homozygotes in this population for rs10513488, however the boxplot and adjacent 
density plots show that heterozygotes for the minor allele had higher clinic SBP than major allele 
homozygotes (Figure 4-8). The boxplot of night DBP distribution by minor alleles of rs2228291 
carried shows a clear increase in DBP proportional to the number of minor alleles carried (Figure
4-10).
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Table 4-5. The 9 ion channel SNPs which were consistently associated with BP variation in both the screening and the replication populations (P<0.05, same direction of effect). All analyses were adjusted for age and sex. Values given are beta (mmHg) per minor allele carried, followed by the P-values for the association in parentheses; uncorrected P-value followed by corrected P-value following 1000 permutations in italics. Red font indicates loci and associations which exceeded Bonferroni correction for 29 SNPs and 3 phenotypes, 5.7x1 O'04 and/or were significant (P<0.05) after 1000 permutations. MAF: minor allele frequency.
Systolic BP | Diastolic BP I Pulse Pressure
Clinic
Day
Night
rs3205229 (KCNAB2)
Screening 
(MAF 0.32)
Replication 
(MAF 0.36)
Screening
(MAF 0.32)
Replication
(MAF 0.36)
Screening 
(MAF 0.32)
Replication 
(MAF 0.36)
-0.9 (0.41) 0.9 (0.30,1.00) 
0.7(0.26,1.00) 
-0.7(0.23,1.00)
-2.4 (1.4E-03) 0.6(0.31,1.00) 
-0.2(0.73,1.00) 
-1.0(0.01,0.65)
1.5 (0.05) 0.3(0.60,1.00) 
0.8 (0.04,0.96)
0.3(0.39,1.00)
Clinic
Day
Night
Screening 
(MAF 0.27)
Replication 
(MAF 0.28)
rslOO
Screening 
(MAF 0.27)
48748 (SCN3A)
Replication 
(MAF 0.28)
Screening 
(MAF 0.27)
Replication 
(MAF 0.28)
3.3(4.3E-03) 0.8(0.39,1.00) 
0.5 (0.41,1.00) 
0.7(0.24.1.00)
1.7(0.03) 1.3(0.03,0.91)
0.5(0.25,1.00) 
0.6(0.16.1.00)
1.6(0.05) 0.5(0.49,1.00) 
0.0(1.0,1.00) 
0.1(0.78,1.00)
Clinic
Day
Night
Screening
(MAF 0.29)
Replication 
(MAF 0.29)
rs64I
Screening 
(MAF 0.29)
12812 (SCN3A)
Replication
(MAF 0.29)
Screening
(MAF 0.29)
Replication 
(MAF 0.29)
3.7 (1.1E-03) 0.7 (0.41,1.00) 
0.5 (0.42,1.00) 
0.7(0.28,1.00)
1.8(0.02) 1.2(0.04,0.96)
0.5(0.29,1.00) 
0.7(0.12,1.00)
1.9(0.01) -0.4 (0.51,1.00) 
0.0 (0.95,1.00) 
0.0(0.98,1.00)
Clinic
Day
Night
Screening
(MAF 0.04)
Replication
(MAF 0.05)
rsl051 
Screening 
(MAF 0.04)
L3488(KCNAB1) 
Replication 
(MAF 0.0S)
Screening
(MAF 0.04)
Replication
(MAF 0.05)
5.5 (0.04) 7.0 (1.9E-04, 0.02) 
3.6 (5.6E-03,0.44) 
3.5 (5.0E-03,0.37}
-0.4 (0.83) 3.0(0.01,0.62)
1.3(0.17,1.00) 
1.0(0.27,1.00)
5.9 (1.1E-03) 4.0 (3.1E-03,0.24) 
2.3 (8.9E-03,0.57) 
2.5 (1.5E-03. 0.14)
Clinic
Day
Night
Screening
(MAF 0.22)
Replication
(MAF 0.24)
rs67' 
Screening 
{MAF 0.22)
70806 (CLCN2)
Replication
(MAF 0.24)
Screening 
(MAF 0.22)
Replication 
(MAF 0.24)
-2.2 (0.06) -1.2(0.21,1.00) 
-1.8 (7.8E-03,0.51)
-1.1(0.08,1.00)
0.1(0.86) 0.3(0.59,1.00) 
-0.9(0.08,0.99) 
-0.4(0.41,1.00)
-2.4 (3.4E-03) -1.6(0.03,0.89) 
-0.9(0.04,0.96)
-0.7(0.07,1.00)
Clinic
Day
Night
Screening 
(MAF 0.22)
Replication 
(MAF 0.21)
rsiZ  
Screening 
(MAF 0.22)
18291 (CLCN2)
Replication 
(MAF 0.21)
Screening 
(MAF 0.22)
Replication 
(MAF 0.21)
2.7 (0.02) 2.9 (2.6E-03,0.21) 
1.8 (8.9E-03, 0.55) 
2.1 (1.3E-03,0.11)
2.1(8.7E-03) 1.0(0.10,1.00)
2.0 (3.3E-05, 5.0E-03)
2.0 (1.3E-05,1.0E-04)
0.6 (0.46) 1.9 (6.3E-03,0.41)
-0.2(0.60,1.00) 
0.1(0.81,1.00)
Clinic
Day
Night
Screening 
(MAF 0.24)
Replication 
(MAF 0.26)
rs934 
Screening 
(MAF 0.24)
11413 (KCNQ5)
Replication
(MAF 0.26)
Screening 
(MAF 0.24)
Replication 
(MAF 0.26)
-2.0(0.08) -0.1(0.88,1.00) 
0.3(0.58,1.00) 
-1.0(0.09,1.00)
-2.1 (7.7E-03) -0.4(0.46,1.00) 
-0.4(0.39,1.00) 
-1.0(0.02, 0.69)
0.1(0.93) 0.3(0.67,1.00) 
0.7(0.08,1.00) 
0.0(0.99,1.00)
Clinic
Day
Night
Screening 
(MAF 0.19)
Replication 
(MAF 0.18)
rsl69 
Screening 
(MAF 0.19)
04603 (KCNQ3)
Replication 
(MAF 0.18)
Screening 
(MAF 0.19)
Replication 
(MAF 0.18)
4.4(6.7E-04) -0.4(0.74,1.00) 
0.7(0.37,1.00) 
1.2(0.10,1.00)
1.0(0.27) -0.1(0.93,1.00) 
0.2(0.64,1.00) 
0.2(0.69,1.00)
3.4(l.lE-04) -0.3(0.70,1.00) 
0.4(0.40,1.00) 
1.0(0.03, 0.92)
Clinic
Day
Night
Screening
(MAF 0.06}
Replication
(MAF 0.08)
rsl2 
Screening 
(MAF 0.06)
75085 (SCN3B)
Replication
(MAF 0.08)
Screening 
(MAF 0.06)
Replication
(MAF 0.08)
-5.7 (8.4E-03) 2.5 (0.10,1.00) 
-1.8(0.08,1.00) 
-2.6 (8.5E-03,0.52)
-4.1(5.4E-03) -1.2(0.20,1.00) 
-0.9 (0.24,1.00) 
-1.9 (8.1E-03, 0.47)
■1.6(0.27) -1.3(0.25,1.00) 
-0.9(0.19,1.00) 
-0.8(0.23,1.00)
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Figure 4-7. Regional plot of the ‘tophit’ SNP in KCNAB1, rs10513488 (purple diamond), and 
the genotyped SNPs within 200kb either side of it. The P-values for association of these SNPs 
with clinic SBP in the study are given on the y-axis. Linkage disequilibrium with rs10513488 is 
colour-coded based on the r2 values from Hapmap phase 3. cM: centimorgans; Mb: megabases. 
This plot was created by Locuszoom (215).
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Figure 4-8. Boxplot and density plots o f c lin ic SBP distribution by rs10513488 genotypes in 
the replication population. There were no subjects in the replication population who were 
homozygous for the minor allele at this locus.
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Figure 4-9. Regional plot of rs2228291, in CLCN2 (purple diamond), and the genotyped SNPs 
within 200kb either side of it. The P-values for association of these SNPs with nighttime DBP in 
the study are given on the y-axis. Linkage disequilibrium with rs2228291 is colour-coded based on 
the r2 values from Hapmap phase 3. cM: centimorgans; Mb: megabases. This plot was created by 
Locuszoom (215).
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Figure 4-10. Boxplot and density plots of nighttime DBP distribution by rs2228291 
genotypes in the replication population.
BP measurements were recorded for the replication population at two time points, an average of 8.4 
years apart. In order to use this information to ascertain whether the statistically significant 
associations observed in this study remained significant after accounting for a model of the time- 
adjusted within-individual variation in BP measurements, a linear mixed model analysis was applied 
to the two SNPs which remained significantly associated with BP phenotypes in this study after 
Bonferroni correction for multiple testing. The results of these analyses are shown in Table 4-6. 
Although inclusion of intra-individual variation in BP measurement predictably reduces the 
significance of the associations somewhat, both the beta and the P-values remain similar to those 
observed without adjustment for individual BP variation, and the P-value for the association 
between rs2228291 and nighttime ambulatory DBP remained in excess of the Bonferroni correction.
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Table 4-6. Linear mixed model (LMM) analysis of the significantly associated SNPs 
rs10513488 and rs2228291 with BP phenotypes in the replication study. The LMM analysis 
included age-adjusted variation in BP measurements between the two study phases for each 
individual as an additional explanatory variable in the model. Bold type indicates P<0.05. As the 
software used for this analysis only outputs P-values correct to 4 decimal places, accurate values at 
P<1x10'04 were not available.
rsl0513488 (KCNAB1)
Systolic BP Diastolic BP Pulse Pressure
BETA P N BETA P N BETA P N
Clinic SBP 7.4 8.7E-03 370 4.8 6.3E-03 370 2.6 0.19 370
Day SBP 3.1 0.12 369 0.9 0.53 369 2.2 0.09 369
Night SBP 3.0 0.12 369 1.2 0.37 369 1.8 0.13 369
rs2228291 (CLCN2)
Systolic BP Diastolic BP Pulse Pressure
BETA P N BETA P N BETA p N
Clinic SBP 4.4 2.8E-03 370 1.3 0.15 370 3.0 3.4E-03 370
Day SBP 1.9 0.07 369 2.0 5.1E-03 369 -0.1 0.85 369
Night SBP 2.7 6.1E-03 369 2.8 C1.0E-04 369 -0.1 0.89 369
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4.4 Results Part 2; Neurotransmitters
4.4.1 Neurotransmitter Screening Study; QQ Plots and Replication SNPs
QQ plots of the P-values for association of the neurotransmitter SNPs with BP phenotyped in the 
screening population are shown below (Figure 4-11). For both common (MAF > 5% ) and rare 
(MAF < 5%) SNPs, observed P-values deviated upwards from the expected line for SBP and DBP, 
and to a lesser extent for PP. P-values for a small number of SNPs associated with each 
phenotype exceeded the 99% probability envelopes, hence the null hypothesis of no influence of 
these variants on BP was rejected and a replication study was carried out to confirm positive 
associations.
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Figure 4-11. QQ plots o f P-values for 
association of the 2292 neurotransmitter SNPs 
used in the screening study with clin ic BP 
a, measurements. Observed P-values for
is association were plotted against those which
^  4 would be expected under the null hypothesis of no
association (black line). Shaded regions are 99% 
probability envelopes (which depend on number of 
« SNPs and hence are different sizes for common
°  ° and low-frequency SNPs). SNPs were divided
dn into those with a minor allele frequency (MAF) in
the population of = 5% (red), or < 5% (blue). 
Genomic control A values were calculated 
including only SNPs with MAF = 0.01 and the 
lower 95% of the distribution and were as follows: 
SNP: A=1.02, DBP: A=1.07, PP: A=0.95. SBP, 
systolic blood pressure; DBP, diastolic blood
All neurotransmitter SNPs which were associated with SBP, DBP or PP with a P-value of =0.01 in 
the screening study were included in the replication study. This included 62 neurotransmitter SNPs 
(Table 4-7).
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Table 4-7. SNPs asso c ia te d  w ith  SBP, DBP o r PP w ith  a P -va lue o f  <0.01 in  the  s c re e n in g  s tud y . TwoSNPs, rs2229155* and , rs10502061** were replaced by surrogates (1^ =1), replacement SNPs are marked with corresponding asterisks. Bold font indicates P-values from the screening study of <0.01.
SNP CHR BP GENE
systolic BP 
BETA P
diastolic BP 
BETA P
pulse pressure 
BETA P
rsl592669 12 13997288 ABCA2 12.30 4.7E-03 6.12 0.04 6.18 0.04
rs2273697 10 101553805 ABCC2 3.09 0.03 2.83 3.0E-03 0.26 0.78
rs2095751 1 111746517 ADORA3 -3.72 2.4E-03 -1.51 0.07 -2.22 8.4E-03
rsl415792* 1 111754674 ADO R A3 -4.22 1.7E-03 -2.13 0.02 -2.09 0.02
rs6S37704 1 111764146 ADORA3 -2.91 0.06 -2.77 7.3E-03 -0.14 0.89
rsl0857888 1 111766407 ADORA3 -2.65 0.07 -2.60 7.6E-03 -0.05 0.96
rs lll0 2 29 0 1 111767126 ADORA3 -2.52 0.08 0.21 0.83 -2.72 5.4E-03
rsl7027880 1 111767569 ADORA3 -3.57 0.05 -0.16 0.90 -3.42 6.2E-03
rs5745568 6 33656371 BAK1 -4.07 6.3E-03 -2.57 0.01 -1.50 0.14
rs395671 6 33661654 BAK1 3.31 1.3E-03 1.68 0.02 1.64 0.02
rs 1005793 18 59041139 BCL2 0.41 0.85 -3.53 0.02 3.94 7.3E-03
rs698708 18 59146240 BCL2 2.59 0.03 0.27 0.73 2.32 3.0E-03
rs8178980 10 50483598 CHAT 4.22 0.02 0.57 0.65 3.66 4.1E-03
rs2075748 11 62444844 CHRM1 1.52 0.23 -0.94 0.28 2.46 4.1E-03
rsl0792363 11 62452992 CHRM1 1.44 0.22 -1.21 0.13 2.64 8.8E-04
rs6863932 5 175261485 CPLX2 -1.62 0.13 -1.98 5.8E-03 0.37 0.61
rs 1934963 10 96724665 CYP2C9 1.59 0.25 -0.84 0.37 2.44 8.2E-03
rs4759783 12 129790389 EPIM 2.96 7.3E-03 2.16 4.0E-03 0.80 0.28
rs29225 6 29689019 GABBRI 3.15 0.05 0.21 0.85 2.95 6.8E-03
rs7672100 4 47106517 GABRB1 2.54 0.03 0.39 0.63 2.14 7.SE-03
rs 10043074 5 160780541 GABRB2 -4.44 1.3E-03 -3.45 2.1E-04 -0.99 0.30
rs7714930 5 160792500 GABRB2 -4.69 1.5E-04 -3.27 9.6E-05 -1.41 0.09
rsl0038621 5 160814548 GABRB2 -4.48 8.2E-03 -3.63 l.SE-03 -0.85 0.47
rs4426954 5 160885608 GABRB2 -1.69 0.09 -1.79 0.007905 0.11 0.8745
rs2266856 23 149759144 GAB RE 2.86 0.03 -0.31 0.7207 3.18 0.000312
rs8024595 15 25400121 GABRG3 3.58 0.08 3.83 5.2E-03 -0.25 0.85
rs454461 6 89963742 GABRR1 -2.59 0.01 -0.47 0.50 -2.12 1.7E-03
rs2150817 6 89970238 GABRR1 -3.50 1.5E-03 -1.28 0.09 -2.22 3.3E-03
rsl7504587 6 89982920 GABRR1 -3.47 0.01 -0.60 0.52 -2.88 2.4E-03
rs3734197 6 90021196 GABRR2 -4.15 0.02 -4.36 3.0E-04 0.21 0,86
rs3781109 10 26608367 GAD2 -3.67 1.7E-03 -1.88 0.02 -1.79 0.02
rsl571930 9 98499386 GPR51 3.11 0.02 0.63 0.50 2.48 7.1E-03
rsl940966** 11 105120462 GRIA4 -5.04 6.9E-03 -3.61 S.0E-03 -1.43 0.27
rs609507 11 105277890 GRIA4 -4.78 7.3E-03 -2.87 0.02 -1.91 0.12
rs2832417 21 29933642 GRIK1 7.61 1.9E-03 2.69 0.10 4.92 3.4E-03
rs2224201 6 102058194 GRIK2 2.89 0.01 0.24 0.77 2.66 9.9E-04
rs2247210 6 102072945 GRIK2 1.98 0.07 -0.57 0.45 2.55 5.5E-04
rs2786249 6 102185692 GRIK2 3.75 0.02 0.50 0.64 3.25 2.3E-03
rsl359439 6 102331193 GRIK2 3.79 5.0E-03 1.90 0.04 1.88 0.04
rs4839802 6 102360996 GRIK2 -5.87 5.9E-03 -3.27 0.02 -2.60 0.08
rsl0892608 11 120054954 GRIK4 -2.98 2.3E-03 -1.58 0.02 -1.40 0.04
rs4582985 11 120059250 GRIK4 -3.00 2.6E-03 -1.61 0.02 -1.39 0.04
rsl0892618 11 120073601 GRIK4 -2.71 8.2E-03 -1.54 0.03 -1.17 0.10
rs3133860 11 120166387 GRIK4 3.57 0.01 3.19 1.2E-03 0.38 0.70
rs2217342 19 47181356 GRIK5 -2.93 0.12 -3.39 7.9E-03 0.46 0.72
rsl806193 12 13612129 GRIN2B 11.17 3.4E-03 3.65 0.16 7.52 3.4E-03
rs 1805482 12 13656040 GRIN2B -3.05 4.5E-03 -1.93 8.1E-03 -1.11 0.12
rs2193512 12 13896291 GRIN2B 3.87 5.5E-04 1.85 0.02 2.02 7.4E-03
rsll563487 7 126421253 GRM8 5.87 0.13 7.01 6.9E-03 -1.15 0.66
rs3852908 19 545598 HCN2 -2.87 3.8E-03 -1.03 0.13 -1.84 6.9E-03
rs830133 19 52666390 NAPA -5.22 0.05 -5.39 2.8E-03 0.17 0.92
rsl054190 3 121019407 NR1I2 3.45 0.04 0.27 0.81 3.18 4.0E-03
rs llll0 3 5 6 12 99275934 SLC17A8 -3.25 8.4E-03 -1.58 0.06 -1.67 0.05
rsl0860589 12 99303530 SLC17A8 7.20 4.SE-04 4.24 2.2E-03 2.96 0.04
rsl0814995 9 4495543 SLC1A1 2.85 7.6E-03 1.75 0.02 1.09 0.13
rs 2026828 9 4533306 SLC1A1 -3.59 1.4E-03 -1.75 0.02 -1.83 0.02
rs 1043101 11 35231404 SLC1A2 3.08 3.8E-03 1.56 0.03 1.52 0.03
rs911562 11 35355928 SLC1A2 -2.93 4.4E-Q3 -1.79 0.01 -1.15 0.10
rs7108848 11 35365916 SLC1A2 4.66 1.5E-03 1.60 0.11 3.06 1.9E-03
rsl2074944 1 53328744 SLC1A7 -4.06 0.01 -3.28 2.7E-03 -0.78 0.48
rs362564 20 10192626 SNAP25 -2.28 0.02 -0.50 0.46 -1.78 7.0E-03
rs7652520 3 12167627 SYN2 6.23 3.2E-03 3.85 7.5E-03 2.38 0.09
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4.4.2 Neurotransmitter Replication Study; Power Calculations
A post-hoc power analysis was again used for this study to help to indicate how likely the study was 
to have identified ‘true’ associations, assuming that they exist. Power was again calculated using 
the Quanto power calculator (http://hydra.usc.edu/gxe/), assuming a continuous variable, an 
additive inheritance model, gene-only effects (no gene-gene or gene-environment interactions were 
accounted for), and a 2-sided test. Power was estimated assuming a variety of minor allele 
frequencies (MAF) of the genetic variants; MAF 0.01, MAF 0.05, and all allele frequencies 
increasing in increments of 0.05 from MAF0.05 to MAF 0.5. In order to correct for the effects of 
testing many thousands of SNPs (multiple testing), it was necessary in this study to impose a type I 
error rate more stringent than the commonly used 5% (0.05). Because of this, power was 
calculated assuming a type I error rate of 2.7x10"04, which was the Bonferroni-corrected error 
threshold used for this study (section 4.4.4).
Figure 4-12 indicates that overall, this study only had good (-80%) power to detect SNPs which 
were both relatively common (MAF>20%) and associated with substantial BP effect sizes (>4mmHg 
change per minor allele), at a type I error rate of 2.7x1 O'04.
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Figure 4-12. Power plots for association between neurotransmitter SNPs and ambulatory (day/night) and clinic BP levels. The power of this study to detect associations between SNPs and SBP and DBP levels in the replication population (N=760), at a type I error (a) level of 2.7x1 O'04 was plotted. The population mean ± standard deviation of daytime SBP (daySBP) was 123mmHg ± 21mmHg, nighttime SBP (nightSBP) was 105mmHg ± 19mmHg and clinic SBP was 119mmHg ± 25mmHg. The population mean ± standard deviation of daytime DBP (dayDBP) was 77mmHg ± 14mmHg, nighttime DBP (nightDBP) was 61 mmHg ± 13mmHg and clinic DBP was 75mmHg ± 16mmHg. Power was plotted assuming five different main effect sizes of SBP associated with carriership of one minor allele (0.5, 1, 2, 4, or 6 mmHg). The maximum effect size per minor allele carried observed in the results of the ion channel study was 6.5mmHg.
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4.4.3 Neurotransmitter Replication Study; QQ Plots
The QQ plots for the 60 neurotransmitter SNPs which were successfully genotyped in the 
replication study (Figure 4-13-Figure 4-15) illustrated a strong enrichment for significant 
associations, indicating that a large number of the SNPs that were significantly associated with BP 
in the screening study (P<0.01) were also associated with BP in the replication study, Observed P- 
values exceed the 99% probability envelopes for association with nighttime and clinic BP values, 
particularly.
daySBP* Replication Population (N=747) dayDBP* Replication Population (N=747)
j  4 ®
5i i
a. cl
1
CD
W o J CO.o 2 - _________ .n
o0501 S’
■  MAF 2: 0.05
■  0.01 < MAF <0.05
■  MAF ä 0.05
■  0.01 < MAF <0.05-----------1----------------- 1---------
2 4
-log10 (expected P-value)
-y- j—
2 4
-log10 (expected P-value)
dayPP* Replication Population (N=747)
= 4 
§ i0.
0m■O
o
O)
o
Figure 4-13. QQ plots of P-values for 
association of the 60 neurotransmitter 
SNPs genotyped in the replication study 
with daytime ambulatory BP 
measurements. Observed P-values for 
association were plotted against those 
which would be expected under the null 
hypothesis of no association (black line). 
Shaded regions are 99% probability 
envelopes. SNPs were divided into those 
with a minor allele frequency (MAF) in the 
population of = 5% (red), or < 5% (blue). 
SBP, systolic blood pressure; DBP, 
diastolic blood pressure, PP, pulse 
pressure. ‘Adjusted for the covariates age 
and sex.
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Figure 4-14. QQ plots o f P-vaiues for 
association o f the 60 neurotransmitter 
SNPs genotyped in the replication study 
with nighttime ambulatory BP 
measurements. Observed P-values for
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association were plotted against those 
which would be expected under the null 
hypothesis of no association (black line). 
Shaded regions are 99% probability 
envelopes. SNPs were divided into those 
with a minor allele frequency (MAF) in the 
population of = 5% (red), or < 5% (blue). 
SBP, systolic blood pressure; DBP, 
diastolic blood pressure, PP, pulse 
pressure. ‘Adjusted for the covariates age 
and sex.
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Figure 4-15. QQ plots o f P-values fo r 
association o f the 60 neurotransmitter 
SNPs genotyped in the replication study 
with clin ic BP measurements. Observed 
P-values for association were plotted 
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into those with a minor allele frequency 
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5% (blue). SBP, systolic blood pressure; 
DBP, diastolic blood pressure, PP, pulse 
pressure. ‘Adjusted for the covariates age 
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4.4.4 Neurotransmitter Replication Study; Results
Table 4-8 summarizes the associations of the ten neurotransmitter SNPs which were consistently 
associated with variation in any BP phenotype in both the screening and replication studies, where 
P-values for both studies were <0.05 and the association had the same direction of effect in both 
studies.
The ten SNPs included two SNPs in the GABA-receptor GABRR1 gene; rs17504587, which was 
associated with decreased SBP, and rs2150817, which was associated with decreased SBP and 
PP. They also included SNPs in two genes encoding the glutamate receptor subunits GRIK2 and 
GRIK4; rs2786249 was associated with increased SBP and rs4582985 was associated with 
decreased PP, respectively. Another SNP, rs10860589, in the sodium-dependent inorganic 
phosphate co-transporter gene SLC 17A 8  (solute family carrier 17 member 8), was associated with 
increased SBP and DBP. rs1592669, situated in the gene encoding ABCA2 (ATP-binding cassette 
(ABC) sub-family A member 2) a member of the superfamily of ABC transporters, was associated 
with increased SBP and PP. Another, rs362564, located in S N A P25  (Synaptosomal-associated 
protein 25) was associated with decreased SBP. A SNP in the BCL2 (B-cell lymphoma 2), gene, 
rs1005793, was associated with increased PP. rs4759783, in the E P IM  gene (epimorphin, now 
more commonly known as syntaxin 2, STX2), was found to be associated with increased DBP. A 
SNP in the BAK1 (BCL2-antagonist/killer 1) gene, rs395671, was associated with increased SBP 
and DBP.
The Bonferroni correction for multiple testing was applied to provide a 5% overall false positive rate 
control and was calculated, based on 60 SNPs and 3 phenotypes, as 0.05/180,or 2.7x10"04. One of 
the ten SNPs consistently associated with BP phenotypes had a P-value for association with PP 
which exceeded the Bonferroni correction for multiple testing; rs4582985 in GR IK 4  (shown in red in 
Table 4-8).
Permutation testing was again performed in order to obtain an empirical P-value for each SNP 
which would control for multiple testing, and reflect the chance of seeing a test statistic of the given 
size, given the number of tests performed. Permutation was performed in PLINK as described in 
section 4.3.4, using the ‘MaxT’ permutation procedure and performing 1000 permutations. The 
empirical P-values are shown in Table 4-8, indicated in italics. They are in accordance with the 
statistical P-values, and indicate that after correction for multiple testing, rs4582985 was associated 
with increased daytime PP at P=0.03 in this study.
108
The regional association plot for rs4582985 (Figure 4-16) shows that three other SNPs in the region 
were genotyped in the replication study, however none of these SNPs was associated with PP, nor 
in high LD with rs4582985.
The boxplots show the distribution of the BP phenotype associated with this SNP, dayPP, based 
on the number of minor alleles carried (Figure 4-17), and shows a modest decrease in PP 
proportional to the number of minor alleles carried.
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Table 4-8. The 10 neurotransmitter SNPs which were consistently associated with BP variation in both the screening and the replication populations (P<0.05, same direction of effect). All analyses were adjusted for age and sex. Values given are beta (mmHg) per minor allele carried, followed by the P-value for the association in parentheses; uncorrected P-value followed by corrected P-value following 1000 permutations in italics. Red font indicates loci and associations which exceeded Bonferroni correction for 60 SNPs and 3 phenotypes, 2.7x1 O'04. MAF: minor allele frequency.
Systolic BP | Diastolic BP I Pulse Pressure
Clinic
Day
Night
Screening 
(MAF 0.05)
Replication 
(MAF 0.09)
n il
Screening 
(MAF 0.05)
05793(802)
Replication 
(MAF 0.09)
Screening 
(MAF 0.05)
Replication 
(MAF 0.09)
0.4 (0.85) 1.2(0.39,1.00) 
-1.2(0.23,1.00) 
-0.1(0.95,1.00)
-3.5(0.02) -1.0(0.28,1.00) 
-0.6(0.39,1.00) 
0.4(0.53,1.00)
3.9 (7.3E-03) 2.2(0.03,0.93)
-0.6(0.40,1.00) 
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Day
Night
Screening
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Replication
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rsl0860589 (SLC17A8) 
Screening j Replication
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Screening
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Replication 
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0.0 (0.98,1.00)
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Night
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Replication 
(MAF 0.01)
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Screening 
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Screening 
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Replication 
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12.3(4.7E-03) 6.5(0.06, 0.94) 
4.3(0.07,1.00) 
5.3(0.02,0.84)
6.1 (0.04) 4.5 (0.56, 0.97) 
2.0(0.25,1.00) 
2.0(0.21,1.00)
6.2 (0.04) 2.0(0.43,1.00) 
2.3(0.16,1.00) 
3.2 (0.03,0.90)
Clinic
Day
Night
Screening 
(MAF 0.18)
Replication 
(MAF 0.19)
rsl75C 
Screening 
(MAF 0.18)
MS87 (GABRR1) 
Replication 
(MAF 0.19)
Screening
(MAF 0.18)
Replication
(MAF 0.19)
-3.5(1.5E-03) 0.9 (0.28,1.00) 
-0.9(0.14,1.00) 
-1.3(0.03,0.59)
-1.3(0.09) 0.7(0.18,1.00) 
-0.1(0.78,1.00) 
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rs45 
Screening 
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Screening 
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(MAF 0.38)
-3.0 (2.6E-03) 0.3(0.71,1.00) 
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-0.5(0.34,1.00)
-1.6(0.02) 0.7(0.19,1.00) 
0.7(0.08,1.00) 
0.4(0.31,1.00)
-1.4(0.04) -0.4(0.54,1.00) 
1.5 (2.5E-04, 0.03) 
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Night
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-0.7(0.07,1.00) 
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Figure 4-16. Regional plot o f rs4582985 in GRIK4 (purple diamond), and the genotyped SNPs 
within 200kb either side o f it. The P-values for association of these SNPs with daytime PP in the 
study are given on the y-axis. Linkage disequilibrium with rs4582985 is colour-coded based on the 
r2 values from Hapmap phase 3. cM: centimorgans; Mb: megabases. This plot was created by 
Locuszoom (215).
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Figure 4-17. Boxplot and density plots of daytime PP  distribution by rs4582985 genotypes in 
the replication population.
A linear mixed model analysis was again performed to ascertain whether the statistically significant 
association observed in this study remained significant after accounting for a model of the time- 
adjusted within-individual variation in BP measurements. The results of this analysis are shown in 
Table 4-9 below. Although inclusion of intra-individual variation in BP measurement predictably 
reduces the significance of the associations somewhat, both the beta and the P-values remain 
similar to those observed without adjustment for individual BP variation, and a strong association 
remains between the rs4582985 S N P s and daytime PP.
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Table 4-9. Linear mixed model (LMM) an a lysis of the significantly  associated SNP, 
rs4582985, with B P  phenotypes in the replication study. The LMM analysis included age- 
adjusted variation in BP measurements between the two study phases for each individual as an 
additional explanatory variable in the model. Bold type indicates P<0.05.
Systolic BP 
BETA P N
Clinic SBP 0.4 0.78 370
Day SBP -0.6 0.49 369
Night SBP -0.6 0.45 ! 369
rs4582985 (GR1K4)
Diastolic BP 
BETA P N
0.7 0.34 370
1.1 0.09 369
0.6 0.33 369
Pulse Pressure 
BETA P N
-0.4 0.67 370
-1.7 4.8E-03 369
-1.2 0.03 369
4.5 Discussion
This study has identified three loci which were consistently associated with BP variation in two 
independent Irish populations with experiment-wide (Bonferroni correction) significance; two in 
genes which encode the voltage-gated ion channels C LCN 2  (rs2228291, associated with an 
increase of 2mmHg nighttime DBP per minor allele carried; P=1.3x1 O'05, permuted P-value 
accounting for multiple testing P=0.02) and KCNAB1  (rs10513488, associated with an increase in 
clinic SB P  of 7mmHg per minor allele carried; P=1.9x10‘04, permuted P-value accounting for 
multiple testing P=5.0x10'°3), and one in the glutamate receptor subunit GRIK4 (rs4582985, 
associated with a decrease of 1.5mmHg daytime PP per minor allele carried; P=2.5x10"04, permuted 
P-value accounting for multiple testing P=0.03). These associations remained after adjusting for 
intra-individual variation in the replication study using a linear mixed model.
This study also identified a number of other SN P s in genes encoding ion channels and 
neurotransmitters which did not exceed correction for multiple testing, but which were strongly and 
consistently associated with BP phenotypes (P<0.05). In general the effect sizes of these SN Ps 
were modest, and given the low power of this study to detect modest associations, it is likely that 
these SN Ps may represent true associations. If followed up in a larger cohort, they may prove to be 
significantly associated with BP at experiment-wide level.
The QQ plots for both the screening and the replication studies indicated that more significant 
associations were observed than would be expected by chance, indication that our strategy of 
choosing candidate pathways and conducting intensive genotyping of genes involved in these 
pathways was successful in enriching for polymorphisms associated with BP variation.
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4.5.1 Discussion of Ion Channel Results
All 9 of the SN Ps which were consistently associated with BP variation in the ion channel study 
(Table 4-5) were in genes encoding voltage-gated ion channels. Voltage-gated ion channels are 
integral membrane proteins that enable the passage of selected inorganic ions across cell 
membranes in response to changes in transmembrane voltage (216). Voltage-gated ion channels 
have several functions including the regulation of cell volume; membrane potential stabilization, 
signal transduction and transepithelial transport.
Associations with two SN Ps were significant after Bonferroni correction for multiple testing. A 
coding (synonymous) SN P in exon 15 of C LC N 2  (chloride channel protein 2), rs2228291, was 
associated with increased nighttime DBP (beta=2.0mmHg, corrected P=1.0x10'°4). rs10513488, in 
intron 2 of KCNAB1 (potassium voltage-gated channel, shaker-related subfamily, beta member 1), 
was associated with increased clinic S B P  (beta=7.0mmHg, corrected P=0.02). Both SN Ps are 
located on the long arm of chromosome 3, approximately 28 million base pairs apart. One other 
SN P in CLCN 2  was genotyped in the replication study, rs6770808 in intron 2, the minor allele of 
which was consistently associated with decreases in S B P  and DBP (Table 4-5), an effect opposite 
to that of rs2228291. The two SN P s are located ~10kb apart, and correlation between rs6770808 
and rs2228291 was very low in this study (^=0.03). It is likely, therefore, that the two SN Ps 
represent independent associations with BP variation. Four other SN Ps in KCNAB1  were 
genotyped in the replication study. None was in high linkage disequilibrium with rs10513488 
(r2<0.3), and none was consistently and significantly associated with BP changes (P<0.05).
Functional annotations from the U C S C  genome browser (http://genome.ucsc.edu/) indicate that 
although none of these SN Ps causes an amino-acid change in an encoded protein, strong evidence 
exists for their regulatory functions. rs2228291 lies within a digital DNase 1 hypersensitivity cluster, 
indicating that the region is likely to be regulatory, as regulatory regions in general, and promoters 
in particular, tend to be DNase sensitive. It is also located 35bp downstream of a conserved 
transcription factor binding site for PPARa. The other SN P in CLCN2, rs6770808, has been 
determined by ChlP-seq assay to be situated within a strong H3K27Ac Mark (a histone mark which 
influences gene expression by changing how accessible the chromatin is to transcription, often 
found near active regulatory elements), again indicating a likely regulatory region, and between 2 
putative binding sites for Pol2 (RNA polymerase 2) (U C SC  browser). The SN P in KCNAB1, 
rs10513488 is situated 14bp downstream of a conserved transcription factor binding site for ER- 
alpha.
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CLCN 2  is ubiquitously expressed in human tissue. The critical role of the C L C  chloride channels in 
renal salt reabsorption affecting BP homeostasis is well documented. For example, mutations in 
CLCN KA  and CLCN K B  are causative of the Mendelian disorder Bartter syndrome; characterised by 
hypokalemia, severe salt-wasting and low BP (171).
KCNAB1 is widely expressed in human tissues. Little is known about its function; potassium 
channels represent the most complex class of voltage-gated ion channels and their diverse 
functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal 
excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. An intronic 
mutation in exon 14 of this gene has been shown to be associated with lateral temporal epilepsy 
(217). Although polymorphisms in KCNAB1 have not been shown previously to be associated with 
cardiovascular phenotypes, a number of studies have implicated differential KCNAB1 expression. 
Differential expression of the gene has been shown in cerebrovascular malformations, where it is 
downregulated in arteriovenous malformations (AVMs) and cavernous malformations (CCM s) 
compared to control superficial temporal arteries (STAs), suggesting the gene is important in the 
physiology of the vasculature (218). KCNAB1 is also part of a group of potassium channels which 
have been shown to be differentially expressed in the carotid body in response to low oxygen 
levels, and may play a part in the hypoxic response in the heart (219). It is also downregulated in 
the mouse heart in response to treatment with the anti-arrhythmic drug amiodarone (220).
Variants in CLCN 2  and KCNAB1  have not previously been implicated in the causation of 
hypertension. They have not been examined in other candidate genes studies so far, and the 
strength of these associations may not have been great enough to overcome the stringent statistical 
cut-offs used in GWAS. Indeed, the SN Ps identified in this study may not even have been tested 
for association in the genome-wide studies, due to poor coverage on the GW AS chips. The large 
genome-wide association studies of BP variation conducted to date have commonly used a strategy 
of collecting populations genotyped on different genome-wide chips, and imputing from these chips 
to acquire a common set of SN Ps for all populations (80, 81). However, this strategy, as explained 
in the introduction to this thesis, results in the loss of a number of SN P s which may be genotyped 
on one platform but not well-imputed from another. Although rs2228291 is genotyped on most 
lllumina arrays (lllumina HumanHap300, 550, 650, 610Quad and HumanIM), it is not genotyped on 
any existing Affymetrix arrays. It is situated in an area of poor linkage disequilibrium, which is not 
well-tagged by other SN Ps genotyped on the GW AS chips (no proxies at ^>0.3 are genotyped on 
any arrays). The same situation exists for rs10513488, which is again genotyped on most lllumina 
arrays, but not on any of the commonly-used Affymetrix arrays (Affymetrix 250K, 5.0 or 6.0). It does 
not have any good (^>=0.5) proxies genotyped on any arrays. It is likely, therefore, that because of 
their poor representation on the Affymetrix arrays, these SN Ps were not well-imputed from the
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Affymetrix arrays and were not included in the set of ‘common’ SN P s tested in many of the genome- 
wide studies conducted so far.
4.5.2 Discussion of Neurotransmitter Results
The ten neurotransmitter SN Ps which were consistently associated with variation in any BP 
phenotype in both the screening and replication studies were located in a variety of genes encoding 
neurotransmitters and other associated proteins (Table 4-8).
Only one of these SN Ps was significantly associated with BP variation in these populations after 
correction for multiple testing. A SN P located in intron 1 of the GRIK4  gene (glutamate receptor 
KA1 precursor), rs4582985, was associated with a decrease in daytime P P  of 1.5mmHg, corrected 
P=0.03). The protein encoded by this gene forms functional heteromeric kainate-preferring ionic 
channels with the subunits encoded by related gene family members. Kainate receptors are 
ionotropic receptors which respond to the neurotransmitter glutamate. The ion channel formed by 
kainate receptors is permeable to sodium and potassium ions. Kainate receptors play a role in both 
pre- and postsynaptic neurons, however their function is not well defined.
Three other SN Ps in GRIK4 were genotyped in the replication study and were associated with 
decreased ambulatory PP, although none were significant (P<0.05). None of these three SN Ps 
was strongly correlated with rs4582985 (r2 < 5.3). A SN P in the gene which encodes a different 
subunit of the same ionotropic kainate glutamate receptor as GRIK4, GRIK2, was associated with 
an increase in daytime SB P  in the replication study (beta=1.5, P=0.04).
Glutamate receptors mediate the majority of excitatory neurotransmission in the brain. Mutations in 
GRIK4  have been implicated in schizophrenia, bipolar disorder and depression (221). No 
associations have been reported to date between cardiovascular phenotypes and GRIK4. Like the 
ion channel hits, GRIK4  has not been the subject of candidate gene studies for BP variation. The 
same possible explanations apply for this SN P not being included in any of the genome-wide study 
results so far as for the ion channel SN Ps -  the association may not have exceeded correction for 
multiple testing, and the SN P may not have been covered in the first place. rs4582985 is 
genotyped on common Affymetrix arrays (Affymetrix 250K, 5.0 and 6.0) but not on any lllumina 
arrays. Again, it is not well-tagged by other SN P s genotyped on genome-wide arrays, and has no 
proxies at r2 > 0.5.
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4.5.3 Study Strengths and Limitations
One of the strengths of this study was the high-quality phenotypic measurements used. Neither the 
screening nor the replication populations were taking anti-hypertensives at time of BP 
measurement, which distorts actual BP values. Ambulatory BP measurement (ABPM), which has a 
higher prognostic value than clinic BP measurement, was available for the replication population. In 
addition, these ABPM measurements were available at two separate time-points, allowing intra­
individual BP variation to be accounted for in the SN P association models used.
Another strength of this study was the fact that intensive genotyping of genes likely to be involved in 
BP regulation was undertaken, which the QQ plots indicated resulted in an enrichment of 
associations. In addition, this strategy meant that we investigated SN P s which are likely to be 
involved in BP regulation but which may not be covered by GW AS chips.
A third strength of this study was the fact that an independent replication population was available 
which was demographically similar to the screening population, avoiding problems such as lack of 
replication due to differences in population ethnicities, etc. The fact that the reported findings of this 
study were associated with BP in two independent populations makes it far less likely that they are 
false positive associations.
The primary weakness of this study was the relatively small sample sizes available. Despite having 
high-quality, repeated phenotypic measures, this study may not have had sufficient power to detect 
the full complement of associations between these SN P s and the BP phenotypes, especially those 
with modest effect sizes, as indicated by the power graphs.
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5 Thromboxane and Prostacyclin Genome- 
Wide Association Studies (GWAS)
5.1 Introduction
5.1.1 Atherosclerosis
Atherosclerosis is a disease of arterial blood vessels, characterized by thickening of the arterial wall 
as a result of the accumulation of fatty materials such as cholesterol (222). It involves a complex 
array of different cell types and biochemical interactions (Figure 5-1).
Cardiovascular risk factors alter the vascular endothelium, triggering a chronic inflammatory 
response in the arterial walls (223), characterized by infiltration of phagocytic white blood cells such 
as macrophages, and smooth muscle cell proliferation (Figure 5-1, (224)). Unstable plaques, rich in 
macrophages and foam cells (formed when oxidized low-density lipoprotein (oxLDL) accumulates in 
phagocytes) form within the arterial wall. This process is promoted by low-density lipoproteins 
(LDLs), which are oxidized by the endothelium to form ox-LDLs, and by inadequate removal of 
oxLDL from the macrophages by functional high-density lipoproteins (HDL) (225, 226). The fibrous 
cap separating the plaque from the arterial lumen is prone to rupture, exposing thrombogenic 
material, such as collagen, to the circulation and inducing thrombus (blood clot) formation in the 
lumen (227). These thrombi can occlude arteries outright, or detach and move into the circulation, 
eventually occluding smaller downstream branches causing thromboembolism. Alternatively, 
chronically expanding atherosclerotic lesions can cause complete closure of the lumen. Any of 
these three scenarios causes an infarction - the death of the tissues fed by the artery due to an 
obstruction of their blood supply. Commonly recognized scenarios include the thrombosis of a 
coronary artery, causing myocardial infarction (heart attack), or thrombosis of an artery to the brain, 
causing cerebral infarction (stroke).
Endothelial cells play an important role in the pathogenesis of atherosclerosis, and endothelial 
dysfunction is one of the earliest events in atherogenesis. Endothelial dysfunction involves a 
plethora of physiological alterations, including disruption of the delicate balance between 
vasoconstrictive and vasodilatory factors (228-230). This balance is maintained in large part by a 
group of bioactive lipids called prostanoids, which include Prostacyclin (PGI2) and Thromboxane A2 
(TxA2). PG I2 and TxA2 are physiological antagonists, and the balance between them plays an 
important role in vascular homeostasis, the balance between thrombus formation and prevention. 
Along with their effects on vasoconstriction and dilation, these two prostanoids play an important 
role in platelet activation and plaque formation and related clinical syndromes including myocardial
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infarction (Ml) and stroke. The biosynthesis of PG I2 and TxA2 has been shown to be altered in 
patients with atherosclerosis (231).
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Figure 5-1 : Atherosclerosis 
disease progression. Adapted 
from (224).
Cardiovascular risk factors alter 
the vascular endothelium, which 
triggers a cascade of events, 
including the recruitment of 
leukocytes. Cytokines and 
growth factors are released by 
inflammatory cells and vascular 
cells, generating a highly 
mitogenic milieu. Vascular 
smooth muscle cells (VSM Cs) 
migrate, proliferate and 
synthesize extracellular matrix 
components, forming the fibrous 
cap of the atherosclerotic lesion. 
Inflammatory mediators induce 
thinning of the fibrous cap by 
expression of proteases, 
rendering the plaque weak and 
susceptible to rupture and 
thrombus formation. In 
advanced disease, fibroblasts 
and VSM Cs with extracellular 
calcification give rise to 
fibrocalcific lesions. VSM C, 
vascular smooth muscle cell; 
LDL, low-density lipoprotein; 
MCP, monocyte
chemoattractant protein; VCAM, 
vascular cell adhesion 
molecule; PDG FBB, platelet- 
derived growth factor (BB, li- 
chain homodimer); TNF, tumour 
necrosis factor; TG F, 
transforming growth factor; IL, 
interleukin 1; IGF, Insulin-like 
growth factor; bFGF, basic 
fibroblast growth factor; Ang II, 
angiotensin II; EG F, epidermal 
growth factor; IFN, interferon.
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5.1.2 Prostacyclin (PGI2) and Thromboxane (TXA2) Production
The prostanoids, including PG I2 and TxA2, are just one class of the eicosanoid products of 
arachidonic acid metabolism (Figure 5-2). Arachidonic acid is an essential polyunsaturated fatty 
acid that is stored in the phospholipids of cell membranes. It is liberated by phospholipases, which 
are activated in response to diverse array of stimuli including hormones, autocoids, cytokines, 
growth factors, and tumour promoters (including histamine (232), platelet-derived growth factor 
(233), interleukin 1 (IL-1) (234), vasopressin (235) and tissue plasminogen activator (TPA) (236)). 
In platelets, the phospholipase thought to be predominantly responsible for release of arachidonic 
acid is cytosolic phospholipase A2Q (cPLA2a) (237).
Once in the cytosol, arachidonic acid can be metabolized into a number of different compounds, 
called the eicosanoids. The term 'eicosanoid' refers to a large family of oxygenated C 2o fatty acids, 
made up of three clans, formed by three distinct pathways; the cyclooxygenase, lipoxygenase and 
epoxygenase pathways (Figure 5-2). Although products of the lipoxygenase and epoxygenase 
pathways have also been implicated in atherogenesis, they are not of direct relevance to the work 
carried out in this thesis and will not be discussed further.
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GROWTH FACTORS, CYTOKINES, HORMONESI
Membrane Phospholipids
I Phospholipases 
ARACHIDONIC ACID
Prostanoids
hydroxyeicosatetraenoic acids, 
leukotrienes and lipoxin
Epoxides
Figure 5-2. Arachidonic Acid Metabolism. Adapted from (238). The interaction of growth 
factors and hormones with their cell surface receptors stimulates a cascade of signalling events, 
including the activation of phospholipases, which can lead to the hydrolysis of membrane 
phospholipids, releasing lipids such as arachidonic acid. Upon liberation into the cytosol, 
arachidonic acid can be metabolized to one of a large family of eicosanoids by one of three major 
pathways, corresponding to the three major eicosanoid clans. These are: the cyclooxygenase 
pathway, which leads to the formation of prostanoids; the lipoxygenase pathway, which forms 
hydroxyeicosatetraenoic acids (H ETEs), leukotrienes and lipoxins; and the cytochrome P-450 
epoxygenase pathway which leads to the formation of epoxides such as epoxyeicosatrienoic acids 
as well as H ETEs.
The prostanoids are produced from arachidonic acid in three stages (Figure 5-3); (i) release of 
arachidonic acid from precursor glycerophospholipids, (ii) oxygenation of free arachidonic acid by 
prostaglandin G/H synthase (CO X) and (Hi) metabolism of the resulting PGH2 to a specific, 
biologically active end-product; P G E 2, PG F2, PG D 2, PGI2 (Prostacyclin), or TxA2 (thromboxane A2). 
Prostanoids are evanescent and function close to their site of synthesis. They are not stored by 
cells, but are synthesized de novo and then rapidly deactivated before being exported to the 
circulation as their inactive metabolites (239). Prostanoids are produced in response to cell-specific 
stimuli; platelets, for example, produce prostanoids (mainly TxA2) in response to activation by a 
number of stimuli, including thrombin and collagen (240, 241). The synthesis of prostanoids is 
regulated at several levels, including arachidonic acid release and levels of cyclooxygenase (COX) 
enzyme.
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Figure 5-3: Arachidonic Acid  metabolism via the cyclooxygenase pathway; Production and 
Actions of Prostaglandins and Thromboxane. Adapted from (242). Arachidonic acid, a 20- 
carbon fatty acid, is liberated from membrane phospholipids by phospholipase A2, which is 
activated by diverse stimuli. Arachidonic acid is converted by cytosolic prostaglandin G/H 
synthases, which have both cyclooxygenase (CO X) and hydroperoxidase (HOX) activity, to the 
unstable intermediate prostaglandin H2. The synthases are colloquially termed cyclooxygenases 
and exist in two forms, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 and 
COX-2 both catalyse the same two reactions: a cyclooxygenase reaction, in which arachidonic acid 
is converted to prostaglandin G2 (PGG2); and a peroxidase reaction, where PGG 2 undergoes a 
two-electron reduction to PGH2. Prostaglandin H2 is then converted by tissue-specific isomerases 
to multiple prostanoids. These bioactive lipids activate specific cell-membrane receptors of the 
superfamily of G-protein-coupled receptors. Some of the tissues in which individual prostanoids 
exert prominent effects are indicated. IP, prostacyclin receptor; TP, thromboxane receptor; DP, 
prostaglandin D2 receptor; EP, prostaglandin E2 receptor; FP, prostaglandin F2a receptor.
5.1.3 Cyclooxygenase (COX) Enzymes
Cyclooxygenase (CO X) plays a pivotal role in the metabolism of arachidonic acid, and is the rate- 
limiting step in the formation of prostanoids (243). The C O X  synthases exist in two bioactive 
isoforms, cyclooxygenase-1 (CO X-1) and cyclooxygenase-2 (COX-2). A third enzyme, COX-3, 
which is a splice variant of COX-1, was reported in 2002 in a canine model, but has not so far been 
shown to be of clinical relevance in humans (244). Although similar in structure and function, COX-
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1 and COX-2 exist as two distinct enzymes, which are encoded by different genes (245), and differ 
in cellular expression and subcellular location. Despite both catalyzing the same rate-limiting step 
in arachidonic acid metabolism (Figure 5-3), they assume different physiological roles, producing 
different eicosanoids in different tissues.
The structure of COX-2 is 60% homologous with the amino acid structure of COX-1 and both 
isoforms have a molecular weight of 71kDa. They are both composed of three domains, a 
membrane-binding domain, an epidermal growth factor like domain and an enzymatic domain. The 
amino acid residues required for catalytic activity are conserved between the two isoforms. There 
are, however, subtle differences in the substrate pocket, which have been exploited to generate 
isoform-specific inhibitors (section 5.1.5).
COX-1 is constitutively expressed under physiological conditions in most tissues (246), where it 
mediates ‘housekeeping’ functions; however it can also be induced, particularly at sites of 
inflammation (247) or in response to factors such as shear stress (248) and vascular endothelial 
growth factor (VEGF) (249). Endothelial cells express high levels of COX-1, where the most 
abundant prostanoid synthase is PGI synthase, hence the majority of the endothelial COX-1- 
derived endoperoxides are transformed to PGI2 (250). In platelets, however, where COX-1 is the 
predominant isoenzyme, it is responsible for production of predominantly TxA2(251), and platelet 
COX-1 is a major source of the increased TxA2 seen in atherosclerosis (252). In atherosclerotic 
plaque, increased expression of COX-1 has been shown in VSMCs underlying the plaque, as well 
as in adjacent sections with normal morphology (253, 254) (Table 5-1).
While COX-1 has traditionally been thought of as the constitutively expressed isoform, COX-2 
expression, in contrast, is mainly induced at sites of inflammation by several stimuli. It has been 
shown to be induced in inflammatory cells such as monocytes and macrophages, endothelial cells 
and VSMCs (Table 5-1) upon stimulation by; cytokines (255, 256), mitogens (257), growth factors 
(258, 259), hypoxia (260), free radicals (261), peroxisome proliferator activated receptor gamma 
(PPARy) (262). As these factors have all been implicated in the development of atherosclerosis, it 
is unsurprising that COX-2, like COX-1, has been shown to be expressed in atherosclerotic plaque; 
in inflammatory cells, endothelial cells, and VSMCs (253, 263-266). Conflicting evidence exists 
regarding COX-2 expression in normal blood vessels - some evidence suggests that COX-2 is 
constitutively expressed in the endothelium (267), where it appears to be a source of systemic 
prostacyclin biosynthesis in healthy humans; however ex vivo studies show no evidence that COX-2 
is expressed in normal blood vessels (268).
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The net effect of COX-2 on atherosclerosis remains controversial, as COX-2 induction has been 
shown to produce both pro- (261, 266, 269, 270) and anti- (271, 272) atherogenic effects. It may be 
that COX-2 is coupled to different downstream prostanoid synthases in different cellular 
environments, resulting in the production of either protective PGI2 , or pro-atherosclerotic 
prostanoids, such as PGE2 and TxA2. Recently, selective inhibition of COX-2 by coxibs such as 
rofecoxib (Vioxx) and valdecoxib (Bextra) has been linked to an increased risk of atherothrombotic 
events (273), however the mechanisms underlying these atherothrombotic events remain unclear.
CO X
Constitutive
expression
Exp ression  induced 
in atherosclerosis Comments
COX-1 Circulating platelets 
Endothelial cells
Macrophage-derived foam cells 
Vascular smooth muscle cells 
Arterial thrombus
Constitutive COX-1 expression in 
platelets generates TXA2; 
increased COX-1 expression 
and TXA„ production in advancing 
atheroscferosis promotes thrombosis
COX-2 — Endothelial cells 
Macrophages
Vascular smooth muscle cells
Increased COX-2 expression in 
atherosclerosis increases 
PGI2 generation
Abbreviations: COX, cyclooxygenase; PGIS, prostacyclin; TXA2, thromboxane A2.
Table 5-1. Sum m ary of COX-1 and COX-2 expression in cell types in normal and diseased 
vasculature. From (274).
5.1.4 Prostacyclin (PGI2) and Thromboxane (TxA2) Function
It was first proposed that two prostanoids, prostacyclin (PGI2) and thromboxane (TxA2), provide an 
important balance in cardiovascular homeostasis in 1976 (275), an idea that was later reinforced by 
receptor knockout studies (276). It is now clear that PGI2 and TxA2, through their respective G- 
coupled receptors, the prostacyclin receptor (IP) and the thromboxane receptor (TP), play critical 
roles in the development of human atherothrombosis.
Thromboxane (TxAo) Function
TxA2 is one of the most powerful known platelet activators, a potent vascular smooth muscle cell 
constrictor and mitogen, and may also play a role in plaque growth and thrombosis. TxA2 is 
produced mainly in blood platelets by COX-1 in response to platelet activation (251), although there
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are also a number of known extra-platelet sources of TxA2 production, such as monocytes, 
endothelial and VSMCs (251).
In order to give an account of the role of TxA2, it is necessary to first outline the process of platelet 
activation. Platelets are produced by megakaryocytes as anucleate cells that lack genomic DNA, 
but contain megakaryocyte-derived mRNA and the translational machinery needed for protein 
synthesis. After leaving the bone marrow, platelets circulate for about 10 days. Their primary 
function is to stop haemorrhage after tissue trauma and vascular injury, which is achieved primarily 
by aggregation of platelets to form a blood clot, or thrombus. Thrombus formation is normal in 
cases of injury, but pathologic in instances of thrombosis, where a blood clot forms inside a vessel 
and obstructs the flow of blood through the circulatory system. In addition, platelets participate in 
the process of forming and extending atherosclerotic plaques.
Platelet adhesion and activation at sites of vascular wall injury is initiated by a multistep process 
involving the interaction of platelets with the subendothelial extracellular matrix, which contains 
adhesive macromolecules such as collagen (Figure 5-4). A rapid interaction between the platelet 
glycoprotein GPIb-V-IX and von Willebrand factor (vWF) immobilized on collagen is crucial for the 
initial tethering of flowing platelets (277), but is reversible and insufficient for stable adhesion, which 
requires additional contacts between the platelet and the ECM. Following initial platelet adhesion, 
the collagen receptor GPVI induces Intracellular signalling processes which promote the inside-out 
activation of integrins such as GPIIb/llla, which interact with the extracellular matrix, resulting in the 
firm adhesion of platelets to the injured vessel wall and formation of a platelet monolayer (278).
Following adhesion, platelet activation occurs in response to the interaction of locally accumulating 
mediators with platelet cell surface receptors (Figure 5-6), following which platelets undergo a 
sequence of responses including shape change, aggregation, and secretion, leading to recruitment 
of circulating platelets from the flowing blood to form a growing hemostatic plug. These mediators 
include ADP/ATP and TxA2, which are secreted or released from activated platelets, and thrombin, 
which is produced on the surface of activated platelets. These diffusible mediators have in common 
that they act via G protein- coupled receptors. Through the activation of G protein-mediated 
signalling pathways, they can further increase their own formation and release, thus acting as 
positive-feedback mediators that amplify the Initial signals to ensure the rapid activation and 
recruitment of platelets into a growing thrombus. TxA2is a powerful activator, and serves to amplify 
the response to weak platelet agonists, such as ADP, epinephrine, and low concentrations of 
collagen and thrombin (279).
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Figure 5-4. Thrombus formation. Adapted from (280). The first step in thrombus formation is 
the adhesion of platelets to thrombogenic substrates, such as collagen and von Willebrand factor 
(vWF). Signals from the adhesion receptors, mainly Glycoprotein VI (GPVI) bound to collagen, act 
in synergy with signals from soluble agonists to induce platelet activation through a network of 
signalling pathways. The main G protein- coupled receptors with a function in platelet function are 
shown. Bi-directional arrows indicate ’outside- in’ signals that originate from specific receptors and 
’inside- out’ signals that regulate specific processes—for example, the induction of TxA2 synthesis 
and the release of ADP and ATP. Platelet aggregation is enabled by the change in ligand binding 
properties of anbP3, which acquires the ability to bind soluble adhesive proteins, including fibrinogen 
and vWF. cPLA 2, cytoplasmic phospholipase A2; AA, arachidonic acid; GPIb-V-IX, glycoprotein Ib- 
V-IX; vWF, von Willebrand factor; A1 and A3 are two domains within vWF; RGD, arginine-glycine- 
aspartic acid (RGD) cell adhesion sequence, a specific sequence of VW F that is located in domain 
C1; GPVI, Glycoprotein VI; P2Y receptors, purinergic G-coupled receptors; ADP, adenosine 
diphosphate; cAMP, cyclic adenosine monophosphate.
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Figure 5-5. Agonists, Receptors, and Effector System s in Platelet Activation. Adapted from 
(281). Inside out (black) and outside-in platelet (red/blue) signalling. After the initial adhesion of 
platelets to the extracellular matrix, platelet agonists such as ADP, thrombin and TxA2, interact with 
receptors on the platelet membrane to amplify and sustain the platelet response. This causes an 
elevation of cytosolic calcium (Ca2T) concentration, which activates protein kinase C  (PKC), an 
important inducer of aggregatory and secretory responses. Intracellular C a2+ increase also 
activates phospholipase A2, liberating arachidonic acid, the first step in prostaglandin and 
thromboxane biosynthesis These platelet agonists also inhibit adenylyl cyclase (AC), which 
catalyses the formation of cAMP from ATP. High levels of platelet cAMP lead to inhibition of 
platelet activation (282).
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As mentioned previously, TxA2 exerts its effects via its receptor, TP. T P  receptors are membrane 
bound, G-protein-coupled receptors and are widely expressed in the cardiovascular system, 
including in platelets and endothelium (283, 284), as well as in other cell types involved in 
atherothrombosis, such as smooth muscle cells (285), macrophages and monocytes (286).
Tissue-specific alternative splicing of the TP  receptor gives rise to two isoforms, TPa and TPIJ, 
which differ only in their cytoplasmic tails (287). Endothelial cells express only the TPIJ isoform, 
whereas human platelets express both isoforms. Some evidence exists for differential regulation of 
the two isoforms (288). The TPa and TPIJ receptors exert different effects, since the C-terminal 
intra-cytoplasmic region acts as a determinant of receptor-G-coupling efficiency. Despite this, both 
isoforms show similar ligand binding and have been shown to couple to members of the Gq 
families, which activate phospholipase C  (PLC ) (281, 289, 290), and show similar P LC  activation 
(Figure 5-6). Their effect on adenylyl cyclase, however, is opposite -  the TPa receptor stimulates 
adenylyl cyclase activity, whereas the TPIJ receptor inhibits it (291).
TP  receptor signal transduction involves calcium signalling (19, 20) which is responsible for platelet 
activation. Activated P LC  degrades the membrane phosphoinositides, releasing two potent 
stimulatory second messengers, inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (289, 
292), which in turn activate calcium release from the endoplasmic reticulum and protein kinase- C 
(PKC), respectively (289, 293). Intracellular increase of calcium causes activation of signalling 
pathways involved in platelet responses, i.e. shape change, aggregation and secretion (294, 295), 
and the increase in Ca2+ resulting from TxA2-mediated P LC  activation has also been shown to 
promote platelet degranulation and aggregation (296, 297). DAG activation of PKC  has also been 
associated with the process of platelet secretion, and PK C  inhibition reduces the release of platelet 
dense granules (298).
Stimulation of G12 family proteins -  G12 and G13 -  activates Rho signalling which modulates 
several biological reactions, including regulation of cell motility, contraction, proliferation and 
apoptosis (299). The importance of Gq and G 12/13 in platelet reactivity is highlighted 
by the observation that platelets lacking Gq and G13 are completely irresponsive to TxA2 (300).
TP receptor mediated platelet shape change is mainly dependent on G12/13, while 
aggregation is dependent on Gq (301, 302). Low concentrations of U46619, a TP  receptor agonist, 
have been shown to cause platelet shape change, while high concentrations are required for 
aggregation (297).
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Figure 5-6. The two sp lice  variants of the TxA 2 receptor, TPa and TPIS. Adapted from (281).
The two splice variants of the TxA2 receptor, TPa and TPIÎ, couple to the proteins Gq and G 12 or 
G 13, all of which activate phospholipase C  (PLC ) (289, 290). This enzyme degrades the 
membrane phosphoinositides (such as phosphatidylinositol 4,5-bisphosphate [PIP2]), releasing two 
potent stimulatory second messengers, inositol triphosphate (IP3) and diacylglycerol (DAG) . DAG 
activates intracellular protein kinase C  (PKC), which causes protein phosphorylation and calcium 
release. The release of IP3 also increases cytosolic levels of Ca2+, which is released from the 
endoplasmic reticulum. ADP, adenosine diphosphate; AC: Adenylyl Cyclase; IP3, inositol 
triphosphate; DAG, diacylglycerol; PKC, protein kinase C; PIP2, phosphatidylinositol 4,5- 
bisphosphate; PLC, phospholipase C; P2Y, purinergic receptor; TP, thromboxane receptor; PAR, 
protease-activated receptor.
In VSM Cs, TxA2 plays an important role in proliferation, migration and constriction. Activated 
platelets release mitogenic factors such as platelet-derived growth factor (PDGF) and epidermal 
growth factor (EGF), which stimulate the proliferation and migration of VSM Cs, leading to 
atherosclerotic plaque formation. However, T xA2 participates in VSM C migration independently of 
this mechanism, by inducing G-protein mediated vascular smooth muscle cell growth and 
proliferation (303), which contributes to plaque development. Like in platelets, TP  receptor 
stimulation in VSM Cs results in P LC  activation (304) and mobilisation of intracellular Ca2+, leading 
to the induction and proliferation of VSM Cs. T xA2 also enhances vasoconstriction through G- 
protein activation of the myosin contractile machinery (305). G12/13/Rho mediated activation of 
Ca2+ entry and Ca2+ sensitization regulates smooth muscle cell contraction (306, 307), and TP 
receptor stimulation in VSM Cs has been shown to result in mobilization of intracellular Ca2+ 
followed by smooth muscle contraction (308).
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Furthermore, in endothelial cells, TP  receptor activation stimulates the expression of adhesion 
proteins, such as inter-cellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 
(VCAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1), which are mediated by PKC  
(309, 310). TP receptor activation also stimulates the monocyte chemoattractant molecule MCP-1, 
increasing leucocyte adhesiveness (311, 312), and TP(3 receptor activation has been shown to 
stimulate the expression of leucocyte adhesion molecules (LAM) on endothelial cells (313).
Although they are known as thromboxane-receptors, TP  receptors are in fact activated not only by 
TxA2, but also by prostaglandins D2, E2, F2, H2, and isoprostanes. By binding to TP receptors, 
these molecules activate several signalling cascades which regulate platelet activation and 
aggregation, VSM C proliferation, migration and contraction, and endothelial cell activation as 
described above, thereby accelerating progression of atherosclerotic lesions. In keeping with this, 
antagonism of the TP receptor has been shown to be protective in animal models: retarding plaque 
formation in hypercholesterolaemic rabbits (314), preventing arterial thrombosis in rats (315) and 
decreasing atherosclerosis in mice with elevated levels of plasma LDL cholesterol (316).
Although its role in platelet activation establishes a role for TxA2 in atherothrombosis, because of 
the promiscuity of the TP receptor, it is difficult to dissect the role played by TxA2 specifically in the 
development and progression of atherosclerosis. Studies using the TP  receptor antagonist S18886 
suggest that blockade of TP  receptors inhibits atherosclerosis by a mechanism independent of 
platelet-derived TxA2, perhaps by preventing the expression of adhesion molecules whose 
expression is stimulated by eicosanoids other than TxA2(316). Aspirin, which inhibits TxA2 
production by COX-1 (section 5.1.5), inhibits platelet-mediated thrombosis at sites of vascular 
injury, confirming that TxA2 plays a role in platelet activation in vivo. However, aspirin does not 
reduce narrowing of the coronary artery (317, 318) and there is, as yet, no evidence that aspirin 
influences the development and progression of atherosclerosis.
Observational studies, however, do suggest a role forTxA2 in atherosclerosis. TxA2 synthesis has 
been shown to be enhanced in subjects with atherosclerosis and/or risk factors: in patients with 
various types of heart disease when measured by plasma concentration (319), in platelets in 
patients with stable and unstable coronary disease when measured by either plasma or urinary 
concentration (320, 321), in patients with unstable angina measured by urinary concentration (97) 
and in patients with pulmonary hypertension, measured by urinary concentration (322). It may be 
that atherosclerosis itself contributes to TxA2 biosynthesis, possibly by up-regulation of COX-2 
production in inflammatory cells.
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Prostacyclin (PGM Function
PG I2 is the physiological antagonist of TxA2 and has potent platelet-inhibitory and vasodilatory 
properties (323) (Table 5-2). In the vascular system, PG I2, is generated predominantly by 
endothelial cells (324, 325), and studies of metabolite excretion suggest that COX-2 is the 
predominant source of PG I2 in normal subjects (324). In humans, the PGI2 receptor, IP, is 
expressed throughout the body (326), with predominant cardiovascular expression on platelets 
(327) and vascular smooth muscle cells (VSM Cs) (328).
One mechanism by which PG I2 achieves its platelet inhibitory and vasodilatory functions is via 
coupling of the IP receptor to G Sl which stimulates adenylate cyclase to catalyze formation of cAMP 
(329, 330). Induced cAMP inhibits platelet aggregation (331, 332), and inhibits VSM C migration 
and proliferation via activation of the cAMP/PKA pathway (328). In addition, PGI2 has been shown 
to inhibit the release of mitogens from platelets, endothelial cells and macrophages and thus inhibit 
the proliferation of smooth muscle cells from atherosclerotic plaque (333, 334).
In vivo work has suggested a protective antithrombotic, antiatherogenic and anti-inflammatory role 
for PGI2 in atherosclerosis. Although some reports show a deficiency of PGI2 in atherosclerosis 
(335), most evidence shows that PGI2 is increased in vascular disease (231, 336, 337). Increased 
PGI2 by overexpression of COX-1 has been shown to prevent thrombus formation in damaged 
arteries in pigs (338). PGI2 has been shown to prevent the accumulation of cholesterol esters in 
macrophages, suppressing atherogenic foam cell formation (339). Disruption of the IP receptor in 
mice has demonstrated an anti-inflammatory as well as an antithrombotic role for PGI2 (340).
Recently, Arehart et al reported that a naturally occurring prostacyclin receptor variant (R212C) is 
defective in adenylyl cyclase activation. They showed that, while not an initiating factor, presence 
of the mutation accelerated the course of disease in those patients with the greatest risk factors, an 
observation consistent with studies in receptor knockout mice (341). Cross-breeding studies of 
atherosclerosis-prone apoE-deficient mice with mice deficient in either the TP receptor or the IP 
receptor have shown that stimulation of the T P  receptor promotes the initiation and progression of 
atherogenesis, while stimulation of the IP receptor is protective (342).
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PGI2 Endothelial cells Antithrombotic and anti-inflammatory
Vascular smooth muscle cells Induces vasodilation
Inhibits platelet aggregation 
Inhibits platelet mitogen release 
Suppresses smooth muscle cell proliferation 
Inhibits leukocyte adhesion
TXA2 Platelets Platelet activator
Monocytes Induces vasoconstriction
Promotes mitogenesis
Stimulates smooth muscle cell proliferation
" PGI2 is mainly derived from the action of COX-2; TXA2 is mainly derived from the action of COX-1. 
Abbreviations: COX, cyclooxygenase; PGI2, prostacyclin; TXA.,, thromboxane A2.
Table 5-2. Sum m ary of the biological effects of PG I2 and TxA 2. From (274). 
Thromboxane (TxA?) and Prostacyclin  (PGM  Regulation and Cross-Talk
The regulation of TxA2 and PG I2 and their receptors is self-balancing, with one side influencing the 
other (Figure 5-7). At the genetic level, overlapping response elements for IP and TP  allow 
simultaneous and independent transcriptional promotion and repression (343, 344). T P  receptor 
activation provides negative feedback by stimulating PG I2 release (345). Similarly, PG I2 activation 
impairs TP  receptor expression. Both receptors also provide positive feedback; IP stimulation 
stimulates PGI2 production through increased COX-2 expression (346), and TP  stimulation 
increases intracellular C a2+ which activates phospholipase A2, liberating arachidonic acid, the first 
step in T xA2 and PG I2 biosynthesis (Figure 5-6).
Receptor hetero-dimerization and hetero-oligomerization confounds dissection of IP and TP 
receptor signalling. Dimerization of the IP and T P  receptors enables cyclic adenosine 
monophosphate (cAMP) formation through TP  receptor activation, a cellular outcome typically 
observed with IP receptor activity (347). Furthermore, IP-TP receptor dimer formation allows 
endocytic cross-regulation, with activation of either receptor driving the internalization of both (348).
Eicosanoid Source3 Effects
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Figure 5-7 Prostacyclin  receptor (IP) and thromboxane receptor (TP) interactions. From 
(349). 1. TP  activation signals primarily through Gq, activating phospholipase C  (PLC) and 
releasing phosphatidyl inositol triphosphate (IP3) and diacylglycerol (DAG) from the membrane. 2. 
IP3 and DAG stimulate the release of intracellular C a2+, producing the primary cellular effects of TP 
activity. 3. IP activation signals primarily through Gs, activating adenylyl cyclase (AC), catalyzing 
conversion of adenosine triphosphate to cyclic adenosine monophosphate (cAMP), the secondary 
messenger responsible for most of the cellular effects. 4. cAMP effectors inhibit thromboxane 
signalling at various levels, including the impairment of IP3-stimulated calcium release. 5. cAMP 
also stimulates protein kinase A (PKA), which phosphorylates TPa, again reducing thromboxane 
activity. 6, cAMP also promotes phosphorylation of extracellular signal response kinase (ER K ) 1/2, 
which downregulates TP  receptor expression. 7. Downregulation of TP  receptor expression is also 
aided by protein kinase C (PKC), activated through the prostaglandin E1 receptor (EP1). 8. TP  
mRNA can undergo alternative splicing generating TPa or TPfi, which may be independently 
regulated. 9. Activated TPa and TP(2> can differentially influence AC activity, with TPa augmenting 
and TPfi reducing A C  activity. 10. As IP and TP receptors are folded, they can be packaged as 
homodimers or heterodimers. Heterodimers of IP with TPa or TPIJ may additionally influence the 
interaction of IP and TP  signalling in uncertain ways (such as via trafficking, binding, signalling, or 
desensitization). PLC, phospholipase C; IP3, inositol triphosphate; DAG, diacylglycerol; AC: 
Adenylyl Cyclase; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; E R K  1/2, 
extracellular signal response kinase 1/2; PKC, protein kinase C; EP1, prostaglandin E1 receptor; 
TP, thromboxane receptor; IP, prostacyclin receptor.
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Nonsteroidal anti-inflammatory drugs (NSAIDs) include aspirin, ibuprofen, and naproxen. NSAIDs 
have anti-inflammatory, analgesic and antithrombotic properties, but are associated with 
gastrointestinal (Gl) toxicity. The cyclo-oxygenase activity of both C O X  isoforms (COX-1 and CO X- 
2) is inhibited by NSAIDs (350, 351). The Gl injury associated with NSAID use has been attributed 
to COX-1 inhibition, and the anti-inflammatory effects to COX-2 inhibition (352), although evidence 
from rats suggests that inhibition of both isoforms is necessary for the gastric damage to occur 
(353).
The role believed to be played by TxA2 in thrombotic events has led to the clinical use of agents 
which inhibit TxA2 production. Low-dose aspirin is one such agent, and has been shown to reduce 
the risk of cardiovascular events by -25%  in a broad category of patients with arterial vascular 
disease (354). Although aspirin was synthesized in 1897 and marketed as an anti-inflammatory 
drug, its mechanism of action remained unknown until, in 1971, John Vane showed that aspirin 
inhibited the synthesis of prostaglandins by inhibition of the enzyme, cyclooxygenase (CO X) (355). 
The anti-thrombotic effects of aspirin are now specifically attributed to its irreversible inactivation of 
-95%  of platelet COX-1 activity (356) and consequent suppression of platelet TxA2 formation (357).
The inactivation of COX-1 in platelets by aspirin is permanent, as platelets are anucleate and 
cannot synthesize new protein, and TxA2 generation is therefore suppressed for the lifetime of the 
platelet. Aspirin suppression of platelet COX-1 is saturable at doses in the range of 75-1 OOmg and 
despite aspirin's short half-life of just -20 minutes within the human circulation, =95% suppression 
is observed with dosing intervals of 24-48 hours, reflecting the permanent nature of platelet COX-1 
inhibition (358-360).
Aspirin inhibits both COX-1 and COX-2 by irreversible acetylation of the serine residue in positions 
529 and 516 respectively, within the CO X substrate-binding site (357, 361). This blocks the 
substrate access channel, thereby physically preventing arachidonic acid access to the enzyme's 
active site (Figure 5-8). Aspirin is 10-100 times more potent against COX-1 than COX-2. Although 
the isoenzymes are structurally similar, a number of amino acid differences in the substrate channel 
mean the acetyl-serine side chain can rotate in the slightly larger COX-2 substrate channel, thereby 
allowing arachidonic acid limited but continued access to the COX-2 active site (357).
5.1.5 Nonsteroidal Anti-inflammatory Drugs
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Figure 5-8: Aspirin  inhibition of COX-1. Adapted from (362). (A) Platelet COX-1 is a dimer, 
with a hydrophobic channel that leads to the core and catalytic site (depicted in red) of the enzyme. 
(B) Aspirin blocks arachidonic acid access to the enzyme’s active site by irreversibly acetylating a 
nearby serine residue 529 within the channel. This prevents arachidonic acid metabolism to 
prostaglandin Hi, which is required for TxA2 formation by thromboxane synthase, thus COX-1 
inhibition by aspirin suppresses platelet TxA2 generation.
In addition to its specific potency for CO X-1, aspirin affects platelet C O X  to a greater extent than 
other cells for two additional reasons. Aspirin has a short half-life, and oral aspirin is very rapidly 
degraded and inactivated by the liver. Platelet cyclooxygenase is acetylated by exposure to aspirin 
in the portal circulation (Figure 5-9), whereas non-circulating cells that lie downstream of the liver, 
such as vascular endothelial cells, are not exposed to active aspirin. The time-course of circulating 
platelets entering the portal circulation is about the same as that of absorption of newly ingested 
aspirin into the portal blood from the stomach and upper gastrointestinal tract (approx 30 mins-1 
hour) (363). In addition, unlike in other cells, irreversible CO X inhibition by aspirin is permanent for 
the life of the platelet, as they are unable to synthesize new enzyme.
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Figure 5-9. Exposure of platelets in portal blood to orally ingested aspirin. Adapted from
(363).
5.1.6 Aspirin Resistance
The risk reduction conferred by aspirin is only moderate, failing to prevent at least 75% of serious 
vascular events in patients with symptomatic atherothrombosis (364). Recurrent vascular events in 
patients taking aspirin (“aspirin treatment failures”) have many possible causes, and the notion of 
‘aspirin resistance’ has emerged as a contender. In 2004, the New York Times reported that up to 
40% of aspirin users are resistant to aspirin (365), and it has become a subject of patient concern.
There are a number of possible reasons for this so-called aspirin ‘resistance’ (Table 5-3). The term 
‘aspirin resistance’ has been used to describe several different phenomena. One is the previously 
mentioned inability of aspirin to protect patients from ischaemic vascular events, termed ‘clinical 
aspirin resistance’. However, ‘aspirin resistance’ has also been used to describe an inability of 
aspirin to produce an anticipated effect on one or more tests of platelet function, such as inhibiting 
biosynthesis of thromboxane (354, 366), inhibiting platelet aggregation (367), and causing a 
prolongation of the bleeding time (368). This has been called ‘biochemical aspirin resistance’.
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Table 5-3. Possib le  cau ses of recurrent ischaem ic vascular events among patients taking 
aspirin. Adapted from (369).
Possible causes of recurrent ischaemic vascular events among patients taking aspirin
Reduced bioavailability of aspirin
• Inadequate intake of aspirin (poor compliance)
• Inadequate dose of aspirin
• Reduced absorption or increased metabolism of aspirin
Altered binding to COX-1
• Concurrent intake of certain non-steroidal anti-inflammatory drugs (for example ibuprofen, 
indometacin), possibly preventing the access of aspirin to COX-1 binding site
Other sources of thromboxane production
• Biosynthesis of thromboxane by pathways that are not blocked by aspirin (for example, by CO X-
2 in monocytes and macrophages, and vascular endothelial cells)
Alternative pathways of platelet activation
• Platelet activation by pathways that are not blocked by aspirin (for example, red-cell induced 
platelet activation; stimulation of collagen, adenosine diphosphate, epinephrine, and thrombin 
receptors on platelets)
• Increased platelet sensitivity to collagen and ADP
Increased turnover of platelets
• Increased production of platelets by the bone marrow in response to stress (for example, after 
coronary artery bypass surgery), introducing into bloodstream newly formed platelets unexposed 
to aspirin during the 24-h dose interval (aspirin is given once daily and has only a 20-min half-
life)
Genetic polym orphism s
• Polymorphisms of COX-1, COX-2, thromboxane A2-synthase or other arachidonate metabolism 
enzymes
• Polymorphisms involving platelet glycoprotein la/lla, lbA//IX, and llb/llla receptors, and collagen 
and von Willebrand factor receptors
• Factor XIII Val34Leu polymorphism, leading to variable inhibition of factor XIII activation by low 
dose aspirin
L o ss  of the antiplatelet effect of aspirin with prolonged administration
• Tachyphylaxis
Non-atherothrombotic causes of vascular events
• Embolism from the heart (red, fibrin thrombi; vegetations; calcium; tumour; prostheses)
• Arteritis
‘Biochemical aspirin resistance’ -  specifically the persistent biosynthesis of TxA2 despite aspirin
inhibition of COX-1, has been reported in patients treated with low-dose aspirin, despite
documented inhibition of >95% of platelet COX-1 activity (321). Although the mechanism of this
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persistent TxA2 production is not known, a number of scenarios which “bypass” aspirin’s inhibition 
of platelet COX-1 have been proposed (Figure 5-10).
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Figure 5-10: Pathways of thromboxane production and the antiplatelet effects of aspirin. 
Adapted from (369). Dotted arrows denote “bypass” of aspirin’s inhibition of platelet CO X-1. Two 
models are proposed, whereby prostaglandin G 2/H2 produced by COX-2 could either be converted 
to T xA2 by thromboxane synthase in the same cell (1) or by providing PG H 2 to the thromboxane 
synthase of aspirin-treated platelets, bypassing the platelet COX-1 blocked by aspirin (2).
Initial studies with low-dose aspirin pointed to platelet COX-1 as the major source of the increased 
T xA2 biosynthesis in atherosclerosis (252), and a recent study has shown that COX-2 dependent 
T xA2 production comprises less than 2% of residual TxA2 production in aspirin-treated patients 
(370). In contrast, a growing amount of evidence suggests that COX-2 may play a role in T xA2 
production, particularly in disease states (253, 254, 268, 360, 371-381).
T xA2 can be generated from monocytes, macrophages, endothelial cells, and perhaps platelets, 
through the action of COX-2. COX-2 is expressed in endothelial cells, VSM Cs and in circulating 
nucleated cells such as monocytes and macrophages upon stimulation by a variety of pro- 
inflammatory mediators of cardiovascular disease (253) (section 5.1.3), and may also be present in 
platelets and megakaryocytes (371-373). In the model shown above, prostaglandin G 2/H2 produced
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by COX-2 could either be converted to TxA2 by thromboxane synthase (present in large quantities 
in monocytes and macrophages (374)) in the same cell (Figure 5-10 (1)), or by providing PGH2 to 
the thromboxane synthase of aspirin-treated platelets (transcellular metabolism) (268, 374-377), 
thus bypassing the platelet COX-1 blocked by aspirin (Figure 5-10 (2)).
Further evidence for the involvement of COX-2 mediated TxA production in 'aspirin resistance’ is 
provided by studies of aspirin dose. Urinary TxA2 levels are substantially affected by the dose of 
aspirin (360, 378, 379). Higher doses of aspirin result in greater inhibition of COX-2, and 
substantially lower concentrations of urinary TxA2 (360, 378, 379). Like COX-2 inhibitors, high dose 
aspirin is associated with excess atherothrombotic events (380), presumably due to diminished 
COX-2 mediated PGI2 production. Additionally, in one study, persistent TxA2 formation in patients 
with unstable angina treated with aspirin was abolished by the addition of a non-selective CO X 
inhibitor (254, 381), suggesting that inhibition of COX-1 in platelets is insufficient to suppress the 
T xA2 generated in atherosclerosis and lending credence to the theory that other sources of TxA2 
are responsible for the enhanced TxA2 formation seen in this disease. However, these findings are 
at odds with clinical trial evidence, showing that aspirin is effective in preventing cardiovascular 
events independent of its dose.
Aside from the mechanisms outlined above, another possible explanation of ‘biochemical aspirin 
resistance’ is measurement error. One commonly used measure of TxA2 levels is urinaryl 1- 
dehydrothromboxane B2 (TxM), which reflects systemic thromboxane production which does not 
exclusively occur in the platelets - renal as well as other, non-platelet, sources of TxA2 affect urinary 
TxM concentrations. Catella & Fitzgerald (382) measured TxM before and after aspirin 
administration and concluded that although platelets are the major source of TxM in urine, up to 
30% of urinary TxM derives from extra platelet sources, a fraction which may increase in 
inflammatory conditions, when inflammatory cells such as monocytes and vascular endothelial cells 
produce TxA2 via COX-2.
Increased platelet turnover is another possible explanation of aspirin 'resistance'. In high platelet 
turnover states, when there are increased numbers of immature platelets (e.g., recent surgery, 
infection, inflammation— perhaps active atherosclerosis) (371, 372), COX-1 and COX-2 have been 
shown to be elevated, and one possibility is that these immature platelets may modulate the anti­
platelet effects of aspirin through uninhibited COX-1 and COX-2 (383).
Recent work by Emily Ho and colleagues (manuscript about to be submitted) in the Anglo- 
Scandlnavian Cardiac Outcomes Trial (ASCO T) also observed an inability of aspirin to inhibit 
biosynthesis of thromboxane, suggesting that extra-platelet formation contributes substantially to
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aspirin-insensitive TxA2 levels in hypertensive individuals. Disease-associated phenotypes, such as 
lower HDL-cholesterol levels, increased atherosclerotic burden (assessed by common carotid IMT) 
and oxidative stress (assessed by urinary iPF2!-lll) were found to predict increased levels of TxA2 
formation irrespective of aspirin-use, further implicating extra-platelet pathways of TxA2 formation, 
which are upregulated in disease states (Figure 5-11 ).
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Figure 5-11. Extra-platelet sources of TxA 2 in aspirin-treated patients. Adapted from (375). 
Aspirin-treated patients metabolise PGH2 derived from vascular cells and macrophages into TxA2. 
COX-2 induction in activated endothelial cells, smooth muscle cells and macrophages may 
contribute to TxA2 biosynthesis by providing PG H 2 to the thromboxane synthase of aspirin-treated 
patients.
5.1.7 Thromboxane (TxM2), Prostacyclin (PGI2) and Cardiovascular Risk
Two studies published by Eikelboom et al within the last decade have shown an independent and 
significant association between increasing baseline urinary concentrations of 11- 
dehydrothromboxane B2 (TxM, a marker of in vivo thromboxane generation) and an increasing risk 
of future Ml or cardiovascular death in patients at high vascular risk who were treated with aspirin.
The first was a case-control sub-study of patients enrolled in the Heart Outcomes Prevention 
Evaluation (HOPE) Study, published in 2002 (354). Urinary levels of 11-dehydro TxB2 (TxM) were 
measured using a commercially available enzyme immunoassay, which had inter-assay and intra- 
assay coefficients of variation of 12.1% and 10%, respectively. From a cohort of 976 subjects
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which had TxM measurements, 488 had a confirmed Ml, stroke or cardiovascular death within the 
75-month trial duration. Urinary TxM measurement was divided into quartiles for analyses. Those 
individuals whose thromboxane levels were in the highest quartlle were found to have an odds ratio 
of 2 (95% Cl 1.2 to 3.4, P=0.006) for having a Ml and an odds ratio of 3.5 (95% Cl 1.7 to 7.4, 
P<0.001) for having a cardiovascular-related death, compared with individuals in the lowest quartile, 
after adjustment for baseline differences between cases and controls. TxM levels were not 
significantly different between cases & control subjects in those who had a stroke (Table 5-4).
Table 5-4. Adjusted* Odds of Future Cardiovascular Death, Myocardial Infarction, and Stroke 
According to Baseline Urinary Concentrations of 11-Dehydro Throm boxane B 2. From (354).
‘Adjusted for baseline differences between cases and controls; conventional cardiovascular risk 
factors (age; sex; BMI; heart rate; SBP; DBP; history of coronary disease, stroke or TIA; peripheral 
vascular disease; hypertension; diabetes; elevated total cholesterol; current cigarette smoking), 
medications (aspirin, P-blocker, lipid-lowering agent, diuretics, calcium channel blockers, ramipril, 
vitamin E) and randomized treatment allocation (ramipril titrated up to 10 mg daily, 400 IU vitamin E 
daily, both, or neither). Ml, myocardial infarction; CV, cardiovascular.
Q u a r t i l e s  o f  1 1 - D e h y d r o  T h r o m b o x a n e  B 2 C o n c e n t r a t i o n ,  n g / m m o l  
C r e a t i n i n e
O u t c o m e < 1 5 . 1 1 5 . 1 - 2 1 . 8 2 1 . 9 - 3 3 . 7 > 3 3 . 7 P
M l / s t r o k e / C V  d e a t h  ( n = 4 8 8 )
O d d s  r a t i o  ( 9 5  C l) 1 . 0 1 . 3  ( 0 . 9 - 2 . 0 ) 1 . 4  ( 0 . 9 - 2 . 2 ) 1 . 8 ( 1 . 2 - 2 7 ) 0 . 0 1
P 0 . 1 3 0 . 0 9 0 . 0 0 9
M l ( n = 3 7 8 )
O d d s  r a t i o  ( 9 5  C l) 1 . 0 1 . 3  ( 0 . 8 - 2 . 1 ) 1 . 5  ( 1 . 0 - 2 . 5 ) 2 . 0 ( 1 . 2 - 3 . 4 ) 0 . 0 0 5
P 0 . 2 6 0 . 0 7 0 . 0 0 6
S t r o k e  ( n = 8 0 )
O d d s  r a t i o  ( 9 5  C l) 1 . 0 2 . 5  ( 0 . 6 - 1 0 . 0 ) 0 . 6  ( 0 . 2 - 2 . 2 ) 0 . 6  ( 0 . 2 - 1 . 8 ) 0 . 2 0
P 0 . 1 8 0 . 4 5 0 . 3 4
C V  d e a t h  ( n = 2 4 4 )
O d d s  r a t i o  ( 9 5  C l) 1 . 0 2 . 0 ( 1 . 0 - 3 . 9 ) 2 . 5  ( 1 . 3 - 4 . 9 ) 3 . 5  ( 1 . 7 —7 * 4 ) 0 . 0 0 1
P 0 . 0 6 0 . 0 0 6  a ' ' , ' > 0 . 0 0 1
In 2008, Eikelboom et al. (366), published a similar study on aspirin-treated patients enrolled in the 
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance 
(CHARISM A) trial. The primary outcome was the composite of stroke, Ml and cardiovascular death. 
144 of the 3261 participants in whom TxM was measured had a primary outcome event during 
follow-up (median 28 months). This study had a higher number of participants (N=3261), but
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proportionally far fewer primary outcome events (144) than the H O PE study. Again, TxM was 
measured by a commercially available enzyme immunoassay.
Similar to the HOPE study, the CHARISM A study again found that urinary TxM concentrations in 
the highest quartile were associated with an increased risk of event (stroke, Ml, or cardiovascular 
death) compared with the lowest quartile (adjusted hazard ratio 1.66, 95% C l 1.06 to 2.61, P=0.03) 
after adjustment for demographic variables, cardiovascular risk factors, history of previous vascular 
events, randomized study treatment, and co-interventions. Broken down by event, there was an 
independent association between urinary TxM concentration and stroke (adjusted hazard ratio 2.36, 
95% Cl 1.19 to 4.68) but not cardiovascular death (adjusted hazard ratio 2.59, 95% Cl 0.91 to 7.42) 
or Ml (adjusted hazard ratio 0.89, 95% Cl 0.45 to 1.75).
Montlne et al published the first study to examine whether TxA2/PGI2 ratio is a risk factor for 
cardiovascular events, which was conducted in ADAPT (Alzheimer’s Disease Anti-inflammatory 
Prevention Trial) (384). Participants were aged 70 years or older, and were randomized to the 
NSAIDs naproxen, celecoxib, or placebo. Participants were permitted voluntary concomitant use of 
aspirin. Over the 46-month trial, 38 of the 315 individuals with TxM measurement had an event 
(cardiovascular death, Ml, or stroke). Urinary prostanoid levels (TxM and PGI-M) were measured 
by mass spectrometry. Adverse cardiovascular events were significantly associated with higher 
urine TxM/PGI-M ratio, mainly due to lowered PGI-M. PGI-M was significantly lower in those who 
had cardiovascular events (0.1±0.01 ng/mg creatinine), than in those who didn’t (0.15±0.01 ng/mg 
creatinine, P=0.01). They reported that urinary TxM tended to be higher in those who had 
cardiovascular events, but did not differ significantly from levels in those who didn’t. Ratio of urine 
TxM/PGI-M was significantly higher in those who had cardiovascular events. Although the number 
of adverse events in the cohort was relatively small, these data suggest that higher urine TxM/PGI- 
M ratio was associated with serious adverse cardiovascular events in AD APT participants.
Recently, Ho and colleagues (manuscript about to be submitted) conducted a study of 903 subjects 
from the hypertension-associated cardiovascular disease (HACVD) subset of the Anglo- 
Scandinavian Cardiac Outcomes Trial (ASCO T), a randomized, multicentre trial comparing the 
long-term effects of two antihypertensive regimen on Ml (385) (further details in section 3.2.1).
There were 117 cardiovascular events and revascularization procedures, including 41 deaths in the 
follow-up (median 5.6 years). Approximately half of the participants were taking aspirin at time of 
prostanoid measurement. Three composite end-points were used in the analysis: total 
cardiovascular events plus revascularization procedures (N=117), total coronary events (fatal 
coronary heart disease and non-fatal Ml) plus coronary revascularization procedures (N=66), and
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fatal plus nonfatal stroke (N=24). TxM levels were measured using liquid chromatography followed 
by tandem mass spectrometry (LC-MS-MS), as described in section 3.2.2.
TxM measurements were divided into quintiles for analysis, and a linear risk gradient was observed 
with increasing TxM after adjusting for aspirin use. After adjusting for all risk factors (age, gender, 
aspirin use, body mass index (BMI), systolic blood pressure (SBP), diabetes mellitus, current 
smoking, total cholesterol and HDL-cholesterol, and statin and antihypertensive therapy), the hazard 
ratios for increased risk per 1-quintile increase in TxM were 1.9 (95% Cl 1.1 to 3.1, P  for trend 0.01) 
for cardiovascular events and 3.1 (95% Cl 1.7 to 5.8, P  for trend <0.0001 ) for coronary events. The 
hazard ratio for those in the highest quintile of urinary TxM was 2.6-fold greater than those in the 
lowest quintile (P=0.01) for cardiovascular events and 4.5-fold greater than those in the lowest 
quintile (P<0.0001) for coronary events.
In the HACVD study, urinary PGI-M predicted neither coronary nor cardiovascular events. 
TxM/PGI-M ratio also did not predict events at statistically significant levels (adjusted hazard ratio 
1.7, 95% Cl 1.0 to 2.9, P=0.06), although in keeping with the study published by Montine et al, this 
result does suggest that higher urine TxM/PGI-M ratio is non-statistically associated with adverse 
cardiovascular events. There were 24 events of fatal and non-fatal stroke in this study, which were 
not predicted by prostanoid levels.
Where subjects are taking aspirin, the source of TxM generation in these studies is not clear. 
Eikelboom et al suggest that it may result from incomplete inhibition of thromboxane biosynthesis by 
acetylsalicylic acid, the possible reasons for which have been discussed previously (section 3.1.6). 
However, as Cattaneo points out in a letter to Circulation (386), some urinary TxM derives from 
extra platelet sources, and elevated TxM in these studies may reflect an increased generation of 
COX-2-dependent prostanoids by monocytes/macrophages in severely inflamed atherosclerotic 
plaques, which are at high risk of thrombotic complication. Cattaneo postulates, therefore, that the 
association between TxM and cardiovascular events in this study is driven by inflammation, and 
would disappear after adjustment for a marker of inflammation, such as C-reactive protein (CRP), 
which is associated with heightened cardiovascular risk (387-389).
In the HACVD study, association between C R P  and cardiovascular events followed a very similar 
pattern to that of TxM, with hazard ratios for increased risk per 1-quintile increase in C R P  of 1.9 
(95% C l 1.3 to 2.8, P  for trend 0.001 ) for cardiovascular events, and 1.9 (95% Cl 1.1 to 3.2, P  for 
trend 0.01) for coronary events. For coronary events, the likelihood ratio chi-square statistic was 
higher for the model based on TxA2 than that based on C R P  (44 versus 33, both with 10 degrees of 
freedom (df)), suggesting that for total coronary events, the model based on TxA2 had better
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discrimination than the model based on C R P . For cardiovascular events, the likelihood ratio chi- 
square statistic was not different between the two models (52 for C R P  and 51 for TxA2, both with 10 
df), Table 5-5.
Considering the additional prognostic contributions of quintiles of serum C R P  and urinary TxM in 
models adjusted for each other, Table 5-5 shows that for cardiovascular events, the likelihood ratio 
test statistic for TxM remains significant after adjustment for C R P  (x2=8.9, P=0.003), and is a better 
predictor than C R P  adjusted for TxM. For coronary events, although the likelihood ratio test statistic 
for TxM does remain significant after adjustment for C R P  (x2=4.3, P=0.04), it is a poorer predictor 
than C R P  adjusted for TxM (Table 5-5).
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Table 5-5. Receiver-operator-characteristic curve statistics and likelihood ratio tests 
com paring predictor models based on serum C R P  and urinary TxM. From Ho et al, 
unpublished, p-value* denotes significance of differences between area under R O C  curves for 
serum C R P  and urinary TxM.
Predictor Models ROC curve analyses Likelihood ratio test
Area under ROC curve Log likelihood ratio a? p-value* a? p-value 
Total cardiovascular events and revascularisation procedures 
Unadjusted models
Serum CRP 0. 5/  7.2 -
Urinary TxM 0.51 0.3 0.1
Models adjusted for risk factors (age, gender, aspirin use, cigarette smoking, diabetes, total cholesterol and 
HDL cholesterol, statin and antihypertensive therapy)
Serum CRP 0.69 52 . . .
Urinary TxM 0.69 51 0.8
CRP model adjusting (or TxM - 3.4 0.07
TxM model adjusting for CRP - - 8.9 0.003
Total coronary events and revascularisation procedures
Unadjusted models
Serum CRP 0.57 4.2 -
Urinary TxM 0.54 1.6 0.6
Models adjusted for risk factors (age, gender, aspirin use, cigarette smoking, diabetes, total cholesterol and 
HDL cholesterol, and statin and antihypertensive therapy)
Serum CRP 0.7 33
Urinary TxM 0.72 44 0.5
CRP model adjusting for TxM 9.7 0.002
TxM model adjusting for CRP - - - 4.3 0.04
In a subset of the CHARISM A cohort for whom TxM and C R P  measurements were available 
(N=2022, 87 events (Cardiovascular Death/Ml/Stroke)), when modelled together, TxM and C R P  
were Independently predictive of events. Hazard ratios for quantile 1 vs. quantile 4 were 1.9 (95% 
Cl 1.065 to 3.336, P= 0.03) for TxM and 2.1 (95% Cl 1.098 to 4.088, P=0.02) for CRP , however 
neither was significantly associated with risk when modelled together in the presence of covariates 
(Eikelboom, private correspondence).
A study by Gum et al supports the notion that the increased cardiovascular risk associated with 
urinary TxM is not simply due to extra-platelet production incited by inflammation. They showed an
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independent and significant association between the failure of aspirin to suppress agonist-induced 
platelet aggregation (measured by optical platelet aggregometry, where resistance’ was defined as 
a mean aggregation of >70% with 10 pM ADP and >20% with 0.5 mg/ml AA) and an increasing risk 
of serious vascular events in 326 patients with coronary or cerebral vascular disease who were 
treated with aspirin (hazard ratio for aspirin resistance versus sensitivity 4.1, 95% Cl 1.4 to 12.1) 
(367).
Taken together, these studies strongly suggest that level of thromboxane generation carries 
prognostic Implications, where up to 20% of future serious vascular events In high risk patients may 
be attributable to a failure of aspirin to suppress thromboxane production and/or platelet 
aggregation. The fact that TxM and C R P  both remain predictive of cardiovascular events after 
adjustment for each other does not support the theory that they are both markers of inflammation.
5.1.8 Aspirin Clinical Indication
Although aspirin reduces cardiovascular risk, it is also associated with an increased risk of serious 
bleeding events (haemorrhagic stroke or major gastro-intestinal haemorrhage) in a dose-dependent 
fashion (390).
Daily low dose Aspirin is established in the secondary prevention of cardiovascular disease (those 
with a previous heart attack or ischaemic stroke), where the risk of an atherothrombotic event is 
large. In these patients, long-term antiplatelet therapy (e.g. with aspirin) has been shown to reduce 
the yearly risk of serious vascular events by about a quarter, outweighing bleeding risk. The use of 
aspirin in primary prevention, however, is less well established, and the published evidence does 
not support the assumption made by some that the benefits clearly outweigh the harms.
In line with this evidence, aspirin is unlicensed for primary prevention in the UK and in the US. 
Despite this, a number of current clinical guidelines recommend the use of aspirin for primary 
prevention in certain groups of patients. The AHA and the European Society of Cardiology 
Taskforce recommend the use of aspirin in those with a cardiovascular disease risk of 10% or more 
over 10 years (391, 392). The Joint British Societies recommend the use of aspirin in certain 
patients with type 2 diabetes and those with a cardiovascular disease risk of 20% or more over 10 
years (393). In 2010, the BHS reaffirmed its guidelines, also recommending low dose aspirin in 
those with an estimated 10 year risk of a cardiovascular event of >20% (394). The US Preventive 
Services Task Force recommend encouraging aspirin use in men age 45 to 79 years and women 
age 55 to 79 years where cardiovascular risk was perceived to outweigh risk of harm (395).
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In 2009, the Antithrombotic Trialists' (ATT) Collaboration published a meta-analysis of individual 
participant data from 6 primary prevention and 16 secondary prevention randomized trials (396), 
which confirmed the use of aspirin in secondary but not in primary prevention. The A TT reported 
that in primary prevention trials, aspirin allocation yielded a 12% proportional reduction in serious 
vascular events (0.51% aspirin vs. 0.57% control per year, p=0.0001), due mainly to a reduction of 
about a fifth in non-fatal Ml. They reported a non-significant increase in haemorrhagic stroke 
(0.04% aspirin vs. 0.03% control per year, P= 0.05) and a non-significant decrease (0.16% aspirin 
vs. 0.18% control per year, P=  0.08) in other stroke. Aspirin use was found to increase major Gl and 
extracranial bleeds (0.10% vs. 0.07% per year, P=0.0001) and the main risk factors for coronary 
disease were also risk factors for bleeding. In secondary prevention, aspirin allocation yielded a 
greater absolute reduction in serious vascular events (6.7% vs. 8.2%, P<0.0001), with a non­
significant increase in haemorrhagic stroke but reductions of about a fifth in total stroke (2.08% vs. 
2.54% per year, P=0.002) and in coronary events (4.3% vs. 5.3% per year, P<0.0001). They 
concluded that for secondary prevention of occlusive vascular disease, low-dose aspirin is of net 
benefit, since the absolute reduction in recurrence substantially exceeds any increase in serious 
bleeds (haemorrhagic stroke or major gastro-lntestinal haemorrhage). For primary prevention, 
however, where the absolute reduction cardiovascular events is much smaller, the balance of 
benefit and haemorrhagic risk is much less definite.
The publication of this 2009 paper fuelled an already raging debate, with several letters In the 
Lancet and the BMJ in the last 2 years (397, 398). The 2009 meta-analysis was criticized for 
having low numbers of high-risk groups in the primary prevention trial. Recently, this meta-analysis 
was updated to include 3 additional high-risk cohorts (399). Even with the inclusion of these 
additional cohorts, the number needed to treat (NNT) and number needed to harm (NNH) were 
desirable (NNT>NNH) for secondary, but not primary, prevention (Table 5-6).
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Table 5-6: Aspirin  Therapy for Prim ary versus Secondary prevention of cardiovascular 
D isease: an Updated Meta-Analysis. Adapted from (399). Major extracranial bleeds were 
primarily gastrointestinal bleeds. Ml, myocardial infarction; CVA, cerebrovascular accident; CHD, 
coronary heart disease; NNT, number needed to treat; NNH, number needed to harm.
Event
Aspirin
(%/vD
Control
(%/yr)
Risk ratio 
(95%CI) P
Heterogeneity
P
NNT or 
NNH (-)
Primary prevention 
(9 trials, N=104,331)
Serious vascular event 0.57 0.63 0.9(0.85, 0.96) 0.001 0.51 1668
Nonfatal Ml 0.21 0.25 0.82(0.74, 0.90) <0.001 0.43 2500
Nonfatal CVA 0.18 0.2 0.92 (0.83, 1.03) 0.15 0.71 5000
CHD death 0.12 0.12 0.99(0.87, 1.13) 0.91 0.1 71
Major extracranial bleed 0.11 0.08 1.47(1.26, 1.71) <0.001 0.13 -3333
Hemorrhagic stroke 0.04 0.03 1.26(0.97, 1.64) 0.08 0.6 -10000
Secondary prevention 
(16 trials, N=18,249)
Serious vascular event 6.69 8.19 0.81(0.75,0.87) <0.001 0.2 67
Nonfatal Ml 1.6 2.3 0.69(0.60, 0.80) <0.001 0.5 143
Nonfatal CVA 2.13 2.6 0.81(0.71,0.92) <0.001 0.1 213
CHD death 2.73 3.07 0.87(0.78, 0.98) 0.007 0.4 294
Major extracranial bleed 0.25 0.06 2.69(1.25, 5.76) 0.002 0.1 -526
5.1.9 Genetics
Urinary TxA2 has been consistently shown to be an independent predictor of cardiovascular events 
(section 5.1.7) but to date, no genetic association studies have been carried out which have looked 
for associations between genetic polymorphisms and levels of TxA2 or PGI2. TxA2 and PGI2 
therefore represent new, specific and accurately measureable cardiovascular risk factors for genetic 
study.
Although there are no published studies which have established the genetic determinants of these 
prostanoids, two studies have looked for associations between polymorphisms in ‘candidate’ genes 
and risk of myocardial and cerebral infarction.
A number of functional polymorphisms in the gene for thromboxane synthase have been identified, 
which were postulated to affect urinary thromboxane levels and which appear to be under selective 
pressure (400, 401). A polymorphism in the promoter region of this gene has been identified as a 
risk factor for Ml in a Japanese population (402).
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Another study has described an association between the thromboxane receptor (TP) gene, 
TBXA2R, and susceptibility to cerebral infarction (Cl) (403). Two SN P s in TBXA2R  were 
significantly associated (P<0.05) with cerebral infarction in a Japanese population comprising 194 
Cl and 365 non-CI subjects.
5.1.10 Mendelian Randomisation
The identification in this study of genetic determinants of TxA2 and PGI2 levels may help to elucidate 
the nature of the association between elevated TxA2 levels and cardiovascular risk. However, 
observed associations such as these are often subject to problems such as confounding and 
reverse causation that may distort their interpretation. Mendelian randomization is a technique 
which can be used to ascertain whether observational associations such as these are real, causal 
associations or a product of confounding and/or reverse causation.
Mendelian randomization is the term applied to the random assortment of alleles at the time of 
gamete formation which results in population distributions of genetic variants that are generally 
independent of factors that typically confound epidemiological associations between putative risk 
factors and disease. Mendelian randomization can be applied to observed associations between a 
risk factor (such as an intermediate phenotype) and a disease where information about genetic 
determinants of the risk factor is available, as outlined in Figure 5-12. Association between genetic 
determinants of levels of the intermediate phenotype and disease indicate a true causal 
relationship, if no such association exists, the possibility remains that the association is due to 
reverse causality.
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Figure 5-12. A  pictorial representation of the model used to test for a causal association 
between intermediate phenotype and disease (IP-D) or to derive an unconfounded estimate 
of the size of that effect. Adapted from (404). G represents the genotype, IP the intermediate 
phenotype (e.g. thromboxane levels), and D the disease (e.g. CHD). The association between G 
and D (shown as a broken line) is induced only through the causal effects of G on IP and of IP on 
D. The model assumes that there is no other pathway through which the gene exerts its effect on 
Ml. Under the assumption of Mendelian randomization, the measurements of the G -D  and G -IP  
associations are unconfounded, while the measured IP -D  association is likely to be confounded 
and subject to reverse causation.
Mendelian Randomisation has been applied to other observational associations with cardiovascular 
disease, where it has helped to dissect the nature of the associations.
A recent meta-analysis of individual participant data from 47 epidemiological studies, evaluated four 
SN Ps in the C-reactive protein (CR P) gene which explain 98% of the variation in C R P  levels in 
populations of European descent (405). These SN Ps were not associated with altered risk ratios 
for coronary heart disease, and the investigators concluded that C  reactive protein concentration 
itself is unlikely to be even a modest causal factor in coronary heart disease.
On the other hand, genetic variants which cause familial hypercholestroleamia associate strongly 
with coronary heart disease, providing strong evidence that the associations between blood 
cholesterol and coronary heart disease seen in general populations reflects a causal relationship 
(406).
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5.1.11 Aims and Objectives
We hypothesized that genetic variation as detected by a genome-wide association study would be 
associated with urinary thromboxane and/or prostacyclin levels. Identification of these genetic 
variants will further both the understanding and prediction of elevated TxA2 levels as a marker of 
cardiovascular disease. Although less is known about the predictive value of PGI2, its role as the 
physiological antagonist of TxA2 implicates it in the same disease processes. Identification of the 
genetic determinants of TxA2 and PGI2 levels, if they exist, may also provide a new 
pharmacogenetic test for those most likely to derive benefit and those most likely to derive harm 
from anti-platelet therapy.
5.2 Methods
Population database collation and “clean-up” and all statistical analyses apart from imputation were 
carried by the author. DNA extraction was carried out in-house at the Royal College of Surgeons in 
Ireland, Dublin. Genotyping on the CVD50K chip was performed in-house at the genome centre at 
the William Harvey Research Centre, Queen Mary University of London, London. Genotyping on 
the CNV370-Duo chip was performed at the Centre National de Génotypage (CNG), Paris.
5.2.1 Population Information
The population examined in this study participated in the HACVD (Hypertensive Arteriosclerotic 
Cardiovascular Disease) study, a phenotype-genotype sub-study of the Anglo-Scandinavian 
Cardiac Outcomes Trial (ASCOT), a randomized, multicentre trial comparing the long-term effects 
of two antihypertensive regimens on myocardial infarction. Methods & study design of A SC O T  
have been described in detail elsewhere (407).
Briefly, 19,342 hypertensive patients, aged between 40-79 years, with at least 3 additional 
conventional cardiovascular risk factors (age > 55 years, male gender, family history of early 
coronary heart disease in a first degree relative, history of cerebrovascular event > 3 months 
previously, cigarette smoking, diabetes mellitus, peripheral vascular disease, electrocardiographic 
evidence of left ventricular hypertrophy, plasma total cholesterol to HDL cholesterol ratio > 6, 
microalbuminuria or proteinuria) were randomized to either a standard antihypertensive regimen (p- 
blocker + diuretic) or to a more contemporary regimen (calcium antagonist + angiotensin converting
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enzyme inhibitor). Patients were not eligible for inclusion if they had any of the following: previous 
myocardial infarction, currently treated angina, a cerebrovascular event within the previous 3 
months, congestive heart failure, uncontrolled arrhythmias, or any major non-cardiovascular 
disease. In addition, the benefits of cholesterol lowering in the primary prevention of coronary heart 
disease in hypertensive patients were assessed in a lipid-lowering arm of this trial (ASCO T-LLA). A 
total of 10,350 patients with a non-fasting cholesterol level of < 6.5 mmol/L were recruited into 
ASCOT-LI_A, and randomized to either atorvastatin 10 mg or placebo. A schematic of the A SC O T 
study is given In Figure 5-13 below.
ExCluSod (urine 
sample inadequate) 
N«10
Urinary TxA. and/or PGI3 
N=900
Caucaban
N=859
Successfully
GonotypodN*B00
T C £  6.5 mmol/L
Alorvastalin 10 mg 
N«5.618
ASCOT LLA Placebo
N=5.137
Ganoiypadon 
CVD50K only 
N=23
Genotypedon 
CVD50K and 
CNV370J5UO 
N=S21
Multinational Randomised Controlled Trial
Genotyped on 
CNV37M)uo only 
N=256
HACVD Substudy
Figure 5-13. Schem atic outline of the A S C O T  study and sub-studies relevant to this thesis.
The right hand schematic outlines the main A S C O T  cohort. The left hand schematic outlines the 
HACVD population. HACVD, hypertensive arteriosclerotic cardiovascular disease; TC , total 
cholesterol; BPLA, blood pressure lowering arm; LLA, lipid lowering arm, CNV370-Duo, lllumina 
HumanCNV370-Duo whole genome BeadChip array; CVD50K, lllumina CVDBeadChip array.
The blood pressure lowering arm (ASCO T-BPLA ) of the study reported that the amlodipine ± 
perindopril based therapy confers an advantage over atenolol ± thiazide based therapy on all major 
cardiovascular events, all-cause mortality and new-onset diabetes mellitus (408). The results of 
A SC O T-LLA  confirmed that cholesterol lowering is beneficial in hypertensive patients (409).
A total of 1006 A SC O T recruits at two trial centres (420 patients from Beaumont Hospital,
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Dublin, and 586 from St. Mary's Hospital, London) participated in the HACVD sub-study (385). The 
HACVD sub-study involved intensive phenotyping of these subjects, along with DNA collection, with 
the intention of identifying unrecognised genetic influences on the development of hypertension 
associated cardiovascular disease.
Baseline demographic data (age, gender, ethnicity), levels of cardiovascular risk factors (cigarette 
smoking, diabetes, dyslipidaemia, blood pressure, body mass index), evidence of target end-organ 
damage (electrocardiographic criteria of left ventricular hypertrophy, proteinuria) and previous 
history of cerebrovascular events or peripheral vascular disease were recorded for all patients in the 
HACVD study. Repeat office blood pressure levels, repeat lipid levels, medication usage, 
antihypertensive treatment, statin therapy, and aspirin use were recorded throughout the trial, as 
were outcome measures of the composite endpoint which included all cardiovascular events and 
procedures plus development of renal impairment. Additional phenotypic measurements, which 
included an index of atherosclerotic burden (common carotid intima-media thickness (IMT)), an 
index of oxidative stress levels (urinary isoprostane iPF2a-lll), a measure of inflammation (high- 
sensitivity serum C-reactive protein (CRP)), an index of systemic PG I2 formation (urinary 2,3- dinor 
6-keto PGF-iq (PGI-M)), and urinary levels of TxM, an index of systemic TxA2 formation, were 
obtained during the second and fourth year post-randomization to A SC O T  treatments. The study 
was approved by the ethics committee at Beaumont Hospital, Dublin (R E C #  99/21). All patients 
gave written informed consent.
5.2.2 Urinary Thromboxane and Prostacyclin Quantification
Urine samples, collected in the morning after an overnight fast (10 to 12 hours), were tested for 
blood, sugar and protein, and 75 ml samples were divided into aliquots and stored at -20°C until 
analyzed.
TxA2 has a short half-life (-30 seconds), and is rapidly and non-enzymatically hydrolyzed to its 
metabolite, TxB2, which is then excreted in the urine (410). Direct measurement of TxB2, may not 
be an accurate reflection of true in vivo TxA2 production, as most of the TxB2 measured in the 
plasma or urine is due to ex vivo platelet activation or intra-renal production respectively (411). To 
circumvent this, it was necessary to measure a stable metabolite of TxB 2 itself, that cannot be 
formed by platelets or the kidney (412). One such metabolite is 11-dehydro TxB2 (TxM), which has 
a circulating half-life of 45 minutes (413, 414). Measurement of plasma or urinary levels of TxM 
have been shown to give a time-integrated indication of TxA2 production (414). To normalize for
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urinary output, TxM levels were expressed as pg of TxM/mg creatinine. Normal urinary TxM levels 
range between 400 to 500 pg/mg creatinine.
Similarly, prostacyclin has a half-life of approximately 3 minutes, and then undergoes non- 
enzymatic hydrolyzation to its metabolite, 6-keto-PGF1a, which is also excreted in the urine (415). 
Again, levels of this metabolite derive from renal biosynthesis of prostacyclin and thus do not reflect 
in vivo levels of its prostanoid parent (416, 417). On the other hand, the enzymatically formed 2,3- 
dinor-6-keto-PGF1a (PGI-M) is mainly derived from systemic prostacyclin, and estimates of this 
urinary metabolite provide an accurate measurement of systemic prostacyclin production (418,
419). To normalize for urinary output, PGI-M levels were expressed as pg of PGI-M/mg creatinine. 
Normal urinary PGI-M levels range between 50 to 230 pg/mg creatinine.
Mass spectrometric methods of eicosanoid and isoeicosanoid measurement are considered "gold 
standard", yielding quantitative results in the low picogram range (420, 421). Its drawbacks are that 
sample preparation and analysis is labour-intensive and expensive equipment is needed.
Alternative approaches using immunologic techniques with analyte-specific antibodies have been 
developed that are low-cost and relatively easy to use (422). However, there is currently limited 
information available with regards their precision and accuracy.
In this study, each urine specimen was quantified for levels of TxM and PGI-M, using liquid 
chromatography and tandem mass spectrometry. Briefly, samples were labelled with known 
amounts of deuterated internal standard for all three compounds. Following solid-phase extraction, 
TxM samples were dried and re-suspended in 20% methanol. Samples for PGI-M required 
derivatisation with 0.5% (v/v) methoxamine (MOX, Sigma, UK) after evaporation to dryness, and 
was reconstituted in 100|jl of deionised water. Each of the urinary eicosanoids was analysed 
separately by liquid chromatography/ tandem mass spectrometry on a triple quadrupole mass 
spectrometer (API 3000, Applied Biosystems, Toronto) equipped with a turbo ionspray source, 
using a Perkin Elmer Series 200 H PLC  system (US) and a Omnisphere C18 reversed phase 
column (3 "m particle size, 2.1 x 100 mm, Varian, UK) as an inlet. Urinary creatinine was measured 
by the Jaffe rate method (Jaffe 1886) with the S YN C H R O N ®  Creatinine reagent in conjunction with 
the SYN CH RO N  L X ®  system (Beckman Coulter, CA, USA). In our laboratory, the limits of 
detection for urinary TxM and PGI-M were 40pg/ml Creatinine and 20pg/ml creatinine respectively. 
Assays for urinary TxM and PGI-M were performed with coefficients of variation consistently below 
15% for both intra- and inter-assay precision.
155
Urinary TxM and PGI-M measurements (pg/mg creatinine) were performed twice, at an average of 
1.5 and 3.5 years post-randomisation. As there was no progression in prostanoid values between 
time-points, an average of the two measures was used for analysis.
5.2.3 Genotyping
Of the 1006 HACVD participants, 990 individuals had successful TxM and/or PGI-M measurements, 
and of these, 859 individuals were Caucasian. 800 of these Caucasians were genotyped on the 
lllumina CVDBeadChip array and/or the lllumina HumanCNV370-Duo array (Figure 5-13). Although 
521 individuals were common to both experiments, for the purposes of this thesis, the two will be 
treated separately.
DNA extraction: Venous blood samples were drawn In the morning after an overnight fast (10 to 12 
hours), and serum aliquots were stored at -80°C until analysed. DNA was extracted from blood 
lymphocytes by standard procedures(423).
Genotyping of HACVD participants was performed on the lllumina CVDBeadChip array (‘CVD50K 
chip’) following the manufacturer's experimental protocol (lllumina Inc, San Diego, CA, USA). The 
CVD50K chip was one of the first genecentric genotyping arrays developed for replication and fine 
mapping of loci with known or putative roles in specific phenotypes or disease areas, and is also 
known as the ITMAT-Broad-CARe or “IBC array”, the CardioChip or the Human Cardiovascular 
Disease BeadChip. It incorporates ~50,000 SN P s to efficiently capture genetic diversity across 
over 2,000 genic regions related to cardiovascular, inflammatory, and metabolic phenotypes. 
Genetic variation within the majority of these regions is captured at density equal to or greater than 
that afforded by genome-wide genotyping products (424). The CVD50K chip has content derived 
from the International HapMap Consortium and re-sequencing data from the SeattleSNPs and 
National Institute of Environmental Health Sciences (NIEHS) SN P s consortia, with a focus upon 
inclusion of lower-frequency variants and variants with a higher likelihood of functionality. Genes 
were selected for inclusion on the CVD50K chip on the basis of pathway analysis and previous 
candidate gene and GW AS reports of a variety of cardiovascular disease (CVD)-related 
phenotypes.
Genotyping of HACVD participants was also performed on the lllumina HumanCNV370-Duo whole 
genome BeadChip array (‘CNV370 chip') following the manufacturer's experimental protocol 
(lllumina Inc, San Diego, CA, USA). This array contains 318,000 uniformly spaced and informative 
single nucleotide polymorphisms (SNPs) and 52,167 CN V markers.
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For both beadchips, intensity data were normalised using lllumina BeadStudio, and genotypes were 
called using llluminus. Genotypes for deliberate duplicate pairs were merged and samples with 
inconsistent data across duplicates were excluded.
Some quality control screening was performed by third parties prior to receipt of the genotype data. 
Quality control checks were performed on receipt of the genetic data and exclusions were made as 
described in Table 5-7 and Table 5-8.
Table 5-7. Quality control procedure and exclu sion s for the SN P s genotyped on the CVD50K 
chip.
Sample Exdusions: Starting sample number N=544
Sample call rate: Excluded samples with genotyping call rate <95% (N=0) N=544
Sample duplicates:
Genotypes for deliberate duplicate pairs were merged and samples with 
inconsistent data across duplicates were excluded (N=0) N=544
Sex check:
Excluded samples with X chromosome heterozygosity inconsistent with 
phenotypic sex (N=0) N=544
Sample relatedness:
Presence of cryptic relatedness was established by estimating identity by 
descent (IBD) using PUNK. If pairs of DNA sampes showed pi-hat >0.125 
(estimated proportion of alleles IBD), the pair would be inspected and 
one sample excluded from further analysis (N=0) N=544
SNP Exclusions: Starting SNP number N =47,657
SNPcall rate: Excluded SNPs with low (<95%) genotype call rate (N=224) N=47,433
Hardy-Weinberg: Excluded SNPs with Hardy-Weinberg P <10’07 (N=360) N =47,073
MAF Excluded SNPs with minor allele frequency (MAF) <5% {N=15,503) N=31,570
10/
Table 5-8. Quality control procedure and exclusions for the SN P s genotyped on the CNV370- 
Duo chip.
Sample Exclusions: Starting sample number N=777
Sample call rate: Excluded samples with genotyping call rate <95% (N=5) N=777
Sample duplicates:
Genotypes for deliberate duplicate pairs were merged and samples with 
inconsistent data across duplicates were excluded (N=0) N=777
Sex check:
Excluded samples with X chromosome heterozygosity inconsistent with 
phenotypicsex (N=0). N=777
Sample relatedness:
Presence of cryptic relatedness was established by estimating identity 
by descent (IBD) using PUNK. If pairs of DNA sampes showed pi-hat 
>0.125 (estimated proportion of alleles IBD), the pair would be 
inspected and one sample excluded from further analysis (N=0). N=777
Sample ancestry:
Ancestry PCA was performed using an LD-pruned set of 14, 000 SNPs. 
Outliers, defined as > 6 standard deviations from the mean in any of the
first 10dimensions, were excluded. N=777
SNP Exclusions: Starting SNP number N=283,291
SNP call rate: Excluded SNPs with low (<95%) genotype call rate (N=75) N=283,216
Hardy-Weinberg: Excluded SNPs with Hardy-Weinberg P <10'07 (N=l) N=283,072
MAF Excluded SNPs with minor allele frequency (MAF) < 5% (N=10,906) N=272,166
The SN Ps genotyped on the CNV370-Duo chip were used to impute the genotypes of a further
1.884.210 ungenotyped SN Ps using phased haplotype data from the densely genotyped individuals 
(of European descent) from the HapMap II release 22 CEU reference panel collection and the 
MACH program (425). Only those SN P s with Information scores of >70% (1,759,333 out of
1.884.210 imputed) were used in the analyses. After all quality control measures, 31,570 SN P s on 
the CVD50K chip and 2,031,499 SN Ps (genotyped and imputed (info score>70%)) on the CNV370- 
Duo chip were analysed In populations of 544 and 777 individuals with TxM and/or PGI-M 
measurements, respectively. TxM and PGI-M were not both successfully measured in all 
individuals, and individual N-numbers are provided for the two phenotypes in the following sections.
Of the 31,570 CVD50K SN Ps which passed quality control, 5,328 were not present in the 2,031,499 
genotyped and imputed SN Ps from the CNV370-Duo chip. Because of the way that the CVD50K 
chip was designed (very deep genotyping across -2,000 genes), and because imputation was done 
using only 272,166 genotyped SN Ps, a low number by ‘genome-wide’ standards, it's unsurprising 
that a substantial number of SN Ps were specific to the CVD50K genotypes. As such, there were 
two reasons why the two datasets (CVD50K and CNV370-Duo) were not merged prior to analysis, 
but rather were treated as two separate analyses. The first was that the genotyping was performed 
in different populations, albeit with considerable overlap (Figure 5-13). The second was the fact
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that >5,000 SN Ps genotyped on the CVD50K chip were not represented in the genome-wide 
dataset.
5.2.4 Data Analysis
Given the relatively modest size of this study, and the tendency of rare variants to cause spurious 
associations in sample sizes which are not sufficiently large to include a number of carriers, it was 
decided to conduct our analyses on only those SN P s present in the study population at a frequency
of > 5%.
The primary analysis for both the CVD50K analysis and the CNV370-Duo analysis was performed 
in all subjects. However, given the drastic effect of aspirin on prostanoid production (section 5.1.5), 
the populations were also divided into those taking aspirin at time of prostanoid measurement, and 
those who were not, for sub-analyses.
For each SNP, a linear regression analysis was performed, assuming an additive genetic model, 
modelling prostanoid levels (pg/mg creatinine) as a quantitative trait and adjusting for the 
covariates; age (years), sex, smoking habit (current smokers vs. never & ex-smokers), diabetes 
(yes/no), systolic blood pressure (mmHg), body mass index (BMI, calculated as mass 
(kg)/(height(m))2), high density lipoprotein (HDL, mmol/L), low density lipoprotein (LDL, mmol/L), 
aspirin use at time of prostanoid measurement (yes/no) and randomized anti-hypertensive regimen 
(Randomisation to antihypertensive was coded 0((3-blocker + diuretic)/1 (calcium antagonist + 
angiotensin converting enzyme inhibitor). Where covariate measurements were different at second 
and fourth years post-randomisation, average values were used in the adjustment. All association 
analyses were performed using PLINK, v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/, (211)).
5.2.5 Population Stratification
For the CVD50K chip analysis, all subjects self-identified themselves as being of European 
descent. A genomic control lambda value for quantifying any potential population stratification 
effects was calculated from the QQ plots of association P-values using WGAViewer (213), 
assuming a 2 df chi distribution of the -2log(e)P measures (214) (section 5.3.4). In each case, the 
lower 95% of the P values were distributed in accordance with random expectation, giving lambda 
values of «1, indicating that any effect of population stratification in this study was minimal.
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For the CNV370-Duo analysis, LD-pruned set of -14,000 genotyped SN P s was used to perform 
ancestry principal component analysis (PCA) using eigenstrat software (426). The first ten PC  
vectors were used as additional covariates in all association analyses. As with the CVD50K 
analysis, genomic control lambda values were calculated from the QQ plots of association P-values, 
and did not indicate inflation of P-values due to population stratification.
5.2.6 Permutation Testing
Permutation testing was performed for the CVD50K chip analysis as a precaution against spurious 
results due to the non-normal distribution of TxM. Permutation analysis was performed in PUNK, 
using the max(T) permutation command. Briefly, (assuming that individuals are interchangeable 
under the null), individual-phenotype labels were swapped to provide a new dataset, sampled under 
the null hypothesis. Only the phenotype-genotype relationship is destroyed by permutation, the 
patterns of LD between SN Ps remain the same under the observed and permuted samples. An 
association analysis was performed for each of the shuffled datasets and the test statistics were 
compared to the observed test statistic.
5.3 Results fo r Thromboxane Genotyped on the CVD50K 
Chip
5.3.1 Baseline Characteristics
TxM levels were significantly lower in subjects on aspirin compared to those not taking aspirin at 
time of TxM measurement. There were also significantly fewer men taking aspirin, significantly 
more diabetics taking aspirin, and subjects taking aspirin on average had significantly higher 
systolic blood pressure. There were no significant differences between subjects taking aspirin and 
those not taking aspirin across the other population characteristics (Table 5-9).
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Demographic & Clinical Characteristics
All Subjects 
(N=540)
Subjects Not On Aspirin 
(N= 272)
Subjects On Aspirin 
(N= 268) P
TxM (pg/mg creatinine): Median (IQR) 482 (290-798) 716 (460-1071) 323 (211-518) 2E-16*
Age (years): MeaniSD 64.7 i  8.1 64.2 + 8.1 65.3 i  8.1 0.11
Male: N (%) 423(78%) 223(82%) 200 (75%) 0.04*
Current smokers: N (%) 110 (20%) 55(20%) 55(20%) 0.93
Current diabetes: N (%) 93(17%) 35 (13%) 58(22%) 7E-03*
SBP(mmHg): MeaniSD 134.8 i  11.8 132.1 i  10.5 137.5 i  12.4 9E-08*
BMI (kg/m2): Mean ±SD 29.2 i  4.5 28.9 i  4.3 29.4 i  4.7 0.23
HDL(mmol/L): MeaniSD 1.3+ 0.3 1.3 i  0.3 1.3 i  0.3 0.49
LDL(mmol/L): MeaniSD 3.0 i  0.9 3.0 i  0.9 3.0 i  0.8 0.69
Randomised to ACE-I: N (%) 275 (51%) 144 (53%) 131 (49%) 0.35
Table 5-9. Population characteristics for the 540 individuals in this study for whom TxM measurements were available. Subjects not 
randomized to the angiotensin-converting enzyme inhibitor and calcium antagonist regimen were randomized to a p-blocker and diuretic regimen. IQR: 
Inter quartile range; SD: Standard deviation; N: number of subjects included in analysis; SBP: Systolic blood pressure; BMI: Body mass index; HDL: 
High density lipoprotein; LDL: Low-density lipoprotein; ACE-I: Angiotensin-converting enzyme inhibitor. Bold font indicates the primary endpoint, TxM. 
*P-value significant at P<0.05.
5.3.2 Thromboxane Distribution
The distribution of TxM levels (pg/mg creatinine) across the study population of 540 subjects was 
non-normal (Figure 5-14). After adjustment for covariates (TxM*), the distribution was less skewed, 
but remained non-normally distributed. Following Log™ transformation of the TxM values, the 
distribution approximated normality.
If a dependent variable (In this case TxM*) is not normally distributed, then it Is likely that the 
residuals resulting from a statistical test which assumes a normal distribution (such as the linear 
regression analyses featured later in this section) will also be non-normal, and this may lead to 
misleading P-values. Figure 5-15 indicates that in this study, the distribution of the residuals was 
slightly skewed. This could reflect the non-normality of the TxM* distribution, or simply an excess of 
significant associations between the SN Ps and TxM*.
Log-transformation of the TxM* values resulted in a more normal distribution (Figure 5-14).
However, transformation of the data would result In the coefficients being on the wrong scale. In 
addition, if based on a reasonable number, most parametric tests are reasonably robust against 
departures from normality. Permutation analysis, which empirically tests for association between 
the SN Ps and the dependent variable (section 5.2.6), was performed for SN Ps found to be 
associated with TxM* in order to rule out spurious association due to the non-normal distribution of 
TxM*. In addition, P-values based on the log-transformed TxM* values are provided in the below 
tables, and where these values failed to exceed P=1x10'03, associations were dismissed.
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Figure 5-14. Histogram s (left) and “Normal” QQ normal plots of the distribution of TxM 
levels in all 540 subjects before (panel A) & after (panel 6) adjustment for covariates, and 
following log10 transformation of the non-normally distributed TxM values (panel C). The red
line on the QQ plots passes through the first and third quartiles. If values were normally distributed, 
they should adhere closely to this line. TxM: urinary thromboxane measurement. *Adjusted for the 
covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and 
anti-hypertensive regimen. Adjustment led to negative thromboxane values which, although 
fictional, can be legitimately used for regression analysis.
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Figure 5-15. The distribution of the residuals of the associations between SN P s on the 
CVD50K chip and TxM* in all subjects.
5.3.3 Power Calculations
The statistical power of a study Is the probability that the test will reject the null hypothesis when the 
null hypothesis is false, and is an important parameter to consider before interpreting the results of 
a study. A post-hoc power analysis was conducted for this study to help to indicate how likely the 
study was to have identified ‘true’ associations, assuming that they exist. Power was calculated 
using the Quanto power calculator (http://hydra.usc.edu/gxe/). Power was calculated assuming a 
continuous variable, an additive inheritance model, gene-only effects (no gene-gene or gene- 
envlronment Interactions were accounted for), and a 2-sided test. Power was estimated assuming 
a variety of minor allele frequencies (MAF) of the genetic variants, beginning at MAF 0.05 and 
Increasing in increments of 0.05 to MAF 0.5. In order to correct for the effects of testing many
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thousands of SN Ps (multiple testing), it was necessary in this study to impose a type I error rate 
more stringent than the commonly used 5% (0.05). Because of this, power was calculated across a 
range of type I error rates.
Figure 5-16 indicates that this study had good (>80%) power to detect associations between SN Ps 
present in the population at a frequency of 5% or above and even small changes in TxM* levels at a 
type I error rate of 0.05. However, this study only had good (>80%) power to detect SN P s which 
were both present at a high frequency in the population (>20%) and were associated with large 
effect sizes (>200pg/mg creatinine TxM* change per minor allele), at a type I error rate of 1.6x10"°6, 
which was the Bonferroni-corrected error threshold used for this study (section 5.3.5).
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TxM* All Subjects (N=540), a=0.05 TxM* All Subjects (N=540), a=1x10 -3
Minor Allele Frequency 
TxM* All Subjects (N=540), a=1x10 -5
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Minor Allele Frequency Minor Allele Frequency
Figure 5-16. Power plots for association between S N P s on the CVD50K chip and TxM* 
levels. The power of this study to detect associations between SN P s on the CVD50K chip and 
TxM* levels in the total population (N=540), assuming a Type I error rate (a) of 0.05 (panel A), 1x10" 
03 (panel B), 1x10'05 (panel C) or 1.6x10'06 (panel D) was plotted. The population mean of TxM* 
was 768 pg/mg creatinine and the standard deviation was 554 pg/mg creatinine. Power was plotted 
assuming four different main effect sizes of TxM* (pg/mg creatinine) associated with carriership of 
one minor allele (150, 200, 250 of 300 pg/mg). The maximum effect size per minor allele carried 
observed in the results of this study was 385 pg/mg creatinine. TxM: urinary thromboxane 
measurement. ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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5.3.4 QQ Plots
QQ plots of the P-values for association of the SN P s on the CVD50K chip with TxM levels In all 
subjects, and in subjects divided by aspirin usage, are shown in Figure 5-17. SN Ps with a minor 
allele frequency (MAF) <5% were not included in the analysis of these results, and were plotted 
separately. In all subjects, six SN Ps with low P-values and MAF = 5% exceeded the 99% 
probability envelopes, indicating that more significant P-values were observed than would be 
expected by chance. When the subjects were divided into those on aspirin and those not taking 
aspirin at time of TxM measurement, the P-values for association remained within the 99% 
confidence envelopes, indicating that the P-value distribution approximated that which would be 
expected under the null hypothesis of no associations.
In all three populations, the P-values for SN Ps with a MAF of <5% deviated substantially from the 
expected line at low P-values. However, with a population size such as the one in this study, these 
are likely to represent spurious associations, and were not included in further analyses.
Genomic control (GC) A values were calculated from the P-value distributions, including only SN Ps 
with MAF = 0.05 and the lower 95% of the distribution. G C  values for each population were 
approximately equal to 1, suggesting that the P-values in this study are not skewed due to 
population stratification, or any other bias.
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TxM* Subjects On Aspirin (N=268) Figure 5-17. QQ plots of P-values for 
association of the S N P s on the CVD 50K chip 
with TxM*. Observed P-values were plotted 
against those which would be expected under the 
null hypothesis of no association (black line). 
SN P s were divided into those with a minor allele 
frequency (MAF) of = 5% (red), or < 5% (blue). 
Shaded regions are 99% probability envelopes 
(which depend on number of SN P s and hence 
are different sizes for common (pink envelope) 
and low-frequency (blue envelope) SNPs). 
Genomic control A values were calculated 
including only SN Ps with MAF = 0.05 and the 
lower 95% of the distribution and were as follows: 
All Subjects: 95% A=0.98; Subjects On Aspirin: 
95% A=1.00; Subjects Not On Aspirin: 95% 
A=1.00. TxM: urinary thromboxane 
measurement. ‘Adjusted for the covariates age, 
sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti­
hypertensive regimen.
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5.3.5 Manhattan Plots
Manhattan plots of the P-values for association of the SN Ps on the CVD50K chip with TxM* in each 
of the three populations are shown below (Figure 5-18-Figure 5-20). In all three populations,
31,570 SN Ps on the CVD50K chip passed quality control, and were present in all subjects at a MAF 
of = 5%. The Bonferroni correction for multiple testing was applied to provide a 5% overall false 
positive rate control and was calculated as 0.05/31,570, giving a value of 1.6X10"06. The Bonferroni 
correction, although widely applied to GW AS because of Its simplicity, is overly-conservative, as it 
assumes Independence between SN Ps, which, because of linkage disequilibrium (LD), is not 
always the case. In particular, on genotyping chips such as CVD50K, where a gene-centric 
approach has been taken, a substantial amount of LD exists between SN Ps, making the Bonferroni 
correction particularly overly-conservative. For this reason, along with the lack of power of this 
study to detect associations at this threshold (section 5.3.3), it was decided to treat as 'interesting' 
all associations with P-values =1x1 O'05. This value was decided arbitrarily, but the same strategy 
has been used to successfully identify SN Ps which went on to replicate significantly by other 
investigators using genotypes from the CVD50K chip (Patricia Munroe, private correspondence).
Loci which contained at least one SN P which was associated with TxM* at P= 1x10"°5 were 
highlighted on the plots and described in the tables underneath them. In addition, the ‘candidate’ 
genes for thromboxane synthase 1 (TBXAS1), COX-1 (PTG S1) and COX-2 (PTG S2 ) are 
highlighted in blue. The gene encoding cytosolic phospholipase A2 (PLA2) is also a candidate for 
influencing TxM* levels, but was not genotyped on this array.
There were no SN Ps in this study which were significant beyond the Bonferroni threshold for 
multiple testing. However, an association peak on chromosome 5, corresponding to the 
PPA RG C1B  gene, almost met this threshold; the most significant SN P at this locus in all subjects 
had a P-value of 4.3x10'06 (Figure 5-18). Two SN Ps, rs4235745 and rs32582, in this gene were 
associated with TxM* at P-values of =1x1 O'05. This association peak was also apparent In subjects 
not on aspirin (Figure 5-19), but did not appear in subjects on aspirin (Figure 5-20).
169
65
5 4
03>I
0. 3
o  
05 
?  2
1
0
TxM* All Subjects (N=540)
CHR SNP BP MAF BETA P
CLOSEST
GENE
SNP
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5 rs4235745 149171304 0.30 166.7 4.3E-06 PPARGC1B Intron 1
peroxisome prollferator-activated 
receptor gamma, coactivator 1
5 rs32582 149185610 0.17 201.1 9.1E-06 PPARGC1B intron 2
peroxisome proliferator-actlvated 
receptor gamma, coactivator 1
Figure 5-18. Manhattan plot of the P-values for association between TxM* in all subjects and 
SN P s on the CVD 50K chip (MAF=0.05). Loci which contain at least one SN P associated with 
TxM* at a P-value of = 1x10 were highlighted in orange on the plot, and described in the table 
underneath it. In addition, the candidate genes encoding thromboxane synthase 1 (TBXAS1); 
COX-1 (PTG S1) and COX-2 (PTG S2) were highlighted in blue. CHR: chromosome, BP: base pair 
position, MAF: minor allele frequency, BETA: change in TxM (pg/mg creatinine) associated with 
carriership of one copy of the minor allele, P: P-value for association. TxM: urinary thromboxane 
measurement. ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen. Using logio(TxM*), the P-values 
for the top two hits in all subjects were: rs4235745, P=2.2x10'05 and rs32582, P=7.1x10'05.
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Figure 5-19. Manhattan plot of the P-values for association between TxM* in sub jects not on 
aspirin and SN P s on the CVD50K chip (MAF=0.05). No SN Ps were associated with TxM* in 
subjects not on aspirin at a P-value of = 1x1 O'5. The candidate genes encoding thromboxane 
synthase 1 (TBXAS1); COX-1 (PTG S1) and CO X-2 (PTG S2) were highlighted in blue. CHR: 
chromosome, BP: base pair position, MAF: minor allele frequency, BETA: change In TxM (pg/mg 
creatinine) associated with carriership of one copy of the minor allele, P: P-value for association. 
TxM: urinary thromboxane measurement. ‘ Adjusted for the covariates age, sex, smoking habit, 
diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-20. Manhattan plots of the P-vaiues for association between TxM* in subjects on 
aspirin and S N P s on the CVD50K chip (MAF=0.05). No SN Ps were associated with TxM* in 
subjects on aspirin at a P-value of = 1x10 . The candidate genes encoding thromboxane synthase
1 (TBXAS1); COX-1 (PTG S1) and COX-2 (PTG S2) were highlighted in blue. CHR: chromosome, 
BP: base pair position, MAF: minor allele frequency, BETA: change in TxM (pg/mg creatinine) 
associated with carriership of one copy of the minor allele, P: P-value for association. TxM: urinary 
thromboxane measurement. ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, 
systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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5.3.6 PPARGC1B Association Peak
Association analysis of SN Ps on the CVD50K chip and TxM* in 540 individuals showed an 
association peak on chromosome 5 which mapped to the PPA R G C1B  gene, which encodes the 
transcriptional coactivator peroxisome proliferator-activated receptor gamma, coactivator 1. This 
gene is located on chromosome 5 at base-pair (bp) position 149,109,874-149,234,585, making it 
124.71kb long. The wildtype version of this gene has 12 exons and a transcript length of 10,568 
bps. The translation length is 1,023 residues.
93 SN Ps genotyped on the CVD50K chip mapped to this gene, including the regions 100kb 
upstream and 10kb downstream of the gene. Of these, 71 SN P s had a MAF of >0.05 in our 
population of 540 individuals. Of these, 24 SN Ps were associated with TxM* in all subjects at 
P<0.01, 23 of which were associated with an increase in TxM* levels. The mean increase 
associated with these 23 SN Ps was 160pg/mg creatinine, the minimum increase was 123pg/mg
03and the maximum was 223pg/mg. 14 SN Ps were associated with TxM* at P<1x10' (
Table 5-10). These SN Ps are also associated with TxM* in subjects not on aspirin, where, 
although the P-values were not as significant, the associated effect sizes per minor allele were 
almost double those of the associations with TxM in all subjects. The SN Ps in PPA RG C1B  
appeared to be only very marginally associated with TxM* levels in subjects who were taking aspirin 
at time of TxM measurement.
The association of the PPA RG C1B  SN Ps with TxM* was confirmed by performing a permutation 
analysis in PLINK. 1000 label-swapping permutations were performed, in which the TxM* levels 
were randomly shuffled & reassigned to individuals. An association analysis was performed for 
each of the 1000 shuffles. For the majority of the SN Ps, the observed test statistic was greater than 
all 1000 permuted test statistics, indicating that the associations observed with the PPARG C1B  
SN Ps were not spurious associations due to the non-normal distribution of TxM.
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Table 5-10. The 14 SNPs in PPARGC1B which were associated with TxM* in all subjects at P<1x10'°3. SNPs are ordered by BP position along the 
chromosome. Bold font indicates SNPs which were associated with TxM* at P<1x10'05. CHR: chromosome, BP: base pair position, A1: allele 1 (minor 
allele), MAF: minor allele frequency, BETA: change in TxM* (pg/mg creatinine) associated with carriership of one copy of the minor allele, P: P-value for 
association, PERM: After 1000 label-swapping permutations, the number of times the permuted test was greater than the observed test. TxM: urinary 
thromboxane measurement. ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti- 
hypertensive regimen.
PPARGC1B All Subjects (N=540) Subjects Not On Aspirin (N=272) Subjects On Aspirin (INI =268)
C H R SNP B P A 1 A F B E T A P P E R M A F B E T A P A F B E T A P
5 r s l 0 5 1 5 6 3 8 1 4 9 1 3 2 7 2 4 T 0 . 0 7 2 2 3 . 1 7 . 3 E - 0 4 3 0 . 0 7 3 9 1 . 9 1 . 9 E - 0 3 0 . 0 7 7 4 . 7 0 . 1 2
5 r s 2 1 6 1 2 5 7 1 4 9 1 7 0 1 9 0 G 0 . 4 4 1 2 3 . 0 2 . 7 E - 0 4 0 0 . 4 3 1 8 3 . 9 2 . 3 E - 0 3 0 . 4 5 5 2 . 1 0 . 0 5
5 r s 4 2 3 5 7 4 5 1 4 9 1 7 1 3 0 4 T 0 . 3 0 1 6 6 . 7 4.3E-06 0 0 . 2 9 2 8 4 . 9 2 . 2 E - 0 5 0 . 3 1 5 0 . 5 0 . 0 6
5 r s 1 7 1 1 0 4 4 7 1 4 9 1 7 3 0 3 9 G 0 . 2 8 1 4 8 . 8 6 . 0 E - 0 5 0 0 . 2 7 2 5 2 . 9 2 . 4 E - 0 4 0 . 2 9 4 6 . 7 0 . 0 9
5 r s 2 5 1 4 6 8 1 4 9 1 7 4 6 7 8 T 0 . 2 6 1 2 5 . 2 9 . 4 E - 0 4 1 0 . 2 6 2 3 6 . 6 9 . 3 E - 0 4 0 . 2 6 2 2 . 8 0 . 4 1
5 r s 2 5 1 4 6 4 1 4 9 1 7 6 4 2 7 C 0 . 2 6 1 2 5 . 2 9 . 4 E - 0 4 1 0 . 2 6 2 3 6 . 6 9 . 3 E - 0 4 0 . 2 6 2 2 . 8 0 . 4 1
5 r s 3 2 5 8 9 1 4 9 1 8 0 0 8 2 A 0 . 1 2 1 7 2 . 5 7 . 6 E - 0 4 2 0 . 1 1 3 6 5 . 2 2 . 1 E - 0 4 0 . 1 2 8 . 8 0 . 8 1
5 r s 3 2 5 8 8 1 4 9 1 8 0 2 3 6 C 0 . 1 2 1 7 2 . 5 7 . 6 E - 0 4 2 0 . 1 1 3 6 5 . 2 2 . 1 E - 0 4 0 . 1 2 8 . 8 0 . 8 1
5 r s 3 2 5 8 6 1 4 9 1 8 1 1 1 3 G 0 . 1 2 1 7 2 . 5 7 . 6 E - 0 4 2 0 . 1 1 3 6 5 . 2 2 . 1 E - 0 4 0 . 1 2 8 . 8 0 . 8 1
5 r s 2 8 2 8 2 1 4 9 1 8 2 3 9 9 G 0 . 3 1 1 5 7 . 2 1 . 1 E - 0 5 0 0 . 3 1 2 6 2 . 1 6 . 2 E - 0 5 0 . 3 1 4 9 . 3 0 . 0 7
5 r s 3 2 5 8 2 1 4 9 1 8 5 6 1 0 A 0 . 1 7 2 0 1 . 1 9.1E-06 0 0 . 1 7 3 5 3 . 1 2 . 1 E - 0 5 0 . 1 7 4 5 . 4 0 . 1 8
5 r s 3 2 5 8 1 1 4 9 1 8 5 8 2 3 T 0 . 2 8 1 5 9 . 0 2 . 1 E - 0 5 0 0 . 2 8 2 5 9 . 8 1 . 4 E - 0 4 0 . 2 9 5 2 . 9 0 . 0 6
5 r s 3 2 5 7 9 1 4 9 1 9 1 0 4 1 T 0 . 3 0 1 2 9 . 5 3 . 7 E - 0 4 0 0 . 3 0 2 2 0 . 5 9 . 2 E - 0 4 0 . 3 0 3 4 . 1 0 . 2 15 r s 3 2 5 7 4 1 4 9 1 9 9 0 7 9 A 0 . 2 3 1 6 4 . 7 5 . 1 E - 0 5 0 0 . 2 1 2 7 3 . 4 3 . 1 E - 0 4 0 . 2 5 5 9 . 8 0 . 0 5
5.3.7 PPARGC1B Conditional Analysis
Linkage disequilibrium (LD) is the non-random association of alleles at two or more loci. It is a 
phenomenon which is commonly responsible for augmented association signals, where SNPs 
which are in LD with a true ‘causative’ SNP appear to be associated with the dependent variable. A 
measure of the LD between two loci is the r2 value (the square of the correlation coefficient between 
the loci). Figure 5-21 shows a regional association plot of the SNPs in the P P A R G C 1 B region with 
TxM* in all subjects. Linkage disequilibrium between each SNP and the 'tophit', rs4235745, is 
colour-coded based on r2 values from Hapmap phase 3, release 2. The second most significant 
SNP, rs32582, is also indicated. The actual r2 between rs4235745 and rs32582 in our all-subjects 
population was 0.42. The phenomenon of LD has also been used to impute SNPs from the 
Hapmap 3 reference panel in this region. In the plot below, genotyped SNPs are square, imputed 
SNPs are round. An imputed SNP in high LD with rs4235745, rs32587, was associated with an 
increase in TxM* of 176 pg/mg creatinine per minor allele carried, P=3.5x10'06.
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Figure 5-21. Regional plot of the ‘tophit’ PPARGC1B SNP, rs4235745 (purple diamond), and 
the SNPs genotyped on (squares) and imputed from (circles) the CVD50K chip within 200kb 
either side of it. The P-values for association of these SNPs with TxM* in the study are given on 
the y-axis. Linkage disequilibrium with rs4235745 is colour-coded based on the r2 values from 
Hapmap phase 3. cM: centimorgans; Mb: megabases. TxM: urinary thromboxane measurement. 
‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, 
LDL, aspirin and anti-hypertensive regimen. This plot was created by Locuszoom (215).
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In order to ascertain whether all of the associations between PPARGC1B SNPs and TxM* were as 
a result of linkage disequilibrium with the ‘tophit’ SNP, rs4235745, a conditional analysis was 
performed, where the association analysis was adjusted for genotype of rs4235745 (coded ‘O’, T  or 
‘2’ according to number of minor alleles), along with all other covariates. The results are shown in 
Table 5-11. Two SNPs remained significantly associated (P<0.05) with TxM* after conditioning on 
rs4235745 genotype, rs32582 and rs10515638. Neither of these SNPs was in strong LD with the 
‘tophit’ rs4235745; the r2 values were 0.42 and 0.07, respectively. The two SNPs were also not in 
strong LD with each other; r2 between rs32582 and rs10515638 was 0.19.
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Table 5-11. Association analysis of PPARGC1B SNPs with TxM*, conditioned on genotype of the ‘tophit’ SNP, rs4235745. CHR: chromosome, 
BP: base pair position, MAF: minor allele frequency, BETA: change in TxM* (pg/mg creatinine) associated with carriership of one copy of the minor allele 
in the unconditioned analysis, P: P-value for association in the unconditioned analysis, POSITION: position of the SNP in the gene, Conditional BETA: 
change In TxM* (pg/mg creatinine) associated with carriership of one copy of the minor allele in the analysis conditioned on rs4235745 genotype, 
Conditional P-value: P-value for association in the analysis conditioned on rs4235745 genotype, r2: the square of the correlation coefficient between the 
genotypes of the SNP and rs4235745. TxM: urinary thromboxane measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
TxM* All Subjects (N=540)
CHR SNP BP MAF BETA P POSITION
Conditional
BETA
Conditional
P-value
r2 with 
rs4235745
5 rs10515638 149132724 0.07 223.1 7.3E-04 intron 1 157.5 0.02 0.07
5 rs2161257 149170190 0.44 123.0 2.7E-04 intron 1 32.4 0.48 0.50
5 rs4235745* 149171304 0.30 166.7 4.3E-06 intron 1 NA NA 1 . 0 0
5 rs17110447 149173039 0.28 148.8 6.0E-05 intron 1 -155.9 0 . 2 1 0.91
5 rs251468 149174678 0.26 125.2 9.4E-04 intron 1 -97.4 0.19 0.72
5 rs251464 149176427 0.26 125.2 9.4E-04 intron 1 -97.4 0.19 0.73
5 rs32589 149180082 0 . 1 2 172.5 7.6E-04 intron 1 70.6 0.23 0.25
5 rs32588 149180236 0 . 1 2 172.5 7.6E-04 exon 2 70.6 0.23 0.25
5 rs32586 149181113 0 . 1 2 172.5 7.6E-04 intron 2 70.6 0.23 0.25
5 rs28282 149182399 0.31 157.2 1.1E-05 intron 2 -97.8 0.59 0.97
5 rs32582 149185610 0.17 2 0 1 . 1 9.1E-06 intron 2 116.2 0.04 0.42
5 rs32581 149185823 0.28 159.0 2.1E-05 intron 2 28.9 0.72 0.84
5 rs32579 149191041 0.30 129.5 3.7E-04 intron 4 -99.4 0 .2 2 0.83
5 rs32574 149199079 0.23 164.7 5.1E-05 intron 8 59.9 0.31 0.56
5.3.8 TxM* Distribution by Genotype
Figure 5-24-Figure 5-24 show boxplots and density plots of the distribution of TxM* values in all 
subjects (N=540), subjects not on aspirin (N=272) and subjects on aspirin (N=268) according to the 
genotype of rs4235745. Each plot shows increasing TxM* with increasing numbers of the minor 
allele carried, this Is most pronounced for those not on aspirin.
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Figure 5-22. Boxplot and density plots of TxM* values in all subjects (N=540) according to 
the genotype of rs4235745, the ‘tophit’ SNP in the PPARGC1B region. TxM: urinary 
thromboxane measurement *Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-23. Boxplot and density plots of TxM* values subjects not on aspirin (N=272) 
according to the genotype of rs4235745, the ‘tophit’ SNP in the PPARGC1B region. TxM: 
urinary thromboxane measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, 
systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-24. Boxplot and density plots of TxM* values in subjects on aspirin (N=268) 
according to the genotype of rs4235745, the ‘tophit’ SNP in the PPARGC1B region. TxM: 
urinary thromboxane measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, 
systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
181
5.3.9 PPARGC1B Haplotype Analysis
The three SNPs which were independently associated with TxM* in the conditional analysis were 
used in haplotype analysis (Table 5-12). Haplotypes were imputed by PLINK using the standard E- 
M algorithm in the ‘all subjects’ cohort. Five of the eight possible haplotypes had a frequency of >= 
0 . 0 1 in the population, and were used in the analysis.
Table 5-12. The three SNPs used in Haplotype analysis with their minor (A1) and major (A2) 
alleles, and (minor allele) frequency in all subjects (N=540).
CHR SNP Position A1 A2 Frequency
5 rsl0515638 149132724 T G 0.08
5 rs4235745 149171304 T C 0.31
5 rs32582 149185610 A C 0.18
Table 5-13. Results of the ‘Each-vs-Others’ haplotype analysis using common (frequency 
>1%) haplotypes of the three SNPs independently associated with TxM*. Analyses were 
adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, 
LDL, aspirin and anti-hypertensive regimen. BETA: change in TxM* (pg/mg creatinine) associated 
with carriership of one copy of the haplotype, P: P-value for association.
All Subjects 
(N=540)
Subjects Not On 
Aspirin (N=272)
Subjects On 
Aspirin (N=268)
HAPLOTYPE FREQUENCY BETA P BETA P BETA P
TTA 0.06 382.4 2.1E-06 658.7 9.5E-06 105.5 0.08
GTA 0.11 136.2 0.01 259.2 0.01 24.0 0.55
GTC 0.14 52.4 0.29 77.8 0.40 27.1 0.46
TCC 0.02 -141.1 0.28 -259.3 0.28 -10.1 0.92
GCC 0.66 -145.7 5.5E-05 -249.0 2.1E-04 -45.3 0.09
The all minor alleles haplotype was associated with an increase of 382pg/mg creatinine in all 
subjects (P=2x10"°6), and 659pg/mg creatinine in those not on aspirin (P=9x10"°6), compared to all 
other haplotypes (Table 5-13). The all major allele haplotype was associated with a decrease of 
146pg/mg creatinine in all subjects (P=5x10'°5) and 249pg/mg creatinine (P=2x10’°4) in those not on 
aspirin, compared to all other haplotypes (Table 5-13). The intermediate haplotypes followed this 
trend. The same trend, although not significant, was observed in subjects on aspirin.
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5.3.10 PPARGC1B R2 Analysis
The coefficient of determination, R2, is the proportion of variability in a data set that is accounted for
by the statistical model. The adjusted R2, or R 2, is a modification of R2 that is adjusted for the
number of explanatory terms in the model. Unlike R2, R 2 increases only if the new term improves 
the model more than would be expected by chance. The individual R2 is the proportion of the 
multiple R2 explained by each individual variable in the model.
In the 'all subjects’ population, the genotypes of the three independently associated PPARGC1B 
SNPs explained 5.2% of the variation in TxM*. Almost half of this was contributed by the rs4235745 
SNP genotype (Table 5-14). For subjects not on aspirin, the three PPARGC1B SNPs explained 
8.8% of the variation in TxM*. Again, rs4235745 explained almost half of this 8.8% (Table 5-15).
For subjects on aspirin, the proportion of variability in TxM* explained by the three PPARGC1B 
SNPs was much lower, at 1.8% (Table 5-16).
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Table 5-14. Multiple linear regression of the 3 independently associated PPARGC1B  SNPs 
with TxM* (urinary thromboxane pg/mg creatinine, adjusted for all covariates, including 
aspirin use) in all subjects (IM=540). ‘Estimate’ = regression coefficients.
All Subjects (N=540) Estimate SE t p Individual R2
Intercept 657.3 31.9 20.61 <2E-16
rs4235745 107.2 45.9 2.33 0.02 0.025
rs32582 83.2 60.1 1.38 0.17 0.015
rs10515638 128.5 70.1 1.83 0.07 0.012
Model statistics:
Multiple R2 0.052
Adjusted R2 0.046
F-statistic on 3 and 536 DF: 9.75
P 2.9E-06
Table 5-15. Multiple linear regression of the 3 independently significant PPARGC1B  SNPs 
with TxM* (urinary thromboxane pg/mg creatinine, adjusted for all covariates, including 
aspirin use) in subjects not on aspirin only (N=272). Estimate’ = regression coefficients.
Subjects Not On Aspirin (N=272) Estimate SE t P Individual R2
Intercept 582.04 57.71 10.09 <2E-16
rs4235745 171.82 84.66 2.03 0.04 0.039
rs32582 163.07 109.86 1.48 0.14 0.030
rs 10515638 213.49 132.66 1.61 0 . 1 1 0.019
Model statistics:
Multiple R2 0.088
Adjusted R2 0.078
F-statistic on 3 and 268 DF: 8.62
P 1.8E-05
Table 5-16. Multiple linear regression of the 3 independently significant PPARGC1B  SNPs 
with TxM* (urinary thromboxane pg/mg creatinine, adjusted for all covariates, including 
aspirin use) in subjects on aspirin only (N=268). 'Estimate' = regression coefficients.
Subjects On Aspirin (N=268) Estimate SE t P Individual R2
Intercept 734.0 24.2 30.29 <2E-16
rs4235745 45.3 34.3 1.32 0.19 0 . 0 1 2
rs32582 -5.8 45.2 -0.13 0.90 0 . 0 0 1
rs 10515638 58.2 51.0 1.14 0.26 0.007
Model statistics:
Multiple R2 0.018
Adjusted R2 0.007
F-statistic on 3 and 264 DF: 1.63
P 0.18
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5.4 R esu lts  fo r  P ros ta cyc lin  G enotyped on the  CVD50K C hip
5.4.1 Baseline Characteristics
PGI-M measurements were available for 540 subjects. 538 of these also had TxM measurements 
and were used in the TxM analysis; two subjects for whom TxM measurements were available did 
not have successful PGI-M assays, and two subjects for whom PGI-M measurements were 
available did not have successful TxM assays.
PGI-M levels were significantly lower in subjects on aspirin compared to those not taking aspirin at 
time of PGI-M measurement. There were also significantly fewer men taking aspirin, significantly 
more diabetics taking aspirin, and subjects taking aspirin on average had significantly higher 
systolic blood pressure. There were no significant differences between subjects taking aspirin and 
those not taking aspirin across the other population characteristics (Table 5-17)
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T a b le  5 -17 . P o p u la tio n  c h a ra c te r is tic s  fo r  th e  540  in d iv id u a ls  in th is  s tu d y  fo r  w h o m  P G I-M  measurements w e re  available. Subjects not 
randomized to the angiotensin-converting enzyme inhibitor and calcium antagonist regimen were randomized to a (3-blocker and diuretic regimen. IQR: 
Inter quartile range; SD: Standard deviation; N: number of subjects; SBP: Systolic blood pressure. BMI: Body mass index. HDL: High density 
lipoprotein; LDL: Low-density lipoprotein; ACE-I: Angiotensin-converting enzyme inhibitor. Bold font indicates the primary endpoint, PGI-M. *P-value 
significant at P<0.05.
Demographic & Clinical Characteristics
All Subjects
(N=540)
Subjects Not On Aspirin
(N=272)
Subjects On Aspirin
(N= 268) P
PGI-M (pg/mg creatinine): Median (IQR) 129 (85-192) 150 (460-1071) 106 (74-157) 0.02*
Age (years): Mean ± SD 64.7 i  8.1 64.2 i  8.2 65.3 i  8.1 0 . 1 0
Male: N (%) 423 (78%) 223(82%) 200 (75%) 0.04*
Current smokers: N (%) 1 1 1  (2 1 %) 55(20%) 56(21%) 0.85
Current diabetes: N (%) 93(17%) 35(13%) 58 (22%) 7E-03*
SBP(m m Hg): M e a n iS D 134.7 i  11.9 132 i 10.5 137.5 i  12.6 6E-08*
BMI (kg/m 2): M e a n iS D 29.2 i  4.5 29 i  4.3 29.4 + 4.7 0.31
HDL(m m ol/L): M e a n iS D 1.3 i  0.3 1.3 i  0.3 1.3 i  0.3 0.54
LDL(m m ol/L): M e a n iS D 3.0 i  0.8 3.0 i  0.9 3.0+  0.8 0.87
Randomised to ACE-I: N (%) 274(51%) 143 (53%) 131 (49%) 0.39
5.4.2 PGI-M Distribution
Like TxM, the distribution of PGI-M levels (pg/mg creatinine) across the study population of 540 
subjects was non-normal (Figure 5-25). After adjustment for covariates (PGI-M*), the distribution 
was less skewed, but remained non-normally distributed. Following log10 transformation of the PGI- 
M values, the distribution approximated normality. Like TxM, the distribution of the residuals was 
slightly skewed (Figure 5-26).
It was decided to adopt the same strategy as for TxM; to use the untransformed, non-normal values 
for the analyses. Like for TxM, permutation analyses were performed for SNPs found to be 
associated with PGI-M* in order to rule out spurious association due to the non-normal distribution 
of PGI-M*. In addition, P-values for the association between SNPs and log10(PGI-M*) are provided 
in the following figures.
One individual was considered an outlier, with a PGI-M value of 4,939pg/mg creatinine, and was 
excluded from the analysis.
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Figure 5-25. Histograms (left) and “ Norm al” Q Q  normal plots of the distribution o f PGI-M levels in all 
540 subjects before (panel A) & a fte r (panel B) adjustm ent fo r covariates, and following logio 
transformation of the non-norm ally distributed PGI-M values (panel C).. The red line on the QQ plots 
passes through the first and third quartiles. If values were normally distributed, they should adhere closely to 
this line. PGI-M: urinary prostacyclin measurement. ‘ Adjusted for the covariates age, sex, smoking habit, 
diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen. Adjustment led to 
negative prostacyclin values which, although fictional, can be legitimately used for regression analysis.
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Figure 5-26. The distribution of the residuals of the associations between SNPs on the 
CVD50K chip and PGI-M* in all subjects.
5.4.3 Power Calculations
As for the TxM analysis, a post-hoc power analysis was conducted for this study to help to indicate 
how likely the study was to have identified ‘true’ associations, assuming that they exist. The power 
of this study was calculated using the Quanto power calculator (http://hydra.usc.edu/gxe/), 
assuming a continuous variable, an additive Inheritance model, gene-only effects and a 2 -sided 
test. As for the TxM analysis, power was estimated assuming a variety of minor allele frequencies 
(MAF) of the genetic variants, assuming a range of effect sizes and across a range of type I error
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rates. Figure 5-27 indicates that this study had good (>80%) power to detect associations between 
SNPs present in the population at a frequency of 5% or above and even small changes in PGI-M* 
levels at a type I error rate of 0.05. However, this study only had good (>80%) power to detect 
SNPs which were both present at a high frequency in the population (>10%) and were associated 
with larger effect sizes (>1 OOpg/mg creatinine PGI-M* change per minor allele), at a type I error rate 
of 1.6x1 O'06, which was the Bonferroni-corrected error threshold for this study (section 5.4.5).
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Figure 5-27. Power plots for association between SNPs on the CVD50K chip PGI-M* levels.
The power of this study to detect associations between SNPs on the CVD50K chip and PGI-M* 
levels in the total population (N=539), assuming a Type I error rate (a) of 0.05 (panel A), 1x10"°3 
(panel B), 1x1 O'05 (panel C) or 1.6x10"°6 (panel D) was plotted. The population mean of PGI-M* was 
81 pg/mg creatinine, and the standard deviation was 157 pg/mg creatinine. Power was plotted 
assuming four different main effect sizes of PGI-M*(pg/mg creatinine) associated with carriership of 
one minor allele (75, 100, 125, 150 pg/mg). The maximum effect size per minor allele carried 
observed in the results of this study was 151 pg/mg creatinine. PGI-M: urinary prostacyclin 
measurement. ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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5.4.4 QQ Plots
QQ plots of the P-values for association of the SNPs on the CVD50K chip with PGI-M levels in all 
subjects, and subjects divided by aspirin usage, are shown below (Figure 5-28). SNPs with a minor 
allele frequency (MAF) <5% were not included in the analysis of these results, and were plotted 
separately. In all subjects and in subjects on aspirin, SNPs with low P-values and MAF = 5% 
exceeded the 99% probability envelopes, indicating that more significant P-values were observed 
than would be expected by chance. In subjects not taking aspirin at time of PGI-M measurement, 
the P-values for association remained within the 99% confidence envelopes, indicating that for this 
group, the P-value distribution approximated that which would be expected under the null 
hypothesis of no associations.
As was seen in the TxM analysis, in all three populations, the P-values for SNPs with a MAF of <5% 
deviated substantially from the expected line at low P-values. However, with a population size such 
as the one in this study, these are likely to represent spurious associations, and were not included 
in further analyses.
Genomic control (GC) A values were calculated from the P-value distributions, including only SNPs 
with MAF = 0.05 and the lower 95% of the distribution. GC values for each population were 
approximately equal to 1, suggesting that the P-values in this study are not skewed due to 
population stratification, or any other bias.
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PGI-M* Subjects Not On Aspirin (N=271)
Figure 5-28. QQ plots of P-values for association 
of the SNPs on the CVD50K chip with PGI-M*.
Observed P-values for association were plotted 
against those which would be expected under the null 
hypothesis of no association (black line). Shaded 
regions are 99% probability envelopes (which depend 
on number of SNPs and hence are different sizes for 
common and low-frequency SNPs). SNPs were 
divided into those with a minor allele frequency (MAF) 
of = 5% (red), or < 5% (blue). Genomic control A 
values were calculated including only SNPs with MAF 
= 0.05 and the lower 95% of the distribution and are 
as follows: All Subjects: 95% A=0.98; Subjects On 
Aspirin: 95% A=1.00; Subjects Not On Aspirin: 95% 
A=1.00. PGI-M: urinary prostacyclin measurement. 
‘Adjusted for the covariates age, sex, smoking habit, 
diabetes, systolic blood pressure, BMI, HDL, LDL, 
aspirin and anti-hypertensive regimen.
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5.4.5 Manhattan Plots
Manhattan plots of the P-values for association of the SNPs on the CVD50K chip with PGI-M* in 
each of the three populations are shown below (Figure 5-29-Figure 5-31). As for TxM, 31,570 
SNPs were used in the final analysis, giving a Bonferroni correction for multiple testing for this study 
of 1.6x1 O'06. However, again given the lack of power of this study to detect associations at this 
threshold (section 3.4.3), it was decided to treat as ‘interesting’ all associations with P-values =1x10'
05
Loci which contained at least one SNP which was associated with PGI-M* at P= IxlO -05 were 
highlighted on the plots and described in the tables underneath them, those associated with PGI-M* 
in all subjects were highlighted in orange and those associated with PGI-M* in subjects on aspirin 
were highlighted in green. In addition, the ‘candidate’ genes for prostacyclin synthase (PTGIS), 
COX-1 (PTGS1) and COX-2 (PTGS2) were highlighted in blue. Cytosolic phospholipase A2 (PLA2) 
is also a candidate for influencing PGI-M* levels, but was not genotyped on this array.
One SNP in this study, rs17690122, upstream of the IL5 gene, was significantly associated with 
PGI-M* in all subjects at Bonferroni threshold, and is marked in red in the tables below (Figure 
5-29). One additional SNP, rs2226633, in the OPCML gene, was associated with PGI-M* in 
subjects on aspirin at P =1x10'05 (Figure 5-31). However, this association was not present when the 
data were analysed for association with log10(PGI-M*), and the association between rs2226633 and 
PGI-M* is therefore probably a spurious one and will not be further discussed in this thesis.
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5 rs 17690122 131895734 0.17 60.9 L6E-06 IL5 upstream interleukin 5 precursor _______
Figure 5-29. Manhattan plot of the P-values for association between PGI-M* in all subjects 
and SNPs on the CVD50K chip (MAF=0.05). Loci which contained at least one SNP associated 
with PGI-M* at a P-value of = 1x10"°5 in all subjects were highlighted in orange on the plot, and 
described in the table underneath it. In addition, the candidate genes encoding prostacyclin 
synthase (PTGIS), COX-1 (PTGS1) and COX-2 (PTGS2) were highlighted in blue. The Bonferroni- 
corrected P-value threshold for this study was 1.6x1 O'06. P-values which exceed this threshold are 
shown in the table in red. CHR: chromosome, BP: base pair position, MAF: minor allele frequency, 
BETA: change in PGI-M (pg/mg creatinine) associated with carriership of one copy of the minor 
allele, P: P-value for association. PGI-M: urinary prostacyclin measurement. ‘ Adjusted for the 
covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and 
anti-hypertensive regimen. Using logio(PGI-M*), the P-value for the top hit, rs17690122, was 
P=6.2x10'05.
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Bonferroni
Position by chromosome
Figure 5-30. Manhattan plot of P-values for association between PGI-M* in subjects not on 
aspirin and SNPs on the CVD50K chip (MAF=0.05). Loci which contained at least one SNP 
which was associated with PGI-M* at a P-value of = 1x1 O'05 in all subjects (Figure 5-29) were 
highlighted in this plot in orange. In addition, the candidate genes encoding prostacyclin synthase 
(iPTGIS), COX-1 (PTGS1) and COX-2 (PTGS2) were highlighted in blue. No SNPs were 
associated with PGI-M* at a P-value of = 1x10'05 in subjects not on aspirin. The Bonferroni- 
corrected P-value threshold for this study was 1.6x10'06. CHR: chromosome, BP: base pair 
position, MAF: minor allele frequency, BETA: change in PGI-M (pg/mg creatinine) associated with 
carriership of one copy of the minor allele, P: P-value for association. PGI-M: urinary prostacyclin 
measurement. ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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CLOSEST SNP
CHR SNP BP MAF BETA P GENE POSITION GENE NAME
11 rs2226633 131825604 0.05 150.7 4.3E-06 OPCML intro n 4 opioid binding protein/ceil adhesion
5 rsl7690122 131895734 0.19 77.2 9.9E-06 1L5 upstream interleukin 5 precursor
Figure 5-31. Manhattan plot of P-values for association between PGI-M* in subjects on 
aspirin and SNPs on the CVD50K chip (MAF=0.05). Loci which contained at least one SNP 
which was associated with PGI-M* at a P-value of = 1x1 O'05 in all subjects (Figure 5-29) were 
highlighted on this plot in orange. Loci which contained at least one SNP associated with PGI-M* at 
a P-value of = 1x1 O'05 in subjects on aspirin are highlighted in green on the plot, and described in 
the table underneath it. In addition, the candidate genes encoding prostacyclin synthase (PTGIS), 
COX-1 (PTGS1) and COX-2 (PTGS2) were highlighted in blue The Bonferroni-corrected P-value 
threshold for this study was 1.6x10'06. CHR: chromosome, BP: base pair position, MAF: minor 
allele frequency, BETA: change in PGI-M (pg/mg creatinine) associated with carriership of one copy 
of the minor allele, P: P-value for association. PGI-M: urinary prostacyclin measurement.
*Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, 
LDL, aspirin and anti-hypertensive regimen. Using log10(PGI-M*), the P-values for the top hits were: 
rs17690122, P=1.9x10"04 and rs2226633, P=0.44.
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5.4.6 IL5 Association Peak
Figure 5-32 shows a regional association plot of the SNPs in the IL5 region with PGI-M* in all 
subjects. Linkage disequilibrium between the SNPs in these plots is colour-coded based on r2 
values from Hapmap phase 3, release 2.
PGI-M* All Subjects (N=539)
Plotted SNPs H U  I I I I I I I I  llll l l l l
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Figure 5-32. Regional plot of the ‘tophit’ SNP in IL5, rs17690122 (purple diamond), and the 
SNPs genotyped on the CVD50K chip within 200kb either side of it. The P-values for 
association of these SNPs with PGI-M* in the study are given on the y-axis and position in Mb on 
the x-axis. Linkage disequilibrium with the ‘tophit’ SNP is colour-coded based on the r2 values from 
Hapmap phase 3. SNPs without available r2 values are shown in grey. cM: centimorgans; Mb: 
megabases. PGI-M: urinary prostacyclin measurement. ‘ Adjusted for the covariates age, sex, 
smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive 
regimen. This plot was created by Locuszoom (215).
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Figure 5-33-Figure 5-35 show the distribution of PGI-M* values in all subjects, subjects not on 
aspirin and subjects on aspirin according to the genotype of rs17690122, the tophit in the region of 
the IL5 gene. Although the increase in PGI-M* levels associated with minor allele carriers appears 
to be driven by the cohort on aspirin, it is worth noting that although the numbers of heterozygotes 
were comparable, while 10 of the 268 subjects on aspirin were minor allele homozygotes, only 4 of 
the 271 subjects not on aspirin were minor allele homozygotes.
PGI-M* All Subjects (N=539)
PGI-M" Distribution In 
Major Allele Homozygotes (N=365)
N u m b e r  of Minor Alleles of rs17690122
0 500 1WO 1MO
PGI-M* (pg/mg creatinine)
PGI-M* Distribution in 
Heterozygotes (N=160)
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Minor Allele Homozygotes (N=14)
60ÍJ tCW t&QO 
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Figure 5-33. Boxplot and density plots of PGI-M* values in all subjects (N=539) according to 
the genotype of rs17690122, the ‘tophit’ SNP in the IL5 region. PGI-M: urinary prostacyclin 
measurement ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-34. Boxplot and density plots of PGI-M* values in subjects not on aspirin (N=271) 
according to the genotype of rs17690122, the ‘tophit’ SNP in the IL5 region. PGI-M: urinary 
prostacyclin measurement ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-35. Boxplot and density plots of PGI-M* values in subjects on aspirin (N=268) 
according to the genotype of rs17690122, the ‘tophit’ SNP in the IL5 region. PGI-M: urinary 
prostacyclin measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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5.5 R esu lts  fo r  T hrom boxane geno typed  on the CNV370-Duo 
Chip
5.5.1 Baseline Characteristics
TxM levels were significantly lower in subjects on aspirin compared to those not taking aspirin at 
time of TxM measurement. There were also significantly fewer men taking aspirin, significantly 
more diabetics taking aspirin, and subjects taking aspirin on average had significantly higher 
systolic blood pressure. There were no significant differences between subjects taking aspirin and 
those not taking aspirin across the other population characteristics (Table 5-18).
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Demographic & Clinical Characteristics
All Subjects 
(N=772)
Subjects Not On Aspirin 
(N= 396)
Subjects On Aspirin 
(N= 376) P
TxM (pg/mg creatinine): Median (IQR) 666 (302-816) 877 (478-1062) 443 (222-559) <2E-16*
Age (years): M ea n ±SD 64.6 i  8.1 6 4 .Ü 8 .1 6 5 .Ü 8 .1 0 . 1 0
Male: N (%) 599 (78%) 319(81% ) 280 (74%) 0.04*
Current sm okers: INI (%) 180(23%) 90 (23%) 90(24% ) 0.69
Current diabetes: N (%) 144 (19%) 53(13% ) 91(24% ) IE-04*
SBP(m m H g): M e a n iS D 135. l i  12.0 133.1 i  11.1 137.2 i  12.4 IE-06*
BMI (kg/m 2): M e a n iS D 29.3 i  4.8 29.2 i  4.7 29.4 i  4.8 0.64
HDL(m m ol/L): M e a n iS D 1.3 i  0.3 1.3 i  0.3 1.3 i  0.3 0.18
LDL(m m ol/L): M e a n iS D 3.0 i  0.9 3.0 i  0.9 3.0 i  0.8 0.31
Random ised to ACE-I: N (%) 394 (51%) 208(52%) 186 (49%) 0.40
T a b le  5 -18 . P o p u la tio n  c h a ra c te ris tic s  fo r  th e  77 2  in d iv id u a ls  in th is  s tu d y  fo r  w h o m  T x M  m e a s u re m e n ts  w e re  a v a ila b le . Subjects not 
randomized to the angiotensin-converting enzyme inhibitor and calcium antagonist regimen were randomized to a (3-blocker and diuretic regimen. IQR: 
Inter quartile range; SD: Standard deviation; N: number of subjects included in analysis; SBP: Systolic blood pressure; BMI: Body mass index; HDL: 
High density lipoprotein; LDL: Low-density lipoprotein; ACE-I: Angiotensin-converting enzyme inhibitor. Bold font indicates the primary endpoint, TxM. 
*P-value significant at P<0.05.
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5.5.2 Thromboxane Distribution
The distribution of TxM levels (pg/mg creatinine) across the study population of 111 subjects 
genotyped on the CNV370-Duo chip, like in the CVD50K population, was non-normal (Figure 5-36). 
After adjustment for covariates (TxM*), the distribution was again less skewed, but remained non- 
normally distributed. Following Log10 transformation of the TxM values, the distribution 
approximated normality. As with the CVD50K analysis, the distribution of the residuals was slightly 
skewed (Figure 5-37).
As with the CVD50K chip analysis, it was decided not to transform the data. The fact that this study 
was based on larger numbers than the CVD50K chip makes it even more likely that the parametric 
tests used were robust against departures from normality. Unfortunately, the far greater number of 
SNPs genotyped in this study meant that permutation analysis was not feasible.
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Figure 5-36. Histograms (left) and “ Norm al” QQ normal plots o f the distribution o f TxM levels in all 772 
subjects before (panel A) & after (panel B) ad justm ent fo r covariates, and following log10 
transform ation o f the non-norm ally d istributed TxM values (panel C). The red line on the QQ plots
passes through the first and third quartiles. If values were normally distributed, they should adhere closely to 
this line. TxM: urinary thromboxane measurement. ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen. Adjustment led to negative thromboxane values which, although fictional, can be legitimately used for regression analysis.
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Figure 5-37. The distribution of the residuals of the associations between SNPs on the 
CVN370-Duo chip and TxM* in all subjects.
5.5.3 Power Calculations
A post-hoc power analysis was conducted for this study to help to indicate how likely the study was 
to have identified ‘true’ associations, assuming that they exist. Power was again calculated using 
the Quanto power calculator (http://hydra.usc.edu/gxe/), assuming a continuous variable, an 
additive inheritance model, gene-only effects (no gene-gene or gene-environment interactions were 
accounted for), and a 2-sided test. Power was again estimated assuming a variety of minor allele 
frequencies (MAF) of the genetic variants, and across a range of type I error rates.
1------1------1------1------r
0 1 2  3 4
ITest Statistic]
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Figure 5-38 indicates that this study had good (>80%) power to detect associations between SNPs 
present in the population at a frequency of 5% or above and even small changes in TxM* levels at a 
type I error rate of 0.05. However, this study only had good (>80%) power to detect SNPs which 
were both present at a high frequency in the population (>2 0 %) and were associated with large 
effect sizes (>200pg/mg creatinine TxM* change per minor allele), at a type I error rate of 1.8x1 O'07, 
which was the Bonferroni-corrected error threshold used for this study (section 3.5.5).
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Figure 5-38. Power plots for association between SNPs on the CNV370-Duo chip and TxM* 
levels. The power of this study to detect associations between SNPs on the CNV370-Duo chip and 
TxM* levels in the total population (N=772), assuming a Type I error rate (a) of 0.05 (panel A), 1x10' 
03 (panel B), 1x10'06 (panel C) or 1.8x10'07 (panel D) was plotted. The population mean of TxM* 
was 781 pg/mg creatinine and the standard deviation was 538 pg/mg creatinine. Power was plotted 
assuming four different main effect sizes of TxM* (pg/mg creatinine) associated with carriership of 
one minor allele (100, 150, 200, or 250 pg/mg). The maximum effect size per minor allele carried 
observed in the results of this study was 290 pg/mg creatinine. TxM: urinary thromboxane 
measurement. ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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5.5.4 QQ Plots
QQ plots of the P-values for association of the SNPs on the CNV370-Duo chip with TxM levels in all 
subjects, and in subjects divided by aspirin usage, are shown below (Figure 5-39). SNPs with a 
minor allele frequency (MAF) <5% were not included in the analysis of these results, and were 
plotted separately. In all subjects, a number of SNPs with low P-values and MAF = 5% slightly 
exceeded the 99% probability envelopes, indicating that more significant P-values were observed 
than would be expected by chance. The pattern for association with TxM* in subjects not taking 
aspirin at time of measurement was similar to that of all subjects, and in subjects on aspirin, a 
smaller number of SNPs exceeded the 99% confidence envelopes.
In all three populations, the P-values for SNPs with a MAF of <5% deviated substantially from the 
expected line at low P-values. However, with a population size such as the one in this study, these 
are likely to represent spurious associations, and were not included in further analyses.
Genomic control (GC) A values were calculated from the P-value distributions, including only SNPs 
with MAF = 0.05 and the lower 95% of the distribution. GC A values for each population were equal 
to 1, suggesting that the P-values in this study are not skewed due to population stratification, or 
any other bias.
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Figure 5-39. QQ plots of P-values for association 
of the SN Ps on the CNV370-Duo chip with TxM*.
Observed P-values for association were plotted 
against those which would be expected under the 
null hypothesis of no association (black line).
Shaded regions are 99% probability envelopes 
(which depend on number of SNPs and hence are 
different sizes for common and low-frequency 
SNPs). SNPs were divided into those with a minor 
allele frequency (MAF) of = 5% (red), or < 5% (blue). 
Genomic control A values were calculated including 
only SNPs with MAF = 0.05 and the lower 95% of the 
distribution and were as follows: All Subjects: 95% 
A=1.00; Subjects On Aspirin: 95% A=1.00; Subjects 
Not On Aspirin: 95% A=1.00. TxM: urinary 
thromboxane measurement. ‘Adjusted for the 
covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti­
hypertensive regimen.
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5.5.5 Manhattan Plots
Manhattan plots of the P-values for association of the SNPs on the CNV370-Duo chip with TxM* in 
each of the three populations are shown below (Figure 5-40-Figure 5-42). In the whole population 
and its two subgroups, 272,166 SNPs genotyped on the CNV370-Duo chip passed quality control, 
and were present in all subjects at a MAF of = 5%. The Bonferroni correction for multiple testing 
was applied to provide a 5% overall false positive rate control and was calculated as 0.05/272,166, 
giving a value of 1.8x10'or. However, given the lack of power of this study to detect associations at 
this threshold (section 3.5.3), it was decided to treat as ‘interesting’ all associations with P-values 
=1x1 O'06. As for the CVD50K chip, this value was decided arbitrarily.
In addition, a further 1,759,333 SNPs were imputed from the genotyped SNPs, using the HapMap II 
CEU reference panel. On the Manhattan plots below, only imputed SNPs are shown. This provides 
an additional quality control measure; spurious associations arising from genotyping artefacts 
should not be present in the imputed dataset as the information score from such SNPs would not 
exceed the cutoff. The subsequent plots show, where a SNP was directly genotyped, the statistics 
from association with genotyped SNPs, which are almost indistinguishable from the statistics arising 
from the imputed dataset in this study.
Loci which contained at least one genotyped SNP which was associated with TxM* at P= 1x1 O'06 
were highlighted on the plots and described in the tables underneath them. In addition, the 
‘candidate’ genes for thromboxane synthase 1 (TBXAS1), COX-1 (PTGS1) and COX-2 (PTGS2) 
are highlighted in brown. The gene encoding cytosolic phospholipase A2 (PLA2) is also a candidate 
for influencing TxM* levels, but was not genotyped on this array.
Four imputed SNPs in the CNTN4 gene were associated with increased TxM* values in subjects not 
on aspirin beyond Bonferroni correction for multiple testing. One imputed SNP in the intergenic 
region between the MYOC and VAMP4 genes was associated with increased TxM* in subjects on 
aspirin beyond Bonferroni correction for multiple testing, and one genotyped SNP in the FAM47E 
gene was associated with increased TxM* beyond Bonferroni correction in the same population. 
These SNPs are marked in red in the following tables (Figure 5-40-Figure 5-42), and the loci are 
analysed further in the following sections (5.5.6-5.5.8).
In addition, four loci were associated with TxM* at a P-value of = 1x10"06, KCNE4 in all subjects, 
LZTS1 and PCDH20 in subjects not on aspirin, and NSUN3 in subjects on aspirin.
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TxM* All Subjects (N=772)
CHR SNP BP MAF BETA P GENO INFO CLOSEST GENE SNP POSITION GENE NAME
2 rs10190010 223714451 0.09 244.6 7.0E-07 NO 0.98 KCNE4 intergenic potassium voltage-gated channel, Isk-related
2 rs11884475 223714735 0.09 244.3 7.1E-07 NO 0.98 KCNE4 intergenic potassium voltage-gated channel, Isk-related
2 rs 11894487 223719165 0.09 244.2 7.1E-07 NO 0.98 KCNE4 Intergenlc potassium voltage-gated channel, Isk-related
2 rs 16864483 223720380 0.09 244.2 7.1E-07 NO 0.98 KCNE4 Intergenic potassium voltage-gated channel, Isk-related
2 rs16864484 223720562 0.09 244.2 7.1E-07 NO 0.98 KCNE4 Intergenlc potassium voltage-gated channel, Isk-related
2 rsll899732 223731461 0.09 244.3 7.1E-07 NO 0.98 KCNE4 Intergenlc potassium voltage-gated channel, Isk-related
2 rsll902770 223736877 0.09 244.6 7.6E-07 NO 0.97 KCNE4 intergenlc potassium voltage-gated channel, Isk-related
3 rs 10510230 2257130 0.15 189.8 5.1E-07 YES NA CNTN4 Intronlc contactin 4isoform a precursor
3 rs4684343 2366098 0.45 -133.4 8.8E07 YES NA CNTN4 intronic contactin 4 Isoform a precursor
Figure 5-40. Manhattan plot of the P-values for association between TxM* in all subjects and 
SNPs on the CNV370-Duo chip (MAF=0.05). Loci which contained at least one SNP associated 
with TxM* at a P-value of = 1x10 in all subjects were highlighted in orange on the plot, and 
described in the table underneath it. In addition, the candidate genes encoding thromboxane 
synthase (TBXAS1), COX-1 (PTGS1) and COX-2 (PTGS2) were highlighted in brown. The 
Bonferroni-corrected P-value threshold for this study was 1.8x10‘07, no P-values exceed this 
threshold. CHR: chromosome, BP: base pair position, MAF: minor allele frequency, BETA: change 
in TxM (pg/mg creatinine) associated with carriership of one copy of the minor allele, P: P-value for 
association, GENO: Genotyped (if ‘no’, the SNP was imputed), INFO: imputation information 
score. TxM: urinary thromboxane measurement. ‘ Adjusted for the covariates age, sex, smoking 
habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen. 
Using log10(TxM*), the P-values for the tophits at each locus were: KCNE4 (rs10190010), 2.7x10'05; 
CNTN4 (rs10510230), 5.1x10'06.
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TxM* Subjects Not On Aspirin (N=396)
CHR SNP BP MAF BETA P GENO INFO CLOSEST GENE SNP POSITION GENE NAME
3 rs 10510230 2257130 0.16 329.5 1.5E-07 YES NA CNTN4 intronic contactln 4 isoform a precursor
3 rsll915941 2310062 0.13 385.7 1.6E-07 NO 0.87 CNTN4 intronic contactin 4isoform a precursor
3 rs11706819 2317976 0.14 368.3 5.3E-08 NO 0.96 CNTN4 intronic contactin 4 isoform a precursor
3 rsll714433 2324793 0.14 364.5 6.4E-08 NO 0.97 CNTN4 intronic contactin 4 isoform a precursor
3 rsl7194273 2330601 0.14 363.9 6.7E-08 NO 0.96 CNTN4 intronic contactin 4isoform a precursor
8 rs1868665 20619066 0.21 280.9 6.9E-07 NO 1.01 LZTS1 intergenic leucine zipper, putative tumour supressor 1
8 rs6984463 20619747 0.21 280.0 7.9E-07 NO 1.00 LZTS1 intergenic leucine zipper, putative tumour supressor 1
8 rs7813612 20616205 0.07 500.4 4.1E-07 NO 0.88 LZTS1 intergenic leucine zipper, putative tumoursupressor 1
13 rs 1807785 61692915 0.06 475.1 6.4E-07 NO 0.97 PCDH20 intergenic protocadherin 20
Figure 5-41. Manhattan plot of P-values for association between TxM* in subjects not on 
aspirin and SNPs on the CNV370-Duo chip (MAF=0.05). Loci which contained at least one SNP
which was associated with TxM* at a P-value of = 1x10'06 in all subjects (Figure 5-40) were 
highlighted in this plot in orange. Loci which contained at least one SNP associated with TxM* at a 
P-value of = 1x10 in subjects not on aspirin were highlighted in purple on the plot and described 
in the table underneath it. In addition, the candidate genes encoding thromboxane synthase 
('TBXAS1), COX-1 (PTGS1) and COX-2 (PTGS2) were highlighted in brown. The Bonferroni- 
corrected P-value threshold for this study was 1.8x1 O'07, P-values which exceed this threshold are 
marked in red. CHR: chromosome, BP: base pair position, MAF: minor allele frequency, BETA: 
change in TxM (pg/mg creatinine) associated with carriership of one copy of the minor allele, P: P- 
value for association, GENO: Genotyped (if ‘no’, the SNP was imputed), INFO: imputation 
information score. TxM: urinary thromboxane measurement. ‘ Adjusted for the covariates age, 
sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive 
regimen. Using log10(TxM*), the P-values for the tophits at each locus were: CNTN4 (rs11706819), 
P=1.2x1 O'07; LZTS1 (rs7813612) P=2.4x10-°6; PCDH20 (rs1807785) P=1.0x10 °4.
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TxM* Subjects On Aspirin (N=376)
CHR SNP BP MAF BETA P GENO INFO CLOSEST GENE SNP POSmON GENE NAME
1 rs11809518 169893061 0.05 325.7 5.5E-07 NO 0.88 MYOC/VAMP4 intergenic myocilln/vesicle-associated membrane protein 4
1 rs10157798 169893564 0.05 327.1 5.0E-07 NO 0.88 MYOC/VAMP4 intergenic myocilin/vesicle-associated membrane protein 5
1 rs7536328 169897560 0.05 326.3 5.2E-07 NO 0.88 MYOC/VAMP4 intergenic myocilin/vesicle-associated membrane protein 6
1 rs11800109 169905722 0.05 326.3 5.2E-07 NO 0.88 MYOC/VAMP4 intergenic myocilin/vesicle-associated membrane protein 7
1 rsll799938 169907511 0.09 247,1 6.0E-07 NO 0.90 MYOC/VAMP4 intergenic myocilin/vesicle-associated membrane protein 8
1 rsll799961 169907642 0.08 263.2 1 5E-07 NO 1.01 MYOC/VAMP4 intergenic myocilin/vesicle-associated membrane protein 9
1 rs10489248 169912212 0.12 212.1 1.9E-07 NO 1.02 MYOC/VAMP4 intergenic myocilin/vesicle-associated membrane protein 10
I rs2014613 169914660 0.12 193.2 1.2E-06 YES NA MYOC/VAMP4 intergenic myocilin/vesicle-associated membrane protein 4
3 rs1580635 95570589 0.07 291.9 4.7E-07 NO 0.86 NSUN3 intergenic NOLl/NOP2/Sun domain family member 3
3 rs548318 95584354 0.06 314.3 2.8E-07 NO 0.85 NSUN3 intergenic NOLl/NOP2/Sun domain family member 3
3 rs548318 95584354 0.06 314.3 2.8E-07 NO 0.85 NSUN3 intergenic NOLl/NOP2/Sun domain family members
4 rs3817118 77418235 0.07 290.9 1.2E-07 YES NA FAM47E intronic family with sequence similarity 47, member E
Figure 5-42. Manhattan plot of P-values for association between TxM* in subjects on aspirin 
and SNPs on the CNV370-Duo chip (MAF=0.05). Loci which contained at least one SNP which 
was associated with TxM* at a P-value of =1x10 6 in all subjects/subjects not on aspirin (Figure 
5-40/Figure 5-41) were highlighted in this plot in orange and purple. Loci which contained at least 
one SNP associated with TxM* at a P-value of = Ix lO -06 in subjects on aspirin are highlighted in 
green on the plot and described in the table underneath it. In addition, the candidate genes 
encoding thromboxane synthase (TBXAS1), COX-1 (PTGS1) and COX-2 (PTGS2) were highlighted 
in brown. The Bonferroni-corrected threshold for this study was 1.8x1 O'07, P-values which exceed 
this threshold are marked in red. CHR: chromosome, BP: base pair position, MAF: minor allele 
frequency, BETA: change in TxM (pg/mg creatinine) associated with carriership of one copy of the 
minor allele, P: P-value for association, GENO: Genotyped (if ‘no’, the SNP was imputed), INFO: 
imputation information score. TxM: urinary thromboxane measurement. ‘Adjusted for the 
covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and 
anti-hypertensive regimen. Using log10(TxM*), the P-values for the tophits at each locus were: 
MYOC/VAMP4 (rs11799961), P=8.9x10‘06; FAM47E (rs3817118), P=1.7x10‘06.
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5.5.6 CNTN4 Association Peak
The CNTN4 locus was most strongly associated with subjects not on aspirin in this study (Figure 
5-41). The upper panel of Figure 5-43 shows a regional association plot of the SNPs in the CNTN4 
region with TxM* in subjects not on aspirin. Genotyped SNPs are square, imputed SNPs are 
circular. In the subjects not on aspirin, the latter two genotyped SNPs, rs1685495 and rs4684343 
were in high LD with each other (r2=0.86), but both were in low LD with the ‘tophit’ SNP, 
rs10510230 (r2=0.1 and ^=0.09, respectively). Four imputed SNPs in the upstream region of this 
plot exceeded Bonferroni threshold, and are shown in the table in red. According to LD estimations 
from HapMap 3 data, these imputed SNPs are in moderate disequilibrium (^"0.5) with rs10510230. 
The SNPs in the upstream region of this plot were associated with an increase in TxM*, the SNPs in 
the downstream region with a decrease in TxM*.
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CHR SNP BP A1 INFO GENO AF BETA P AF BETA P AF BETA P
3 rs 10510230 2257130 C NA Y 0.15 191.3 6.0E-07 0.16 328.9 1.9E-07 0.14 37.6 0.34
3 rs 11915941 2310062 A 0.84 N 0.13 199.1 8.6E-06 0.13 385.7 1.6E-07 0.13 -16.3 0.73
3 rsll706819 2317976 C 0.94 N 0.14 182.8 5.3E-06 0.14 368.3 5.3E-08 0.15 -12.7 0.75
3 rs 11714433 2324793 C 0.95 N 0.14 180.4 6.3E-06 0.14 364.5 6.4E-08 0.15 -12.8 0.75
3 rsl7194273 2330601 G 0.94 N 0.14 179.7 6.9E-06 0.14 363.9 6.7E 08 0.15 -13.9 0.73
3 rs 1566382 2362439 C 0.99 N 0.49 -130.0 2.0E-06 0.51 -198.4 2.1E-05 0.47 -54.6 0.05
3 rs 1685495 2365612 C NA Y 0.49 -129.8 2.0E-06 0.49 -198.6 2.0E-05 0.47 -54.1 0.05
3 rs4684343 2366098 A NA Y 0.45 -133.4 8.9E-07 0.47 -194.6 2.5E-05 0.44 -65.2 0.02
3 rs968057 2367644 A 0.99 N 0.49 -130.3 2.0E-06 0.51 -199.4 2.0E-05 0.47 -54.1 0.05
3 rs4685517 2367718 G 1.00 N 0.49 -125.7 4.1E-06 0.52 -190.1 4.7E-05 0.47 -54.6 0.05
3 rs4685518 2383010 A 1.03 N 0.40 -123.7 6.5E-06 0.41 -187.1 8.0E-05 0.39 -58.6 0.03
Figure 5-43. Upper panel: Regional plot of the ‘tophit’ SNP in C N T N 4 , rs10510230 (purple diamond), 
and the SNPs genotyped on (square) and im puted from  (circular) the CNV370-Duo chip w ithin 200kb  
either side o f it. The P-values for association of these SNPs with TxM* in the study are given on the y-axis 
and position in Mb on the x-axis. Linkage disequilibrium with the 'tophit' SNP is colour-coded based on the r2 
values from Hapmap phase 3. SNPs without available r2 values are shown in grey. cM: centimorgans; Mb: 
megabases. Lower panel: Table of imputed & genotyped SNPs in the region which were significantly 
associated with TxM* at P=1x10'05. A1: allele 1, INFO: information score reflecting imputation quality, GENO: 
genotyped (yes/no), AF: allele frequency of A1, BETA: change in TxM* (pg/mg creatinine) associated with 
carriership of one copy of the minor allele. TxM: urinary thromboxane measurement ‘Adjusted for the 
covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti­
hypertensive regimen. The association plot was created using Locuszoom (215).
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Figure 5-44-Figure 5-46 show the distribution of TxM* values in all subjects, subjects not on aspirin 
and subjects on aspirin, according to the genotype of rs10510230, the tophit genotyped SNP in the 
region of the CNTN4 gene. The boxplots all display a trend of increasing TxM with additional minor 
alleles of rs10510230 carried, which is particularly pronounced in subjects not on aspirin.
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Figure 5-44. Boxplot and density plots of TxM* values in all subjects according to the 
genotype of rs10510230, the ‘tophit’ genotyped SNP in the CNTN4 region. TxM: urinary 
thromboxane measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-45. Boxplot and density plots of TxM* values in subjects not on aspirin according 
to the genotype of rs10510230, the ‘tophit’ genotyped SNP in the CNTN4 region. TxM: 
urinary thromboxane measurement ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, 
systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-46. Boxplot and density plots of TxM* values in subjects on aspirin according to 
the genotype of rs10510230, the ‘tophit’ genotyped SNP in the CNTN4 region. TxM: urinary 
thromboxane measurement ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-47-Figure 5-49 show the distribution of TxM* values in all subjects, subjects not on aspirin 
and subjects on aspirin, according to the genotype of rs4684343, the tophit genotyped SNP in the 
downstream region of the CNTN4 gene, which was associated with decreased TxM*. The boxplots 
all display a trend of decreasing TxM with additional minor alleles of rs4684343 carried, although 
this is less pronounced in subjects on aspirin.
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Figure 5-47. Boxplot and density plots of TxM* values in all subjects according to the 
genotype of rs4684343, the ‘tophit’ genotyped SNP in the downstream region of CNTN4, 
which was associated with a decrease in TxM*. TxM: urinary thromboxane measurement 
*Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, 
LDL, aspirin and anti-hypertensive regimen.
22 0
S u b j e c t s  N o t  O n  A s p i r i n  ( N = 3 9 6 )
TxM* Distribution in
5000 -
0
c
'-4—'
CD
0i—
O
O)
E
C l
4 0 0 0
3 0 0 0  -
2 0 0 0
X
H
1 0 0 0
o
o
> MCO 401»
TxM* (pg/mg creatinine)
TxM* Distribution In 
Heterozygotes (N=107)
TxM* Distribution in 
Minor Allele Homozygotes (N=89)
0  1  2  
N u m b e r  of Minor Alleles of rs4684343
Figure 5-48. Boxplot and density plots of TxM* values in subjects not on aspirin according 
to the genotype of rs4684343, the ‘tophit’ genotyped SNP in the downstream region of 
CNTN4, which was associated with a decrease in TxM*. TxM: urinary thromboxane 
measurement ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-49. Boxplot and density plots of TxM* values in subjects on aspirin according to the 
genotype of rs4684343, the ‘tophit’ genotyped SNP in the downstream region of CNTN4, 
which was associated with a decrease in TxM*. TxM: urinary thromboxane measurement 
‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, 
LDL, aspirin and anti-hypertensive regimen.
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All Subjects (N=772)
Minor Allele Carriers
Figure 5-50. Boxplot of TxM* values in all subjects according to the genotypes of rs10510230 
and rs4684343, the tophits in the upstream and downstream regions of the CNTN4 locus, 
respectively. TxM* values were plotted according to the following groupings: major allele 
homozygotes at both loci (“neither SIMP”, N=144); individuals who were minor allele carriers for 
rs10510230 but major allele homozygotes for rs4684343 (“rs10510230”, N=87); individuals who 
were minor allele carriers at both loci (“both SNPs”, N=219) and those who were minor allele 
carriers for the rs4684343 SNP, but major allele homozygotes at the rs10510230 SNP 
(“rs4684343”, N=316). TxM: urinary thromboxane measurement ‘ Adjusted for the covariates age, 
sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive 
regimen.
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Figure 5-50 shows the distribution of TxM* values according to the genotyped of rs10510230, 
located in intron 1 of CNTN4 and associated with increased TxM*, and rs4684343, located in intron 
2 of CNTN4 and associated with decreased TxM*. Although the association with rs10510230 is 
strongest in subjects not on aspirin, rs4684343 is not strongly associated with TxM* in those not on 
aspirin, and as both associations are strong in all subjects this figure has been based on that 
population. Those who carry a minor allele at rs10510230 only appear to have higher TxM* than 
those who do not carry minor alleles at either locus, although this difference is less pronounced 
than that of rs10510230 minor allele carriers compared to all other subjects (Figure 5-44). Similarly, 
those who carry a minor allele at rs4684343 only appear to have lower TxM* than those who do not 
carry minor alleles at either locus, although this difference is less pronounced than that of 
rs4684343 minor allele carriers compared to all other subjects (Figure 5-47). Minor allele carriers at 
both loci appear to have a very similar TxM* distribution to those who are major allele homozygotes 
at both loci. When the association between rs10510230 and TxM* was examined in all subjects, 
conditioning on the genotype of rs4684343, it remained strongly associated, albeit with a less 
significant P-value (BETA 147.5, P=2.2x10'04). Similarly, when the association between rs4684343 
was adjusted for rs10510230 genotype, it remained strongly associated with decreased TxM* in all 
subjects (BETA -101.3, P=3.6x10'04). These data are consistent with the two loci being associated 
with two independent effects on TxM* levels.
These two independently associated SNPs were used in a haplotype analysis (Table 5-20). 
Haplotypes were imputed by PUNK using the standard E-M algorithm in the ‘all subjects’ cohort. All 
four of the possible haplotypes had a frequency of >= 0.01 in the population, and were used in the 
analysis.
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Table 5-19. The two CNTN4 SNPs used in Haplotype analysis with their minor (A1) and major 
(A2) alleles, and (minor allele) frequency in all subjects (N=772).
CHR SNP Position A1 A2 Frequency
3 rs 10510230 2257130 C A 0.143
3 rs4684343 2366098 A G 0.452
Table 5-20. Results of the ‘Each-vs-Others’ haplotype analysis using all haplotypes of the 
two CNTN4 SNPs independently associated with TxM*. ‘ Adjusted for the covariates age, sex, 
smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive 
regimen. BETA: change in TxM* (pg/mg creatinine) associated with carriership of one copy of the 
haplotype, P: P-value for association.
All Subjects 
(N=772)
Subjects Not On 
Aspirin (N=396)
Subjects On 
Aspirin (N=376)
HAPLOTYPE FREQUENCY BETA P BETA P BETA P
CA 0.02 -202.0 0.10 -202.6 0.25 -113.8 0.50
AA 0.44 203.5 4.2E-06 301.4 7.6E-05 46.5 0.02
CG 0.13 486.5 2.0E-09 795.1 1.3E-10 121.9 0.24
AG 0.42 273.9 0.31 364.4 0.87 105.7 0.11
5.5.7 M YOC/VAM P4 Association Peak
The upper panel of Figure 5-51 shows a regional association plot of the SNPs in the M Y O C N A M P 4  
region with TxM* in subjects on aspirin. Genotyped SNPs are square, imputed SNPs are circular. 
One imputed SNP in this region exceeded Bonferroni threshold, and is shown in the table in red. 
This imputed SNP appears in the upper panel in green, indicating that it is relatively well-correlated 
with the genotyped SNP, rs2014613 (^=0.56, according to estimations of LD from HapMap 3). 
Another imputed SNP, rs10489248, which was also highly associated with increased TxM* in 
subjects on aspirin in this study (BETA 212.1, P=1.9x10'07), appears in the upper panel in red, 
indicating high correlation with the genotyped SNP (r2=0.92, according to HapMap 3 estimations).
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MYOC/VAMP4 All Subjects (N=772) Subjects Not On Aspirin (N=396)
Subjects On Aspirin 
(N=376)
CHR SNP BP A1 INFO GENO AF BETA P AF BETA P AF BETA P
1 rs 11809518 169893061 G 0.84 N 0.05 220.9 9.5E-04 0.05 115.5 0.32 0.05 325.7 5.5E-07
1 rs10157798 169893564 T 0.85 N 0.05 221.3 9.3E 04 0.05 115.3 0.32 0.05 327.1 5.0E-07
1 rs7536328 169897560 T 0.85 N 0.05 220.8 9.4E-04 0.05 115.0 0.32 0.05 326.3 5.2E-07
1 rs7541132 169897920 G 0.72 N NA NA NA NA NA NA 0.06 320.5 1.1E-06
1 rs16864740 169900494 C 0.70 N NA NA NA NA NA NA 0.06 318.4 1.3E-06
1 rs 11800109 169905722 C 0.85 N 0.05 220.8 9.4E-04 0.05 115.0 0.32 0.05 326.3 5.2E-07
1 rs11799938 169907511 A 0.88 N 0.09 155.7 2.1E-03 0.09 65.1 0.45 0.09 247.1 6.0E-07
1 rs 11799961 169907642 A 0.96 N 0.08 151.9 3.0E-03 0.08 45.1 0.61 0.08 263.2 1.5E-07
1 rs12145527 169908368 C 0.97 N 0.08 140.0 5.2E-03 0.08 43.7 0.62 0.08 233.6 l.SE-06
1 rs10913455 169908579 c 0.97 N 0.08 139.9 5.2E-03 0.08 43.7 0.62 0.08 233.3 1.5E-06
1 rs 10489248 169912212 c 0.95 N 0.13 93.6 0.03 0.13 -27.2 0.71 0.12 212.1 1.9E-07
1 rsll811876 169913895 c 0.97 N 0.08 142.2 4.5E-03 0.08 48.1 0.58 0.08 233.7 1.4E-06
1 rsll800358 169914098 T 0.97 N 0.08 140.0 5.2E-03 0.08 43.8 0.62 0.08 233.4 1.5E-06
1 rs2014613 169914660 T NA Y 0.13 84.6 0.04 0.13 -31.3 0.67 0.12 198.2 1.0E-06
Figure 5-51. Upper panel: Regional p lot of the ‘tophit’ genotyped SNP in the M Y O C /V A M P 4  region, 
rs2014613 (purple diamond), and the SNPs genotyped on (square) and imputed from  (circular) the 
CNV370-Duo chip w ithin 200kb either side o f it. The P-values for association of these SNPs with TxM* in 
the study are given on the y-axis and position in Mb on the x-axis. Linkage disequilibrium with the 'tophit' SNP is colour-coded based on the r2 values from Hapmap phase 3. SNPs without available r2 values are shown in grey. cM: centimorgans; Mb: megabases. Lower panel: Table o f im puted & genotyped SNPs in the 
region which were significantly associated w ith TxM * at P ^ x lO -03. SNPs with NA values were below the 
MAF cut-off in the relevant populations. A1: allele 1, tNFO: information score reflecting imputation quality, GENO: genotyped (yes/no), AF: allele frequency of A1, BETA: change in TxM* (pg/mg creatinine) associated with carriership of one copy of the minor allele. TxM: urinary thromboxane measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti- 
hypertensive regimen. The association plot was created using Locuszoom (215).
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Figure 5-52-Figure 5-54 show the distribution of TxM* values in all subjects, subjects not on aspirin 
and subjects on aspirin, according to the genotype of rs2014613, the tophit genotyped SNP in the 
MYOC/VAMP4 region. The boxplots all display a trend of increasing TxM* with additional minor 
alleles of rs2014613 carried. This is less pronounced in subjects not on aspirin, however it should 
be noted that the number of minor allele homozygotes at this locus in this sub-population is only 2, 
whereas there are 7 minor allele homozygotes for rs2014613 in the subjects on aspirin.
Figure 5-52. Boxplot and density plots of TxM* values in all subjects according to the 
genotype of rs2014613, the ‘tophit’ genotyped SNP in MYOC/VAMP4 region. TxM: urinary 
thromboxane measurement ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-53. Boxplot and density plots of TxM* values in subjects not on aspirin according 
to the genotype of rs2014613, the ‘tophit’ genotyped SNP in MYOCA/AMP4 region. TxM: 
urinary thromboxane measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, 
systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-54. Boxplot and density plots of TxM* values in subjects on aspirin according to 
the genotype of rs2014613, the ‘tophit' genotyped SNP in MYOC/VAMP4 region. TxM: urinary 
thromboxane measurement ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
5.5.8 FAM47E Association Peak
The upper panel of Figure 5-55 shows a regional association plot of the SNPs in the FAM47E 
region with TxM* in subjects on aspirin. Genotyped SNPs are square, imputed SNPs are circular. 
The tophit SNP in this region was the genotyped SNP, rs3817118, in intron 1 of FAM47E, which 
was significant beyond Bonferroni threshold, and is shown in the table in red. Two imputed SNPs , 
also located in intron 1, were also strongly associated with increased TxM, rs17001726 and 
rs12646634, both of which are shown in the upper panel of Figure 5-53 in red, indicating high 
linkage disequilibrium with rs3817118 (^=1 at both loci, according to HapMap 3 estimates).
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F A M 4 7 E All Subjects (N=772)
Subjects Not On 
Aspirin (N=396)
Subjects On Aspirin 
(N=376)
CHR SNP BP Al INFO GENO
4 rsl7001726 77396051 G 0.89 N 
4 rs12646634 77399840 G 0.89 N 
4 rs3817118 77418235 C NA V
AF BETA P
0.09 76.3 0.13 
0.09 76.3 0.13 
0.07 83.5 0.11
AF BETA P
0.10 -56.5 0.49 
0.10 -56.6 0.49 
0.08 -67.4 0.43
AF BETA P
0.08 262.2 1.0E-06 
0.08 262.2 1.0E-06 
0.07 290.9 1.2E-07
F ig u re  5 -5 5 . U p p e r p a n e l: R e g io n a l p lo t o f th e  ‘to p h it ’ g e n o ty p e d  SNP in  th e  F A M 4 7 E  re g io n , 
rs3817118 (p u rp le  d ia m o n d ), an d  th e  SNPs g e n o ty p e d  o n  (s q u a re )  an d  im p u te d  fro m  
(c irc u la r)  th e  C N V 3 7 0 -D u o  c h ip  w ith in  2 0 0 k b  e ith e r  s id e  o f  it. The P-values for association of 
these SNPs with TxM* in the study are given on the y-axis and position in Mb on the x-axis.
Linkage disequilibrium with the 'tophit' SNP is colour-coded based on the r2 values from Hapmap 
phase 3. SNPs without available r2 values are shown in grey. cM: centimorgans; Mb: megabases. 
Lower panel: Table of imputed & genotyped SNPs in the region which were significantly 
associated with TxM* at P=1x10‘05. A1: allele 1, INFO: information score reflecting imputation 
quality, GENO: genotyped (yes/no), AF: allele frequency of A1, BETA: change in TxM* (pg/mg 
creatinine) associated with carriership of one copy of the minor allele. TxM: urinary thromboxane 
measurement ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen. The association plot was created 
using Locuszoom (215).
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Figure 5-56-Figure 5-58 show the distribution of TxM* values in all subjects, subjects not on aspirin 
and subjects on aspirin, according to the genotype of rs3817118, the tophit genotyped SNP in the 
FAM47E gene. Only the boxplots for subjects on aspirin display a notable trend of increasing TxM 
with additional minor alleles of rs3817118 carried, and this is reflected in the P-values for 
association of this SNP with TxM* in all subjects and in subjects not on aspirin (Figure 5-55, table). 
Although the trend appears strong in the subjects on aspirin, and the heterozygotes appear to have 
raised TxM* compared to major allele homozygotes, it should be noted that there is only one minor 
allele homozygote at this locus in this sub-population.
All Subjects (N=772)
TxM* Distribution in 
Major Allele Homozygotes (N=665)
0  1  2  
N u m b e r  of Minor Alleles of rs3817118
TxM* Distribution in 
Heterozygotes (N=102)
TxM* Distribution in 
Minor Allele Homozygotes (N^S)
awo mm 
TxM* (pg/mg creatinine)
Figure 5-56. Boxplot and density plots of TxM* values in all subjects according to the 
genotype of rs3817118, the ‘tophit’ genotyped SNP in FAM47E gene. TxM: urinary 
thromboxane measurement ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-57. Boxplot and density plots of TxM* values in subjects not on aspirin according 
to the genotype of rs3817118, the ‘tophit’ genotyped SNP in FAM47E gene. TxM: urinary 
thromboxane measurement ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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Figure 5-58. Boxplot and density plots of TxM* values in subjects on aspirin according to the 
genotype of rs3817118, the ‘tophit’ genotyped SNP in FAM47E gene. TxM: urinary 
thromboxane measurement ’ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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5.6 R esults  fo r  P ros ta cyc lin  G enotyped on the  CNV370-Duo C hip
5.6.1 Baseline Characteristics
PGI-M measurements were available for 771 subjects. 767 of these also had TxM measurements 
and were used in the TxM analysis; five subjects for whom TxM measurements were available did 
not have successful PGI-M assays, and four subjects for whom PGI-M measurements were 
available did not have successful TxM assays.
PGI-M levels were significantly lower in subjects on aspirin compared to those not taking aspirin at 
time of PGI-M measurement. There were also significantly fewer men taking aspirin, significantly 
more diabetics taking aspirin, and subjects taking aspirin on average had significantly higher 
systolic blood pressure. There were no significant differences between subjects taking aspirin and 
those not taking aspirin across the other population characteristics (Table 5-18).
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Table 5-21. Population characteristics for the 771 individuals in this study for whom PGI-M measurements were available. Subjects not 
randomized to the angiotensin-converting enzyme inhibitor and calcium antagonist regimen were randomized to a (3-blocker and diuretic regimen. IQR: 
Inter quartile range; SD: Standard deviation; N: number of subjects included in analysis; SBP: Systolic blood pressure; BMI: Body mass index; HDL: 
High density lipoprotein; LDL: Low-density lipoprotein; ACE-I: Angiotensin-converting enzyme inhibitor. Bold font indicates the primary endpoint, PGI- 
M. *P-value significant at P<0.05.
Demographic& Clinical Characteristics
All Subjects
(N=771)
Subjects Not On Aspirin
(N= 395)
Subjects On Aspirin
(N= 376) P
PGI-M (pg/mg creatinine): Median (IQR) 126(85-189) 147(97-203) 108 (74-161) 0.01*
Age (years): M e a n lS D 64.6 ± 8 .1 64 .11 8.1 65.118.1 0.08
Male: N (%) 599 (78%) 319(81% ) 280 (74%) 0.04*
Current sm okers: N (%) 181(23%) 89 (22%) 92(24% ) 0.53
Current diabetes: N (%) 145 (19%) 53(13% ) 92 (24%) 9E-05*
SBP: Mean ± S D 135.0111.9 133.0111.0 137.2112.5 6E-07*
BMI: M e a n iS D 29 .31 4.8 29 .21 4.7 29 .31 4.9 0.77
HDL: Mean ± SD 1 .310 .3 1 .310 .3 1.310 .3 0 .2 0
LDL: Mean ± S D 3 .0 1 0 .9 3 .0 1 0 .9 3 .0 1 0 .8 0.56
Random ised to ACE-I: N (%) 391(51%) 206(52%) 185 (49%) 0.41
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5.6.2 PGI-M Distribution
The distribution of PGI-M levels (pg/mg creatinine) across the study population of 771 subjects was 
again non-normal (Figure 5-59). After adjustment for covariates (PGI-M*), the distribution was 
again less skewed, but remained non-normally distributed. Following Logi0 transformation of the 
PGI-M values, the distribution approximated normality. As with the CVD50K analysis, the 
distribution of the residuals was slightly skewed (Figure 5-60).
As with the CVD50K chip analysis, it was decided not to transform the data. The fact that this study 
was based on even larger numbers than the CVD50K chip makes it even more likely that the 
parametric tests used were robust against departures from normality. Unfortunately, the far greater 
number of SN Ps genotyped in this study meant that permutation analysis was not feasible.
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PGI-M All Subjects (N=540) PGI-M All Subjects (N=771)
PGI-M (pg/mg creatinine) 
PGI-M* All Subjects (N=771)
PGI-M* (pg/mg creatinine)
Log10 PGI-M All Subjects (N=771)
Theoretical Quantités 
PGI-M* All Subjects (N=771)
Theoretical Quantiles 
Log10 PGI-M All Subjects (N=771)
log10 PGI-M (pg/mg creatinine)
Figure 5-59. Histograms (left) and “Normal" QQ normal plots of the distribution of PGI-M levels in all 
771 subjects before & after adjustment for covariates, and logio transformation of the non-normal
distribution. The red line on the QQ plots passes through the first and third quartiles. If values were normally 
distributed, they should adhere closely to this line. PGI-M: urinary prostacyclin measurement. ‘Adjusted for 
the covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti­
hypertensive regimen. Adjustment led to negative thromboxane values which, although fictional, can be 
legitimately used for regression analysis.
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w i t h  P G I - M *  in  A l l  S u b j e c t s  ( N = 7 7 1 )
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Figure 5-60. The distribution of the residuals of the associations between S N P s on the 
CVN370-Duo chip and PGI-M* in all subjects.
5.6.3 Power Calculations
A post-hoc power analysis was conducted for this study to help to indicate how likely the study was 
to have identified ‘true’ associations, assuming that they exist. Power was again calculated using 
the Quanto power calculator (http://hydra.usc.edu/gxe/), assuming a continuous variable, an 
additive inheritance model, gene-only effects (no gene-gene or gene-environment interactions were 
accounted for), and a 2-sided test. Power was again estimated assuming a variety of minor allele 
frequencies (MAF) of the genetic variants, and across a range of type I error rates.
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Figure 5-61 indicates that this study had good (>80%) power to detect associations between SN P s 
present in the population at a frequency of 5% or above and even small changes in TxM* levels at a 
type I error rate of 0.05. However, this study only had good (>80%) power to detect SN P s which 
were both present at a high frequency in the population (>10%) and were associated with large 
effect sizes (>75pg/mg creatinine TxM* change per minor allele), at a type I error rate of 1.8x10"07, 
which was the Bonferroni-corrected error threshold used for this study (section 3.6.5).
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Figure 5-61. Power plots for association between SN P s on the CNV370-Duo chip and PGI-M* 
levels. The power of this study to detect associations between SN Ps on the CNV370-Duo chip and 
PGI-M* levels in the total population (N=771), assuming a Type I error rate (a) of 0.05 (panel A), 
1x10"03 (panel B), Ix lO -06 (panel C) or 1.8x10"07 (panel D) was plotted. The population mean of 
PGI-M* was 117 pg/mg creatinine and the standard deviation was 159 pg/mg creatinine. Power 
was plotted assuming four different main effect sizes of PGI-M* (pg/mg creatinine) associated with 
carriership of one minor allele (25, 50, 75, or 100 pg/mg). The maximum effect size per minor allele 
carried observed in the results of this study was 95 pg/mg creatinine. PGI-M: urinary prostacyclin 
measurement. ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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5.6.4 QQ Plots
QQ plots of the P-values for association of the SN Ps on the CNV370-Duo chip with PGI-M levels in 
all subjects, and in subjects divided by aspirin usage, are shown below (Figure 5-62). SN Ps with a 
minor allele frequency (MAF) <5% were not included in the analysis of these results, and were 
plotted separately. In all subjects, only one SN Ps with a low P-value and MAF = 5% slightly 
exceeded the 99% probability envelopes. In subjects not taking aspirin at time of measurement, 
several SN Ps had P-values outside of the 99% probability envelopes, indicating that more 
significant SN Ps were observed than would be expected under the null hypothesis, whereas in 
subjects on aspirin, the pattern was similar to all subjects.
In all three populations, the P-values for SN P s with a MAF of <5% deviated substantially from the 
expected line at low P-values. However, with a population size such as the one in this study, these 
are likely to represent spurious associations, and were not included in further analyses.
Genomic control (GC) A values were calculated from the P-value distributions, including only SN Ps 
with MAF = 0.05 and the lower 95% of the distribution. GC A values for each population were equal 
to 1, suggesting that the P-values in this study are not skewed due to population stratification, or 
any other bias.
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Figure 5-62. QQ plots of P-values for 
association of the SN P s on the CNV370-Duo 
chip with PGI-M*. Observed P-values for 
association were plotted against those which would 
be expected under the null hypothesis of no 
association (black line). Shaded regions are 99% 
probability envelopes (which depend on number of 
SN Ps and hence are different sizes for common 
and low-frequency SN Ps). SN Ps were divided into 
those with a minor allele frequency (MAF) in the 
population of = 5% (red), or < 5% (blue). Genomic 
control A values were calculated including only 
SN Ps with MAF = 0.05 and the lower 95% of the 
distribution and were as follows: All Subjects: 95% 
A=1.00; Subjects On Aspirin: 95% A=1.00;
Subjects Not On Aspirin: 95% A=1.00. PGI-M: 
urinary prostacyclin measurement. ‘Adjusted for 
the covariates age, sex, smoking habit, diabetes, 
systolic blood pressure, BMI, HDL, LDL, aspirin and 
anti-hypertensive regimen.
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5.6.5 Manhattan Plots
Manhattan plots of the P-values for association of the SN Ps on the CNV370-Duo chip with PGI-M* 
in each of the three populations are shown below (Figure 5-63-Figure 5-65). As with the TxM 
analysis, 272,166 SN Ps with MAF of = 5% passed quality control, giving a Bonferroni correction 
value of 1.8x1 O'07. Again, given the lack of power of this study to detect associations at this 
threshold (section 3.5.3), it was decided to treat as ‘interesting’ all associations with P-values =1x10'
05
In addition, a further 1,759,333 SN P s were imputed from the genotyped SN Ps, using the HapMap II 
CEU  reference panel. On the Manhattan plots below, only imputed SN Ps are shown. This provides 
an additional quality control measure; spurious associations arising from genotyping artefacts 
should not be present in the imputed dataset as the information score from such SN Ps would not 
exceed the cutoff. The subsequent plots show, where a SN P was directly genotyped, the statistics 
from association with genotyped SN Ps, which are almost indistinguishable from the statistics arising 
from the imputed dataset in this study.
Loci which contained at least one genotyped SN P which was associated with TxM* at P= Ix lO -06 
were highlighted on the plots and described in the tables underneath them. In addition, the 
‘candidate’ genes for prostacyclin synthase 1 (P T G IS ), COX-1 (P T G S1 ) and CO X-2 (P T G S2 ) are 
highlighted in brown. The gene encoding cytosolic phospholipase A2 (PLA2) is also a candidate for 
influencing PGI-MVTxM* levels, but was not genotyped on this array.
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Position by chromosome
PGI* All Subjects (N=771)
CHR SNP BP MAF BETA P GENO INFO CLOSEST GENE SNPPOSmON GENE NAME
3 rs4148584 185160195 0.06 78.7 9.2E-07 YES Q BE intronic______ABCC5_______ multidrun resistance-associated protein 5
Figure 5-63. Manhattan plot of the P-vaiues for association between PGI-M* in all subjects 
and SN P s on the CNV370-Duo chip (MAF=0.05). Loci which contained at least one SN P 
associated with PGI-M* at a P-value of = 1x1 O'05 in all subjects were highlighted in orange on the 
plot, and described in the table underneath it. In addition, the candidate genes encoding 
prostacyclin synthase (PT G IS ), COX-1 (PTG S1 ) and COX-2 (P T G S2 ) were highlighted in brown. 
The Bonferroni-corrected P-value threshold for this study was 1.8x1 O'07, no P-values exceed this 
threshold. CHR: chromosome, BP: base pair position, MAF: minor allele frequency, BETA: change 
in PGI-M (pg/mg creatinine) associated with carriership of one copy of the minor allele, P: P-value 
for association. PGI-M: urinary prostacyclin measurement. * Adjusted for the covariates age, sex, 
smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive 
regimen. Using logi0(PGI-M*), the P-values for the tophit was P=1.1x10'06.
244
9 - 
8 -  
« 7-3
jo 6  -
CL. 5-o
6> 4 - o
' 3-
2 - 
1 - 
0 -
P G I *  S u b j e c t s  N o t  O n  A s p i r i n  ( N = 3 9 5 )
1 0  -
PGI* Subjects Not On Aspirin (N=395)
CHK SNP BP MAF BETA P INFO GENO CLOSEST GENE SUPPOSITION GENE NAME
1 rsl213B672 67755460 0,19 65 3 3.6E-07 1,00 NO SERBP1 intergenic SERPINE1 mRNA binding protein
3 rs4148584 185160195 0.06 106.3 3.7E-07 NA YES ABCC5 intronic ATP-blnding casette subfamily C, member5
i rs3805111 185172683 0.06 106.3 3.7E-07 NA YES ABCC5 Intronlc ATP-binding casette subfamily C, member5
Ì rsl3093614 185173937 0.06 106.3 3.7E-07 1.02 NO ABCC5 intronic ATP-binding casette subfamily C, member5
S rsll741791 152896844 0.09 91.4 8.9E-07 NA YES GRIA1 Intronic glutamate receptor, ionotropîc, AMPA1
7 rs 13236236 100984128 0.25 60.6 5.9E-07 0.93 NO EMID2 intronlc EMI containing domain 2
7 rsl2536201 153780535 0.08 101.5 1.9E-07 0.97 NO DPP6 Intronic dipeptidyl-peptidase 6
f rs12703354 153781483 0.11 99.3 7.1E-08 0.77 NO DPP6 intronic dipeptidyl-peptidase 6
7 rs9655649 153782684 0.09 104.1 L4E-07 0.80 NO DPP6 Intronic dipeptidyl-peptidase 6
H rsl395614 59244105 0.09 89.4 6.1E-07 0.98 NO FAMllOB intergenic family with sequence similarity 110, member B
8 rs2939976 59244503 0.09 88.2 5.9E-07 NA YES FAMllOB intergenic family with sequence similarity 110, member B
8 rs1354816 59245176 0.10 86.2 6.2E-07 0.99 NO FAMllOB Intergenic family with sequence similarity 110, member B
Ï rs2939977 59246340 0.10 86.2 6.3E-07 0.98 NO FAMllOB intergenic family with sequence similarity 110, member B
i rs2318336 139843091 0.14 78-2 9.7E-07 0.82 NO PREX2 Intronic phosphatidylinositol-3,4(5-trIsphosphate-dependent Rac exchange factor 2
è rs6981648 139844327 0.14 78.2 9.7E-07 0.82 NO PREX2 intronlc phosphatldylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2
13 rs9576636 38369709 0.06 113.3 2.8E-07 0.98 NO FREM2 intergenic FRASl-related extracellular matrix protein 2
21 f*118331 38911925 O.OG 110.4 5.2E-07 0.98 NO ERG ilntro nlc v-ets ervThrciblastosIs virus £26oncogene like
Figure 5-64. Manhattan plot of the P-values for association between PGI-M* in all subjects and SNPs 
on the CNV370-Duo chip (MAF=0.05). Loci which contained at least one SNP which was associated with 
PGI-M* at a P-value of = 1x1 O'05 in all subjects (Figure 5-63) were highlighted in this plot in orange. Loci which 
contained at least one SNP associated with PGI-M* at a P-value of = 1x1 O'05 in subjects not on aspirin were 
highlighted in purple on the plot, and described in the table underneath it. . In addition, the candidate genes 
encoding prostacyclin synthase (PTGIS), COX-1 (PTGS1) and COX-2 (PTGS2) were highlighted in brown.
The Bonferroni-corrected P-value threshold for this study was 1.8x1 O'07, no P-values exceed this threshold. 
CHR: chromosome, BP: base pair position, MAF: minor allele frequency, BETA: change in PGI-M (pg/mg 
creatinine) associated with carriership of one copy of the minor allele, P: P-value for association. PGI-M: 
urinary prostacyclin measurement. ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen. Using logi0(PGI-M*), the P-values 
for the tophits at each locus were: SERBP1 (rs12188672), P=0.08; ABCC5 (rs4148584), P=1.3x10'06; 
GRIA1 (rs11741791), P=0.02; EMID2 (rs13236236), P=2.1x10'04; DPP6 (rs12703354) P=1.2x1Cr°5. FAM110B 
(rs2939976), P=1.9x1004; PREX2 (rs2318336), P=1.1x10'®: FREM2 (rs9576636), P=1.4x10^3; ERG 
(rs118331), 2.8x1 O'06.
SERBPI FFEM2 Bon terroni
EUID2 FAU110B 
GRW1 * »PREX2 ♦ * ♦• ♦ +* » 1
ERG
* * % I M ». ♦ ;i Li * * * * ♦ .* * ‘V # *. ♦ * *
1 • •:*! :* v  L i t  * A ? i  W  Û  '•• > : frit it ..c Jl a iuM Li*.. i  1 »5 < tf- «
1 3 5 7 9 11 13 15 17 1021 Y
2 4  6 8 10 12 14 16 18 2022
Position by chromosome
245
P G I *  S u b j e c t s  O n  A s p i r i n  ( N = 3 7 6 )
10
9
8
o> 73n> 6 
¿ 5
CD6) 4 o
* 3
2 
1 
0
1 3 S 7 9 11 13 16 17 1921 Y
2 4  6 8 10 12 14 16 18 2022
Position by chromosome
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2 rs6711052 67777372 0.10 103.4 2.5E-07
2 rs13016805 67785876 0.06 162.5 6. IE-10
2 rs17034184 67789905 0.06 156.4 4.3E-09
2 rs12999529 67795707 0.06 156.4 4.3E-09
2 rs1864572 67797716 0.06 156.4 4.3E-09
2 rs6546327 67800470 0.06 156.4 4.3E-09
3 rs 1154399 9243507 0.07 128.1 8.8E-07
rs1383228 1.23E+08 0.08 107.7 8.8E-07
A rs3109091 1.23E+08 0.09 109.0 8.7E-07
7 rs17133056 3135055 0.14 103.4 5.4E-07
7 rs12532214 3136416 0.18 82.6 5.7E-07
7 rs4324842 3138190 0.19 85.3 2.8E-07
8 rs6991227 8300962 0.10 102.9 6.7E-07
8 rsl7669632 8301478 0.10 102.9 6.7E-07
8 rsl0099571 8322712 0.11 96.2 8.0E-07
INFO GENO CLOSEST GENE SNP POSITION
1.06 N ETAA1/C1D intergenic
1.03 N ETAA1/C1D intergenic
1.03 N ETAA1/C1D Intergenic
1.03 N ETAA1/C1D intergenic
1.03 N ETAA1/C1D intergenic
1.01 N ETAA1/C1D intergenic
0.91 N SRGAP3 introni c
NA Y ANXA5/TMEM155 intergenic
0.97 N ANXA5/TMEM155 intergenic
0.74 N CARD11 intergenic
0.96 N CARD11 intergenic
0.92 N CARD11 intergenic
1.00 N SGK223 intergenic
1.00 N SGK223 intergenic
NA Y SGK223 intergenic
GENE NAME
ETAA16 protein/nuclear DNA-binding protein 
ETAA16 protein/nuclear DNA-binding protein 
ETAA16 protein/nuclear DNA-binding protein 
ETA A16 protein/nuclear DNA-binding protein 
ETAA16 protein/nuclear DNA-binding protein 
ETAA16 protein/nuclear DNA-binding protein 
SUT-ROBO Rho GTPase activating protein 3 
annexin 5/hypothetica! protein 
annexln 5/hypothetica I protein 
caspase recruitment domain family 11 
caspase recruitment domain family 11 
caspase recruitment domain family 11 
tyrosine-protein kinase SgK223 
tyrosine-protein kinase SgK223 
tyrosine-protein kinase 5gK223____________
Figure 5-65 Manhattan plot of the P-values for association between PGI-M* in all subjects and SNPs on 
the CNV370-Duo chip (MAF=0.05). Loci which contained at least one SNP which was associated with PGI- 
M* at a P-value of = 1x10'0f’ in all subjects {Figure 5-63) were highlighted in this plot in orange. Loci which 
contained at least one SNP which was associated with PGI-M* at a P-value of = 1x1 O'05 in subjects not on 
aspirin (Figure 5-64) were highlighted on this plot in purple. Loci which contained at least one SNP associated 
with PGI-M* at a P-value of = 1x10"05 in subjects on aspirin are highlighted in green on the plot, and described 
in the table underneath it. In addition, the candidate genes encoding prostacyclin synthase (PTGIS), COX-1 
(PTGS1) and COX-2 (PTGS2) were highlighted in brown. The Bonferroni-corrected P-value threshold for this 
study was 1.8x10"07, no P-values exceed this threshold. CHR: chromosome, BP: base pair position, MAF: 
minor allele frequency, BETA: change in PGI-M (pg/mg creatinine) associated with carriership of one copy of 
the minor allele, P: P-value for association. PGI-M: urinary prostacyclin measurement. ‘Adjusted for the 
covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti­
hypertensive regimen. Using log-|0(PGI-M*), the P-values for the tophits at each locus were: 
ETAA1/C1D (rs13016805), P=2.3x10'05; SRGAP3 (rs1154399), P=1.4x1 O'04; ANXA5/TMEM155 (rs3109091), 
P=1.5x10‘OB; CARD11 (rs4324842), P=2.4x10-°7; SGK223 (rs6991227) P=2.7x10'°\
ETAA1C 1D
BonfetronL
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246
5.6.6 A B C C 5  A ssociation  Peak
Although there were no SN P s in the A BCC5 region with P-values which exceeded Bonferroni 
correction of 1.8x1 O'07, there were persuasive peaks in this region in both all subjects (Figure 5-63) 
and those not on aspirin (Figure 5-64). In subjects not on aspirin, two genotyped SN Ps had P- 
values very close to the Bonferroni cut-off; rs4148584 (P=2.2x10'°7) and rs3805111 (P=3.7x10'°7).
The upper panel of Figure 5-66 shows a regional association plot of the SN Ps in the A B C C 5  region 
with PGI-M* in subjects not on aspirin. Genotyped SN Ps are square, imputed SN Ps are circular. 
Two genotyped SN Ps, rs4148584 (in intron 12) and rs3805111 (in intron 18) were strongly 
associated with increased PGI-M* in all subjects and in the subgroup not on aspirin, and are 
indicated in the upper panel of Figure 5-66. These two SN P s were completely correlated with each 
other in this study (^=1). Two imputed SNPs, rs764967 (upstream of ABCC5) and rs13093614 (in 
intron 18) were also strongly associated with increased PGI-M*, and were also in complete linkage 
disequilibrium (^=1) with rs4148584, based on HapMap3 estimates.
A number of SN Ps in the A B CC5 region were also genotyped on the CVD50K chip, although only 
one of the SN Ps found to be associated with PGI-M* in the CNV370-Duo analysis was genotyped 
(Figure 5-67).
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A B C C 5 All Subjects (N=771)
Subjects Not On 
Aspirin (N=395)
Subjects On Aspirin 
(N=376)
CHR SNP BP A1 INFO GENO AF BETA P AF BETA P AF BETA P
3 rs7646967 185114936 G 1.01 N 0.06 78.9 1.8E-06 0.06 104.6 1.2E-06 0.07 53.3 0.03
3 rs4148584 185160195 C NA Y 0.06 80.1 8.9E-07 0.06 109.4 2.2E-07 0.07 51.0 0.04
3 rs3805111 185172683 A NA Y 0.06 78.7 1.2E-06 0.06 106.3 3.7E-07 0.07 51.0 0.04
3 rs 13093614 185173937 G 1.02 N 0.06 78.7 1.2E-06 0.06 106.3 3.7E-07 0.07 51.0 0.04
Figure 5-66. Upper panel: Regional plot of the 'tophit’ SN P in A B CC5, rs4148584 (purple 
diamond), and the SN P s genotyped on (square) and imputed from (circular) the CNV370-Duo 
chip within 200kb either side of it. The P-values for association of these SN Ps with PGI-M* in the 
study are givert on the y-axis and position in Mb on the x-axis. Linkage disequilibrium with the 
'tophit' SN P is colour-coded based on the r2 values from Hapmap phase 3. SN Ps without available 
r2 values are shown in grey. cM: centimorgans; Mb: megabases. Lower panel: Table of imputed 
& genotyped SN P s in the region which were significantly associated with TxM* at P s Ix lO -05. 
A1: allele 1, INFO: Information score reflecting imputation quality, GENO: genotyped (yes/no), AF: 
allele frequency of A1, BETA: change in PGI-M* (pg/mg creatinine) associated with carriership of 
one copy of the minor allele. PGI-M: urinary prostacyclin measurement ‘ Adjusted for the 
covariates age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and 
anti-hypertensive regimen. The association plot was created using Locuszoom (215).
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Figure 5-67. Regional plot of the S N P s in the A B C C 5  region which were genotyped on the 
CVD50K chip. rs13093614 (purple diamond) was the ‘tophit1 SN P on the CVD50K chip and was 
associated with an increase of 96.2pg/mg creatinine, P=1.5x10"05 in subjects not on aspirin. None 
of the other 3 SN Ps which were associated with PGI-M* in the CNV370-Duo analysis (Figure 5-66) 
were genotyped on the CVD50K chip. Linkage disequilibrium with the ‘tophit’ SN P is colour-coded 
based on the r2 values from Hapmap phase 3. SN Ps without available r2 values are shown in grey. 
cM: centimorgans; Mb: megabases.
Figure 5-68-Figure 5-70 show the distribution of PGI-M* values in all subjects, subjects not on 
aspirin and subjects on aspirin, according to the genotype of rs4148584, the tophit genotyped SN P 
in the A B CC5  gene. These boxplots and density plots show a trend of increasing PGI-M* with 
additional minor alleles of rs4148584 carried in all subjects and both sub-populations, although it is
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less pronounced in the subjects on aspirin. Numbers of minor allele homozygotes are small (N=4 in 
the total population).
All S u b j e c t s  ( N = 7 7 1 )
PGI-M* Distribution In 
Major Allele Homozygoles (N=675)
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Figure 5-68. Boxplot and density plots of PGI-M* values in all subjects according to the 
genotype of rs4148584, the ‘tophit’ genotyped S N P  in the A B C C 5  gene. PGI-M: urinary 
prostacyclin measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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PGI-M’ Distribution in
S u b j e c t s  N o t  O n  A s p i r i n  ( N = 3 9 5 )
Figure 5-69. Boxplot and density plots of PGI-M* values in subjects not on aspirin according 
to the genotype of rs4148584, the ‘tophit’ genotyped SN P in the A B C C 5  gene. PGI-M: urinary 
prostacyclin measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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S u b j e c t s  O n  A s p i r i n  ( N = 3 7 6 )
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Figure 5-70. Boxplot and density plots of PGI-M* values in subjects on aspirin according to 
the genotype of rs4148584, the ‘tophit’ genotyped SN P in the A B C C 5  gene. PGI-M: urinary 
prostacyclin measurement ’ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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5.6.7 D PP6 A sso ciatio n  Peak
The upper panel of Figure 5-71 shows a regional association plot of the SN P s in the D PP6  region 
with PGI-M* in subjects not on aspirin. Genotyped S N P s are square, imputed SN P s are circular. 
Two imputed SN Ps, rs12703354 and rs9655649, in intron 2 of the DPP6  gene exceeded Bonferroni 
threshold, and are shown in the table in red. They appear in the upper panel in red (rs9655649) 
and yellow (rs12703354), indicating predicted r2 values of 0.9 and 0.64 with the genotyped SNP, 
respectively, based on HapMap3 estimates.
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DPP6 All Subjects (N=771) Subjects Not On Aspirin (N=395) Subjects On Aspirin (N=376)
CHR SNP BP A1 INFO GENO AF BETA P AF BETA P AF BETA P
7 rs 6464425 153778506 G 0.97 N 0.17 18.8 0.09 0.15 69.4 3.0E-06 0.19 -25.6 0.1
7 rs6464427 153778712 T 0.96 N 0.17 18.8 0.09 0.15 69.4 2.9E-06 0.19 -25.6 0.1
7 rs 12536201 153780535 C 0.99 N 0.08 24.9 0.10 0.08 101.5 1.9E-07 0.08 -46.9 0.04
7 rs6978845 153780621 C 0.97 N 0.17 18.8 0.09 0.15 69.4 3.0E-06 0.19 -25.6 0.1
7 rs12703354 153781483 c 0.83 N 0.1 22.4 0.10.11 99.3 7.1E-08 0.12 -44.3 0.03
7 rs9655649 153782684 G 0.82 N 0.09 24.9 0.10 0.09 104.1 1.4E-07 0.10 -49.2 0.03
7 rs6966462 153788371 G NA Y 0.10 10.9 0.41 0.09 81.8 4.9E-06 0.1 -48.7 0.01
7 rs6966478 153788388 C 1.03 N 0.10 10.5 0.43 0.09 82.2 4.6E-06 0.11 -50.0 0.01
7 rs 12538964 153789506 C 1.03 N 0.10 10.5 0.43 0.09 82.2 4.6E-06 0.1 -50.0 0.01
Figure 5-71 Upper panel: Regional plot of the ‘tophit’ genotyped SN P  in the DPP6  region, 
rs6966462 (purple diamond), and the SN P s genotyped on (square) and imputed from 
(circular) the CNV370-Duo chip within 200kb either side of it. The P-values for association of 
these SN Ps with PGI-M* in the study are given on the y-axis and position in Mb on the x-axis. 
Linkage disequilibrium with the ‘tophit’ SN P is colour-coded based on the r2 values from Hapmap 
phase 3. SN Ps without available r2 values are shown in grey. cM: centimorgans; Mb: megabases. 
Lower panel: Table of imputed & genotyped SN P s in the region which were significantly 
associated with PGI-M* at P=1x10"05. A1: allele 1, INFO: information score reflecting imputation 
quality, GENO: genotyped (yes/no), AF: allele frequency of A1, BETA: change in PGI-M* (pg/mg 
creatinine) associated with carriership of one copy of the minor allele. PGI-M: urinary prostacyclin 
measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen. The association plot was created 
using Locuszoom (215).
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Figure 5-72-Figure 5-74 show the distribution of PGI-M* values in all subjects, subjects not on 
aspirin and subjects on aspirin, according to the genotype of rs6966462, the tophit genotyped SN P 
in the DPP6  gene. These boxplots and density plots show a trend of increasing PGI-M* with 
additional minor alleles of rs6966462 carried only in the sub-population not on aspirin (Figure 5-73), 
with no changes evident in the total population, or in the subpopulation on aspirin (Figure 5-72, 
Figure 5-74).
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Figure 5-72. Boxplot and density plots of PGI-M* values in all subjects according to the 
genotype of rs6966462, the ‘tophit’ genotyped SN P  in the DPP6  gene. PGI-M: urinary 
prostacyclin measurement ‘ Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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IFigure 5-73. Boxplot and density plots of PGI-M* values in subjects not on aspirin according 
to the genotype of rs6966462, the ‘tophit’ genotyped SN P in the DPP6  gene. PGI-M: urinary 
prostacyclin measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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S u b j e c t s  O n  A s p i r i n  ( N = 3 7 6 )
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Figure 5-74. Boxplot and density plots of PGI-M* values in subjects on aspirin according to 
the genotype of rs6966462, the ‘tophit’ genotyped SN P in the D PP6  gene. PGI-M: urinary 
prostacyclin measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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5.6.8 ETAA1 A sso ciatio n  Peak
The upper panel of Figure 5-75 shows a regional association plot of the SN P s In the ETAA1/C1D  
region with PGI-M* in subjects on aspirin. Genotyped SN P s are square, imputed SN P s are circular. 
A  number of imputed SN P s in this region exceeded Bonferroni threshold, and are shown In the 
table In red. They appear in the upper panel in blue indicating very low predicted r2 values with the 
genotyped SN P, based on HapMap3 estimates.
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ETAA1/C1D All Subjects (N=771) Subjects NotOn Aspirin (N=395) Subjects On Aspirin (N=376)
CHR SNP BP A1 INFO GENO AF BETA P AF BETA P AF BETA P
2 rs4671841 67774915 A NA Y 0.36 6.6 0.46 0.37 -14.7 0.19 0.36 29.5 0.03
2 rs6711052 67777372 C 1.01 N 0.11 42.9 1.0E-03 0.11 -13.7 0.41 0.10 103.4 2.5E-07
2 rs13016805 67785876 G 1.03 N 0.07 57.8 3.4E-04 0.07 -16.9 0.38 0.06 162.5 6. IE-10
2 rsl7034184 67789905 T 1.03 N 0.06 54.1 8.3E-04 0.07 -16.9 0.38 0.06 156.4 4.3E-09
2 rsl2999529 67795707 T 1.03 N 0.06 54.1 8.3E-04 0.07 -16.9 0.38 0.06 156.4 4.3E-09
Figure 5-75. Upper panel: Regional plot of the ‘tophit’ genotyped S N P  in the ETAA1/C1D  
region, rs4671841 (purple diamond), and the S N P s genotyped on (square) and imputed from 
(circular) the CNV370-Duo chip within 200kb either side of it. The P-values for association of 
these SN Ps with PGI-M* in the study are given on the y-axis and position in Mb on the x-axis. 
Linkage disequilibrium with the ‘tophit’ SN P is colour-coded based on the r2 values from Hapmap 
phase 3. SN Ps without available r2 values are shown in grey. cM: centimorgans; Mb: megabases. 
Lower panel: Table of imputed & genotyped SN P s in the region which were significantly 
associated with PGI-M* at P=1x10"05. A1: allele 1, INFO: information score reflecting imputation 
quality, GENO: genotyped (yes/no), AF: allele frequency of A1, BETA: change in PGI-M* (pg/mg 
creatinine) associated with carriership of one copy of the minor allele. PGI-M: urinary prostacyclin 
measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic blood 
pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen. The association plot was created 
using Locuszoom (215).
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Figure 5-76-Figure 5-78 show the distribution of PGI-M* values in all subjects, subjects not on 
aspirin and subjects on aspirin, according to the genotype of rs4671841, the tophit genotyped SN P 
in the ETAA1/C1D region. These boxplots and density plots do not show marked differences in 
PGI-M* levels with additional minor alleles of rs4671841.
PGI-M* Distribution in
Figure 5-76. Boxplot and density plots of PGI-M* values in all subjects according to the 
genotype of rs4671841, the ‘tophit’ genotyped SN P  in the ETAA1/C1D  region. PGI-M: urinary 
prostacyclin measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, systolic 
blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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PGI-M’ Distribution in
Figure 5-77. Boxplot and density plots of PGI-M* values in subjects not on aspirin according 
to the genotype of rs4671841, the ‘tophit’ genotyped SN P in the ETAA1/C1D  region. PGI-M:
urinary prostacyclin measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, 
systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
261
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Figure 5-78. Boxplot and density plots of PGI-M* values in subjects on aspirin according to 
the genotype of rs4671841, the ‘tophit’ genotyped SN P in the ETAA1/C1D  region. PGI-M: 
urinary prostacyclin measurement ‘Adjusted for the covariates age, sex, smoking habit, diabetes, 
systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen.
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5.6.9 Candidate G enes
SN Ps in ‘Candidate genes’ likely to influence levels of thromboxane and prostacyclin based on what 
is known about their synthesis (SN Ps in CO X-1, COX-2, thromboxane synthase and prostacyclin 
synthase) were genotyped on both chips, and identified in Manhattan plots.
Of the four candidate genes, only SN Ps in the thromboxane synthase gene (TBXAS1) were 
associated with TxM* or PGI-M* levels at P<0.01 in this study. A number of SN Ps in TBXAS1 were 
marginally (P=0.01-P=0.03) associated with a decrease in TxM* levels of up to 141pg/mg per minor 
allele carried in all subjects in this study. The association at this locus was strongest in subjects on 
aspirin, and two SN Ps on the CVD50K chip, rs7785584 in intron 9 and rs1019178, 3328bp 
upstream of the transcriptional start site, were associated with increased TxM in subjects on aspirin 
(beta=76pg/mg, P=0.003; beta=68pg/mg, P=0.005, respectively). On the CNV370K chip, the only 
SN P associated with TxM* at P<0.05 was rs2072190 in intron 12 of TBXAS1, which was associated 
with a decrease of 78pg/mg in subjects on aspirin (P=0.004).
5.7 Discussion
Overall, this investigation into the genetic determinants of urinary TxA2 and PGI2 levels provides, for 
the first time, good evidence that such determinants exist. QQ plots for associations between SN Ps 
on both chips and both phenotypes indicated that more significant associations were observed than 
would be expected under the null hypothesis of no associations between these phenotypes and 
genetic polymorphisms. This study again benefitted from good phenotypic measurement; these 
eicosanoids were measured by mass spectrometry, which is considered the gold standard. The 
major drawback to this study was the relatively small sample size available.
In total, SN Ps in three separate loci were associated with TxM* after correction for multiple testing 
(CNTN4, MYOCA/AMP4 and FAM47E), and SN P s in three other, separate loci were associated 
with PGI-M* after correction for multiple testing (A B C C 5 , DPP6, ETAA1/C1D). A further two loci, 
PPA RG C1B  and ABCC5, showed very strong evidence for association with TxM* and PGI-M* 
respectively, although these associations were not significant after Bonferroni correction. It is not 
known how the protein products of these genes might influence production of TxA2 and PGI2.
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None of the ‘Candidate genes’ likely to influence levels of thromboxane and prostacyclin based on 
what is known about their synthesis (SN Ps in CO X-1, COX-2, thromboxane synthase and 
prostacyclin synthase) were strongly associated with either prostanoid in this study.
Of the four candidate genes, only SN Ps in the thromboxane synthase gene were associated with 
TxM* or PGI-M* levels at P<0.01 in this study (section 5.6.9). Although a polymorphism in the 
promoter region 386 bp upstream of the transcriptional start site of the thromboxane synthase gene 
('TBXAS1) has been identified as a risk factor for Ml in a small Japanese population (402), the 
association between SN Ps in TBXAS1  and levels of urinary thromboxane in this study was only 
marginal. A SN P 122bp upstream of the SN P reported in this study was genotyped on the CVD50K 
chip, but was not found to be associated with TxM* levels, However, another SNP, 74kbp upstream 
of the transcriptional start site, rs1015122, was marginally associated (P=0.03) with a decrease in 
TxM* levels of 95pg/mg per minor allele carried in all subjects in our study.
5.7.1 Associations with Thromboxane
The QQ plots for all subjects from the CVD50K study indicated that a small number of SN P s were 
more significantly associated with TxM* than would be expected by chance, suggesting that this 
study identified a small number of genetic variants which are associated with urinary TxM levels.
All three QQ plots of the SN Ps genotyped on the CVN370-Duo chip showed evidence of SN Ps 
which slightly exceeded the 99% confidence envelopes of the expected P-value distribution.
Imputed SN Ps in two loci, CNTN4  and MYOCA/AM P4  exceeded Bonferroni correction for multiple 
testing, as did one genotyped SN P in FAM47E.
In both the CVD50K and the CNV370-Duo studies, the P-values of low-frequency SN Ps (MAF<5%) 
deviated substantially from the expected. This may be due to genotyping error, or spurious 
associations due to the low number of minor allele carriers in these studies. However, these 
deviations may indicate true associations, and as such are worth follow-up in replication analyses.
5.7.1.1 Findings from the CVD50K chip; PP A R G C1B
On the CVD50K chip, the inflated P-values were accounted for entirely by associations with the 
PPA RG C1B  locus. Although the PPARG C1B  gene showed strong evidence for association in this 
study, the P-values individually failed to exceed Bonferroni correction for multiple testing. As 
mentioned in section 5.3.5, however, Bonferroni correction is likely to be overly-conservative,
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especially for the gene-centric CVD50K chip. The fact that three SN Ps which were not in high 
linkage disequilibrium with each other (R 2<0.5) were independently associated with TxM values 
indicates that the association of this locus with TxM is likely to be a true positive association.
Haplotype analysis using these three independently associated SN Ps showed that the haplotype 
which contains all 3 minor alleles of these genes, which was present in this population at a 
frequency of 6%, was associated with an increase of 659pg/mg creatinine TxM in those not on 
aspirin (Table 5-13). This is almost twice the average difference between subjects not on aspirin 
and those on aspirin, of 393 pg/mg creatinine (Table 5-9). The multiple regression analysis showed 
that for subjects not on aspirin, the three PPA RG C1B  SN P s explained 8.8% of the variation in 
TxM*. By comparison, all covariates (age, sex, smoking habit, diabetes, systolic blood pressure, 
BMI, HDL, LDL, aspirin and anti-hypertensive regimen) accounted for 20% of the variation in TxM in 
all subjects, with aspirin usage accounting for 17% of this.
PPARG C1B Function
PPARs are a family of nuclear receptors that are activated by nutrient molecules and their 
derivatives. PPARG  activators may play a role in hypertension and atherosclerosis through 
modification of inflammation and the innate immunity system in vascular cells (427, 428).
Peroxisome proliferator-activated receptor gamma co-activator 1 p (PPARGC1 (3) is a member of the 
PPA R  y coactivator-1 family of transcriptional coactivators. Peroxisome proliferator-activated 
receptor y co-activator 1a (P P A R G C Ia ) was the first of this family to be identified, through its 
functional interaction with the nuclear receptor PPAR y in brown adipose tissue (429). Following 
this, its homologue PPARGC1(3 and a related coactivator, PGC-1-related coactivator, were 
discovered (430, 431). P P A R G C Ia  and PPARGC1 p are preferentially expressed in tissues with 
high oxidative capacity, such as heart, slow-twitch skeletal muscle, and brown adipose tissue. Their 
interaction with PPAR-y and other nuclear receptors permits the interaction of these nuclear 
receptors with multiple transcription factors that regulate mitochondrial functional capacity and 
cellular energy metabolism (429, 431-434). The gene encoding p is situated on chromosome 5q33. 
Because of differential splicing at the 5’ and 3' ends, at least four isoforms of P P A R G C Ip  exist. 
P P A R G C ip ia , which is the most abundant isoform in skeletal muscle, heart, and brain, co- 
activates the nuclear receptors PPAR a and PPARy (431, 435).
Aswell as their well-established role in fatty acid catabolism and metabolic regulation, there is good 
evidence for a protective role of the peroxisome proliferator-activated receptors (PPAR) in 
atherosclerosis. Both PPARa and y are expressed in vascular cells, including endothelial and
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smooth muscle cells and macrophages/foam cells, and expression of PPA R a and y has been 
shown in atherosclerotic lesions and macrophage foam cells (436-440). Clinical observations 
indicate that the PPARy agonist troglitazone decreases intimal thickness in human carotid arteries 
(441). Activation of PPAR-y in macrophages and foam cells inhibits the expression of activation- 
dependent genes such as matrix metalloproteinase-9 (MMP-9) (436), inducible nitric oxide synthase 
(¡NOS), and scavenger receptor A (442). PPARy activators also inhibit the expression of MMP-9 of 
human and vascular smooth muscle cells, interfering with vascular smooth muscle cell proliferation 
(443). PPARy inhibits the production of the inflammatory cytokines TNF-a, IL-6, and IL-1 (3 by 
activated monocytes (444) and decreases the transcription of monocyte chemoattractant protein 
(MCP)-1 (445). PPAR-y might also affect monocyte recruitment in atherosclerotic lesions through 
the regulation of the adhesion molecules VCAM-1 and ICAM-1 in vascular endothelial cells (446). 
Furthermore, a partial PPAR-y agonist has been shown to reduce atherosclerosis in LDLRmice 
(447).
PPAR y is activated by a structurally diverse group of compounds including fatty acids (especially 
arachadonic acid), their eicosanoid derivatives and hypolipidemic drugs (used in treatment of insulin 
resistance and type 2 diabetes) such as fibrates and thiazolidinediones (448-451). In addition, 
other pharmacological compounds such as NSAIDs (nonsteroidal anti-inflammatory drugs) 
indomethacin and ibuprofen have been identified as PPAR ligands (452).
Differences in subcellular location of COX-1 and COX-2 have lead to the implication of COX-2 in 
PPA R  signalling. As COX-2 preferentially localizes in the perinuclear region, its products may have 
more access to nuclear receptors, and COX-2 might be a major source of prostaglandins involved 
in a PPAR-mediated nuclear signalling system (453). The C O X  products PG J2 and its metabolite 
15-deoxy-PGJ2 are PPAR-y agonists and have been shown to regulate the expression of genes in 
VSM Cs, including those involved in cell growth and/or apoptosis (454). A role for the COX-2 
product PG I2 in PPAR signalling in angiogenesis has been suggested based on a series of PG I2 
analogs more selective for nuclear, compared with traditional cell surface, receptors (455). 
Overexpression of COX-2 or prostacyclin synthase suppresses the development of vascular lesions 
and the growth of VSM Cs (271, 272), an effect which has been proposed to be mediated through 
PP A R  signalling.
In turn, PPAR-y has been reported to regulate COX-2 through a negative-feedback loop (456), a 
mechanism which may seem to potentially explain why polymorphisms in the PPAR-y coactivator, 
PPARGC1 (3, seem to influence levels of TxA2. However, the fact that this association is seen 
predominantly in subjects not on aspirin would seem to implicate the primary aspirin target COX-1, 
and not COX-2, in this association.
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Disease Associations With PPARGC1B Genetic Variants
P P A R G C Ia  and PPARG C10 are selective coactivators of oestrogen receptor alpha (457), which 
mediates the mitogen effect of ovarian oestrogen. A German candidate gene study of 816 
familial breast cancer patients and 1012 controls identified two non-synonymous mutations in 
PPARGC1A  (7M512/Wef in exon 5) and PPA RG C1B (Ala203Pro,a\so in exon 5) as risk factors for 
familial breast cancer susceptibility (458).
Recently, in a large study of two independent samples of ER-positive breast cancer cases and 
controls from Sweden and Finland, seven SN Ps showed consistent association with in the two 
independent samples, six of which were located within PPARGC1B, with the strongest association 
at rs741581 in intron 2 (459).
A Danish study found that one of the variants associated with breast cancer risk in the German 
breast cancer study, PPA RG C1B A!a203Pro, was associated with obesity in a case-control analysis 
of 7790 subjects, where the Pro allele was significantly less frequent among obese participants, but 
not with type 2 diabetes in 1433 patients with type 2 diabetes and 4935 glucose tolerant control 
subjects (460).
In a Korean study of 775 type 2 diabetes patients and 316 controls, Arg292Ser in exon 5 showed 
marginally significant associations with the risk of type 2 diabetes, where carriership of the minor 
(Ser) allele was associated with decreased risk of type 2 diabetes. Among controls, serum 
triglyceride levels were lower in individuals who carried one or two copies of the Ser allele than 
among others.
The Pro allele of the obesity and breast cancer -associated PPA R G C1B  Ala203Pro polymorphism 
has also been shown to be associated with increased physical performance of athletes (461).
The three PPARG C1B  SN Ps independently associated with TxM* in our study are intronic and are 
not known to alter protein sequence. They do have some proxies (r2>0.8) in the region not 
genotyped on this array, according to a SN AP annotation and proxy search based on 1000 
genomes pilot 1 data (462). However, none of these SN Ps is exonic or has any known function.
The ‘tophit’ genotyped SN P in our study, rs4235745, lies within an N FkB transcription factor 
binding site, identified by ChlP-seq assay (chromatin immunoprécipitation with antibodies specific to 
the transcription factor followed by sequencing of the precipitated DNA). In experiments conducted 
at the Michael Snyder lab in Stanford, NFkB was observed to bind to a region 334bp long and 
encompassing rs4235745 in two immortalized cell lines; a lymphoblastoid cell line treated with the
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N FkB agonist TNFa, and an untreated B-lymphocyte cell line. Neither rs32582 nor rs10515638 is 
situated within a known transcription factor binding site. These data were obtained on the U C SC  
genome browser (http://genome.ucsc.edu/).
5.7.1.2 Findings from the CNV370-Duo chip; CNTN4, MYOC/VAMP4 and FAM 47E 
CNTN4 Locus
From the CNV370-Duo chip, four imputed SN Ps in CNTN4, all located in intron 1 of the CNTN4 
gene, were significantly associated with TxM* beyond the Bonferroni threshold in subjects not on 
aspirin (Figure 5-41). This association was driven by a genotyped SNP, also in intron 1, 
rs10510230, which was associated with an increase in TxM* of 191pg/mg per minor allele 
(P=6.0x10'°7) in all subjects, and 329pg/mg per minor allele in subjects not on aspirin (P=1.9x1 O'07) 
(Figure 5-43). The most strongly associated imputed SNP, rs11706819, has been shown to be 
located within a binding site for the transcription factor p300 in an untreated neuroblastoma cell line 
(U C SC  genome browser (http://genome.ucsc.edu/)). rs11706819 does not have any known exonic 
proxies (r2>0.8), according to a SN AP annotation and proxy search based on 1000 genomes pilot 1 
data (462).
Another cluster of SN Ps in intron 2 of the CNTN4 gene, including the genotyped SN P rs4684343, 
were associated with a decrease in TxM* (Figure 5-43).
Boxplots of TxM* distribution according to rs10510230 genotype indicated an additive effect of 
increasing numbers of minor alleles on increasing TxM* levels, which was particularly pronounced 
in the subpopulation not on aspirin (Figure 5-44-Figure 5-46). Boxplots of TxM* distribution 
according to rs4684343 genotype, on the other hand, indicated an additive effect of increasing 
numbers of minor alleles on decreasing TxM* levels.
Conditional analysis indicated that each locus remained independently associated with changes in 
TxM* after adjustment for the other, and boxplots of combined genotypes at both loci (Figure 5-50) 
indicated additive effects of genotypes at the two loci, in line with our assertion that the two 
represent independent associations.
Haplotype analysis showed that in subjects not on aspirin, the haplotype made up of the minor 
allele of rs10510230 and the major allele of rs4684343, present in the population at a frequency of 
13%, was associated with a 795pg/mg increase in TxM* per copy of the haplotype carried 
compared to all other haplotypes. The haplotype analysis suggests that the minor allele of
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rs10510230 is only associated with increased TxM* in the presence of the major allele of 
rs4684343. When present with the minor allele of rs4684343, the minor allele of rs10510230 is 
associated with decreased TxM*. A very similar pattern exists in the all subject population.
The CNTN4 gene is located on the short arm of chromosome 3, at 3p26. It encodes a 113.45 kDa 
protein, contactin 4, which is a member of the immunoglobulin superfamily. It is a 
glycosylphosphatidylinositol (GPI)-anchored neuronal membrane protein that functions as a cell 
adhesion molecule. Axon-associated cell adhesion molecules (AxCAMs) such as contactin 4 play 
important roles in the formation, maintenance, and plasticity of functional neuronal networks. 
CNTN4  expression has been shown in many tissue types other than neuronal, however its role(s) 
there are not known (463). Several alternatively spliced transcript variants of this gene have been 
described, however their biological relevance is not known.
Copy number variations of CNTN4 have been implicated in mental retardation associated with 3p- 
syndrome (464, 465) and autism (466)
A genome-wide linkage analysis in a large cohort of Mexican Americans found that the the 3p26 
locus, containing 25 genes including CNTN4, was significantly associated with serum uric acid 
levels, itself correlated with a variety of C V  risk factors, such as BMI, plasma insulin, HDL and C R P  
(467).
MYOCA/AMP4 Lo cu s
The imputed SN P rs11799961 was significantly associated with an increase in TxM* of 263pg/mg 
per minor allele in subjects on aspirin (Figure 5-51). It is situated in an intergenic region between 
the genes encoding M YOC and VAMP4. It does not have any known exonic proxies (^>0.8), 
according to a SN AP annotation and proxy search based on 1000 genomes pilot 1 data (462), and 
is not located in or near any sites of known regulatory significance.
This association appears to have been driven by a correlated genotyped SNP, rs2014613, which 
was also associated with increased TxM* in subjects on aspirin (212pg/mg creatinine per minor 
allele carried, P=1.9x1 O'07). Boxplots of TxM* distribution by rs2014613 genotype show an additive 
increase in TxM* per minor allele carried (Figure 5-52-Figure 5-54). This is particularly pronounced 
in subjects on aspirin, where heterozygotes have a larger associated increase in TxM* compared to 
major allele homozygotes than in the population not on aspirin. This is suggestive of this locus 
being a marker for aspirin resistance, however it should be noted that numbers of minor allele
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homozygotes differed between the two subpopulations (2 in subjects not on aspirin vs 7 in those on
aspirin).
The MYOC  gene is situated on chromosome 1q24 and encodes the protein Myocilin, the precise 
function of which is unknown. Mutations in M YOC  are the most common known genetic cause of 
glaucoma (468). Myocilin is secreted into the aqueous humor of the eye, and glaucomatous MYOC 
mutations lead to inhibition of myocilin secretion (469) and accumulation of mutant myocilin in the 
endoplasmic reticulum (ER) (470), where it interacts with peroxisomal targeting signal type 1 
receptor PTS1R, leading to co-localization with peroxisomes (471).
VAMP4 encodes Vesicle-associated membrane protein 4, a member of the vesicle-associated 
membrane protein (VAMP)/synaptobrevin family. This family of proteins, along with syntaxin 1 and 
25-kD synaptosomal-associated protein (SNAP25) are the main components of the SN A R E protein 
complex involved in membrane fusion in eukaryotic cells. This complex is involved in the fusion of 
synaptic vesicles with the presynaptic membrane, and in the fusion of lipid droplets (472).
FAM 47E Lo cu s
A genotyped SNP, rs3817118, in intron 1 of FAM47E was significantly associated with an increase 
in TxM* of 291 pg/mg per minor allele carried in subjects on aspirin (Figure 5-55). It does not have 
any known exonic proxies (^>0.8), according to a SN AP annotation and proxy search based on 
1000 genomes pilot 1 data (462). rs3817118 is situated 26bp upstream of a conserved 
(human/mouse), 23bp long transcription factor binding site for PPAR-y (U C SC  genome browser 
(http://genome.ucsc.edu/)).
Boxplots of TxM* distribution by rs3817118 genotype showed increased levels of TxM* with 
increasing minor alleles carried in subjects on aspirin only (Figure 5-56-Figure 5-58). Again, this 
may implicate rs3817118 as a marker of aspirin resistance.
The FAM47E gene is situated on 4q21, and is 97kb long. It encodes the hypothetical, 45.6kDa 
protein ‘family with sequence similarity 47, member E ’, the functions of which are unknown. 
Recently, another SN P located 225bp upstream of rs3817118 in intron 1 of FAM47E, rs6812193, 
was found to be associated with Parkinson’s disease (473). There are no other known disease 
associations for this gene.
The four loci that were associated with TxM* at a P-value of < 1x1 O'06 in this study may also be true 
associations, and warrant follow-up in a replication study. KCN E4  encodes Potassium voltage-
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gated channel subfamily E member 4 and was associated with TxM* in all subjects. LZ T S 1 , 
encoding leucine zipper, putative tumor suppressor 1 and PCDH20, encoding Protocadherin-20, 
were associated with TxM* in subjects not on aspirin. NSUN3 was associated with TxM* in subjects 
on aspirin, and encodes NOP2/Sun domain family, member 3.
5.7.2 Associations with Prostacyclin
The QQ plots of P-values for association of SN Ps on the CVD50K chip with PGI-M* in all subjects 
(N=539) showed that one SN P with MAF > 0.05 exceeded the 99% confidence envelopes of the 
expected distribution. When subjects were divided into subpopulations according to aspirin use, a 
number of P-values with MAF > 0.05 in the on-aspirin population exceeded the 99% confidence 
envelopes, whereas those for the population not on aspirin fell within the confidence envelope.
SN Ps with low MAF showed significant departure from the expected distribution in all three groups 
(Figure 5-28).
The QQ plots of the SN Ps genotyped on the CNV370-Duo chip showed evidence of SN Ps with 
MAF > 0.05 which exceed the 99% confidence envelopes of the expected distribution when 
subjects were divided into those on aspirin and those not taking aspirin at time of PGI-M 
measurement (Figure 5-62).
As for the thromboxane study, in both the CVD50K and the CNV370-Duo studies, the P-values of 
low-frequency SN Ps (MAF<5%) deviated substantially from the expected and may be worth follow- 
up in replication analyses.
5.7.2.1 F indings from the CVD50K chip; IL5  
IL5  Locus
One SN P genotyped on the CVD50K chip was significantly associated with PGI-M* beyond the 
Bonferroni threshold for this study (1.6x10'os). rs17690122, situated approximately 10kb upstream 
of the IL5 gene on chromosome 5, was associated with an increase in PGI-M* of 61pg/mg 
creatinine per minor allele carried in all subjects (N=539) (Figure 5-29). This locus did not appear 
as an association peak in the analysis of the subpopulation of subjects not on aspirin (Figure 5-30), 
but was associated with increased PGI-M* in those on aspirin (Figure 5-31).
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The boxplots of PGI-M* distribution by rs17690122 genotype indicate an additive effect of 
carriership of minor alleles on PGI-M* levels (Figure 5-33-Figure 5-35). This appears to be more 
pronounced in subjects on aspirin, possibly implicating rs17690122 as a marker of aspirin 
sensitivity. However, it should also be noted that a number of minor allele homozygotes with 
particularly high PGI-M* levels are present in the subpopulation on aspirin, whereas the number of 
minor allele homozygotes in the subpopulation not on aspirin is lower (N=4 compared to N=10), and 
this may account, at least in part, for the pronounced association in subjects on aspirin. In keeping 
with this theory, levels of PGI-M* in heterozygotes in the two subpopulations are similar.
IL5  encodes the protein interleukin 5, which is produced by T-helper cells, mast cells and 
eosinophils (474) It stimulates B-cell growth (475), increases immunoglobulin secretion (476) and is 
a key mediator in eosinophil activation (477). Its role in eosinophelia has implicated IL-5 in many 
allergic diseases of which eosinophelia is a characteristic, including asthma (478).
The rs17690122 SN P is located 72bp upstream of a transcription factor binding site for the 
transcription factor EBF-1 (early B-cell factor 1), named for its role as a determinant of B-cell
differentiation (U C SC  genome browser; http://genome.ucsc.edu/).
Although no data have been published on IL-5, another interleukin, IL-1, has been shown to 
stimulate prostacyclin production by cultured human endothelial cells by increasing arachadonic 
acid mobilisation and conversion (479), and may also stimulate C O X  expression (256).
5.7.2.2 Findings from the CNV370-Duo chip; A BCC5, DPP6, ETAA1/C1D  
A B C C 5  Locus
The A B C C 5  region contained two genotyped SN Ps which, although their P-values did not exceeded 
Bonferroni correction of 1.8x10'07, had P-values very close to the Bonferroni cut-off; rs4148584 
(P=2.2x10‘07) and rs3805111 (P=3.7x10'°7) in subjects not on aspirin. These genotyped SN Ps were 
both associated with an increase in PGI-M* of >100pg/mg in subjects not on aspirin, and the locus 
was also associated with an increase in PGI-M* in all subjects (P<1x10‘05) (Figure 5-63-Figure
5-65).
Boxplots of PGI-M* distribution according to rs4148584 indicate an additive effect of increasing 
numbers of minor alleles of the SN P on PGI-M* levels, which is particularly pronounced in subjects 
not on aspirin (Figure 5-68-Figure 5-70).
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rs4148584 is situated in intron 12 of the A B CC5  gene, 55bp downstream of a binding site for the 
transcription factor p300, and 81 bp upstream of a conserved binding site for the transcription factor 
EVI-1. rs3805111 is situated in intron 18, 399bp downstream of a conserved (human/mouse) 
binding site for the transcription factor PPARy. Neither SN P has any known exonic proxies (^>0.8), 
according to a SN AP annotation and proxy search based on 1000 genomes pilot 1 data (462). The 
A B C C 5  gene is situated on chromosome 3q27, and encodes Multidrug resistance-associated 
protein 5, a member of the superfamily of ATP-binding cassette (ABC) transporters which transport 
molecules across extra- and intra-cellular membranes.
Accumulation of cholesterol by macrophages, leading to their transformation into foam cells is a key 
event in the initiation of atherosclerosis (section 3.1.1). The protective effect of HDL against 
macrophage foam cell formation and atherosclerosis is primarily attributed to its role in reverse 
cholesterol transport (RCT), a process by which excess cholesterol in peripheral tissues is 
transported to the liver for excretion. ABC transporters are known to mediate the efflux of 
cholesterol and phospholipids from plasma membranes of cells such as macrophages to lipid 
acceptors, such as HDL (480).
DPP6  Locus
Two imputed SN Ps in intron 2 of DPP6  were associated with an increase in PGI-M* beyond the 
Bonferroni threshold in subjects not on aspirin; rs12703354 was associated with an increase of 
99pg/mg per minor allele carried (P=7.1x10‘08) and rs9655649 was associated with an increase of 
104pg/mg per minor allele carried (P=1.4x10'°7). This association appeared to be driven by a
genotyped SN P also in intron 2, rs6966462, which was associated with an increase in PGI-M* of 
82pg/mg per minor allele carried (P=4.9x10'°6) (Figure 5-71).
Boxplots of PGI-M* distribution according to rs6966462 genotype indicate similar increases in PGI- 
M* levels in carriers of one or two copies of the minor allele, however this increase is absent in the 
subpopulation on aspirin (Figure 5-72-Figure 5-74).
The DPP6  gene is located on chromosome 7q36 and encodes the 97.6kDa protein dipeptidyl- 
peptidase 6, This gene encodes a type II membrane glycoprotein that is a member of the S9B 
family in clan S C  of the serine proteases, and is expressed predominantly in the CN S. Despite 
being associated with numerous diseases, no functional role is known for the DPP6  protein. The 
DPP6  protein is structurally similar to DPP4, a serine protease and cell adhesion protein with 
important functions in the endocrine and immune systems, but lacks enzymatic activity due to
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mutations in the catalytic region. DPP6  has been found to regulate the membrane trafficking of the 
potassium voltage-gated channel Kv4 in neurons and to modify channel properties (481).
A linkage analysis has implicated DPP6  in Familial Idiopathic Ventricular Fibrillation (482), and a 
GW AS in population of European descent identified a SN P in intron 3 of DPP6, rs10260404, 
associated with sporadic amyotrophic lateral sclerosis (ALS) (483). In addition, copy number 
variation in the DPP6  gene has been linked to Autism Spectrum Disorder (484).
ETAA1/C1D  Locus
A number of imputed SN P s on chromosome 2, situated between the genes ETAA1 and C1D, were 
significantly associated with PGI-M* in subjects on aspirin in the CNV370-Duo chip study, beyond 
Bonferroni correction for multiple testing (Figure 5-75). The same group of SN Ps were non- 
significantly associated with a decrease in PGI-M* in subjects not on aspirin. The most strongly 
associated genotyped SN P  in the 40kb region surrounding these SN P s was rs4671841, which was 
only marginally associated with increased PGI-M* in subjects on aspirin (29.5 pg/mg creatinine per 
minor allele carried, P=0.03). Boxplots of the distribution of PGI-M* by rs4671841 genotype did not 
show any marked differences between carriers of minor alleles and major allele homozygotes 
(Figure 5-76-Figure 5-78). Despite the indication of the high INFO scores that these SN P s were 
well-imputed, some inconsistencies existed in the names of the alleles imputed, and this association 
peak may be an artefact of inaccurate imputation. However, it may be worth genotyping one of 
these imputed SN Ps in this population to ascertain whether or not this is the case.
5.7.3 Conclusions
The discovery for the first time in this study of genetic determinants of the physiological antagonists 
thromboxane and prostacyclin may help to elucidate the physiological mechanisms which help to 
determine levels of these important prostanoids.
None of the 'tophit' SN Ps in our study were exonic, or in strong linkage disequilibrium with 
mutations known to cause amino acid change. The majority of them were intronic, and a number of 
these were located in or near transcription factor binding sites. Despite this apparent lack of 
‘functional’ (protein-altering) variants, the results of this study did implicate a number of 
physiological systems which appear to be associated with urinary levels of thromboxane and 
prostacyclin.
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Peroxisome proliferator-activated receptor gamma (PPA RG ) was strongly implicated in the genetic 
determination of thromboxane and prostacyclin levels in this study. Variations in the gene of Its 
transcriptional co-activator, PPARGC1(3, genotyped on the CVD50K chip were associated with 
large Increases in TxM*. In addition, SN Ps in two other loci, FAM47E associated with increased 
TxM* and A B CC5  associated with increased PGI-M*, were situated within or close to transcription 
factor binding sites for PPARG.
Of the eight loci identified in this study as being associated with eicosanoid levels, two (CNTN4, 
associated with thromboxane, and DPP6, associated with prostacyclin) encode proteins involved in 
cell adhesion/fusion, suggesting that this process may be important in regulating the levels of these 
prostanoids.
There is a proposed role in the literature for physiological involvement in
atherosclerotic/atherothrombotic disease progression for only one of the eight loci identified in this 
study as being associated with eicosanoid levels -  ABCC5. A number of these loci, however, have 
reported associations with relevant cardiovascular phenotypes, including type 2 diabetes and 
obesity (PPA RG C1B , associated with TxM*) and uric acid levels (CNTN4, associated with TxM*). A 
large number of these loci also have a known role in neurological processes, and a number have 
prior associations with neurological diseases, such as mental retardation (CNTN4, associated with 
TxM*), Parkinson’s (FAM47E, associated with TxM*), Autism and Amyotrophic lateral sclerosis 
(ALS) (both DPP6, associated with PGI-M*).
In addition to furthering the knowledge of the physiological determinants of the levels of these 
compounds, the findings of this study may also have clinical utility. This is particularly true of 
variants associated with thromboxane, as thromboxane levels are known to be predictive of 
cardiovascular events. For example, the finding that loci such as PPA RG C1B  appear to account for 
a large proportion of TxM variation suggests huge potential as a marker for those at 
atherothrombotic risk. In addition, thromboxane is the target of the anti-platelet agent aspirin, 
which, due to its associated bleeding risk, is established in secondary prevention but controversial 
in primary prevention of cardiovascular events. Variants identified in this study could help to inform 
the decision to advise aspirin use on a patient-by-patient basis. For instance, loci such as 
PPARG C1B  and CNTN4, which were associated with high thromboxane in those not on aspirin, 
may be pharmacogenetic markers for those most likely to benefit from antiplatelet therapy. In 
addition, SN Ps which were associated with increased thromboxane particularly in the subgroup on 
aspirin, such as the MYOC/VAMP4 and FAM47E loci, may serve as markers of people in whom 
aspirin use does not effectively lower thromboxane levels, and in whom additional or alternative 
anti-platelet therapies are warranted.
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Although the utility of variants found to be associated with prostacyclin may not be as immediately 
obvious, the role of prostacyclin as the physiological antagonist of thromboxane means that 
associations with prostacyclin may also be markers of atherothrombotic risk.
6 Thesis Conclusions & Future Directions
The results of this thesis add to the current knowledge of the genetic contributions to cardiovascular 
disease. They address some of the obstacles to finding positive associations outlined in the 
introduction to this thesis, including the need for study designs complimentary to GW AS, good 
phenotypic characterisation, and interrogation of specific cardiovascular risk factors for better power 
and cleaner associations.
The positive associations identified in these studies provide important starting points for further 
work. Despite the stringent correction for multiple testing imposed in each of the studies in this 
thesis, genetic association studies such as these still harbour a propensity for false positive results. 
One way of ensuring the validity of a positive result is to replicate the finding in an independent 
population. Potential replication, where necessary, of the results described in this thesis are 
detailed in the following paragraphs.
Following confirmation of an association by replication study, additional genotyping or sequencing, 
known as fine-mapping, may be necessary in order to try to identify the true causal variant at the 
locus. Identification of the causal variants at associated loci is necessary to advance understanding 
of the underlying physiology of these cardiovascular risk factors. Following this, functional studies 
are a vital step in the translation of variants identified in genetic association studies to clinically 
useful pharmacological and/or pharmacogenetic targets which will improve the prevention and 
treatment of cardiovascular diseases.
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6.1 Candidate Gene Association Study of Genetic Variants in the (Pro)Renin 
Receptor with Blood Pressure Variation
Chapter 3 described the first candidate-gene assessment of the (P )R R  in Caucasian populations. 
This gene and 20kb of its upstream region were comprehensively genotyped in this study, 
accounting for all genetic variation present in Caucasian populations at a frequency of > 5%.
The results of the association study indicated that polymorphisms in the (P)RR  gene were 
associated with slightly (up to 1mmHg per minor allele carried) lower BP in healthy populations. 
These associations, however, were not statistically significant after correction for multiple testing. 
The modest size of these BP changes are typical of findings from other genetic association studies 
of BP variation. A commonly-held biological hypothesis is that common variants associated with 
common diseases are many and that each is individually associated with minor phenotypic change. 
Despite the well-phenotyped populations used in this study, the sample size may have been 
insufficient to detect associations between BP and (P)RR  polymorphisms with statistical 
significance. Replication in a larger, similarly well-phenotyped Caucasian cohort will be necessary 
to confirm or refute these associations.
There is sound biological evidence for the involvement of (P )RR  polymorphisms in BP variation, 
given its role in the renin-angiotensin system. However, there is much work left to be done in 
accurately describing such associations. If replication studies support the finding of this thesis that 
(P )RR  polymorphisms are associated with lower BP, fine-mapping will have to be undertaken to try 
& identify causal variant(s), and functional studies begun. This is a stage which has proven 
problematic for other studies, resulting in relatively few publications of findings from genetic 
association studies which have been shown to be functional variants. Indeed, in this study, the 
(P)RR  polymorphisms did not appear to correlate with (P)RR expression levels in the adrenal 
glands of 18 donors. As mentioned in section 3.5.2, there are many possible reasons for this. One 
possibility is that none of the SN Ps genotyped in this study is the true causal variant. Another likely 
explanation is that expression levels of the (P)RR  are tissue-specific, and polymorphisms in the 
gene may affect mRNA expression in other tissues.
This chapter also included the results of the first investigation into the effects of (P )RR  SN P s on BP- 
lowering with anti-hypertensive agents in a hypertensive population. Although the associations 
between (P)RR  SN Ps and response to BP-lowering therapies in the hypertensive population were 
not statistically significant after correction for multiple testing, some variants were associated with a 
substantial effect (~5mmHg) on response to BP-lowering therapies which target the renin 
angiotensin system. These pharmacogenetic findings have potential therapeutic implications, and 
warrant further investigation. A follow-up study in a cohort of 100 individuals each randomised to
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the A C E  inhibitor perindopril 10mg, the renin inhibitor aliskiren 300mg and the angiotensin receptor 
blocker candesartan 32mg in a cross-over design is being conducted by our group.
If I were to conduct this study again in an ideal world (with unlimited resources!), I would begin with 
much larger sample sizes. I would sequence the (P)RR  gene and its upstream region to capture all 
genetic variation, including rare variation, at the locus. I would undertake a much more 
comprehensive tissue study, including other organs where the (P)RR is known to be expressed, 
such as the kidney.
6.2 Candidate Pathway Association Study of Genetic Variants in Ion
Channel Studies and Neurotransmitter Receptors with Blood Pressure 
Variation
Chapter 4 described the results of two candidate gene pathway association studies. Like the (P)RR 
study, this study benefitted from comprehensive genotyping and good phenotypic measurements. 
Following replication of initial findings in an independent population, this study strongly implicated 
three new ion channels, CLCN2, KCNAB1 and GRIK4  in BP regulation. Two of these channels, 
CLCN 2  and KCNAB1 are expressed in the kidney and are likely to play a role in fluid homeostasis. 
The third, GRIK4, is a neurotransmitter receptor and may affect BP control by the sympathetic 
nervous system.
As described in the previous section, the loci identified in this study will need to be taken forward to 
fine-mapping and functional studies, where they may provide new insights into the pathophysiology 
of BP regulation, and point to novel drug targets for the treatment of hypertension. In addition, they 
may serve as pharmacogenetic markers to inform choice of optimal anti-hypertensive therapy at an 
individual level.
Targeted studies, such as the ones described in this thesis, have uncovered SN Ps which have 
been ‘passed over’ by GW AS studies, because of poor coverage or because the P-values were not 
strong enough to overcome correction for multiple testing. Although they are not a replacement for 
sequencing studies, I think that until undertaking good quality, large-scale sequencing studies 
becomes more financially feasible, targeted studies such as this and the previous study will play an 
important role in uncovering the remaining BP heritability.
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6.3 Thromboxane and Prostacyclin Genome-Wide Association Studies 
(GWAS)
Chapter 5 describes the results of a genome-wide association study of urinary TxA2 and PGI2 
levels. This was the first study to look at genetic determinants of these prostanoids, which play an 
important role in atherothrombosis, and to observe that such determinants do exist. As mentioned 
previously, cardiovascular disease is a multifactorial disease, which may be best studied as a 
collection of intermediate phenotypes, which all contribute to cardiovascular risk via various different 
pathways. In terms of unravelling the genetics of cardiovascular disease, this approach has been 
adopted with some success. Genetic variants associated with intermediate phenotypes such as 
BP, lipids, and physical measures such as intima-media thickness (a measurement of the thickness 
of the arterial walls) have been identified which are also associated with risk of cardiovascular 
disease. In order to reach a comprehensive understanding of the genetic architecture of 
cardiovascular disease, it will be necessary to continue and expand this approach to include new 
intermediate phenotypes of emerging importance to cardiovascular risk, such as prostanoid levels.
Although it suffered from relatively small sample size and relatively low genome-wide genotyping 
coverage, this study identified a number of genetic determinants of these prostanoids. Replication 
studies will now be necessary to confirm these findings.
Replication of genotyped SN P s which were found to be associated with either thromboxane or 
prostacyclin in this study will take place in -300 additional HACVD participants in whom urinary 
thromboxane and prostacyclin were measured, but who were not genotyped on the CVD50K chip. 
This work is currently underway.
In addition, SN Ps which were imputed from the CNV370-Duo chip and found to be significantly 
associated with prostanoid levels in this study will be genotyped in all -900 HACVD participants 
with urinary prostanoid measurements, in order to ensure that the association is not an artefact of 
imputation.
It was proposed in the planning of the GW AS to use positive findings to conduct a Mendelian 
Randomisation study to try to elucidate the nature of the relationship between increased TxA2 and 
heightened cardiovascular risk. Information on all major cardiovascular events and all-cause 
mortality are available for all A SC O T  participants for the duration of follow-up. However, although 
genetic determinants of TxA2 and PGI2 levels were identified in this study, none of the eight ‘tophit’ 
loci were genes known to be directly involved in the synthesis of these eicosanoids. We cannot 
therefore rule out the possibility these eight genes in which the ‘tophit’ genetic variants associated
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with TxA2/PGI2 were found affect levels of some hypothetical confounding factor, such as CRP , 
invalidating the Mendelian Randomisation approach in this case.
Although SN P s in four 'candidate genes’ likely to influence levels of thromboxane and prostacyclin 
based on what is known about their synthesis - CO X-1, COX-2, thromboxane synthase and 
prostacyclin synthase -  were genotyped in this study, only SN P s in thromboxane synthase were 
found to be even weakly associated with thromboxane/prostacyclin in this study (section 5.6.9). A 
Mendelian randomisation study may be feasible using this locus, but may be detrimentally affected 
by the lack of strength of the association.
Although Mendelian randomisation may not be appropriate in this study, there is still value in 
assessing whether the variants identified in this study are predictive for atherothrombotic and 
bleeding events. To this end, we intend to genotype the variants identified in this study in 8,950 
A SC O T participants who have contributed DNA, approximately 15% of whom suffered a heart 
attack or stroke, and perform cardiovascular and bleeding event-free survival analyses for variant 
carriers versus non-carriers, in aspirinated and non-aspirinated subjects.
Other future work may include sequencing to further dissect loci which are consistently associated 
with prostanoid levels following replication studies, in the hope of identifying true causal variants.
Further work is planned to assess functional implications of the polymorphisms identified in this 
study, and to investigate their use as novel pharmacogenetic assays of thrombotic and bleeding 
risks with anti-platelet therapy, using a range of clinical and laboratory studies.
I think that given the important role played by these prostanoids in atherothrombosis, identification 
of genetic variants affecting their levels represents an important part of the investigation of the 
genetic risk of cardiovascular disease. Furthermore, because of current difficulties with the use of 
anti-platelet agents, variants associated with prostanoid levels may prove to be clinically useful 
pharmacogenetic markers, especially given the complexity and expense involved in measuring 
urinary levels of these prostanoids. Given how important I believe this study is, in an ideal world I 
would have conducted it in a larger population, and with more intensive genotyping. However, the 
further studies described above will go some way to rectifying these shortcomings.
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L i s t  o f  A b b r e v i a t i o n s
ABPM ambulatory blood pressure monitoring
ACE angiotensin converting enzyme
ADP adenosine diphosphate
A IB I Allied Irish Bank phase I
AIB II Allied Irish Bank phase II
AIB III Allied Irish Bank phase III
Ang 1 angiotensin I
Ang II angiotensin II
ARB angiotensin receptor blocker
ASCOT Anglo-Scandinavian Cardiac Outcomes Trial
ASCOT-BPLA ASCOT Blood Pressure Lowering Arm
ASCOT-LLA ASCOT Lipid Lowering Arm
ATP adenosine triphosphate
AT1 Angiotensin II type 1
BMI body mass index
BP blood pressure
BP base pairs (nucleotides)
bp base pairs (DNA bases)
Cl cerebral infarction
CNV(s) copy number variants
COX cyclooxygenase
cPLA2a cytosolic phospholipase A2a
CRP C-reactive protein
DAG diacylglycerol
DBP diastolic blood pressure
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FHS Framingham Heart Study
GC genomic control
GPIb-V-IX glycoprotein Ib-V-IX
GWAS genome-wide association studies
HACVD hypertension-associated cardiovascular disease
HDL high-density lipoproteins
HRP handle region peptide
IFN interferon
IL1 interleukin 1
IP prostacyclin receptor
IP3 inositol-1,4,5-trisphosphate
IQR inter quartile range
kDa kilo Daltons
LC-MS-MS liquid chromatography - tandem mass spectrometry
LD linkage disequilibrium
LDL low-density lipoprotein
MAF minor allele frequency
MCP monocyte chemoattractant protein
Ml myocardial infarction
mmHg millimetres of mercury
mRNA messenger RNA
NSAIDs nonsteroidal anti-inflammatory drugs
PGI2 prostacyclin
PGI-M urinary 2,3- dinor 6-keto PGF1a
PKC protein kinase- C
PLC phospholipase C
PP pulse pressure
EGF epidermal growth factor
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PPARy peroxisome proliferator activated receptor gamma
(P)RR (pro)renin receptor
PRA plasma renin activity
RAS renin-angiotensin system
SBP systolic blood pressure
SD standard deviation
SNP single nucleotide polymorphism
TGF transforming growth factor
TNF tumour necrosis factor
TP thromboxane receptor
TPA tissue plasminogen activator
TxA2 thromboxane A2
TxM urlnary11-dehydrothromboxane B2
VCAM vascular cell adhesion molecule
VSCMs vascular smooth muscle cells
vWF von Willebrand factor
WTCCC Welcome Trust Case Control Consortium
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